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SUMMARY 
 
  Investigations into Human Cytomegalovirus (HCMV) pathogenesis should be based on 
strains that closely reflect the causative agent of disease, however HCMV invariably mutates in 
vitro, generating phenotypically distinct laboratory-adapted strains. In particular, mutations are 
selected in the HCMV genome UL128 locus (UL128L) that encodes sub-units of a virion 
envelope pentameric complex that impedes virus propagation in fibroblasts (the cell type most 
commonly used in vitro), but is required for infection of several naturally targeted cell-types 
(e.g. epithelial, endothelial, and myeloid cells). Addressing this issue, the genome of wildtype 
HCMV strain Merlin was cloned as a stable bacterial artificial chromosome (BAC), however 
similarly to clinical isolates, viruses reconstituted from the Merlin-BAC grow poorly and are 
prone to de novo mutation in cell culture.  
 Direct comparison to viruses from the Merlin-BAC revealed that viruses from the BAC-
cloned versions of strains TR (TR-BAC), TB40E (TB40-BAC4) and VR1814 (FIX-BAC) could 
be propagated more efficiently in fibroblasts, despite containing intact UL128L ORFs. Unique 
nucleotide variations identified in TB40-BAC4 and FIX-BAC UL128L ORFs were transferred 
into the Merlin-BAC, generating variants that produced greater titres of cell-free virus following 
reconstitution. Virions from these novel Merlin variants displayed reduced pentameric complex 
content, but remained able to infect epithelial cells, albeit with slightly compromised efficiency. 
The greater fitness of viruses from these novel Merlin-BAC variants alleviated the selective 
pressures for the selection of de novo UL128L mutations in fibroblasts. The Merlin virion 
proteome was determined, with up to 30 novel components identified to provide a more 
comprehensive picture of wildtype HCMV virion composition. Comparison of virions from 
several Merlin variants demonstrated that varying pentameric complex content impacted the 
incorporation of other components, however virions from the novel Merlin variants produced in 
this work closely matched those from the parental Merlin variant containing wildtype UL128L 
ORFs. Thus, the novel Merlin-BAC variants produced in this work represent valuable reagents 
for future HCMV research.  
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1.1 Human Cytomegalovirus (HCMV) - Human Herpesvirus 5 (HHV5) 
 Taxonomy  1.1.1
Human Cytomegalovirus (HCMV) is one of the nine currently recognised herpesviruses 
that infect humans. The herpesviruses are a large group of DNA viruses with diverse animal 
hosts, collectively assigned to the order Herpesvirales (McGeoch, Rixon et al. 2006, Davison, 
Eberle et al. 2009). Herpesviruses of mammals, reptiles, and birds are assigned to the family 
Herpesviridae that contains 3 major sub-families distinguished by nucleotide sequence and 
biological characteristics: the Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae 
(Roizmann, Desrosiers et al. 1992, Davison 2010). The human herpesviruses (HHV1-8; 
including HHV6A and HHV6B) include representatives of each sub-family, with HCMV 
(HHV5) the prototype species of the betaherpesvirinae and the genus Cytomegalovirus. 
 Evolution, phylogeny and related species 1.1.2
Studies into the evolutionary origins and phylogenetic relationship between the 
herpesviridae members have been based on the alignment of amino acid sequences encoded by 
genes conserved amongst the herpesviruses (Figure 1.1.). Data from these studies suggest that 
the alpha-, beta- and gammaherpesvirinae lineages evolved from a common ancestor that 
existed 350-400 million years ago, with genera within each sub-family having arisen prior to the 
mammalian radiation event that occurred 60-80 million years ago (McGeoch, Cook et al. 1995, 
McGeoch and Gatherer 2005). The closest relatives of HCMV are the other members of the 
genus Cytomegalovirus that comprises viruses of apes and other primates. More distantly 
related viruses with biological similarities to HCMV are often called ‘cytomegaloviruses’, yet 
are not members of the Cytomegalovirus genus. These include murine CMV (MCMV) and rat 
CMV (RCMV) from the genus Muromegalovirus, and guinea pig CMV (GPCMV) yet assigned 
to any genus (Davison 2002, Davison 2013). 
Since they are derived from a common ancestor the herpesviruses share many 
biological qualities, and several aspects of HCMV biology have been elucidated by comparison 
to other human herpesviruses and betaherpesviruses of other animals. One common biological 
feature is the establishment of life-long persistent infections, contributing to the survival of 
HCMV in host populations. However, herpesviruses have also undergone divergent speciation 
during co-evolution with their respective hosts; this was suggested by the observation that the 
branching pattern of the mammalian herpesvirus phylogenetic trees closely overlapped the 
phylogenetic trees for the corresponding mammalian host lineages (McGeoch, Cook et al. 1995, 
McGeoch, Dolan et al. 2000). As a result, humans are the exclusive host of HCMV, with the 
evolutionary success of this virus in part due to the acquisition of mechanisms to evade or 
subvert the human host immune response; reviewed in (Vossen, Westerhout et al. 2002). 
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Figure 1.1. Herpesviridae Phylogenetic Tree. Phylogenetic tree constructed following alignment of 
amino acid sequences of 6 ORFS conserved amongst the herpesviruses. HCMV ORFs assessed include 
four that encode DNA replication and packaging functions (UL54, viral DNA polymerase sub-unit; 
UL56, DNA encapsidation terminase complex sub-unit 2/TER2; UL57, single-stranded DNA binding 
protein/SSB; UL89, DNA encapsidation terminase complex sub-unit 1/TER1), and two ORFs encoding 
virion structural proteins (UL86, major capsid protein/MCP; UL55, virion envelope glycoprotein gB). 
Human herpesviruses 1-8  (italics) dispersed across the major Herpesviridae sub-family lineages – 
Herpes Simplex virus 1 (HSV-1/HHV1), Herpes Simplex virus 2 (HSV-2/HHV2) and Varicella Zoster 
virus (VZV/HHV3) in the alphaherpesvirinae (orange); Human Cytomegalovirus (HCMV/HHV5), 
Roseolaviruses (HHV6A*, HHV6B* and HHV7) in the betaherpesvirinae (green); Epstein Barr virus 
(EBV/HHV4) and Kaposi’s Sarcoma Associated herpes virus (KSHV/HHV8) in the gammaherpesvirinae 
(purple). *HHV6A and HHV6B have recently been classified as distinct viral species, whereas previously 
they had been considered variants of single herpesvirus species (Adams and Carstens 2012). Members of 
the genus Cytomegalovirus (encircled, bold): HCMV, Simian Cytomegalovirus (SCMV) variants (a) & 
(b), and Rhesus Cytomegalovirus (RhCMV). Betaherpesviruses closely related to HCMV/HHV5: Murine 
Cytomegalovirus (MCMV) and Rat Cytomegalovirus (RCMV) of the genus Muromegalovirus; Tupia 
Herpesvirus (THV) and Guinea Pig Cytomegalovirus (GPCMV), yet assigned to any genus. Figure 
adapted from (McGeoch, Rixon et al. 2006), with the permission of Elsevier publishers. 
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1.2 Discovery, isolation, and propagation of HCMV in vitro  
The earliest documented accounts of HCMV pathogenesis date back to the late 19th 
century when HCMV-infected cells were observed during histological examination of the 
kidney tissues of a stillborn, and the parotid glands of infants suffering unknown diseases. 
However, these observations were reported some years later (Ribbert 1904) following 
independent reports of similar clinical findings (Jesionek 1904). Each report described abnormal 
cellular structures containing a large central nuclear body surrounded by a clear halo, together 
termed ‘nuclear inclusions’ or ‘Owl’s eye’ inclusions, as well as cytoplasmic inclusions at 
juxtanuclear sites (Figure 1.2.). These cellular structures were initially considered ‘protozoan-
like’, however investigation into their occurrence and intra-host distribution led to their 
identification as human cells, albeit with an unusual morphology that was termed ‘cytomegalia’ 
(cyto – cell, megalia – large) (Goodpasture and Talbot 1921). A viral aetiology was postulated 
(Von Glahn 1925) on comparison to reports of similar inclusion-containing cells from 
individuals with then known herpesvirus infections (Lipscheutz 1921). The presentation of 
cytomegalia was soon correlated with a lethal congenital infection in humans and other animals, 
for which the term ‘cytomegalic inclusion disease’ (CID) was applied, and it was also 
recognised that similar phenomena occurred in other animals (Wyatt, Saxton et al. 1950). The 
term ‘cytomegalic inclusion disease virus’ (CIDV) was proposed, as was ‘salivary gland virus’ 
(SGV) as cytomegalic cells were consistently identified in the salivary glands of CID patients. 
Early attempts to isolate and propagate human CIDV/SGV were generally unsuccessful; 
this may be attributed to the use of non-human tissues together with the high degree of host-
specificity displayed by this virus, whilst various human tissue types targeted in vivo also did 
not support propagation in vitro. However successful isolation and serial propagation of 
CIDV/SGV in vitro was achieved following the development of techniques for the routine 
culture of diploid fibroblast cells, reported almost simultaneously by three independent groups 
(Rowe, Hartley et al. 1956, Smith 1956, Weller, Macauley et al. 1957). During each of these 
studies, propagation of the same clinical isolates in non-human tissues and non-fibroblast 
human tissues was conclusively shown to be inefficient, indicating that clinical HCMV isolates 
displayed specificity for fibroblasts in vitro. Serological testing demonstrated antigenic 
heterogeneity amongst these isolates to identify distinct strains of a single viral species that was 
subsequently named Cytomegalovirus (Weller 1960, Weller 1970). The prototype laboratory 
strain AD169 was derived from these earliest isolations, and has since been the virus reagent of 
choice for historic HCMV research (Rowe, Huebner et al. 1953, Rowe, Hartley et al. 1956). 
However during these works, AD169 and the other clinical isolates were subjected to extensive 
passaging to produce virus stocks, and it is now widely appreciated that this occurred with 
concomitant selection of mutations during adaptation to cell culture (see Section 1.7.). 
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Figure 1.2. Cytomegalic cells. Haematoxylin and eosin stained tissue biopsies derived from HCMV infected individuals with CID. (A) Infection foci (encircled) of liver bile duct 
cells (at 400X magnification). (B) HCMV infected renal tubule epithelial cells (at 960X magnification), displaying enlarged nucleus and surrounding clear halo (nuclear, or ‘Owl’s 
eye’ inclusion), as well cytoplasmic inclusions. Images reproduced from (Wyatt, Saxton et al. 1950), with permission of Elsevier publishers. 
    7 
1.3 Classification of HCMV as a herpesvirus 
Prior to the availability of nucleic acid sequencing technologies, virus species 
classification was based on observation of common biological properties (i.e. pathologies, 
replication characteristics, host range etc.), as well as the biochemical and architectural features 
of virus particles. Under these criteria, HCMV was tentatively classified based on biological 
similarities with then known herpesviruses (Andrews 1961), and more conclusively when 
electron microscopy (EM) analysis of HCMV particles revealed structural similarities with 
herpes simplex virus particles (Smith and Rasmussen 1963). An interesting observation made 
during the earliest analysis of HCMV particles was a high particle: infectivity ratio (Smith and 
Rasmussen 1963). Later investigations, including those aided by gravity-flow sedimentation 
techniques for the purification of viral particles (Figure 1.3.A), identified three distinct HCMV 
particle variants (Craighead, Kanich et al. 1972, Talbot and Almeida 1977, Irmiere and Gibson 
1983). EM analysis of purified infectious HCMV particles (virions) further demonstrated the 
four-layered architecture definitive of the herpesviruses (see section 1.3.1). Characterisation of 
the two alternative particle variants demonstrated that they were morphologically and/or 
biochemically distinct from virions, and represented defective non-infectious particles (see 
sections 1.3.2 and 1.3.3). However, these investigations were based on virus that had been 
propagated in cell-culture, and neither defective particle variant has been identified in clinical 
samples.  Hence the significance of these defective particle variants during natural infection 
remains speculative. 
1.3.1 HCMV Virions 
HCMV virions (Figure 1.3.B) are the largest and most complex of all studied human 
herpesviruses, ~200-230 nm in diameter, with pleomorphic quasi-spherical morphology 
(Irmiere and Gibson 1983, Chen, Jiang et al. 1999). The four-layered herpesvirion architecture 
includes, from the innermost regions outwards: a dsDNA genome; a highly ordered protein 
structure, termed the capsid; a matrix predominantly composed of viral proteins, termed the 
tegument; and a limiting membrane envelope (Roizmann, Desrosiers et al. 1992, Pellet 2013). 
As with other herpesviruses, the linear dsDNA genome of HCMV virions is arranged in a torus 
of concentric hexagonal shells within the capsid (Furlong, Swift et al. 1972); these two layers 
form the core structure termed the nucleocapsid. HCMV contains the largest genome of any 
human herpesvirus (~236 Kbp in length), which is in turn packaged with considerable density in 
the largest capsid of any human herpesvirus (~130 nm in diameter) (Chen, Jiang et al. 1999, 
Bhella, Rixon et al. 2000, Dolan, Cunningham et al. 2004). Like all herpesviruses, HCMV 
capsids are assembled from 162 capsomeres (capsid sub-units) and 320 hetero-trimeric protein 
triplexes, and these are arranged into icosahedral lattices with T=16 symmetry to display 20 
triangular faces and 12 vertices (Chen, Jiang et al. 1999, Brown and Newcomb 2011, Pellet 
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2013). 161 capsomeres are multimers of a single protein; 150 hexamers form the capsid faces 
and walls, whilst 11 pentamers are located at the vertices. One specialised capsomere at the final 
vertice forms a channel through which the genome is inserted during virion assembly, and 
released following de novo infection. The HCMV virion tegument is ~50 nm thick and arranged 
into two distinct layers: the innermost nucleocapsid-proximal layer contains densely packaged 
materials with a highly ordered arrangement; the envelope proximal layer contains less densely 
materials with amorphous arrangement (Irmiere and Gibson 1983, Chen, Jiang et al. 1999, Yu, 
Shah et al. 2011). The HCMV virion envelope is a ~10 nm thick host-cell derived lipid bilayer, 
and contains an array of viral encoded glycoproteins as a further hallmark of herpesvirion 
morphology (Irmiere and Gibson 1983, Pellet 2013).   
1.3.2 Defective particles: Non-infectious enveloped particles (NIEPs) 
Non-infectious enveloped particles (NIEPs) (Figure 1.3.C) are biochemically and 
structurally similar to virions, however they lack a copy of the viral genome and are therefore 
unable to support viral replication (Irmiere and Gibson 1983). Compared to virions, NIEPs are 
less densely packaged and are separated from other viral particles by gravity-flow sedimentation 
as slower migrating particles (Figure 1.3.A). In place of the fully matured nucleocapsid, NIEPs 
contain a smaller immature capsid variant (Irmiere and Gibson 1985), and are therefore 
distinguishable on EM analysis by their less electron dense core.  
1.3.3 Defective particles: Dense bodies (DBs) 
Dense bodies (DBs) (Figure 1.3.D) are composed of enveloped tegument materials, and 
lack both the viral genome and capsid (Craighead, Kanich et al. 1972). In contrast to NIEPs, 
DBs are more densely packaged than virions, and therefore migrate at a greater rate during 
gravity-low sedimentation (Figure 1.3.A). These defective virus particles are distinguishable 
from both virions and NIEPs on EM analysis by the presence of electron dense material 
throughout the entirety of their structure. DBs are also the most heterogeneous particle variant, 
existing in a range of sizes that are often up to twice the diameter of virions and NIEPs 
(Craighead, Kanich et al. 1972, Talbot and Almeida 1977). 
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Figure 1.3. HCMV particle variants observed in vitro. (A) Separation of virus particle variants by gravity-flow sedimentation over gradients. (B) EM image and schematic of 
infectious virion architecture. (C) EM image and schematic of defective NIEPs. (D) EM image and schematic of defective DBs. In virions, the linear dsDNA genome is encased in 
the capsid, together forming the nucleocapsid. The capsid is surrounded by tegument arranged in two distinct layers: a densely packed and highly ordered capsid-proximal layer 
(dark brown), and the amorphous envelope proximal layer (light brown). The envelope (pink) contains an array of embedded viral encoded glycoproteins (pink, yellow, purple). 
NIEPs differ from virions in containing an immature capsid devoid of an inserted genome. DBs lack both a viral genome and also the capsid structure. Gradient purified virus 
particles and EM images adapted from (Irmiere and Gibson 1983) with the permission of Elsevier publishers. 
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1.3.4 HCMV lytic replication cycle – overview  
 The core mechanisms employed at each phase in the HCMV lytic (productive) 
replication cycle (Figure 1.4.) are common amongst the herpesviruses. Infection with cell-free 
HCMV commences with virions binding onto cells, then subsequently penetration occurs 
following fusion between the virion envelope and cellular membranes; either by direct fusion at 
the plasma membrane, or with endosomal membranes after internalisation by receptor-mediated 
endocytosis, depending on cell type (Compton 2004, Vanarsdall and Johnson 2012). The 
binding and membrane fusion mechanisms are orchestrated by virion envelope glycoproteins 
via interactions with receptor and entry mediator molecules on the host cell membranes. HCMV 
can also spread by the direct cell-to cell route. This is believed to involve the same viral 
envelope glycoproteins that facilitate the entry of cell-free virus, though when they are 
presented at the infected cell plasma membrane to interact with closely opposed receptor and 
entry–mediator molecules on an adjacent cell (Kinzler and Compton 2005).  
Following the deposition of virion contents into cells, the outermost tegument materials 
diffuse to specific sites where they perform a wide range of activities (e.g. priming the cellular 
environment for viral replication, and also subverting both intrinsic and innate cellular 
responses to viral pathogens) (Kalejta 2008, Kalejta 2013). The nucleocapsid is then transported 
to the nucleus where herpesvirus genome transcription and replication occur. Viral lytic genes 
are transcribed in a temporal cascade: the first genes transcribed encode transcriptional trans-
activators of other viral genes; next are genes that encode functions for replication of the viral 
genome; and last are genes that encode virion structural components (Stinski 1978, Chambers, 
Angulo et al. 1999). There is also considerable crossover between genes with different 
transcription kinetics that encode functions to modulate the cellular environment and also the 
host immune response. The viral genome circularises following delivery into the nucleus and is 
replicated by the rolling circle mode; a concatamer of genomes is produced, with cleavage into 
single genome-length copies occurring concurrently with insertion into pre-formed capsids 
shells (Mcvoy and Adler 1994).  
Newly formed nucleocapsids then enter the virion maturation pathway, acquiring 
tegument materials at the nucleus, on transit through the cytoplasm, and at the juxtanuclear 
virion assembly compartment (VAC) (Tandon and Mocarski 2012). Herpesvirions undergo 
sequential envelopment processes during maturation (Skepper, Whiteley et al. 2001). On 
nuclear egress, nascent HCMV nucleocapsids undergo primary envelopment at the inner nuclear 
membrane during deposition into the peri-nuclear space, and de-envelopment at the outer 
nuclear membrane during deposition into the cytoplasm (Buser, Walther et al. 2007). 
Nucleocapsids undergo final envelopment at the VAC where they bud into secretory vesicles 
destined for release from the cell by exocytosis (Cepeda, Esteban et al. 2010). Alternatively, 
HCMV disseminates via the direct cell-to-cell route by unkown mechanisms.  
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Figure 1.4. HCMV lytic replication cycle – overview. 1 – virions bind at plasma membrane (black 
line). 2 – virion penetration following fusion at plasma membrane (black line) (2a), or following 
internalisation by vesicle membranes (black circle) following endosomal uptake (2b), and deposition of 
virion contents in cytoplasm (light blue). 3 – diffusion of outermost tegument materials. 4 – migration of 
nucleocapsid and deposition of viral genome into nucleus. 5 – temporal genome transcription. 6 – rolling 
circle genome replication. 7 – initiation of progeny virion morphogenesis. 8 – nuclear egress following 
primary envelopment at inner nuclear membrane (red), deposition into peri-nuclear space (purple), and 
de-envelopment at outer nuclear membrane, and migration of nascent nucleocapsid to juxtanuclear VAC. 
9 – secondary envelopment following budding into secretory vesicles. 10 – egress of progeny virions 
from producer cells by exocytosis into extracellular space (10a), or by direct cell-to-cell spread (10b). 
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1.4 HCMV infection in vivo  
 Following initial acquisition of HCMV (primary infection), an acute phase of 
productive viral replication occurs where the host sheds high titres of virus (Zanghellini, 
Boppana et al. 1999). This acute infection typically lasts weeks to a few months. The mounting 
of an immune response results in markedly restricted viral replication and shedding during the 
ensuing convalescent phase. However, HCMV is never completely eliminated and remains 
throughout the lifetime of the host, requiring constant immune surveillance (Goodrum, Caviness 
et al. 2012). In an immuno-competent host two potential outcomes arise, though are not 
necessarily mutually exclusive: chronic persistent infection, with lytic replication and 
dissemination limited to discrete infection foci, and continued shedding of low titres of virus 
(Britt 2008); or latent infection, with viral genomes maintained within particular cellular subsets 
in a state of quiescence by epigenetic repression of lytic genes (Ioudinkova, Arcangeletti et al. 
2006, Reeves 2011). Acute infection can again be encountered following re-activation of 
chronic persistent or latent infections, whilst carriers also remain susceptible to re-infection with 
new strains.  
 Immune response to HCMV  1.4.1
 Both innate and adaptive immunity are critical for the control of HCMV infection 
(Loewendorf and Benedict 2010) (Figure 1.5.). The importance of Natural Killer (NK) cells is 
demonstrated by NK-cell deficiency being correlated with severe outcomes of infection (Biron, 
Byron et al. 1989). NK cells have several modes of activity for the control of HCMV infection: 
activated NK cells induce IFN-β production from infected cells, which in turn stimulates 
various pathways that limit virus replication in an autocrine fashion (Iversen, Norris et al. 
2005); activated NK cells also release IFN-γ that activates other effector cells of the innate 
immune system (e.g. macrophages), and also up regulates MHC class II molecule expression in 
infected cells, thereby facilitating viral antigen presentation for recognition by cytotoxic T-cells; 
NK cells directly eliminate HCMV infected cells directly via cytolytic mechanisms (Wilkinson 
2013). A defining immunological hallmark of HCMV infection includes CMV specific CD4+ 
and CD8+ T-cell sub-sets representing a significant proportion of the total memory T-cell 
population in an immuno-competent individual (Sylwester, Mitchell et al. 2005, Wills 2013). 
Furthermore, T-cell depletion correlates with the progression of more severe disease (see 
section 1.5.2). These observations suggest a critical role for the cellular branch of adaptive 
immunity for the control of infection. The contribution of the humoral branch of adaptive 
immunity is evident with titres of anti-HCMV antibodies in the sera of infected individuals 
increasing throughout the lifetime of the host (Wang, Li et al. 2011, Aberle and Puchhammer-
Stöckl 2012). The earliest investigations into the composition of virions and the immune 
response elicited during natural infection identified virus-encoded envelope glycoproteins as 
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major targets for neutralising antibodies that limit virus dissemination by alternative activities; 
i) targeting of glycoproteins incorporated into virions to prevent the binding and entry of cell-
free virus into cells, ii) targeting glycoproteins presented at the infected cell surface to prevent 
cell-to-cell spread (Stinski 1976, Pereira, Hoffman et al. 1982, Farrar and Oram 1984, Nowak, 
Sullivan et al. 1984). 
 
 
 
 
Figure 1.5. Immune response to HCMV infection. Figure reproduced from (Hanley and Bollard 2014), 
with permission of MDPI publishers. 
 
 Tropism of HCMV in vivo 1.4.2
 During phases of overt lytic replication, virus is capable of disseminating throughout 
the host and establishing infection in most major visceral organs (Myerson, Hackman et al. 
1984, Bissinger, Sinzger et al. 2002). Histological examination of tissues from immuno-
compromised hosts, in which HCMV replication is not efficiently suppressed and infections are 
broadly disseminated, has highlighted the broad range of cell types that are targeted in vivo 
(Sinzger, Muntefering et al. 1993, Sinzger, Grefte et al. 1995, Sinzger, Plachter et al. 1996, 
Sinzger, Bissinger et al. 1999, Bissinger, Sinzger et al. 2002). However, the major cell types 
infected vary amongst different organs, as can the organs implicated in different HCMV-related 
pathologies (Emery 2001).  
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 Sites of primary infection and shedding  1.4.2.1
 The principal mode of horizontal transmission is believed to occur by direct contact 
with infectious bodily secretions e.g. saliva, breast milk or semen (Britt 2007). Following 
transmission via the oral route or via sexual contact, the first tissues encountered are likely 
mucosal epithelial tissues of the rhinopharynx or the genital tract, respectively (Revello and 
Gerna 2010). When transmission occurs via haematogeneous transfer, e.g. via blood 
transfusions, solid organ transplants, or during intra-uterine transmission, the first tissues 
encountered are likely vascular endothelial tissues (Revello and Gerna 2010). Glandular 
epithelial tissues are recognised as sites where virus is secreted into bodily fluids including 
saliva, urine, breast milk, semen and cervical secretions (Britt 2007).  
  Intra-host dissemination 1.4.2.2
 Intra-host dissemination of HCMV relies on direct cell-to-cell transfer. This includes 
localised radial dissemination within any single or adjacent solid tissues, and also dissemination 
to distal tissues that occurs via the haematogeneous route. Epithelial and endothelial tissues 
other than those at sites of primary infection are also major targets in visceral organs (Sinzger, 
Muntefering et al. 1993, Sinzger, Grefte et al. 1995, Bissinger, Sinzger et al. 2002). Vascular 
endothelial tissues located at the interface between solid tissues and circulating blood are crucial 
in the haematogeneous dissemination of HCMV (Adler and Sinzger 2009, Revello and Gerna 
2010). Virus in the blood tends to be cell-associated, with detached and circulating infected 
cytomegalic vascular endothelial cells (ECs) representing one source of viraemia (Grefte, van 
der Giessen et al. 1993, Percivalle, Revello et al. 1993). The major sites of viraemia are 
polymorphonuclear leukocytes (PMNLs) (Gerna, Zipeto et al. 1992, Gerna, Furione et al. 1994) 
and cells of the monocyte/macrophage (M/M) lineage (Taylor-Wiedeman, Sissons et al. 1991, 
Gerna, Zipeto et al. 1992, Gerna, Furione et al. 1994). Each of these cell types are recruited to 
infected vascular endothelial tissues, and acquire virus following transient membrane micro-
fusion interactions with infected ECs (Grundy, Lawson et al. 1998, Gerna, Percivalle et al. 
2000). Transfer of virus between these cell types is bi-directional (Waldman, Knight et al. 
1995), with PMNLs and M/Ms ferrying virus through the blood to initiate infection at distal 
vascular endothelial tissues. PMNLs are non-permissive to lytic replication or the maintenance 
of viral genomes as a site of latent infection, and HCMV establishes abortive replication in this 
cell type (Gerna, Percivalle et al. 2000). Naïve monocytes are also non-permissive to lytic 
replication, though they do maintain viral genomes as a site of latent infection (see section 
1.4.2.4) (Ibanez, Schrier et al. 1991, Taylor-Wiedeman, Sissons et al. 1991). Thus, PMNLs and 
naïve monocytes ferry pre-formed virions between distal vascular endothelial tissues. 
Productive replication may be initiated from within infected naïve monocytes following 
infiltration into solid tissues and transition to more terminally differentiated monocytes, 
macrophages and dendritic cells (DCs) (Ibanez, Schrier et al. 1991, Sinzger, Plachter et al. 
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1996, Riegler, Hebart et al. 2000, Smith, Bentz et al. 2004, Bentz, Jarquin-Pardo et al. 2006). 
PMNLs are also implicated in the direct delivery of virus to solid tissues, and can acquire virus 
following recruitment and during extravasion through infected EC tissues (Sinzger, Grefte et al. 
1995, Grundy, Lawson et al. 1998). These modes of dissemination, together with their 
proximity to epithelial and endothelial tissues, potentially underlie various stromal tissue cells 
(fibroblast, smooth muscle cells) and parenchyma tissue cells (hepatocytes, neurons, glial cells) 
as targets of natural infection (Sinzger, Grefte et al. 1995, Sinzger, Bissinger et al. 1999).  
 Sites of chronic persistent infections 1.4.2.3
 Epithelial and endothelial tissues are proposed sites of persistence (Fish, Soderberg-
Naucler et al. 1998, Jarvis and Nelson 2002), as suggested by the prolonged shedding of virus 
from these tissues during chronic infection (Britt 2008). Terminally differentiated monocytes, 
macrophages and DCs are also proposed as sites of persistent infection (Taylor-Wiedeman, 
Sissons et al. 1991, Taylor-Wiedeman, Sissons et al. 1994, Jarvis and Nelson 2002, Goodrum, 
Caviness et al. 2012, Gredmark-Russ and Soderberg-Naucler 2012).  
 Reservoirs of latency 1.4.2.4
 Contentiously, bone marrow derived endothelial cells have been proposed as sites of 
latency (Reeves, Coleman et al. 2004, Jarvis and Nelson 2007). However, more widely accepted 
sites of latency are bone-marrow derived CD34+ precursors of monocytes, macrophages and 
DCs, and also CD14+ monocytes (Taylor-Wiedeman, Sissons et al. 1991, Minton, Tysoe et al. 
1994, Mendelson, Monard et al. 1996, Hahn, Jores et al. 1998, Khaiboullina, Maciejewski et al. 
2004, Sinclair and Sissons 2006, O'Connor and Murphy 2012). The reactivation of lytic 
replication in these cells occurs following differentiation into macrophages and DCs (Taylor-
Wiedeman, Sissons et al. 1994, Reeves and Sinclair 2013).  
1.5 Clinical manifestations of HCMV infection 
 Infection in an otherwise healthy host is most commonly asymptomatic, yet in rare 
cases, mild febrile illness, infectious mononucleosis, prolonged fever, and mild hepatitis can be 
encountered (Sissons and Carmichael 2002, Gandhi and Khanna 2004). More recently, HCMV 
has been associated with a range of chronic inflammatory and other progressive degenerative 
disorders in the immuno-competent host (Rafailidis, Mourtzoukou et al. 2008). Examples 
include malignancies of the CNS (Soderberg‐Naucler 2006, Soroceanu and Cobbs 2011), 
accelerated immune senescence (Pawelec and Derhovanessian 2011), and exasperation of 
pathologies during critical illness (Cook and Trgovcich 2011). However, HCMV pathogenesis 
has classically been appreciated in the immune-naïve and immuno-compromised host. In these 
settings, the lytic viral replication that occurs unabated can result in significant tissue 
destruction, and ultimately end-organ failure and fatality.  
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 Congenital and perinatal infection 1.5.1
 HCMV is the leading viral cause of congenital malformation, affecting ~0.5-1% of live 
births in the developed countries, with the prevalence of congenital CMV greater still in 
developing countries (Sissons and Carmichael 2002, Kenneson and Cannon 2007). Vertical 
transmission of HCMV in utero to the immuno-naïve host frequently results in disseminated 
infection affecting multiple organ systems. HCMV’s ‘predilection’ for the central nervous 
system (CNS) can result in severe neurological sequelae, with microcephaly, mental retardation, 
sensory neural hearing loss (SNHL) or visual impairment, amongst the most frequently 
encountered outcomes of congenital infection. Clinical presentations of Cytomegalic Inclusion 
Disease (CID) may also include petechiae, hepatosplenomegaly, jaundice, as well as growth 
retardation (Sissons and Carmichael 2002, Malm and Engman 2007). Symptomatic congenital 
infection (as defined by the presentation of clinical abnormalities in neonates) accounts for ~10-
15% of cases, whilst ~85-90% of congenital infections are asymptomatic (Dollard, Grosse et al. 
2007). The prognosis is generally poorer in symptomatic infection, and the risk of developing a 
permanent disability correlates with increased viral load (Boppana, Fowler et al. 2005). 
Symptomatic infection is also more frequent when HCMV is transmitted to the developing 
foetus from a mother experiencing a primary infection, as opposed to a pregnant mother 
experiencing re-activation of an existing infection or re-infection with new strains. (Reynolds, 
Stagno et al. 1978, Fowler, Stagno et al. 1992). Therefore, whilst maternal antibodies do not 
prevent the acquisition of CMV by the developing foetus, they do offer some protection. 
Approximately 17-20% of all congenitally infected neonates will develop permanent 
neurological sequelae, whilst mortality is predicted in ~0.5% of all congenital HCMV infections 
(Dollard, Grosse et al. 2007). Perinatal and post-natal infection can also occur following 
transmission to new-borns via the ingestion of cervical secretions during birth, or breast milk 
during lactation (Reynolds, Stagno et al. 1973, Stagno, Reynolds et al. 1980, Dworsky, Yow et 
al. 1983). Long-term outcome studies indicate that post-natal HCMV infection may have a 
negative impact on cognitive outcome, particularly when acquired by pre-term infants (Bevot, 
Hamprecht et al. 2012, Goelz, Meisner et al. 2013). 
 Infection in the immuno-compromised 1.5.2
  HCMV is an important opportunistic pathogen in immuno-compromised individuals, 
including allograft recipients undergoing immunosuppressive therapy, as well as those who are 
immuno-deficient due to infection e.g. HIV-AIDS (Emery 2001). The major commonality 
amongst these patients is compromised adaptive cellular immunity, and therefore a reduced 
ability to respond to primary infection. Acute productive infection can also arise in the immuno-
compromised host due to re-activation of existing persistent/latent infections, or re-infection 
with different strains. A common clinical presentation in these groups is the development of a 
HCMV syndrome that presents as a mononucleosis–like synd
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in the immuno-competent host, but generally more severe (Emery 2001, Fishman 2007). 
Various tissue invasive inflammatory diseases can manifest in allograft recipients, most 
frequently during phases of acute infection. These outcomes of infection predominantly, though 
not exclusively, affect the particular transplanted tissues. Common clinical presentations 
include, pneumonitis, gastroenteritis, hepatitis, retinitis (Emery 2001, Boeckh, Nichols et al. 
2003, Boeckh 2011), as well as myelo-suppression and pancytopenia bone marrow hyperplasia 
particularly in bone marrow (BM) transplant recipients (Emery 2001, Castagnola, Cappelli et al. 
2004). Chronic persistent infection can result in prolonged stimulation of a pro-inflammatory 
environment that can contribute to accelerated allograft destruction and rejection (Streblow, 
Orloff et al. 2007, Arthurs, Eid et al. 2008). HCMV co-infection is also frequent in HIV-
infected patients, with high level HCMV viraemia a marker of poor prognosis and correlated 
with accelerated progression to AIDS defining pathologies (Deayton, Prof Sabin et al. 2004, 
Griffiths 2006). The most frequently encountered HCMV-related clinical manifestation in AIDS 
patients is retinitis, whilst gastroenteritis, encephalopathy and poly-radiculopathy are also 
common (Emery 2001, Fishman 2007).  
1.6 Current anti-HCMV Therapies: successes and short-comings 
 Anti-viral chemotherapeutics 1.6.1
 Anti-viral chemotherapeutic drugs currently available for the management of HCMV 
infection target viral DNA replication. However, these therapies are only modestly effective and 
also convey dose-limiting toxicity to the host (Lurain and Chou 2010, Prichard and Kern 2011). 
Moreover, prolonged antiviral therapy is associated with the selection of resistant strains 
(Emery and Griffiths 2000, Lurain and Chou 2010, Prichard and Kern 2011). The most 
commonly used antiviral drug is ganciclovir (GCV), a synthetic analogue of 2’-deoxy-
gunanosine (Matthews and Boehme 1988, Sullivan, Talarico et al. 1992). GCV is administered 
in an inactive form that is sequentially phosphorylated, firstly by viral encoded protein kinase 
enzyme (VPK), and subsequently by cellular kinase enzymes, ultimately forming GCV-
triphosphate that is a competitive inhibitor of deoxy-guanosine triphosphate (dGTP) (Matthews 
and Boehme 1988, Sullivan, Talarico et al. 1992). GCV-triphosphate is incorporated into DNA 
chains during viral genome replication, preferentially inhibiting viral DNA polymerase and 
arresting chain elongation. Resistance to GCV arises following the acquisition of mutations in 
either the viral protein kinase (VPK) or viral DNA polymerase-encoding genes (Smith, 
Cherrington et al. 1997, Chou 2008). 
 Immunoprophylaxis 1.6.2
 A vaccine with high efficacy for the prevention and control of HCMV infection has 
long been sought, though trials to date have been met with limited success (Krause, Bialek et al. 
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2013). In one early trial the vaccination potential of live attenuated virus derived from the 
classical laboratory strain Towne (Plotkin, Furukawa et al. 1975) was investigated in renal 
transplant recipients (Plotkin, Smiley et al. 1984). Vaccination did not prevent the acquisition of 
virus or development of acute infection, as seronegative vaccinees remained susceptible to 
infection when receiving transplants from seropositive donors, and seropositive vaccinees 
remained prone to reactivation of existing persistent/latent infection, or re-infection with new 
strains. However, some degree of protection was afforded in vaccinees, and pathologies 
encountered in these people were often less severe compared to those that received placebo. To 
further investigate the protective immunity bestowed by vaccination with this live attenuated 
virus, vaccinees were exposed to pathogenic challenge virus Toledo, and the occurrence and 
severity of clinical outcomes was compared to those in seronegative and naturally seropositive 
people exposed to the challenge virus (Quinnan, Delery et al. 1984, Plotkin, Starr et al. 1989). 
Whilst acute infection was less readily induced in vaccinees compared to seronegative persons, 
it was more readily induced than in naturally seropositive persons. Furthermore, severe 
symptomatic infection occurred in vaccinees. Thus, vaccination with this live attenuated virus 
could not recapitulate the degree of immunity as seen in natural infection. More recent strategies 
have focused on recombinant sub-unit vaccines for the delivery of specific HCMV antigens. 
These have frequently been based on virion envelope glycoproteins that are major targets for 
neutralizing antibodies in natural infection. However, like the previous live-attenuated virus 
vaccines, these approaches have been only moderately effective for the prevention of later virus 
acquisition (Pass, Duliege et al. 1999, Pass, Zhang et al. 2009). There was some success in 
controlling infection in allograft recipients where cellular mediated immunity is compromised, 
and also for the boosting of existing antibody and T-cell responses in people with chronic 
persistent infection (Griffiths, Stanton et al. 2011, Sabbaj, Pass et al. 2011). Encouragement for 
the development of better antibody-mediated immunoprohylaxis strategies comes from the 
observable benefits of administering hyper-immune globulin (HIG) preparations to those in 
high-risk groups (e.g. pregnant women with primary infection, transplant recipients); this 
preparation is derived from the sera of naturally infected individuals and the anti-HCMV 
antibodies therein bestow passive immunity to recipients (Snydman, Werner et al. 1993, Nigro, 
Adler et al. 2005, Alexander, Hladnik et al. 2010). However, the degree of protection afforded 
by administration of HIG in certain groups has been questioned, particularly in HSCT transplant 
recipients (Cordonnier, Chevret et al. 2003, Raanani, Gafter-Gvili et al. 2009).  
 The sera of naturally infected individuals and the derived HIG preparations has been 
shown to display potent neutralising activity in cell types implicated in primary infection and 
dissemination (e.g. epithelial and endothelial cells), yet this was not re-capitulated in the sera of 
individuals who received previous vaccines (Figure 1.6.) (Cui, Meza et al. 2008, Gerna, Sarasini 
et al. 2008). Since the trials of the above-described vaccines, it has become clear that HCMV 
employs different envelope glycoproteins to gain entry into different cell types, and it was later 
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demonstrated that the early vaccines did not include important envelope glycoproteins that virus 
requires for entry into epithelial and endothelial cells. Antibodies against a recently identified 
virion envelope glycoprotein complex (gH/gL/gpUL128/gpUL130/gpUL131A; see section 
1.4.2) are those with greatest potency for the inhibition of epithelial and endothelial cell 
infection, and these have been detected at high titres in the sera of naturally infected individuals 
(Cui, Meza et al. 2008, Genini, Percivalle et al. 2011, Cui, Lee et al. 2013). Thus, it is 
envisioned that there is scope for the development of novel vaccines/immunotherapies with 
superior efficacy where the pentameric complex is included (Schleiss 2010, Lilja and Mason 
2012). 
 
 
 
 
Figure 1.6. Relative titres of anti-bodies that neutralise Epithelial Cell/Fibroblast infection of in 
sera of individuals with natural infection, HIG preparations, and sera of individuals vaccinated 
with live-attenuated virus, or recombinant sub-unit vaccines. Ratios of Epithelial Cell/Fibroblast 
Neutralising titres in human sera following natural exposure to wildtype virus (sero-positive), in CMV-
HIG preparation, in sera of subjects vaccinated with live attenuated virus (derived from strain Towne), or 
subjects vaccinated with glycoprotein sub-unit vaccine (gB/MF59). Lines (green) represent logarithmic 
means; brackets (blue) represent one standard deviation above/below means. Figure reproduced from 
(Cui, Meza et al. 2008), with permission of Elsevier publishers. 
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1.7 Historic limitations in HCMV research 
 In efforts to develop better therapeutics, the complete biology of HCMV encompassing 
interactions with all naturally targeted cell-types warrants investigation. However, HCMV 
research has to date been hindered by the limited availability of virus strains in vitro that 
accurately reflect the biology of wildtype virus in vivo. Over the last 3 decades it has become 
clear that HCMV undergoes rapid adaptation to cell culture, resulting in the generation of 
laboratory-adapted strains that are genetically and phenotypically distinct from wildtype strains.  
 Adaptation of HCMV to cell culture  1.7.1
 The isolation and propagation of wildtype virus from clinical samples has historically 
been performed on cultured fibroblast cells. This is due to the relative ease by which this cell 
type can be infected with clinical isolates as compared to other cultured cell types (Weller 1970, 
Weller 1971, Weller 1971), and possibly relates to clinical samples containing neutralising anti-
bodies that prevent infection of non-fibroblasts (e.g. epithelial cells, endothelial cells). Initially, 
the development of cytopathic effects (CPE) by new or recent clinical isolates following 
inoculation of fibroblasts is timely. Furthermore, infectivity remains mostly cell-associated with 
low-titres of cell-free virus released into the infected cell culture supernatant, and dissemination 
is predominantly driven by the cell-to-cell route to form discrete infectious foci plaques (Weller 
1971, Weller 1971, Sinzger, Knapp et al. 1997). As a result, inoculated fibroblasts require 
extensive sub-culturing to encourage the dissemination of clinical HCMV isolates. In contrast to 
this, virus that has already undergone extensive in vitro passage disseminates faster, and 
produces greater titres of cell-free virus (Weller 1971, Weller 1971, Sinzger, Knapp et al. 1997). 
Hence, efficient propagation of HCMV in vitro has historically been achieved following 
adaptation to fibroblast cell culture.  
 Definition of wildtype and ‘laboratory–adapted’ strains, and strain variants 1.7.2
 HCMV strains used in vitro can be defined by their cell culture passage history and 
adaptation status (Cha, Tom et al. 1996). Viruses/strains that have been passaged extensively 
and adapted to fibroblasts are often described as ‘laboratory’ or ‘high-passage’ strains. The 
more ambiguous term ‘clinical strain’ is often used to describe virus undergone limited 
fibroblast passage, or indeed no passage at all. For clarity, virus undergone no passage at all 
shall hereon be referred to as ‘wild-type’, and virus undergone relatively few passages in shall 
be referred to as ‘low-passage’. The generation of genetically and phenotypically distinct 
variants of a given strain is also correlated with passage history, and these variants can arise 
from both ‘wildtype’ and ‘laboratory’ strains; however variants differ from the parental virus by 
a lesser degree than distinct wildtype and laboratory strains. 
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 Genetic heterogeneity between ‘laboratory-adapted’ strains  1.7.3
 Separate virus stocks used in laboratories worldwide often contain phenotypically 
distinct variants derived from a common ‘laboratory-strain’ progenitor (Brown, Kaneshima et 
al. 1995, MacCormac and Grundy 1999, Hahn, Rose et al. 2003). Retrospective analysis of 
variants from the most frequently used ‘laboratory-strain’ AD169 (Rowe, Hartley et al. 1956) 
has correlated their divergence with continued propagation following distribution to different 
laboratories; this work concerned whole-genome sequencing analysis of viruses derived from 
the same lineage, though differing in passage history (Bradley, Lurain et al. 2009). Following 
initial isolation, strain AD169 was passaged up to 14 times in fibroblast in order to produce the 
virus stock NIH76559 (Rowe, Hartley et al. 1956). The two AD169 variants most commonly 
used in HCMV research were derived from the NIH76559 lineage. Following distribution to 
laboratories at St George’s Hospital Medical School in London, NIH76559 was initially 
subjected to ~40 passages in fibroblasts, then another 16-24 additional passages in attempts to 
generate an attenuated vaccine strain (Elek and Stern 1974). Virus from these latter passages 
was plaque purified, and genome restriction fragments were cloned into plasmids that were 
subsequently used to determine the genome of AD169 variant AD169varUK (Oram, Downing 
et al. 1982, Chee, Bankier et al. 1990). The passage history of NIH76559 following distribution 
to laboratories in America is not as well documented, but gave rise to the variant 
AD169varATCC. Whilst all in vitro mutations identified NIH76559 stocks were also identified 
in AD169varUK and AD169varATCC, each variant also contained further mutations. In 
particular, AD169varATCCC contained the greatest number of unique mutations, potentially 
reflecting that this virus had been subject to more extensive in vitro passage history. A less 
commonly used AD169 variant (AD169varUC) was also assessed; this variant was predicted to 
have arisen from a progenitor that was subjected to a minimum of 50 passages in fibroblasts 
following distribution to laboratories in the University of Chicago. However, unlike the most 
commonly used variants, AD169varUC did not contain all of the mutations identified in 
NIH76559. Thus, AD169varUC contained mutations that were selected during the earliest of 
the first 14 passages of the AD169 clinical isolate, but was derived from a progenitor earlier 
than NIH76559. Similar variation in coding potential of variants from ‘laboratory-strain’ Towne 
(Plotkin, Furukawa et al. 1975) (TownevarL and TownevarS) were also noted during this work, 
however each of these variants are contained in a mixed population virus, and no correlation 
between divergence and in vitro passage history was made. 
 The lack of genetic equivalence amongst the commonly used ‘laboratory-strains’ 
compounded the difficulties in early HCMV research, with many of the earliest reported 
phenotypes of HCMV not demonstrated in the context of the full wildtype HCMV gene 
complement. Thus, since the growing appreciation that the classically used ‘laboratory-strains’ 
are genetically heterogeneous, better descriptions of wildtype HCMV coding potential have 
since continuously been sought. 
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1.8 HCMV genetics 
 The first complete HCMV genome sequence to be determined was that of the prototype 
laboratory strain AD169 variant AD169varUK (Chee, Bankier et al. 1990). However 
subsequent studies soon revealed this ‘high-passage’ strain to be a multiple mutant with lesions 
at several genome loci (Cha, Tom et al. 1996, Skaletskaya, Bartle et al. 2001). Sequencing of 
several ‘low-passage’ strains contributed to the incremental identification of further HCMV 
genes that are absent in AD169 (Murphy, Yu et al. 2003, Dolan, Cunningham et al. 2004, 
Cunningham, Gatherer et al. 2010). However, by far the most comprehensive picture of the 
HCMV gene complement was gained by sequencing the un-passaged wildtype strain Merlin 
directly from the clinical sample from which it was isolated (urine of a congenitally infected 
infant) (A. Davison – Personal Communication). In light of this, strain Merlin been designated 
the reference HCMV genome sequence by the National Centre for Biotechnology Information 
(GenBank AY446894; RefSeq NC_006273) (Dolan, Cunningham et al. 2004).  
 Genome organisation  1.8.1
 The HCMV genome is organised in class E herpesvirus genome configuration (Figure 
1.7.); ORFs are dispersed over distinct ‘long’ and ‘short’ genome segments, each containing 
central regions of unique sequence flanked by shorter sequences that are repeated in inverted 
orientation at each end (Kilpatrick and Huang 1977, Roizman 1980, Weststrate, Geelen et al. 
1980, Spector, Hock et al. 1982, Pellet 2013). Annotations for genome regions include a prefix 
to indicate their location in unique or repeated sequence genome regions, as well as a suffix to 
indicate their location in either the long or short genome segments: UL and US in the long and 
short genome segments respectively, with repeated sequence regions denoted TRL/TRS at the 
termini and IRL/IRS at the UL/US junction. Under this scheme, the physical HCMV genome map 
is represented as TRL-UL-IRL-IRS-US-TRS.  At the termini of each genome segment as direct 
repeats, and also in the IRL-IRS junction as an inverted repeat, are short sequences (~300-600 
bp) termed the a sequence (Spaete and Mocarski 1985). The genome configuration can 
therefore be alternatively denoted as ab-UL-b’a’c’-US-ca, with b and c sequences specific to 
either the ‘long’ and ‘short’ genome segment terminal repeats, respectively (‘ indicates inverted 
orientation). The a sequences contain signals for genome packaging and cleavage (Kemble and 
Mocarski 1989). Since these sequences are repeated in inverse orientation at the junction 
between the UL and US genome segments, they can facilitate genome segment inversion by 
homologous recombination during replication. This can give rise to four natural isomeric 
genome arrangements that contain UL and US segments in alternative orientations with respect 
to one another (Weststrate, Geelen et al. 1980) (Figure 1.7.B). 
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Figure 1.7. HCMV genome organisation and natural isomeric variants. (A) Layout and alternative 
nomenclature for genome regions. In wide boxes are repeat sequences that flank the long (TRL and IRL) 
and short (TRS and IRS) genome segments: a sequences (black); b sequences (red) that; c sequences 
(purple). Unique, single-copy sequences in the long segment (dark blue) and short segment (light blue) 
are depicted by arrows showing the progressive order of ORFs contained therein. (B) Alterative isomeric 
genome configurations, with UL and US genome segments arranged in various orientations to one another.  
 
 
 
 
 HCMV coding potential 1.8.2
 Preliminary HCMV genome annotations based on the nucleotide sequence data from 
strain AD169varUK included 189 putative protein-coding genes (Chee, Bankier et al. 1990). 
The criteria applied for the identification of protein coding genes focused on sizeable ORFs (≥ 
100 contiguous amino acid coding nucleotides) with no significant overlap (< 60%), with gene 
defining features (e.g. transcriptional elements) used to identify smaller ORFs. This preliminary 
annotation has since been subjected to multiple revisions, aided by nucleotide sequence data 
from the wildtype strain Merlin, as well as interpretation by several alternative and 
complimentary approaches. These include: comparative genomics analysis between distinct 
HCMV strains and CMVs of other animals to identify conserved ORFs, and also for the re-
interpretation of previously described ORFs (Cha, Tom et al. 1996, Davison, Dolan et al. 2003); 
in silico pattern-based approaches to validate putative protein coding genes by identification of 
structural motifs and functional domains with homology to those of known proteins (Novotny, 
Rigoutsos et al. 2001, Murphy, Rigoutsos et al. 2003, Rigoutsos, Novotny et al. 2003); and 
transcriptional analysis to investigate RNA encoding genome regions and deduce intricate gene 
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splicing patterns (Akter, Cunningham et al. 2003, Mitchell, Savaryn et al. 2009, Gatherer, 
Seirafian et al. 2011). According to current estimates, the HCMV genome contains ~170 
canonical protein-coding genes (See Figure 1.8.). More recently, analysis of HCMV strain 
Merlin by a ribosome profiling approach has predicted as many as 751 translated ORFs (Stern-
Ginossar, Weisburd et al. 2012). This complexity is due to the use of alternative transcription 
start sites for numerous overlapping ORFs. However the functional significance of many of 
these proteins remains to be demonstrated.  
   The alphanumeric nomenclature for the naming of HCMV genes includes a prefix to 
indicate their location in the genome (UL or US in unique regions; TRL or IRL in repeat 
regions flanking the long genome segment; TRS or IRS in repeat regions flanking the short 
genome segment), as well as a numeric suffix to indicate their positional order. To maintain this 
nomenclature, revised and newly discovered genes are often afforded an additional suffix to 
distinguish them from existing genes, or to reflect the existence of alternative splice variants of 
any given gene. It should be noted that the prefixes TRL or IRL are not used in the annotation 
of all HCMV genomes, with ORFs located in the TRL genome region often simply denoted 
with the prefix RL. This alternative nomenclature arose since strain AD169varUK that was the 
basis for the preliminary HCMV genome annotation has undergone duplication of sequences in 
the TRL genome region which were inserted into the UL/b’ genome region (Cha, Tom et al. 
1996). As a result, the ‘laboratory-strain’ AD169varUK is therefore diploid for ORFs that are 
haploid in wildtype strains, which normally contain no recognised ORFs in the IRL region.  
 Protein-coding gene products 1.8.2.1
 A striking feature of the HCMV genome is the large number of genes predicted to 
encode integral membrane proteins, as well as proteins that are post-translationally modified by 
glycosylation or phosphorylation (Novotny, Rigoutsos et al. 2001, Rigoutsos, Novotny et al. 
2003). To reflect the post-translational modification of particular gene products, annotation of 
encoded proteins often includes a prefix to indicate their existence in un-modified form (p-), or 
alternatively glycosylated (gp-) and phosphorylated states (pp-). Alternative naming schemes 
for HCMV gene products reflect the biochemical properties and function of proteins. HCMV 
genes are also frequently described by their transcriptional kinetics class, classically defined as 
immediate early (IE/α), delayed early (DE/β) and late (L/γ) genes (Chambers, Angulo et al. 
1999). However, similar to recent re-interpretations of the HCMV coding potential, these 
transcriptional kinetic classes have also been subject to recent re-assessment (Weekes, Tomasec 
et al. 2014).  
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Figure 1.8. Wildtype HCMV strain Merlin genome. Genome organised in TRL-UL-IRL-IRS-US-TRS 
orientation. Repeat regions are depicted in broad lines, unique regions in thinner lines. Canonical ORF 
blocks from, left to right, include: RL1-RL13 and UL1-UL150A in the UL genome segment; IRS1, US1-
US34A, and TRS1 in the US genome segment. Herpesvirus conserved (core) genes are in red. Gene 
families are colour coded. Figure kindly supplied by Dr Andrew Davison (MRC-University of Glasgow 
Centre for Virus Research, Glasgow, UK).  
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 Non-coding RNAs 1.8.2.2
 The HCMV genome contains vast expanses of sequence that contain no protein-coding 
genes, and instead specify non-coding poly-adenylated RNAs. These include a 2.7 Kb RNA 
(β2.7) described to have anti-apoptotic activity (McSharry, Tomasec et al. 2003, Reeves, Davies 
et al. 2007), and a 1.1 Kb spliced RNA and its associated 5 Kb stable intron (RNA 5.0, which 
by homology to a similar transcript encoded by MCMV, is predicted to be a virulence factor 
(Kulesza and Shenk 2004). HCMV also specifies 1.2 Kb (RNA 1.2) and 4.9 Kb RNAs (RNA 
4.9), though neither has a function assigned (Hutchinson and Tocci 1986, Gatherer, Seirafian et 
al. 2011). Further non-coding RNAs include those that are transcribed in anti-sense orientation 
to the ORFs they over-lap (Zhang, Raghavan et al. 2007), as well as various micro RNAs 
(miRNAs) derived from longer transcripts and implicated in the regulation of genome 
expression and replication (Pfeffer, Sewer et al. 2005). It should be noted that several of the 
non-canonical ORFs described by ribosome-profiling over-lap these regions (Stern-Ginossar, 
Weisburd et al. 2012).  
 Unique and conserved functions encoded by HCMV 1.8.2.3
 The substantial divergence of HCMV during co-speciation with the human host is 
reflected the fact that as few as 40 of the ~170 canonical protein-coding genes (~24%) are 
conserved across all herpesviruses, whilst only 75 canonical protein-coding genes (~45%) are 
conserved amongst the beta-herpesviruses (Davison and Bhella 2007, Davison 2007). Genes 
encoding conserved herpesvirus core functions are dispersed amongst 7 genome blocks 
(Gompels, Nicholas et al. 1995) located centrally within the UL genome segment (UL44-
UL115) (Figure 1.8.), and likely represent the minimal genetic content derived from the 
ancestor of all herpesviruses (Dolan, Cunningham et al. 2004). Genes located progressively 
closer to the termini of each genome segment are those more recently acquired. In general, 
genes flanking the blocks of herpesvirus core gene are specific to the betaherpesvirinae (UL124-
UL115, and several ORFs in the US genome region) (Gompels, Nicholas et al. 1995), whilst 
genes located in the outermost terminal regions are more unique to CMVs, or indeed HCMV 
alone.  
 Tropism and immuno-modulatory/immune evasion functions  1.8.2.4
 Genes specific to HCMV include those that encode tropism factors and immuno-
modulatory/immune evasion functions, and these are important determinants of HCMV 
virulence (Davison 2002, Davison 2013). Intriguingly, several of the proteins encoded by these 
genes share significant amino acid sequence and structural homology with host cell gene 
products (Holzerlandt, Orengo et al. 2002). In particular, immuno-modulatory/immune evasion 
strategies employed by HCMV are commonly centred on molecular mimicry to subvert cellular 
signalling pathways, and include homologues of cellular cytokines and chemokines, as well as 
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their receptors (McSharry, Avdic et al. 2012). These observations indicate that HCMV has 
acquired genetic material from the human host, with evolution of immuno-modulatory/immune 
evasion mechanisms occurring in parallel with the evolution of the host immune response 
(Michelson 2004). HCMV also appears to encode proteins with significant homology to those 
encoded by other viruses, potentially reflecting the acquisition of genetic material from other 
infections co-existing in the human host (Davison, Akter et al. 2003). Several distinct HCMV 
genes of this class encode proteins with conserved amino acid sequence and structural motifs, 
and are assumed to have arisen by divergence following duplication of a single progenitor gene. 
Such genes are assigned to the 15 currently described gene families (Figure 1.8.), most 
frequently existing in clusters at the genome segment termini (Chee, Bankier et al. 1990, 
Davison 2013). 
 Natural intra-strain genetic variation  1.8.3
 The genomes of wildtype HCMV strains are co-linear with ORFs in each genome 
segment presented in the same relative order (Murphy, Yu et al. 2003, Dolan, Cunningham et al. 
2004, Cunningham, Gatherer et al. 2010). Inter-strain variability is most apparent with genetic 
polymorphisms at several discrete genome loci, particularly involving genes that encode 
membrane associated or secreted proteins, such as virion envelope glycoproteins and immune 
evasion functions (Murphy, Yu et al. 2003, Cunningham, Gatherer et al. 2010). These genes 
often exist as divergent alleles that are believed to have arisen due to immune selection 
processes. Investigations into the significance of these polymorphisms have focussed on inter-
strain differences in tropism and virulence in vivo, though to date, no conclusive correlation has 
been demonstrated; these investigations are reviewed in (Pignatelli, Monte et al. 2004, 
Puchhammer-Stöckl and Görzer 2011). These genetic signatures are frequently used in the 
differentiation and monitoring of multiple-strain infections, however this is made difficult given 
that the recombination that can occur during viral genome replication can result in generation of 
chimeric strains with diverse genotype pairings (Rasmussen, Geissler et al. 2003). However, 
analysis of multiple clinical isolates derived from several geographic locations has 
demonstrated appreciable genotype linkage for virion envelope glycoproteins encoded by 
adjacent ORFs UL73 (gN) and UL74 (gO) in eight groups (Mattick, Dewin et al. 2004, Bates, 
Monze et al. 2008, Yan, Koyan et al. 2008, Gorzer, Guelly et al. 2010). Each of these 
glycoproteins are incorporated into distinct multimeric complexes implicated in the entry of 
cell-free virus, the cell-to-cell dissemination of virus, and also the formation and/or release of 
nascent progeny virions (see sections 1.13.2, 1.14.1, and 1.14.3). However, any direct 
interaction between glycoproteins gN and gO in the virus replication cycle has yet to be 
demonstrated, and the linkage between these genotypes may simply reflect the fact that adjacent 
ORFs are less likely to be separated by recombination. In contrast to this, the adjacent ORFs 
UL146 and UL147 that each encodes viral homologues of α CXC chemokines are also 
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polymorphic (see section 1.11.3.1), but do not display any observable genotype linkage in 
distinct strains (Arav-Boger, Zong et al. 2005, Bradley, Kovacs et al. 2008). 
 Analysis of viruses over time had previously led to the conclusion that HCMV 
genotypes are relatively stable in vivo and also in cell culture, indicating that the selective 
pressures that resulted in their divergence were no longer as stringent (Mattick, Dewin et al. 
2004, Stanton, Westmoreland et al. 2005, Lurain, Fox et al. 2006, Bradley, Kovacs et al. 2008, 
Gorzer, Guelly et al. 2010). However, with the development of more sensitive high-throughput 
whole-genome sequencing technologies to assess the genetic content of clinical HCMV isolates, 
a new picture regarding the stability of these polymorphic alleles is unfolding. It has recently 
been reported that polymorphic and also well-conserved HCMV ORFs do in fact diverge and 
give rise to novel variants within a given host (Renzette, Bhattacharjee et al. 2011). As a result, 
clinical samples from an infected individual often contain variants derived from a single strain. 
Despite this, the consensus genetic content of wildtype strains is relatively consistent. A 
potential explanation for this includes distinct quasi-species arising within a host following 
acquisition and dissemination to different tissues, with a bottleneck process occurring following 
transmission to a new host (Renzette, Gibson et al. 2013). With regards to hosts experiencing 
multi-strain infections, deep sequencing analysis over an extended time-course has 
demonstrated complex dynamics of strain/genotype dominance (Gorzer, Guelly et al. 2010, 
Ross, Novak et al. 2011). 
1.9 BAC-mid cloning of HCMV genomes 
 The capture of HCMV genomes as bacterial artificial chromosome (BAC) clones 
represented a major turning point in HCMV research. These clones provided for the first time a 
genetically stable source of clonal, single-strain genomes, from which virus of known coding 
potential can be reconstituted. BAC-cloning was first demonstrated to be an effective strategy 
for the stable capture and maintenance of large DNA fragments (Shizuya, Birren et al. 1992), 
and subsequently adapted for the capture of entire CMV genomes; firstly that of MCMV strain 
Smith (Messerle, Crnkovic et al. 1997), and later HCMV strain AD169 (Borst, Hahn et al. 
1999). Since this, the genomes of several ‘low-passage’ strains have also been captured as BAC 
constructs. 
 BAC-targeting vectors are based on the sizeable single copy fertility plasmid (F-
plasmid) from E.coli, and contain several features to ensure BAC constructs are replicated and 
retained in bacterial cells with exquisite stability (Borst, Hahn et al. 1999, Stanton, Baluchova et 
al. 2010). To capture HCMV genomes in BAC constructs, linearised BAC targeting vectors are 
first engineered to contain flanking arms with homology to sequences at the site of BAC 
insertion in the viral genome. These BAC-targeting vectors are then delivered into HCMV 
infected cells where they are integrated into the HCMV genome by homologous recombination. 
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Insertion of the BAC targeting vector increases the total genome size, and given the constraints 
for genome packaging, this can in turn reduce the efficiency of virus replication (Yu, Smith et 
al. 2002, Cui, McGregor et al. 2009). To limit the likelihood of virus acquiring large 
compensating deletions following reconstitution from the BAC, genome regions encoding 
functions known to be dispensable for growth in cell culture are often replaced by stably 
incorporated BAC vectors; this commonly includes the sacrifice of ORFs in the US genome 
region that have been shown to be dispensable (Jones and Muzithras 1992). In an alternative 
approach, self-excising BAC sequences can be inserted. BAC vectors can be engineered to 
encode mediators of excision (Cre-recombinase), and the signals they recognise (lox P) flanking 
the BAC vector sequence (Messerle, Crnkovic et al. 1997). The insertion of an intron to disrupt 
the Cre gene ensures Cre recombinase is not produced in the bacterial cells where BACs are 
maintained, and the BAC vector sequence is only excised following reconstitution of virus in 
eukaryotic cells (Yu, Smith et al. 2002). This approach is advantageous as no compromise in 
coding potential is required to accommodate stably incorporated BAC vector sequences. 
1.10 HCMV genes that are essential, dispensable, and/or inhibitory, for virus growth in 
cell culture 
 The contribution of single genes in the context of productive infection has been 
investigated by global mutational analysis of BAC-cloned HCMV genomes and phenotype 
analysis of the viruses they produce. Applying a reverse genetics approach to BAC-cloned 
versions of the ‘laboratory-strains’ AD169 or Towne, the viability of single gene knockout 
mutants has been used to distinguish genes that are essential or non-essential for virus 
propagation in vitro (Dunn, Chou et al. 2003, Yu, Silva et al. 2003). Whilst mutants lacking 
non-essential genes remained viable, they often displayed a distinct growth phenotype 
compared to parental virus. Mutants often grew less efficiently than parental virus, 
demonstrating that whilst the corresponding deleted gene was not essential, it 
enhanced/augmented virus replication. Conversely, particular mutants grew more efficiently 
than parental virus, demonstrating that the corresponding deleted genes are inhibitory to the 
growth of virus in cell culture; genes encoding functions inhibitory to virus growth in cell 
culture are commonly termed 'temperance factors’ (Dunn, Chou et al. 2003, Yu, Silva et al. 
2003, Stanton, Baluchova et al. 2010). However, since each of the laboratory-adapted HCMV 
strains used in these investigations lack the full complement of wildtype genes, these analyses 
cannot be considered comprehensive. It should be appreciated that the true impact of any given 
gene may only be demonstrable in the presence of functional partners, competitive inhibitors, or 
regulatory components that modulate the expression and functionality of the products they 
encode. Whilst the ‘laboratory-strains’ used in these studies contain similar genetic lesions, they 
also contain unique mutations. This likely explains the few discrepancies in the data from these 
previous studies where the impact of particular genes was reported differently. However, the 
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impact of the vast majority of HCMV genes were reported similarly, and these works provided 
a reliable picture of the of the HCMV genome complexity, and also highlighted the redundancy 
of numerous encoded functions for the growth of virus in cell culture.  
 Cell-type specific functions 1.10.1
As little as 25-30% of the genes encoded by HCMV are essential for growth in cultured 
fibroblasts, mostly involving those that are conserved amongst the herpesviruses and encode 
core functions in the viral replication cycle (Figure 1.9) (Dunn, Chou et al. 2003, Yu, Silva et al. 
2003). There is considerable overlap within this sub-set of genes that are essential for the 
growth of virus in other cultured cell types, as well as with the genes that are dispensable for the 
growth of virus in different cell types – the latter commonly involve those genes that encode 
immuno-modulatory functions. Furthermore, some genes are essential or enhance the growth of 
virus in one cell type, yet are dispensable or even temperance factors in others.  
 Mutations acquired during adaptation of HCMV to cell culture 1.10.2
 The identification of temperance genes offered some explanation to the selective 
pressures imposed for the adaptation of HCMV in vitro. Dispensable genes encoding 
‘temperance-factors’ are distributed throughout the genome, with lesions identified at several 
loci in the genomes of extensively passaged laboratory viruses (Cha, Tom et al. 1996, Davison, 
Dolan et al. 2003). The number of mutations contained in lab-adapted strains correlates with 
increasing passage history, yet consistent themes are observed amongst all passaged viruses. 
This sequential adaptation of HCMV has been demonstrated experimentally, and also shown to 
occur during repeated passage in cultured epithelial cells and endothelial cells, as well as 
fibroblasts (Dargan, Douglas et al. 2010). Gene ablating mutations are found as frame-shifting 
insertions and deletions (indels); substitutions that introduce premature stop coding codons; 
sequence inversions interrupting ORFs; and large deletions of sequence that encompass entire 
genes. Non-synonymous amino acid substitutions are also frequently observed.  
 Genes that encode integral membrane proteins performing non-essential functions are 
generally those most prone to ablating mutation. Genes encoding core functions in the viral 
replication cycle, e.g. genome replication and packaging machinery, have been shown to 
acquire non-synonymous mutations in vitro (Dargan, Douglas et al. 2010), however the 
essential functions these genes encode suggest that such mutations will not be totally ablating 
(Dunn, Chou et al. 2003, Yu, Silva et al. 2003). Of the genes encoding virion structural 
components, those that encode capsid proteins rarely mutate. Tegument protein encoding genes 
frequently mutate, but genes most prone to mutation are those encoding virion envelope 
components.  
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Figure 1.9. Impact of single ORFs on virus growth in fibroblasts. Data based on strain Towne BAC-derived virus. ORFs are colour-coded to reflect growth phenotype of 
mutants; no growth (red) - the corresponding ORF was classified as essential; severely or moderately defect (pink/green) - corresponding ORF enhanced/augmented replication; no 
differential phenotype (grey) – corresponding ORF dispensable, but neither enhances or tempers virus growth; enhanced (yellow) – corresponding ORFs were inhibitory and 
tempered virus growth. Figure reproduced from (Dunn, Chou et al. 2003), with permission of PNAS publishers 
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1.11 Biological differences between wildtype and ‘laboratory-adapted’ HCMV strains 
 Restricted tropism 1.11.1
‘Laboratory-strains’ display restricted tropism as a hallmark of their adaptation to cell 
culture, such that increased fitness in fibroblasts occurs with a reduced fitness in other naturally 
targeted cell types (Figure 1.10.). Efficient infection of cultured epithelial cells (Miceli, 
Newsome et al. 1989), endothelial cells (Kahl, Siegel-Axel et al. 2000), monocytes, 
macrophages (Ibanez, Schrier et al. 1991, Minton, Tysoe et al. 1994) and PMNLs (Gerna, 
Percivalle et al. 2000), has to date been a particular challenge in HCMV research. Thus, 
investigations in these naturally targeted cell types have only been possible with ‘low-passage’ 
viruses that grow slowly and to limiting titres.  
 
 
Figure 1.10. Differential tropism of HCMV strains with contrasting cell-culture passage history. As 
demonstrated by infectious focus expansion assay (Sinzger, Knapp et al. 1997), ‘laboratory-strain’ 
AD169 displays greater fibroblast tropism, yet drastically restricted endotheliotropism, compared to the 
low-passage strain TB42. Figure reproduced from (Sinzger, Schmidt, 1999), with the permission of 
Society of General Microbiology publishers. 
 
 
 
 The association between fibroblast passage history and tropism was verified by the 
successful re-capitulation of lab-adaptation under controlled experimental conditions (Sinzger, 
Schmidt et al. 1999, Revello, Baldanti et al. 2001). Sequential passage of broad tropism ‘low-
passage’ strains in fibroblasts resulted in the generation of tropism-restricted ‘laboratory-
adapted’ progeny, and this occurred concurrently with changes in the viral genome. The 
hereditary nature of HCMV tropism determining factors was demonstrated in these 
investigations, and the restricted tropism of extensively passaged strains was shown not to be 
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due to epigenetic phenomena. Firstly, fibroblasts transfected with DNA extracted from either 
‘broad-tropism’ or ‘restricted-tropism’ strain variants produced progeny virus with tropism 
identical to that of the respective parental viruses. Secondly, fibroblasts simultaneously infected 
with two distinct ‘restricted-tropism’ lab-adapted strain variants produced ‘broad-tropism’ 
progeny. This latter observation indicated that the restricted tropism of each parental strain was 
due to loss of distinct genetic functions, and together these strains provided the full range of 
genes encoding all necessary tropism determining factors, as contained in the recombinant 
broad-tropism progeny virus that was produced.  
 Interestingly, similar growth kinetics and productivity improving adaptations have also 
been observed following prolonged propagation of low-passage virus in endothelial cell culture; 
viruses with an extensive passage history in this cell type grew more efficiently in endothelial 
cells compared to fibroblasts (James Waldman, Sneddon et al. 1989). Thus, adaptation of 
HCMV to cell culture occurs in a cell-type specific manner, and is not restricted to fibroblasts. 
This observation has been exploited for the propagation of virus that retains broad tropism, 
although the titres produced following adaptation to ECs were still lower than that of virus 
adapted to fibroblasts (Waldman, Roberts et al. 1991, Sinzger, Schmidt et al. 1999). 
Furthermore, broad-tropism progeny have been recovered from within stocks of laboratory-
adapted strains following sequential passage in cell types other than fibroblasts (Gerna, 
Percivalle et al. 2002, Gerna, Percivalle et al. 2003).  
 A genetic determinant of broad-tropism: the UL128L genome region 1.11.2
 Assessment of the genetic differences between broad-tropism and restricted-tropism 
strains identified three adjacent ORFs in the UL/b’ genome region (Figure 1.11.) as determinants 
of tropism: UL128, UL130 and UL13A, together comprising the UL128 locus (UL128L) 
(Hahn, Revello et al. 2004). The proposed role of these ORFs as tropism determinants was 
supported by observation that all sequenced restricted-tropism strains contained mutations in 
this genome region (Revello, Baldanti et al. 2001, Akter, Cunningham et al. 2003, Davison, 
Dolan et al. 2003, Dolan, Cunningham et al. 2004, Cunningham, Gatherer et al. 2010, Stanton, 
Baluchova et al. 2010). The observation that ‘laboratory-adapted’ strains were often mutated in 
just one UL128L gene suggested that the functions they encode acted in concert. The specific 
contribution of each of UL128, UL130 and UL131A was investigated by a reverse genetics 
approach for the repair or ablation of each gene in ‘restricted-tropism’ and ‘broad-tropism’ 
strains, respectively, as well as complementation of ‘restricted-tropism’ strains with wildtype 
copies of UL128L genes for the rescue of broad tropism. These investigations demonstrated that 
each of the UL128L genes was required for infection of epithelial cells (Wang and Shenk 2005), 
endothelial cells (Patrone, Secchi et al. 2005, Adler 2006), monocytes (Straschewski, Patrone et 
al. 2011), and dendritic cells (Riegler, Hebart et al. 2000, Gerna, Percivalle et al. 2005). 
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 UL128L gene structure 1.11.2.1
The UL128L genome region in AD169 was originally described to contain four genes 
(UL128, UL129, UL130, UL131) (Chee, Bankier et al. 1990). Later interpretations identified 
novel splice patterns for UL128 and UL131, and ultimately the identification of 3 genes (Akter, 
Cunningham et al. 2003, Davison, Dolan et al. 2003). The newly interpreted UL128 over-lapped 
and included UL129, and thus retained its original name. UL131 was frame-shifted in AD169, 
with the proteins encoded by the original and re-interpreted ORFs sharing no significant amino 
acid sequence homology, resulting in renaming of UL131 as UL131A. UL128 contains 516 
coding nucleotides dispersed over three exons (exon 1 – 164 nt, exon 2 – 135 nt, and exon 3 – 
217 nt); UL130 contains 645 coding nucleotides with no introns; and UL131A contains 390 
coding nucleotides dispersed over two exons (exon 1 – 236 nt, and exon 2 – 154 nt) (Akter, 
Cunningham et al. 2003, Baldanti, Paolucci et al. 2006, Sun, Ji et al. 2009).  
 UL128L gene diversity 1.11.2.2
Nucleotide sequence analysis of distinct wildtype strains from separate geographic 
locations has demonstrated that each of the three UL128L genes are highly conserved in vivo: 
UL128, UL130 and UL131A amongst clinical strains display 94.3-96.0%, 92.3-95.8% and 95.9-
96.2% nucleotide sequence identity, respectively (Baldanti, Paolucci et al. 2006, Sun, Ji et al. 
2009). Each gene shares no significant sequence homology with genes in other herpesviruses, 
though positional and functional homologues are found in CMVs of other animals (Davison, 
Dolan et al. 2003, Gnanandarajah, Gillis et al. 2014, Malouli, Hansen et al. 2014). 
 UL128L gene transcription 1.11.2.3
A number of transcripts have been identified in UL128L (Akter, Cunningham et al. 
2003, Hahn, Revello et al. 2004, Sun, Ren et al. 2010). Read-through transcripts corresponding 
to the coding regions of all 3 genes and originating from a start site situated upstream of 
UL131A have consistently been identified. UL128-specific transcripts are also produced, most 
likely derived from an initiation site located within the UL130 coding region. All observed 
UL128L transcripts are co-terminal, determined by the same poly-adenylation site downstream 
of UL128. 
 There are conflicting reports of the temporal kinetics with which the UL128L genes are 
expressed. Two groups report the detection of transcripts exclusively with late (L/γ) kinetics 
(Akter, Cunningham et al. 2003, Hahn, Revello et al. 2004), whilst another group detected 
UL128L transcripts with immediate early (IE/α) and late (L/γ) kinetics (Sun, Ren et al. 2010). 
This latter observation opens up the possibility that the UL128L genome region, particularly the 
UL128 gene that appears to be transcribed independently of UL130 and UL131A, encodes 
multiple protein variants that potentially perform different functions at different phases in the 
lytic replication cycle. 
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Figure 1.11. UL128 locus (UL128L): location and ORF structure.  (A) Position of the UL128 locus (UL128L) in HCMV UL/b’ genome region. (B) In focus are UL128, UL130 
and UL131A ORFs, and part of UL132: entire ORFs  (blue); coding domain sequences (CDS) (yellow); introns (arches linking CDS regions). Arrow directions reflect 5’-3’ direction 
of UL128L ORF transcription, in complementary orientation to the conventional genome annotation. Highlighted are (C) the putative polyadenylation common to all UL128L 
transcripts downstream of UL128 (dark blue); (D) the putative TATA element for UL128-specific transcripts initiated from within the UL130 coding domain (green); and (E) the 
region upstream of UL131A predicted to contain the UL128L common promoter. 
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 Impact of UL128L expression on virus propagation in cell culture 1.11.2.4
The UL128L genome region encodes functions required for efficient infection of a 
broad range of naturally targeted cells types, yet are dispensable for infection of fibroblasts. In 
fact, UL128L encoded functions are temperance factors for the growth of virus in fibroblasts, as 
demonstrated when the repair of mutated UL128L genome regions, or alternatively 
complementation of viruses with intact UL128L ORFs, each resulted in reduced dissemination 
kinetics and cell-free virus production of infections compared to parental virus (Patrone, Secchi 
et al. 2005, Wang and Shenk 2005, Adler 2006, Dargan, Douglas et al. 2010, Stanton, 
Baluchova et al. 2010). These observations explained the pressure for the rapid selection of 
virus containing ablating mutations in this genome region when passaged in fibroblasts, and the 
subsequent alterations in tropism when virus undergoes adaptation to cell culture. Furthermore, 
the selection of UL128L mutant progeny occurs only slightly less rapidly than that of RL13 
mutant progeny (see section 1.11.3.2), and within as few as 1-5 passages (Dargan, Douglas et 
al. 2010, Stanton, Baluchova et al. 2010).  
 Restricted virulence 1.11.3
 Laboratory strains are generally avirulent, as can be seen from previous vaccine clinical 
trials based on live-attenuated viruses from strains with varying in vitro passage history. The 
classical laboratory strains AD169 and Towne were each subjected to extensive in vitro passage 
during vaccine development, passaged more than 50 and 128 times in fibroblasts respectively 
(Rowe, Hartley et al. 1956, Elek and Stern 1974, Plotkin, Furukawa et al. 1975). In contrast to 
this, the challenge virus strain Toledo developed during clinical trials of Towne vaccine was 
subjected to less extensive in vitro passage (5 fibroblast passages) (Quinnan, Delery et al. 1984, 
Plotkin, Starr et al. 1989). As previously mentioned, exposure to strain Toledo resulted in the 
development of acute infection and often severe clinical symptoms, whilst vaccination with 
AD169 and Towne most frequently resulted in no clinical outcome at all (Just, Buergin-Wolff et 
al. 1975, Fleisher, Starr et al. 1982, Quinnan, Delery et al. 1984, Plotkin, Starr et al. 1989). The 
reduced virulence of the more extensively passaged strains may be in part due to restricted 
tropism and the inability to establish infection in a wide range of normally targeted tissues. 
However, genome regions that encode virulence factors have since been shown to be prone to 
mutation during the passage of virus in vitro.  
  UL/b’ encoded functions 1.11.3.1
 The UL/b’ genome region (UL148-UL150 in Merlin genome figure above – Figure 1.8.) 
is a major site of heterogeneity amongst laboratory strains, first evidenced by RFLP analysis of 
related laboratory strain variants (Tamashiro and Spector 1986). These observations, together 
with the phenotypic differences between ‘laboratory-adapted ‘and ‘low-passage’ strains, 
inspired the comparative analysis of the UL/b’ genome regions of strains with differing passage 
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history (Cha, Tom et al. 1996, Davison, Dolan et al. 2003, Dolan, Cunningham et al. 2004). 
These investigations identified up to 15 Kb of sequence in the ‘low-passage’ strain Toledo that 
was absent in extensively passaged strains AD169varATCC and Towne. Furthermore, Towne 
contained sequence absent in the UL/b’ region of both AD169 and Toledo, whilst Toledo also 
contained inverted sequence in this genome region. Ultimately, 22 putative UL/b’ ORFs were 
identified compared to that in annotations based on strain AD169varUK, although subsequent 
analysis now indicates there are 21 ORFs in this region. However, the selective pressures for 
mutations in this genome region are not well understood like that for mutation in the UL128L 
genome region. In particular, the inhibitory impact of specific ORFs in this genome region has 
not been demonstrated experimentally, and therefore many may have been lost during the 
passage of strains AD169 and Towne co-incidentally along with ORFs that do indeed encode 
temperance factors. 
 A general commonality amongst the ORFs in the UL/b’ genome region is the encoding 
of integral membrane proteins with immuno-modulatory/immune evasion functions. These 
include (in order of presentation in the Merlin genome): the polymorphic gene UL144, a 
member of the RL1 gene family that encodes a tumour necrosis factor receptor (TNFR) 
homologue that subverts lymphocyte responses (Lurain, Kapell et al. 1999, Arav-Boger, 
Willoughby et al. 2002, Poole, King et al. 2006); UL142 of the MHC homologue gene family, 
and UL141 of the UL14 gene family, that both encode integral membrane proteins that subvert 
natural killer (NK) detection and elimination of virus infected cells (Tomasec, Wang et al. 2005, 
Wills, Ashiru et al. 2005, Prod'homme, Sugrue et al. 2010); the poly-cistronic UL138-UL133 
locus (ORFs UL138, UL136, UL135 and UL133) that encodes four integral membrane proteins 
which act in synergy to repress viral replication in CD34+ myeloid cells during latency 
(Umashankar, Petrucelli et al. 2011). Each of UL144, UL142, and UL141 has been shown to 
mutate independently during the passage of virus in cultured fibroblasts and endothelial cells, 
whilst UL141 has also been shown to mutate in epithelial cells (Dargan, Douglas et al. 2010). 
Hence the functions encoded by these ORFs may indeed by inhibitory to the growth of virus in 
cell culture. Interestingly, whilst the UL138-UL133 locus is dispensable for growth in 
fibroblasts and epithelial cells, the functions they encode may enhance virion morphogenesis in 
endothelial cells (Umashankar, Petrucelli et al. 2011, Bughio, Elliott et al. 2013). Other than 
ORFs encoding integral membrane proteins, the polymorphic genes UL147 and UL146 each 
encode secreted viral homologues of α CXC chemokines (vCXC-2 and vCXC-1 respectively), 
and together comprise the UL146 CXC chemokine homologue gene family (Arav-Boger, Foster 
et al. 2006, Lurain, Fox et al. 2006, McSharry, Avdic et al. 2012). 
 Other genes within the UL/b’ region encode putative membrane proteins of unknown 
function. This includes UL140, as well as the polymorphic genes UL139, UL148A, UL148B, 
UL148C and UL148D (Ji, Rong Sun et al. 2006). UL150 and UL50A each encode putative 
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secreted proteins with unknown function {Mocraski, 2013 #777}. Many of these genes have 
also been shown to acquire mutations independently (Dargan, Douglas et al. 2010). For 
example, although UL140, UL145 and UL150 were identified in Toledo, each contained frame-
shifting mutations that likely ablated the functionality of proteins encoded (Dolan, Cunningham 
et al. 2004). Thus, as well as being dispensable, the functions encoded by these genes may be 
inhibitory to the growth of virus in cell culture. 
 RL11 gene family 1.11.3.2
 Encompassing the TRL/UL junction are 14 polymorphic genes that comprise the RL11 
gene family, each predicted to encode integral membrane glycoproteins, including several that 
are incorporated into the virion envelope (Davison, Akter et al. 2003, Davison, Dolan et al. 
2003). Several members encode immuno-modulatory functions and potentially tropism factors, 
although the function of others remains to be determined. Many of these genes are non-essential 
for growth in fibroblasts, and have been observed to undergo mutation independent of other 
RL11 genes following passage in this cell type (Dolan, Cunningham et al. 2004, Spaderna, 
Hahn et al. 2004, Cunningham, Gatherer et al. 2010, Dargan, Douglas et al. 2010). Interestingly, 
RL5A mutations have also been identified in wildtype virus undergone no cell culture passage 
at all (Cunningham, Gatherer et al. 2010). RL13 is a ‘temperance factor’ for the growth of virus 
in both fibroblasts and epithelial cells, and is the most commonly reported RL11 family member 
to acquire mutations in vitro (Dolan, Cunningham et al. 2004, Stanton, Baluchova et al. 2010). 
Indeed, it is the most rapidly mutated gene within the entire genome (Dargan, Douglas et al. 
2010, Stanton, Baluchova et al. 2010). UL1 is dispensable for growth in fibroblasts, though loss 
of this gene causes a growth defect in epithelial cells (Shikhagaie, Mercé-Maldonado et al. 
2012). Like RL5A, naturally occurring UL1 mutants have been identified in wildtype virus 
(Sekulin, Gorzer et al. 2007). Conversely, UL10 has been demonstrated to be inhibitory and 
dispensable for the growth of virus in epithelial cells, though not fibroblasts (Dunn, Chou et al. 
2003). 
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1.12 HCMV virus particle composition and morphogenesis 
 Descriptions of the HCMV particle composition have been subject to incremental 
revision in parallel to that of the genome coding potential. The identification of virion 
components has historically relied on the analysis of purified virions by biochemical and 
immunological methods, with the assignment of components to particular virion compartments 
deduced by a combination of direct and indirect experimental approaches (Sarov and Abady 
1975, Fiala, Honess et al. 1976, Baldick Jr and Shenk 1996). The identification of glycoproteins 
as components of the virion envelope relied on their detection by immuno-blot analysis of 
purified virions, coupled with infectivity neutralization assays to demonstrate their exposure to 
the external environment and involvement in virus entry and binding (Stinski 1976, Farrar and 
Oram 1984). Identification and compartmentalization of other components has been aided by 
indirect observations that include: confocal microscopy analysis to identify proteins that co-
localise with known virion components at the virion assembly compartment (VAC); yeast-two-
hybrid and other protein-protein binding assays to determine interactions between known 
components already assigned to a virion compartment; as well as in silico analysis of amino 
acid sequence and structural motifs to identify features indicative of virion envelope insertion 
(e.g. trans-membrane domains and signal peptide sequences). Direct approaches have included 
proteolytic profiling, based on a combination of biochemical fractionation, proteolytic 
digestion, and detection of recovered proteins from both intact and detergent solubilized virions. 
More recently, mass spectrometry analysis of HCMV virions has been applied in a global 
proteomics approach using the AD169 strain. This identified 71 viral encoded proteins and 
more than 70 host cell derived proteins that co-purified with virions (Varnum, Streblow et al. 
2004).  
 HCMV particle nucleocapsid compartment 1.12.1
 The HCMV nucleocapsid is structurally constrained and thus the virion compartment 
with greatest homogeneity amongst strains. There are currently 5 known capsid protein 
components, all of which are encoded by herpesviruses core genes. These include: the major 
capsid protein (MCP; pUL86) (Chee, Rudolph et al. 1989) present at 955 copies per virion, and 
forming the previously described pentameric and hexameric capsomeres at the capsid faces, 
walls and vertices; portal protein (PORT; pUL104) (Dittmer, Drach et al. 2005), present at 12 
copies per virion, and forming the single specialised capsomere through which the genome is 
inserted and released; 320 copies the minor capsid protein (mCP; pUL85) (Baldick Jr and Shenk 
1996), and 640 copies of the minor capsid binding protein (mC-BP; pUL46) (Gibson, Baxter et 
al. 1996), together forming the 320 hetero-trimeric triplexes that link three adjacent capsomeres, 
in a 1:2 ratio respectively; and 900 copies of the smallest capsid protein (SCP; pUL48A) that 
decorate the MCP hexons in 6-member ring-like structures (Gibson, Clopper et al. 1996, Yu, 
Shah et al. 2005).   
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 Descriptions of the HCMV capsid assembly pathway (Figure 1.12.) have been heavily 
dependent on observations made for other herpesviruses (Homa and Brown 1997, Brown and 
Newcomb 2011, Cardone, Heymann et al. 2012). In HCMV, two proteins orchestrate capsid 
assembly: the assembly protein (AP/pUL80.5) and protease assemblin (PR/pUL80), each 
initially contained as precursors within a fusion protein (pPR-pAP). Assembly begins with the 
formation of capsid sub-unit protomers in the cytoplasm, where pUL86/MCP associates with 
pAP and pPR, and then the nuclear localisation sequences (NLS) of pAP facilitate the delivery 
of protomers into the nucleus (Wood, Baxter et al. 1997, Plafker and Gibson 1998). Similarly, 
the capsid hetero-triplexes also form in the cytoplasm, and the single copy pUL46/mC-BP is 
also thought to contain NLS sequences (Gibson 1996). Following migration into the nucleus, 
capsid protomers coalesce to form a spherical pre-capsid shell via protein-protein interactions 
between different AP molecules, as well as between the hetero-trimers and capsomeres. Auto-
activation of PR results in excision of AP and PR itself, occurring concurrently with genome 
insertion (Yu, Trang et al. 2005). Nucleocapsid maturation culminates in a transitional change 
to the final icosahedral structure. Three capsid isoforms are produced, two of which are 
defective and commonly observed in NIEPs: A capsids, lacking AP and a copy of the viral 
genome, and B capsids, containing the AP but no genome. C capsids contain a copy of the viral 
genome and represent the fully matured capsid incorporated into virions (Irmiere and Gibson 
1985). 
 HCMV particle tegument compartment 1.12.2
 ~32 viral proteins have been identified as tegument components, the most abundant by 
mass being phosphoproteins. The tegument materials are incorporated to the capsid-proximal 
and envelope-proximal layers (Figure 1.12.) by sequential protein-protein interactions (Phillips 
and Bresnahan 2011, To, Bai et al. 2011, Tandon and Mocarski 2012).  
 Initial tegumentation occurs in the nucleus where tegument protein pp150 (ppUL32) 
associates with pro-capsid shells through interactions with SCP (Sampaio, Cavignac et al. 2005, 
Dai, Yu et al. 2013). Following nuclear egress, pp150 recruits pUL96, both of which are critical 
in offering structural support to nucleocapsids in the cytoplasm (Tandon and Mocarski 2008, 
Tandon and Mocarski 2011). Further capsid-proximal materials include the high molecular 
weight protein (HMWP; pUL48), and also with the HMWP-binding (HMWP-BP; pUL47) (Yu, 
Shah et al. 2011). These components are predicted to support intracellular transport of the 
nucleocapsids along microtubule filaments during de novo infection, and also control un-coating 
and release of genome at the infected cell nucleus (Bechtel and Shenk 2002, Brock, Kruger et 
al. 2013). The major site of virion tegumentation is the VAC; formed from re-modelled cellular 
secretory apparatus (endosome/exosomes) at the ER-Golgi intermediate compartment (ERGIC) 
(Tooze, Hollinshead et al. 1993, Sanchez, Greis et al. 2000, Das, Vasanji et al. 2007). Materials 
incorporated into the virion from this site likely include those that reside in the envelope- 
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Figure 1.12. HCMV virion maturation pathway. (A) HCMV virion maturation pathway:  1 – pAP and 
pPR oligomerise in the cytoplasm; 2 – pAP oligomers bind MCP; 3 – nuclear translocation of pAP-MCP 
aggregates; 4 – mCP and mC-BP associate to form hetero-trimers that move in to the nucleus; 5 – capsid 
protomers (pUL86/pUL80.5, pUL85/pUL46, and pUL104) coalesce to form spherical pro-capsid shell; 6 
+ 7 – auto-activation of pUL80 results in cleavage of pUL80 itself and pUL80.5, forming transition B-
capsids. Nucleocapsids then: i) undergo defective maturation, loose all pUL80 and pUL80.5, yet gain no 
genome and became A capsids; ii) retain pUL80 and pUL85, yet gain no genome and become B capsids; 
iii) loos all pUL80 and pUL80.5, gain a genome and become fully matured C capsids; 8 – initi8al 
tegumentation occurring in the nucleus stabilises nascent nucleocapsids; 9 + 10 – nuclear egress of 
nascent nucleocapsids, by primary envelopment and deposition into the peri-nuclear space, and de-
envelopment at outer nuclear membrane and deposition into cytoplasm; 10 + 11 – further tegumentation 
at cytoplasmic sites and secondary envelopment during budding into secretory vesicles at the VAC. (B) 
Fully matured icosahedral C capsids: MCP hexons at surfaces and walls are (yellow); MCP pentamers at 
vertices (purple); triplex sub-units at capsid floor (green). (C) Density map showing distinct protein 
layers in the HCMV virion, including: genome containing core region (red); capsid (yellow); capsid-
proximal tegument (green); envelope proximal tegument (purple); envelope (pink). Figure A reproduced 
from (Gibson, Bogner et al. 2013); Figure B adapted from (Chen, Jiang et al. 1999), with permission of 
Elsevier publishers; Figure C adapted from (Yu, Shah et al. 2011), with permission of Elsevier publishers.  
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proximal tegument layer. The phosphoprotein pp65 (ppUL83) is the most abundant protein in 
the virion, with a broad range of immuno-modulatory activities to subvert both innate and 
adaptive immune response pathways (Odeberg, Plachter et al. 2003, Arnon, Achdout et al. 
2005). This highly abundant protein performs a role during the assembly of the virion, 
providing structural support as a scaffold to which other materials are incorporated (Chevillotte, 
Landwehr et al. 2009). However, whilst pp65 has been demonstrated to augment/enhance virus 
growth (Becke, Fabre-Mersseman et al. 2010), it is not absolutely required (Schmolke, Kern et 
al. 1995). The phosphoprotein pp71 (ppUL82) is a trans-activator of IE gene transcription, and 
virus that does not produce pp71 displays a considerable growth defect in fibroblasts (Cantrell 
and Bresnahan 2005, Nicholson, Sutherland et al. 2009). Tegument protein pp28 (ppUL99) 
localizes at the VAC where it orchestrates nascent virion secondary envelopment via 
interactions with the ER resident chaperone cellular protein Bip/GRP78 (Sanchez, Sztul et al. 
2000, Silva, Yu et al. 2003, Seo and Britt 2008, Buchkovich, Maguire et al. 2009). Several 
cellular proteins, as well as both cellular and virus encoded RNAs, are contained in the virion 
tegument compartment (Terhune, Schroer et al. 2004, Varnum, Streblow et al. 2004). Whilst 
virions and NIEPs have similar tegument profiles, DBs contain dis-proportionate levels pp65 
(Varnum, Streblow et al. 2004). 
 HCMV particle envelope 1.12.3
 21 viral proteins have been identified as envelope components, 19 of which are 
predicted or known to be glycosylated {Mocraski, 2013 #777}. One further putative envelope 
glycoprotein encoding ORF (UL74A) is predicted though, yet to be detected in virions. As few 
as 5 of the viral encoded virion envelope components are essential for growth in fibroblasts, and 
of the 16 proteins which are dispensable, only one enhances virus growth in this cell type 
(Hobom, Brune et al. 2000, Dunn, Chou et al. 2003, Yu, Silva et al. 2003, Spaderna, Kropff et 
al. 2005). Consequently, several envelope glycoproteins are absent in laboratory strains. In fact, 
this virion compartment is currently recognised as the major site of heterogeneity amongst 
laboratory and clinical virus, as demonstrated by the detection of as few as 13 envelope 
glycoproteins identified in the virions derived from strain AD169 (Varnum, Streblow et al. 
2004). 
 Virion envelope glycoproteins often contain membrane anchors (transmembrane 
domains or signal peptide sequences) that dictate their transition through the cellular secretory 
pathway, and also their ultimate retention in vesicle membranes at the VAC where virions 
acquire undergo secondary envelopment (Sanchez, Greis et al. 2000, Rigoutsos, Novotny et al. 
2003). Exosome trafficking can result in glycoproteins being presented at the infected cell 
surface, with endosomal re-cycling often employed for retrieval and delivery of glycoproteins 
back to the VAC. Many glycoproteins sequester cellular membrane receptors and their ligands 
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during endosomal recycling, providing a mechanism by which HCMV modulates cell-signalling 
pathways to subvert an anti-viral response (Mocarski Jr 2002). Cell-surface presentation of 
glycoproteins is also believed to induce micro-fusion events between the plasma membranes of 
adjacent cells, forming pores through which virus can spread by the cell-to-cell route (Gerna, 
Percivalle et al. 2000). This model is supported by the observation of syncytia formation by 
‘broad-tropism’ strains in dendritic cell and epithelial cell cultures (Gerna, Percivalle et al. 
2005, Wang and Shenk 2005), and also by the fact that cytoplasmic material can be transferred 
between adjacent infected and non-infected cells (Digel, Sampaio et al. 2006).  
 The most widely studied glycoproteins are those implicated in the binding and entry of 
virus into cells, as well as the secondary envelopment of nucleocapsids during virion budding 
into secretory vesicles (see section 1.13.). Besides these, the virion envelope contains several 
RL11 gene family encoded glycoproteins, with gpRL11 the best described functionally (Lilley, 
Ploegh et al. 2001, Cortese, Calo et al. 2012). This type I membrane glycoprotein binds the IgG 
Fc domain and has antibody sequestering activity based on endosomal retrieval. A similar 
function has been suggested for both gpRL12 and gpRL13, however this has not been 
demonstrated in the context of infection (Lilley, Ploegh et al. 2001, Atalay, Zimmermann et al. 
2002, Cortese, Calo et al. 2012, Cortese 2013). Furthermore, gpRL12 has yet to be identified as 
a virion envelope component. Another virion envelope glycoprotein, gpUL118-119, has IgG Fc 
binding properties, and thus may perform similar functions (Mocarski 2004). The GPCR 
homologue gene family products (pUL33x1, gpUL78, gpUS27 and gpUS28) are best known for 
their activity in the interference of cell-signalling pathways by sequestration of cellular GPCR 
ligands (chemokines) (Vischer, Leurs et al. 2006). Interestingly, gpUS28 is capable of binding 
cell-associated chemokine CX3CL1, potentially contributing to the initial binding of virus to 
cells during infection (Casarosa, Waldhoer et al. 2005). The function of gpUL132 has yet to be 
determined, but it has been reported to enhance virus replication in fibroblasts (Hobom, Brune 
et al. 2000, Spaderna, Kropff et al. 2005).  
 Two further proteins are frequently co-purified with virions, though are not considered 
bona fide envelope components. This includes the non-glycosylated pUL76 with unknown 
function, as well as gpUL22A, a secreted glycoprotein with reported chemokine binding and 
subversion activity (Wang, Bresnahan et al. 2004, Wang, Duh et al. 2004).  
1.13 HCMV particle envelope glycoproteins in binding, entry and maturation/egress 
 Glycoproteins that orchestrate essential mechanisms in the HCMV replication cycle are 
incorporated into the virion envelope in the form of multimeric glycoprotein complexes. Three 
distinct glycoprotein complex families have been described: gCI, gCII, gCIII (gC; glycoprotein 
complex) (Gretch, Kari et al. 1988). Most members of these families are conserved amongst the 
herpesviruses, and were named (gB, gH, gL, gM and gN) to reflect their functional homology 
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with glycoproteins in other herpesviruses. The assembly, processing, and composition of these 
complexes have been investigated by a combination of pulse-chase assays coupled with SDS-
PAGE and immuno-blot detection. The stoichiometry of the glycoprotein members contained 
with each complex has been inferred by comparison of the molecular weight of complete intact 
complexes, to that of sub-units released under reducing conditions. However, multiple variant 
complexes have been identified within each family, and it remains possible that glycoprotein 
complexes exist as a range of variants that may perform distinct functions.  
 Glycoprotein complex family gCI 1.13.1
 Glycoprotein complex family gCI comprises homo-oligomers of the type I glycoprotein 
gB that is encoded by HCMV ORF UL55 (Cranage, Kouzarides et al. 1986, Mach, Utz et al. 
1986, Gretch, Gehrz et al. 1988, Kari, Liu et al. 1990). The primary UL55 translation product is 
a contiguous polypeptide of ~906-907 amino acids in length that is co-translationally 
glycosylated to a 150 KDa precursor then modified to 160 KDa form (Britt and Auger 1986, 
Spaete, Thayer et al. 1988, Britt and Vugler 1989). The 160 KDa intermediate subsequently 
undergoes proteolytic cleavage by cellular furin-like enzymes to generate a ~55 KDa C-terminal 
sub-unit (denoted gp55) and a ~116 KDa N-terminal sub-unit (denoted gp116) (Spaete, Thayer 
et al. 1988, Vey, Schäfer et al. 1995). The mature gB is a homodimer of both gp55 and gp116 
sub-units, each held together by di-sulphide bonding that occurs during oligomerisation prior to 
protein folding in the ER (Britt and Auger 1986, Spaete, Thayer et al. 1988, Britt and Vugler 
1989, Britt and Vugler 1992, Billstrom and Britt 1995). The gp55 sub-unit contains a signal 
sequence and forms the gB transmembrane (TM) domain, and the gp116 sub-unit forms the 
surface (SU) domain presented at the exterior of the virion, and also externally to cell when 
presented at the infected cell plasma membrane (Rigoutsos, Novotny et al. 2003).  
 The HCMV ORF UL55 is polymorphic, with four main genotypes described (gB1, 
gB2, gB3 and gB4) (Chou and Dennison 1991, Meyer-Konig, Haberland et al. 1998), though 
further less common genotypes (gB5, gB6, and gB7) have also been described (Rasmussen, 
Hong et al. 1997, Shepp, Match et al. 1998, Trincado, Scott et al. 2000). Amino acid sequence 
variation is observed in both the gp55/TM and gp116/SU sub-units (Chou 1992). 
 Glycoprotein complex family gCII 1.13.2
 Glycoprotein complexes assigned to the family gCII exist as hetero-oligomers of 
glycoproteins gM and gN, and are heterogeneous in terms of the composition and size (Kari, 
Goertz et al. 1990, Kari and Gehrz 1993, Mach, Kropff et al. 2000, Dal Monte, Pignatelli et al. 
2001, Mach, Kropff et al. 2005). Glycoprotein gM, encoded by HCMV ORF UL100 (Lehner, 
Meyer et al. 1989, Kari, Li et al. 1994), is a ~372 amino acid type III transmembrane protein 
with seven membrane spanning regions (Mach, Kropff et al. 2000, Rigoutsos, Novotny et al. 
2003). gM contains one N-linked carbohydrate modification that is acquired in the ER, and 
    45 
exists as a 42 KDa glycoprotein in its fully mature state (Mach, Kropff et al. 2000). 
Glycoprotein gN, encoded by HCMV ORF UL73, is a type I transmembrane glycoprotein or 
~138 amino acids, predicted to contain an N-terminal signal peptide and C-terminal TM domain 
(Mach, Kropff et al. 2000, Rigoutsos, Novotny et al. 2003, Mach, Osinski et al. 2007). This 
gCII family member is translated as an 18 KDa glycoprotein pre-cursor and is subsequently 
modified to a 50-60 KDa glycoprotein following the addition of O-linked sugars (Kari and 
Gehrz 1993, Mach, Kropff et al. 2000). Oligomerisation of gM and gN is required for the 
progression of either glycoprotein through the secretory pathway, yet complex formation by 
covalent bonding is not a strict requisite as non-covalently bonded gM/gN complexes have been 
detected in purified virions (Mach, Kropff et al. 2000, Mach, Kropff et al. 2005).  
 HCMV ORF UL100 (gM) is highly conserved amongst different strains. In contrast to 
this, UL73 (gN) that is one of the most polymorphic HCMV ORFS and exists in four main 
genotypes, two of which contain further divergent variants (gN1, gN2, gN3a, gN3b, gN4a, 
gN4b, gN4c, and gN4d), with amino acid variation is most commonly isolated to the N-terminal 
domain that is exposed to the external, environment (Lehner, Stamminger et al. 1991, Dal 
Monte, Pignatelli et al. 2001, Pignatelli, Dal Monte et al. 2003).  
 Glycoprotein complex family gCIII  1.13.3
  Glycoprotein complexes of the family gCIII contain glycoproteins gH and gL as a 
disulphide bonded heterodimer (Kaye, Gompels et al. 1992, Huber and Compton 1999), 
forming a scaffold to which alternative auxiliary glycoproteins associate. Glycoprotein gH, 
encoded by the HCMV ORF UL75, is a ~742-744 amino acid type I transmembrane protein 
containing a C-terminal TM domain, and an N-terminal signal sequence (Rigoutsos, Novotny et 
al. 2003). gH is first translated to a 75 KDa precursor, than modified to an 86 KDa mature 
glycoprotein (Cranage, Smith et al. 1988, Kinzler, Theiler et al. 2002). Glycoprotein gL, 
encoded by HCMV ORF UL115 (Kaye, Gompels et al. 1992), is a ~278 amino acid in length, 
and whilst no TM domain is predicted, an N-terminal signal peptide is predicted (Rigoutsos, 
Novotny et al. 2003). gL contains just a single glycosylation modification and in its mature state 
is 34 KDa (Kinzler, Theiler et al. 2002). The gH/gL heterodimer is formed shortly following 
translation at the ER, and this interaction is sufficient for the progression through the secretory 
pathway and presentation at the cell surface (Cranage, Smith et al. 1988, Kaye, Gompels et al. 
1992, Spaete, Perot et al. 1993).  
 HCMV ORFS UL75, existing in two genotypes (gH1 and gH2) (Chou 1992, 
Rasmussen, Geissler et al. 2002), and UL115, existing in four distinct genotypes (gL1, gL2, gL3 
and gL4) (Rasmussen, Geissler et al. 2002), are moderately polymorphic. Furthermore, amino 
acid variation is most commonly observed in the N-terminal regions in each of these gCIII 
family members. 
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 Entry of HCMV particles into cells  1.13.4
 The binding and entry of HCMV into cells is a multi-phase process, engaging 
sequential glycoprotein complex-host cell receptor interactions (Figure 1.13.). Envelope 
glycoprotein-host cell receptor interactions also stimulate host-cell signalling cascades that may 
contribute to entry, cell migration, and/or prime the cell for virus replication (Compton 2004, 
Isaacson, Juckem et al. 2008). Whilst NIEPs and DBs contain envelopes comparable to that in 
virions and can also achieve penetration of cells, this section will focus on the entry of virions. 
 Binding and docking of virions at cell surface 1.13.4.1
 The first step in binding is the tethering of virions to the cell surface, facilitated by low-
affinity interactions with virion envelope glycoproteins and heparan sulfate proteoglycans 
(HSPGs); these molecules that are ubiquitous on all cell types permissive to infection. Both gB 
and gM/gN have heparan sulphate binding abilities, underlying the fact that virus-cell binding 
can be reduced using anti-bodies against these glycoprotein complexes (Compton, Nowlin et al. 
1993, Kari and Gehrz 1993). The next phase includes the docking of virions at the cell surface 
via more stable glycoprotein-receptor interactions. gB is also implicated in the docking of 
virions, and has been shown to bind cells in a bi-phasic manner, firstly through low affinity 
interaction with HSPGs, and subsequently through higher affinity interaction with other 
receptors (Boyle and Compton 1998). Several candidate host-cell receptor/entry mediator 
molecules have been proposed, though their significance in cell-signalling, virion docking, or 
mediating entry is not clearly defined. Epidermal growth factor receptor (EGFR) is one 
proposed participant, as suggested when cells expressing EGFR were permissive to infection, 
whilst otherwise identical EGFR knock out cells were refractory to infection (Wang, Huong et 
al. 2003). Furthermore, in this work, gB was been shown to co-precipitate with EGFR from 
infected cell lysates, and also contain an epitope with homology to EGF ligand. However, 
contrasting reports claim no such reduction in virus infection efficiency in fibroblasts, epithelial 
and endothelial cells when EGFR was blocked using antibodies, implicating the use of other 
receptors in the absence of available EGFR (Isaacson, Feire et al. 2007). One group has 
demonstrated the blocking of infection using anti-bodies and siRNAs to PDGFR (Soroceanu, 
Akhavan et al. 2008), whilst another group reported no such effect, instead suggesting this 
receptor invokes entry by an abnormal pathway (Vanarsdall, Wisner et al. 2012). Integrins are 
also proposed as entry mediators, and gB contains a disintegrin like domain that has been shown 
to interact with β1 integrin (Feire, Koss et al. 2004). The proposed involvement of this 
interaction was supported by the blocking of infection in fibroblasts using synthetic gB 
disintegrin peptides, as well as integrin blocking antibodies (Feire, Roy et al. 2010). 
Alternatively, gH has been shown to bind αVβ3 integrins, offering further support to the 
proposed role of this class of cell surface molecule in the early stages of infection (Wang, 
Huang et al. 2005). 
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Figure 1.13. Sequential phases of HCMV virion binding and entry into cells.  Model summarises entry into fibroblasts, with fusion of the virion envelope and cell plasma 
membrane prior to penetration. Figure reproduced form (Compton 2004), with the permission of Elsevier publishers. 
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 Virion envelope-cell membrane fusion – penetration of the cell and internalisation 1.13.4.2
of virion contents 
 Fusion between the virion envelope and cellular membranes is orchestrated by 
glycoproteins gB and gH/gL complexes; together, gB, gH, and gL form the core fusion 
machinery conserved amongst the herpesviruses (different HCMV gH/gL complexes are 
required for infection of different cell-types; see section 1.14). The observation that virus retains 
the ability to bind, but not enter cells when these glycoproteins are absent or blocked by 
antibodies, together with the use of the chemical fusogen polyethylene glycol (PEG) to 
overcome these entry defects, confirmed the activity of gB and gH/gL complexes in membrane 
fusion (Keay and Baldwin 1991, Vanarsdall, Ryckman et al. 2008, Isaacson and Compton 2009, 
Wille, Wisner et al. 2013). The contribution of gH/gL and gB complexes to membrane fusion 
has been further investigated in cells transduced to endogenously express each glycoprotein 
complex singly or in combination, with fusogenic potential displayed by the formation of 
syncytia. Cell surface presentation of gH/gL or gB alone was insufficient to induce cell fusion, 
while co-presentation of all three glycoproteins, whether in cis (in the same cells) or in trans (on 
opposing cells), was necessary and sufficient (Milne, Paterson et al. 1998).   
 The currently accepted model of HCMV glycoprotein induced fusion includes gB as the 
major fusogenic component, and gH/gL complexes as a receptor-binding activator of gB, and is 
supported by several experimental observations. Firstly, gB expressing cells are permissive to 
infection by gB-null mutant virus, whilst gH/gL-expressing cells could not support infection of 
gH-null mutants (Vanarsdall, Ryckman et al. 2008, Wille, Wisner et al. 2013). This was 
interpreted to suggest that presentation of gB in any orientation was sufficient for fusion; in this 
case gB was inserted into the virion envelope and fusion was led from within the transduced cell 
plasma membrane, whilst gH/gL was required to be presented in an orientation emanating from 
the virion, suggestive of receptor binding activity. Furthermore, this interpretation was in 
agreement with results from interference assays where endogenous expression of gH/gL 
complexes, but not gB, could block infection by cell-free virus into cells (Ryckman, Chase et al. 
2008, Vanarsdall, Chase et al. 2011). This finding was again interpreted to indicate that gB did 
not bind any saturable cellular receptor, whilst gH/gL did. 
 Thus, whilst gB contributes to the initial binding of virions to the cell and potentially 
stimulates cellular signalling pathways with various outcomes (Simmen, Singh et al. 2001, 
Isaacson and Compton 2009), the major activity of this glycoprotein is in the post-attachment 
fusion of cellular and virion membranes. Further evidence for the specific contribution of each 
of these components has come from investigation of the conformational and structural features 
of each glycoprotein(s). The crystal structure of the HSV-2 gH/gL ectodomain has been 
determined, and contains no architectural features that resemble those of known viral fusogen 
proteins (Chowdary, Cairns et al. 2010). However, determination of the HCMV gB crystal 
structure identified two internal hydrophobic fusion loops that are a hallmark of class III viral 
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fusion proteins (Sharma, Wisner et al. 2013). In the virion envelope, the ectodomain of three 
adjacent gB molecules form trimers to bury the hydrophobic regions of this glycoprotein 
complex when in the pre-fusion conformation. Conformational changes in fusion proteins result 
in the exposure of the hydrophobic fusion loops to the external environment, then the triggered 
fusogen protein is rapidly inserted into the adjacent membrane (host cell). This disrupts the 
outer membrane layer and ultimately culminates in fusion between the opposed membranes 
(Baquero, Albertini et al. 2013). Furthermore, each of gB and gH have been shown to contain 
alpha helical coiled-coil domains, in the gp55 TM domain gB and near the N-terminal region in 
gH; interaction between these amino acid structural motifs are believed to necessary for the gB 
conformational change required to trigger fusion (Lopper and Compton 2004). 
 
 Progeny virion maturation and egress 1.13.5
 Glycoprotein complexes of the gCII (gM/gN), and gCIII (gH/gL) families are also 
implicated in the maturation and egress of progeny virions. Site-directed mutagenesis 
experiments demonstrated the presence of motifs that orchestrated secondary envelopment at 
the VAC in cytoplasmic tails of both gM and gN (Krzyzaniak, Mach et al. 2007, Mach, Osinski 
et al. 2007). The contribution of gH/gL complexes to virion maturation and egress is less clearly 
established (see 1.14.3). 
1.14 Variant gH/gL glycoprotein complexes encoded by HCMV 
 More recently, distinct glycoprotein complex variants in the gCIII family have been 
identified and each has been shown to be required for efficient virus replication in different cell 
types (Figure 1.14.).  
 gCIII; gH/gL/gO 1.14.1
 The classically described gCIII variant is a 240 KDa hetero-trimeric complex that 
includes gH/gL, along with glycoprotein gO encoded by HCMV ORF UL74 (Huber and 
Compton 1997, Li, Nelson et al. 1997, Huber and Compton 1998, Huber and Compton 1999) 
(Figure 1.14.A). This glycoprotein is variable in length, ranging from 464-472 amino acids. 
Like gL, gO is not predicted to contain a transmembrane domain, though is predicted to contain 
a N-terminal signal peptide sequence (Rigoutsos, Novotny et al. 2003). Efficient transport of gO 
from the ER is achieved only when incorporated into gH/gL/gO (Huber and Compton 1999, 
Theiler and Compton 2001, Kinzler, Theiler et al. 2002). The assembly of the hetero-trimeric 
gH/gL complex variant commences with the addition of a 100 KDa gO pre-cursor that is 
subsequently modified at the Golgi to contain both N-linked and O-linked carbohydrates in its 
fully matured 125 KDa isoform (Huber and Compton 1999). The inclusion of gO increases the 
efficiency of gH/gL transport through the secretory pathway, and thus has gO been assigned 
chaperone-like activities (Ryckman, Chase et al. 2010, Wille, Knoche et al. 2010).  
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 HCMV ORF UL74 (gO) is one of the most polymorphic HCMV genes that exists as 4 
distinct genotypes, two of which contain further distinguishable variants (gO-1a, gO-1b, gO-1c, 
gO-2a, gO-2b, gO-3, gO-4), with amino acid variation commonly centred around the first 100 
N-terminal residues (Huber and Compton 1998, Paterson, Dyer et al. 2002, Rasmussen, Geissler 
et al. 2002, Mattick, Dewin et al. 2004).  
 
 
 
Figure 1.14. Predicted conformations of alternative gH/gL glycoprotein complexes. (A) The classical 
gCIII glycoprotein complex gH/gL/gO. (B) The more recently described gCIII family member containing 
UL128L ORF-encoded glycoprotein sub-units: gH/gL/UL128/gpUL130/gpUL131A. Lines depict 
covalent bonds; cross-hatching depicts non-covalent bonds. The surface created by gH/gL to which 
gpUL131A bind is depicted by dark dots. Image 1.14. (B) reproduced from (Ryckman, Rainish et al. 
2008) and adapted for 1.14.A, with permission of American Society for Microbiology Publishers. 
 
 
 gH/gL/gpUL128/gpUL130/gpUL131A 1.14.2
 The most recently described gH/gL variant is a hetero-pentameric complex containing 
UL128L-encoded glycoproteins: gH/gL/gpUL128/gpUL130/gpUL131A (Wang and Shenk 
2005, Ryckman, Rainish et al. 2008) (Figure 1.14.B).  
 gpUL128 contains 171 amino acids with a signal peptide sequence predicted to span the 
first 27 N-terminal residues (Akter, Cunningham et al. 2003, Sun, Ji et al. 2009). A single site 
for N-linked glycosylation is predicted at amino acid position 55 (Rigoutsos, Novotny et al. 
2003), and gpUL128 can be detected by immunoblot analysis as multiple bands that include a 
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16 KDa entity likely representing the fully mature glycoprotein (Wang and Shenk 2005). A 
putative beta (cc) chemokine-like domain is observed in the N-terminal half of the gpUL128, 
consisting of conserved cysteine residues at positions 30, 31, 49 and 64 (Akter, Cunningham et 
al. 2003, Rigoutsos, Novotny et al. 2003, Hahn, Revello et al. 2004). Amino acid diversity is 
low in gpUL128 (95.4-96.9% aa identity in wildtype virus), and most frequently observed in the 
N-terminal region (Baldanti, Paolucci et al. 2006).  
 gpUL130 is the largest of the UL128L encoded glycoproteins, 214 amino acids long, 
with a signal peptide sequence that spans the first 25 N-terminal residues (Rigoutsos, Novotny 
et al. 2003, Sun, Ji et al. 2009). gpUL130 is a triglyceride containing sites for N-linked 
glycosylation modifications at residues 85, 118 and 201, as well as a putative methylation site at 
residue 145 (Rigoutsos, Novotny et al. 2003, Patrone, Secchi et al. 2005). Thus, gpUL130 
identified by multiple bands on immunoblot analysis, with a 35 KDa band representing the fully 
mature glycoprotein (Patrone, Secchi et al. 2005, Wang and Shenk 2005).  Like gpUL128, 
gpUL130 also contains a putative chemokine domain; the amino acid tract 46-120 resembles the 
structure of CXC chemokines, although only two of the four cysteine residues definitive of this 
chemokine class are present (aa residues 52 and 83) (Akter, Cunningham et al. 2003, Rigoutsos, 
Novotny et al. 2003, Hahn, Revello et al. 2004). gpUL130 displays the lowest amino acid 
sequence identity of the UL128L-encoded glycoproteins (91.1-96.6% aa identity in wildtype 
virus), with variation more diffuse than in UL128 and UL131A, though most commonly 
observed within residue tracts 8-78 and 128-151 (Baldanti, Paolucci et al. 2006).  
 gpUL131A is the smallest of the UL128L encoded glycoproteins, 129 amino acids in 
length, and predicted to contain a single N-linked glycosylation site located at amino acid 
residue 70 (Rigoutsos, Novotny et al. 2003, Sun, Ji et al. 2009). This UL128L–encoded 
glycoprotein is detected as a band of 14-15 KDa on immunoblot analysis (Adler 2006). 
gpUL131A is the most conserved UL128L-encoded glycoprotein (97.0-97.2% aa identity in 
wildtype virus), with variations localized to the amino acid tract covering residues 22-51 in the 
first exon that also contains a peptide signal spanning the first 18 N-terminal amino acids 
(Rigoutsos, Novotny et al. 2003, Adler 2006, Baldanti, Paolucci et al. 2006, Sun, Ji et al. 2009).  
 The UL128L encoded sub-units are stabilized in the pentameric complex by both di-
sulphide and non-covalent bonds (Ryckman, Rainish et al. 2008). gpUL130 and gpUL131A 
form associations stabilized by di-sulphide bonds, whilst gpUL130 forms further associations 
with both gH and gpUL128 via non-covalent bonds. gpUL128 in turn associates with gL via 
non-covalent interactions, and gpUL131A forms non-covalent association with a surface 
created by both gH and gL (Ryckman, Rainish et al. 2008). The inclusion of each UL128L 
encoded sub-unit promotes the incorporation other sub-units, with gpUL128 incorporation in 
turn promoting incorporation of gpUL130 and gpUL13A, whilst the absence of gpUL131A 
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leads to incorporation of an immature gpUL130 variant. Each of the UL128L encoded sub-units 
is absolutely required for complex assembly, with loss of any one component resulting in the 
retention of the remaining complex sub-units in the ER (Adler 2006, Ryckman, Rainish et al. 
2008). Furthermore, the incorporation of UL128L proteins increases the efficiency of gH/gL 
transport via the secretory pathway, in a similar manner to gO. Peptides within the UL128L 
encoded sub-units that contribute to the pentameric complex functionality have been 
investigated by charge-cluster-to-alanine mutagenesis. Functionally significant peptides have 
been proposed to exist within the central region of gpUL128 (aa 72-106), in particular, residue 
tracts 72-74, 82-86, and 104-108 (Schuessler, Sampaio et al. 2008); in the C-terminal region (aa 
142-214) of gpUL130, particularly involving an amino acid sequence motif (PNLIV) that 
closely resembles a cell-penetrating penta-peptide (CPP) motif implicated in internalization of 
proteins by endocytosis (Rhee and Davis 2006, Schuessler, Sampaio et al. 2010); as well as in 
numerous regions dispersed throughout gpUL131A (Schuessler, Sampaio et al. 2012). 
 Roles of gH/gL complex variants in entry of cell-free HCMV into cells 1.14.3
 HCMV enters different cell-types by different pathways. In fibroblasts, virus 
penetration is achieved by direct pH-independent fusion of the virion envelope and host cell 
plasma membrane (Compton, Nepomuceno et al. 1992), whilst in endothelial cells and 
epithelial cells, virions are first internalised by endocytosis prior to fusion of the virion envelope 
and endosomal membranes (Bodaghi, Slobbe-van Drunen et al. 1999, Ryckman, Jarvis et al. 
2006, Sinzger 2008). There are conflicting reports as to the requirement of endosomal 
acidification for the induction of fusion between the virion envelope and endosomal membranes 
(Ryckman, Jarvis et al. 2006, Sinzger 2008). Internalisation into dendritic cells has been 
reported to occur by a macropinocytosis-like pathway, with subsequent fusion occurring via a 
pH-independent mechanism (Haspot, Lavault et al. 2012). The alternative gH/gL glycoprotein 
complexes facilitate the internalisation of cell-free virus in different cell types. This model is 
supported by data from interference assays where endogenous expression of gH/gL/gO rendered 
fibroblasts but not epithelial cells refractory to infection, whilst endogenous expression of 
gH/gL/gpUL128/gpUL130/gpUL131A blocked infection in epithelial cells but not fibroblasts 
(Ryckman, Chase et al. 2008, Vanarsdall, Chase et al. 2011). Hence each distinct gH/gL 
complex potentially engages alternative saturable receptor molecules present on different target 
cell types (Figure 1.14.B).  
 Whilst the gH/gL/gO complex facilitates the entry of cell-free virus into fibroblasts, the 
specific contribution of gO to this activity is unclear. A direct contribution of glycoprotein gO 
to fusion has been suggested since anti-gO antibodies can prevented virus-mediated cell fusion 
(fusion-from-without) (Paterson, Dyer et al. 2002). However, syncytia formation in cells 
endogenously expressing gH/gL and gB was not enhanced by co-expression of gO (fusion-
from-within) (Vanarsdall, Chase et al. 2011). Glycoprotein gO has also been reported to reduce 
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the inhibitory impact of anti-gH and anti-gB antibodies on the entry of virus in to cells, 
suggesting that gO may play an indirect role by preventing exposure of the HCMV virion core 
fusion machinery to components of the humoral immune system (Jiang, Sampaio et al. 2011); a 
similar role has been postulated for glycoprotein gN (Kropff, Burkhardt et al. 2012). A role for 
gH/gL/gO during the entry of non-fibroblasts has also been suggested (Wille, Knoche et al. 
2010). In this work, virions from a gO-null mutant remained at the surface of inoculated 
epithelial and endothelial cells, and were only internalised following treatment with fusogenic 
agents, suggestive of an entry defect. 
 
 
 
 
Figure 1.15. Requirement of alternative gH/gL complexes for entry into different cell types. 
gH/gL/gO, required for infection of fibroblasts, and gH/gL/gpUL128/gpUL130/gpUL131A, required for 
entry into epithelial and endothelial cells, as well as others. Figure reproduced from (Vanarsdall and 
Johnson 2012), with permission of Elsevier publishers. 
   
 
 
 No reports detailing any specific role of the UL128L-encoded glycoproteins during the 
entry of cell-free virus into fibroblasts are currently available. However the requirement of the 
pentameric complex for entry into non-fibroblasts is strict, with UL128L-null mutants markedly 
restricted in the ability to infect epithelial and endothelial cells (Sinzger, Knapp et al. 1997, 
Hahn, Revello et al. 2004, Adler 2006, Straschewski, Patrone et al. 2011). Furthermore, anti-
bodies specific for UL128L encoded proteins block HCMV infection of epithelial and 
endothelial cells, but not fibroblasts (Wang and Shenk 2005, Adler 2006). The pentameric 
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complex is active in a post-attachment step, though prior to penetration of virus following 
fusion between the viral envelope and endosomal membranes; virions lacking the pentameric 
gH/gL complex variant are internalised into endothelial cells by endocytosis, but are unable to 
deliver its genome to the nucleus (Slobbe-van Drunen, Hendrickx et al. 1998, Sinzger, Kahl et 
al. 2000). The UL128L proteins have also been suggested to mediate interactions between gH 
and gB, which in turn trigger the conformational changes that occur in gB to facilitate 
membrane fusion and the entry of virus into endothelial cells (Patrone, Secchi et al. 2007).  
 
 Roles of gH/gL complex variants in cell-to-cell spread of HCMV 1.14.4
 Assembly of the trimeric gH/gL complex variant (gH/gL/gO) is not absolutely required 
for HCMV replication and dissemination in fibroblasts; gO-null mutants reconstituted from 
BAC-cloned HCMV genomes display a severe growth defect compared to parental virus, but do 
remain viable (Hobom, Brune et al. 2000, Dunn, Chou et al. 2003). Thus, gO enhances the 
growth of HCMV in fibroblasts. Whilst gO-null mutant virus has been described to display a 
small plaque phenotype in fibroblasts, cell-to-cell spread in epithelial or endothelial cells has 
been observed to be unaffected, if not enhanced (Hobom, Brune et al. 2000, Paterson, Dyer et 
al. 2002, Jiang, Adler et al. 2008, Wille, Knoche et al. 2010). Therefore, assembly of the 
trimeric gH/gL complex is potentially inhibitory to the cell-to-cell spread of virus in non-
fibroblasts.  
 A hallmark of ‘laboratory-strains’ that contain ablating UL128L mutations is greater 
plaque formation in fibroblast cultures; hence assembly of the pentameric complex is correlated 
with reduced cell-to cell spread in this cell type. Interestingly, a UL74-null (gO-null) and 
UL128L-null double mutant virus has been shown to be completely non-viable in fibroblasts 
(Jiang, Adler et al. 2008). Thus, whilst UL128L is non-essential and impedes the cell-to-cell 
spread of virus in fibroblasts, the pentameric gH/gL complex does apparently contribute to this 
activity in the absence of the trimer. As with the dissemination of cell-free virus, the cell-to-cell 
spread of a UL128L-null mutant is also heavily restricted in non-fibroblasts (Sinzger, Knapp et 
al. 1997, Hahn, Revello et al. 2004, Adler 2006, Straschewski, Patrone et al. 2011).  
 
 Roles of gH/gL complex variants in cell-free HCMV production 1.14.5
 The trimer has been implicated in progeny virion morphogenesis and/or release, and is 
potentially involved in the secondary envelopment of nascent nucleocapsids similar to gM/gN 
complexes (Jiang, Adler et al. 2008). This was based on the observation that reconstitution of a 
gO-null mutant in fibroblasts resulted in the accumulation of non-enveloped nucleocapsids in 
the cytoplasm, whilst infections with the gO-null mutant in both fibroblasts and endothelial cells 
were predominantly cell-associated and produced low titres of cell-free virus. However these 
results contradicted those from the previously mentioned study (Wille, Knoche et al. 2010), 
where a gO-null mutant displayed no difference in cell-free virus production compared to 
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parental virus. Expression of intact UL128L ORFs has been clearly demonstrated to result in a 
vast reduction in cell-free virus production, but the mechanism by which pentameric complex 
assembly contributes to this growth phenotype is not established. Interestingly, a gO-null 
mutant has also been reported to produce virions containing increased quantities of 
gH/gL/gpUL128/gpUL130/gpUL131A, suggesting competition for available gH/gL for the 
formation of either complex variant (Wille, Knoche et al. 2010). 
 The role of HCMV gH/gL complex variants during virus replication: summary 1.14.6
 The requirements for each the distinct gH/gL complexes in different cell types are 
widely contrasting, however each complex variant may not be totally redundant in cell types 
where they are not strictly required. In summary, the trimer complex (gH/gL/gO) is necessary 
for the entry of cell-free virus in to fibroblasts, and is a major participant in the cell-to-cell 
dissemination of virus in this cell-type. Furthermore, gH/gL/gO may also be involved in the 
entry of cell-free virus in non-fibroblasts (e.g. epithelial and endothelial cells). The pentameric 
complex (gH/gL/gpUL128/gpUL130/gpUL131A) is necessary for the entry and cell-to-cell 
dissemination of HCMV in a range of naturally targeted cell types other than fibroblasts. The 
specific contribution of either gH/gL variant to the production of cell-free virus during infection 
of fibroblasts and non-fibroblasts remains unclear. 
1.15 Biologically relevant HCMV strains currently available for research in vitro 
 There is a clear need for translational HCMV research to be based on strains that best 
reflect the causative agent of disease, including those that assemble the pentameric complex and 
are suitable for investigation in a broad range of naturally infected cell types. The availability of 
low-passage BAC-cloned strains partially addressed the problem where recent clinical isolates 
undergo rapid adaptation to cell culture, and provided a stable source from which the same 
‘broad-tropism’ virus could be reconstituted.  
 ‘Broad-tropism’ BAC-cloned strains  1.15.1
 Several of the currently used BAC-cloned HCMV strains produce virus with broad 
tropism resembling that of wild type virus, and by extension, contain intact UL128L genome 
regions. The most widely used ‘broad-tropism’ BAC-cloned strains include: TR-BAC, captured 
from isolate TR derived from the ocular swab of an AIDS patient with retinitis, with unknown 
passage history (Smith, Taskintuna et al. 1998, Murphy, Yu et al. 2003); TB40-BAC4, cloned 
from the mixed virus population TB40/E derived from the throat wash of a bone marrow 
transplant recipient, following 5 passages in fibroblasts and 22 passages in endothelial cells 
(Sinzger, Schmidt et al. 1999, Sinzger, Hahn et al. 2008); and FIX-BAC, cloned from the 
clinical strain VR1814 derived from the cervical swab of a pregnant lady with primary 
infection, following 46 passages in fibroblasts (Revello, Baldanti et al. 2001, Hahn, Khan et al. 
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2002). However, none of these BAC-cloned strains contain the full complement of wildtype 
genes contained by virus in vivo: each lack sequences in US genome region where the BAC 
vector sequences were stably inserted; and each has been demonstrated to contain lesions 
affecting ORFs throughout the genome. Importantly, sequencing data from the un-passaged 
wildtype progenitors viruses from which these strains were cloned are not available, and it is not 
possible to confirm whether the ORFs in these strains contain wildtype sequence. 
 Cloning of the wildtype Merlin genome as a BAC-construct 1.15.2
In light of the uncertainties regarding the coding potential of the above-described 
‘broad-tropism’ BAC-cloned strains, the genome from the wildtype strain Merlin was captured 
as a BAC construct (Stanton, Baluchova et al. 2010). The Merlin isolate was subjected to 
limited passaging in fibroblasts prior to BAC cloning, in which time virus containing mutations 
at 2 genetic loci were selected: RL13, and UL128. The premature stop codon in UL128 
abrogated gH/gL/gpUL128/gpUL130/gpUL131A functionality, and virus displayed a growth 
phenotype and tropism range similar to that of ‘laboratory-adapted’ strains (i.e. was propagated 
efficiently and produced high titres of cell-free virus, though displayed restricted tropism for 
non-fibroblasts). This mutation was repaired in the BAC by reference to sequencing data 
derived directly from the un-passaged wildtype virus in the clinical sample. Furthermore, unlike 
many other BAC-cloned strains, the Merlin-BAC contains a self-excising BAC vector sequence 
and no genes were sacrificed during the clonal of this strain. As a result, the Merlin-BAC 
represents the only cloned HCMV genome with coding potential identical to that of wildtype 
virus in vivo.  
 Limitations of the wildtype Merlin-BAC construct 1.15.3
 Following the repair of ORF UL128 in the BAC-cloned Merlin genome, the inhibitory 
impact of wildtype UL128L (and by extension the pentameric gH/gL complex variant) on the 
production of cell-free virus was clearly demonstrated; infections with virus from the Merlin-
BAC variant containing wildtype UL128L produced peak titres of cell-free virus that were 
~1000-fold lower than that produced by otherwise identical virus containing the ablating UL128 
mutation (UL128Lmut) (Stanton, Baluchova et al. 2010). Furthermore, de novo UL128L 
mutations were repeatedly selected following attempts to propagate of virus from the Merlin-
BAC containing wildtype UL128L sequence. Thus, similar to low-passage clinical isolates, this 
newly generated reagent is limited in it’s utility. Interestingly, indirect comparisons between 
growth kinetics data for viruses from the wildtype Merlin-BAC to that published for viruses 
from the TR-BAC, TB40-BAC4 and FIX-BAC clones, suggested that infections with these 
latter strains produced greater titres of cell-free progeny virus. Furthermore, unlike Merlin, 
these strains have not been reported to lose their broad tropism when passaged on fibroblasts. 
Thus, these strains potentially contain features that allow virus to be propagated more efficiently 
without involvement of mutations in the UL128L genome region.  
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1.16 Aims of current study 
This project aimed to investigate ways by which viruses derived from the wildtype 
Merlin BAC-cloned strain could be propagated more efficiently, and more stably in vitro, as 
well as to assess the biochemical composition of virions from this strain. There were four 
avenues of exploration: 
• Investigate whether viruses reconstituted from the TR-BAC, TB40-BAC4 and FIX-
BAC cloned genomes grow more efficiently compared to virus from the Merlin-BAC, 
and also whether each contained features that could be transferred to the Merlin-BAC 
genome to produce viruses that grow more efficiently. 
• Determine the impact of any such features on specific activities in the viral replication 
cycle. 
• Assess the impact of any altered growth phenotype displayed by viruses from the 
Merlin-BAC variants produced on the genetic stability of virus in cell culture, and 
develop methods of growing Merlin virus without the risk of mutations in UL128L 
being selected. 
• Determine the proteome composition of wildtype Merlin virions to inform studies of 
tropism, entry of virus into cells, and vaccine development. 
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2.1 Solutions, buffers and media  
Unless otherwise stated, the tissue culture reagents used were from the Gibco product line of 
Invitrogen/Life Technologies, and the analytical grade chemicals and bacterial culture reagents 
used were from Sigma and/or Fisher. Double-distilled ultra-pure water (ddH2O) used for the 
preparation of solutions, buffers, and media was delivered from a Purelab Ultra water system 
(Elgin).   
 
2 x DMEM: 50% (v/v) ddH20, 20% (v/v) 10X MEM, 20% (v/v) FBS, 
1000 U.L-1 penicillin, 1000 μg.L-1 streptomycin, 4 mM L-1 
glutamine, 0.45% (w/v) sodium bicarbonate. 
TE buffer (pH 8.0): 10 mM Tris, 1 mM EDTA in ddH2O. 
DNA loading buffer: ddH20, 10 mM Tris-HCl, 0.03% bromophenol blue, 
60% glycerol, 60 mM EDTA. 
DNA running buffer: 1x TAE (0.04M tris acetate, 2 mM Na2 EDTA), in ddH20 
Luria-Bertani (LB) broth: ddH20, 1% (w/v) tryptone (Fluka), 0.5% (w/v) yeast extract, 
0.85M NaCl. 
All formulated bacterial culture media was sterilized by 
autoclaving. Prior to addition of supplements, media was 
tempered to 50°C. 
LB Agar: LB broth, 15% (w/v) agar (Oxoid). 
LB Agar + Sucrose: ddH20, 1% (w/v) tryptone (Fluka), 0.5% (w/v) yeast extract, 
15% (w/v) agar (Oxoid) 5% (w/v) sucrose. 
Ampicillin solution: 
 
50 mg/mL Ampicillin (Melford) in ddH2O, sterilised by 
passage through 0.22 μm filters. 
Chloramphenicol solution: 12.5 mg/mL chloramphenicol (Melford), in 100% ethanol 
IPTG solution: 100 mM isopropyl β-D-1-thiogalactopyranoside (Melford), 
in ddH2O. 
X-gal solution: 40 mg/mL 5-bromo-4-chloro-3-indolyl β-D-
galactopyranoside (Melford) in N-dimethyl formamide. 
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PBS (pH 7.3): 0.8% (w/v) sodium chloride, 0.02% (w/v) potassium 
chloride, 0.115 % (v/v) di-sodium hydrogen phosphate, 
0.002% potassium di-hydrogen phosphate (Oxoid) in ddH20. 
4% PFA solution PBS, 4% (w/v) paraformaldehyde. 
IF wash/block buffer: PBS, 1% (w/v) BSA. Depending on use, IF buffers differed 
on the inclusion or exclusion of sodium azide. For IE1 
immuno-staining, 0.01 % (w/v) sodium azide was added to 
IF buffer. 
SILAC ‘L’ Medium: SILAC DMEM (Thermo) supplemented with 10% (v/v) 
dialysed FBS, 500 U.L-1 penicillin, 500 μg.L-1 streptomycin, 
250 μg.L-1 ‘light’ L-Proline, 50 μg.L-1 ‘light’ L-Lysine 
dihydrochloride (CK Isotopes), 50 μg.L-1 
Dialysed FBS was cleared of large debris by centrifuging at 
x g for 10 mins at room temperature, and passed through a 
0.45 filter prior to addition. Isobaric-labeled amino acids 
were dissolved in excess SILAC DMEM and passed 
through a 0.22 filter prior to addition. 
 SILAC ‘M’ Medium: SILAC DMEM (Thermo) supplemented with 10% (v/v) 
dialysed FBS, 500 U.L-1 penicillin, 500μg.L-1 streptomycin, 
250 μg.L-1 ‘light’ L-Proline, 50 μg.L-1 ‘medium’ L-Lysine 
di-hydrochloride (CK Isotopes), 50 μg.L-1 ‘medium’ L-
Arginine di-hydrochloride (CK Isotopes). 
SILAC ‘H’ Medium: SILAC DMEM (Thermo) supplemented with 10% (v/v) 
dialysed FBS, 500U.L-1 penicillin, 500 μg.L-1 streptomycin, 
250 μg.L-1 ‘light’ L-Proline, 50 μg.L-1 ‘heavy’ L-Lysine di-
hydrochloride (CK Isotopes), 50 μg.L-1 ‘heavy’ L-Arginine 
di-hydrochloride (CK Isotopes). 
Dexamethasone solution: 25 mM Dexamethasone, in ethanol 
NaPh buffer: 0.0076 M sodium di-hydrogen phosphate, 0.0324 M di-
sodium hydrogen phosphate, in ddH2O 
Gradient ‘Light’ solution: NaPh buffer, 15% (w/w) sodium tartrate, 30% (w/w) 
glycerol 
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2.2 Cells and Viruses 
 Cells 2.2.1
Human cell lines used include: two variant hTERT-immortalised epithelial cell lines, RPE-1 
(ATCC #: CRL-4000) and ARPE-19 (ATCC #: CRL-2302); and Human Foetal Foreskin 
Fibroblast (HFFF) cells, kindly supplied by Dr. Graham Farrar (CAMR, Salisbury, UK). 
Further cell lines used were derived from hTERT-immortalised HFFFs (HFFF-hTERTs) 
(McSharry, Jones et al. 2001). The HFFF-tet cell line was generated by transducing HFFF-
hTERTs to constitutively express tetracycline (Stanton, Baluchova et al. 2010); these were used 
for the selective repression of viral genome regions engineered to contain tetracycline-binding 
operators. The HF-hCAR cell line was generated from HFFF-hTERT cells engineered to 
express the human Coxsackie Adenovirus Receptor (hCAR) (McSharry, Burgert et al. 2008); 
these were used for the expression of HCMV transgenes from RAdZ-5 vectors. The 293-TREx 
helper cell-line (Invitrogen/Life Technologies), based on HEK293 cells transduced to express 
the Adenovirus E1 genome region (Graham, Smiley et al. 1977), were used for the propagation 
of AdZ-5 vectors.  
 HCMV strains 2.2.2
HCMV strains used are detailed in Table 2.1. Several Merlin-BAC variants were readily 
available prior to the onset of this work. BAC-cloned versions of strains TR (TR-BAC), TB40/E 
(TB40-BAC4), and VR1814 (FIX-BAC) were kindly supplied by Jay Nelson (OHSU, Portland 
Oregon, USA), Christian Sinzger (University of Tubingen, Germany) and Gabi Hahn 
(Universitätklinikum Carl Gustav Carus, Dresden, Germany), respectively. Each was received 
in the form of purified cell-free DNA. To provide an observable marker of infection, all BAC-
Gradient ‘Heavy’ solution: NaPh buffer, 35% (w/w) sodium tartrate 
Sorbitol cushion: PBS, 20% (w/v) sorbitol 
MOPs SDS running buffer: 2.5 mM MOPS, 2.5 mM Tris Base, 0.005% (w/v) SDS, 0.05 
mM EDTA 
Carbonate transfer buffer: 3 mM sodium carbonate, 10 mM sodium bicarbonate, 10% 
(v/v) methanol 
PBS-T: PBS, 0.1% (v/v) Tween 20 
Immunoblot block/stain buffer: PBST, 5% (w/v) fat-free milk proteins (Marvel) 
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cloned genomes were engineered to express enhanced green fluorescent protein (eGFP) from 
the same transcriptional unit as the immediate early genes IE1/IE2 (UL122/UL123), as 
previously described (Stanton, Baluchova et al. 2010). Purified cell-free genomic DNA from the 
un-passaged HCMV strain 3301 was kindly donated by Andrew Davison.  
 
Table 2.1. HCMV Strains investigated 
a – several Merlin-BAC variants were used. 
 
 Adenovirus vectors 2.2.3
AdZ-5 vector constructs (Stanton, McSharry et al. 2008) contained within E.coli SW102 cells 
were readily available prior to the onset of this work. The AdZ-5 vectors lacked the essential E1 
and E3 genome regions, and thus were replication deficient. In place of the deleted genome 
regions, the AdZ vector contained features that allowed the efficient insertion and expression of 
HCMV-derived transgenes. These included, in tandem: the HCMV major immediate early 
(MIE) promoter, a selectable cassette (see section 2.5) occupying the transgene insertion site, 
and an HCMV MIE polyadenylation sequence (polyA tail).  
2.3 Tissue and virus culture 
 Human cell master stocks  2.3.1
Master stocks of each cell type were stored in cell banks at -196°C in liquid nitrogen. Cells were 
suspended in ‘freezing medium’ [90% (v/v) FBS, 10% (v/v) DMSO], and stored in Cryo.S 1mL 
cryovials (Grenier Bio-One). To ensure cells remained viable during freezing, cells were 
initially cooled to -70°C at a rate of -1°C min-1 using a Cryo 1°C Freezing Container (Nalgene), 
before being transferred to the cell bank. All cell-lines were screened for Mycoplasma infection 
using the VenorGeM Mycoplasma PCR detection kit (Sigma-Aldrich), and deemed suitable for 
use only when found to be negative. 
Strain BAC-cloned version GenBank no. 
References 
Merlina Merlin-BAC GU179001.1 (Stanton, Baluchova et al. 2010) 
TR TR-BAC AC146906.1 (Murphy, Yu et al. 2003) 
TB40E TB40-BAC4 EF999921.1 (Sinzger, Hahn et al. 2008) 
VR1814 FIX-BAC AC146907.1 (Hahn, Khan et al. 2002) 
3301 n/a GQ466044.1 (Cunningham, Gatherer et al. 2010) 
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 Tissue culture reagent preparation and manipulations  2.3.2
Tissue culture reagents were defrosted and warmed to 37°C in a water bath prior to use. All 
manipulations of human cells and viruses were conducted within a Class II biological safety 
cabinet (BSC), and performed with aseptic technique. Internal surfaces of the BSC and external 
surfaces of sample and reagent containers were de-contaminated using a solution of 70% (v/v) 
IMS before performing any manipulations.  
 Growth of human cells 2.3.3
Standard tissue culture conditions for the growth of human cells were: 37°C, in an environment 
of 5% CO2. Unless otherwise stated, cells were propagated in standard tissue culture media 
[DMEM supplemented with 10% (v/v) FBS, 100 U.mL-1 penicillin, and 100 µg.mL-1 
streptomycin]. Cells were fed with fresh media every 2-3 days. All cell types utilised were 
adherent and grown in monolayers attached to the surface of flat-bottomed tissue culture flasks 
and plates (Corning). 293TREx cells adhered less sturdily than other cell types and were grown 
in culture vessels of the ‘Cell Bind’ product line (Corning). When grown to confluency, cells 
were harvested for use in assays, or for continued growth by ‘splitting’. 
 Harvesting adherent cells 2.3.3.1
Cell culture supernatants were removed before cells were washed in excess PBS. Cells were 
then dissociated from the culture flask surface by the addition of 0.05% trypsin/EDTA and 
incubation at 37°C for 3-5 mins. Flasks were then gently tapped to disrupt the cell monolayer, 
with detached cells aspirated in excess culture medium to quench residual trypsin, and generate 
a homogenous single-cell suspension. 
 Counting harvested cells 2.3.3.2
Harvested cells were counted using a glass haemocytometer. The counting chamber was loaded 
with 10 μL of homogenous single-cell suspensions, and the number of cells within grids that 
held 0.1 μL (1 x 10-4 mL) was counted. The averaged cell count from several grids was 
multiplied by a factor of 10,000 (104) to determine the number of cells in 1 mL of the original 
suspension. 
 Seeding cell culture vessels 2.3.3.3
To maintain cell cultures at optimal sub-confluency by ‘splitting’, absolute cell counts were not 
determined and harvested cells were instead diluted by nominal factors. For use in infections 
and assays, cell culture flasks and plates were seeded with a known number of cells predicted to 
grow overnight to a suitable degree of confluency (40-80%). Media volumes, nominal dilution 
factors for splitting, and cell numbers used to seed all culture vessels are depicted in Table 2.1. 
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Table 2.2. Dilution factors and seed numbers for planned growth of cell 
a – culture vessel and volume of media used for growth of cells therein. 
 Infections  2.3.4
Unless otherwise stated, all virus infections were performed under standard culture conditions. 
To maximise virus-cell interactions, inocula were prepared in the minimal volume sufficient to 
cover all cells. Inoculated cell cultures were initially incubated on a rocking platform (at 5-10 
RPM) for two hours during which time virus was adsorbed onto cells. Following adsorption, the 
inoculum was removed and replaced with fresh culture medium. To limit virus dissemination to 
the cell-to-cell route only, infected cell cultures were incubated under a semi-solid overlay 
composed of a mixture (1:1) of 2X DMEM and Avicel; a mixture of microcrystalline cellulose 
and sodium carboxymethylcellulose (FMC Biopolymer), as previously described (Matrosovich, 
Matrosovich et al. 2006). 
Cell Type 
 
Fibroblasts 
(HFFF, HF-hCAR, HF-tet) 
Epithelial cells 
(RPE-1, ARPE-19) 
293TREx 
Dilution factor for cell stock ‘splitting’ 
Culture 
vesselsa 1:3 – 1:5 1:6 – 1:8 1:8 – 1:10 
Cell number for seeding cell culture flasks 
T150 
(15-20 mL) 
4 x 106 4 x 106  
T75 
(10-15 mL) 
3 x 106 2 x 106  
T25 
(5-7 mL) 
6 x 105 7 x 105 2 x 106 
Cell number for seeding cell culture cluster plates 
6-well 
(2 mL) 
2.5 x 105 3.0 x 105  
12-well 
(1 mL) 
1.25 x 105 1.5 x 105 5 x 105 
96-well 
(100 µL) 
1.5 x 104 2.0 x 104  
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 Monitoring infections  2.3.5
 Microscopy and photography 2.3.5.1
Infections were monitored by phase-contrast microscopy for observable cytopathic effects 
(CPE), and by fluorescence microscopy for eGFP expression using DM:IL or DM:IRBE 
microscopes (Leica) (Figure 2.1.). Photographic imaging of infected cell cultures was 
performed using an ORCA-ER camera attached to the Leica DM:IRBE microscope. Image 
analysis was performed using Image J 64 and OpenLab 3 software (Perkin Elmer), with 
measurements of plaque dimensions made using tools within each software package following 
calibration using a 100-micron graticule. Estimation of the sizes of approximately elliptical 
plaques formed in HCMV-infected cell cultures, in μm2, was performed using the following 
calculation: 
 
Plaque length (μm) x Plaque width (μm) x 0.8 
 
 
 
Figure 2.1. HFFF and RPE-1 plaque imaging and size measurement. Representative HFFF and RPE-
1 plaques formed Merlin BAC-derived viruses either lacking intact UL128L, or containing wildtype 
UL128L. Magnification of images is shown. w - indicates plaque width; l - indicates plaque leng 
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 Flow cytometry 2.3.5.2
Infections in epithelial cell cultures were monitored by flow-cytometry using an Accuri C6 (BD 
Bioscience) (Figure 2.2.). Samples were prepared as follows: total cells (infected and un-
infected) were harvested as previously described, then collected by centrifuging the resultant 
suspensions at 470 in x g for 3 mins at room temperature. Following removal of the supernatant, 
cells were washed by re-suspending the pellet in excess PBS and repeat of the centrifuging. 
Washed cells were re-suspended in PBS and then fixed in 2% (w/v) PFA for 15 mins at 4°C. 
Samples were analysed on the Accuri C6 flow cytometer with 20,000 events recorded under 
parameters defined using the CFlow software. Gating of live cells was based on two criteria: 
size and granularity. Non-infected and infected cells were distinguished by fluorescence signal, 
indicative of eGFP expression. To account for auto-fluorescence, and also any fluorescence 
from the originally transfected cells and not disseminated infectivity, the proportion of eGFP+ 
epithelial cells in cultures transfected with Merlin virus lacking intact UL128L (and unable to 
disseminate in epithelial cells) was used as a threshold (~ 1%) to which all other infections were 
compared.  
 
 
 
Figure 2.2. Monitoring infection of epithelial cell culture by flow cytometry. Example of data 
analysis. (A) The recorded events considered to represent live cells were gated for (red dash line), based 
on granularity (SSC-A), and size (FSC-A). (B) eGFP expression was detected in channel FL1-A. 
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2.4 Molecular Biology Techniques 
 In silico analysis of nucleic acid and amino acid sequences 2.4.1
Nucleic acid and amino acid sequence comparisons, recombineering experiment design, primers 
and oligonucleotide design, and sequencing data analysis, was performed using CLC MAIN 6 
software (CLC Bio). Primers and oligonucleotide attributes were verified using Oligo Explorer 
1.4 Beta (GeneLink) and Oligo Analyser (GeneLink) software packages.  
 Molecular biology reagent storage and preparation 2.4.2
Unless otherwise stated, all thermo-labile reagents and reaction products were stored at -20°C. 
To increase thermo-stability, nucleic acids were dissolved and stored in TE buffer, unless 
otherwise stated. All thermo-labile reagents were defrosted gradually and stored on ice during 
use, whilst thermo-stable reagents were defrosted in a water bath and stored at room 
temperature.  
 Nucleic acid modification and amplification 2.4.3
Modification and amplification of nucleic acids was performed with various commercial kits 
(indicated below), with all reactions performed within thin-walled DNAse and RNAse-free 
tubes (ELKay), under thermal cycling conditions as specified for each kit using a T3000 
Thermocycler (Biometra). When not included in a given kit, dNTPs (New England BioLabs) 
and PCR-grade ddH20 supplied by the user were used. PCR reaction mixtures were 
supplemented with 3% (v/v) DMSO to limit template secondary structure formation and 
increase amplification efficiency.  
 Primer Design 2.4.4
Where possible, primers were designed to have a melting temperature (Tm) 60-65°C, as well as 
display limited self/pair annealing and secondary structure formation. All primers and 
oligonucleotides were acquired from Sigma-Aldrich as Reverse Phase Cartridge purified 
lyophilised DNA. Primers were reconstituted by the addition of an appropriate volume of ddH20 
to achieve a final 100 μM concentration. 
 DNA gel electrophoresis 2.4.5
DNA fragments were resolved and isolated from mixed samples by agarose gel electrophoresis. 
Gels were formed by dissolving agarose in tris-acetate-EDTA (TAE) buffer, and were 
supplemented with ethidium bromide to stain captured DNA. Gels were cast using trays and 
accompanying well-forming combs, and allowed to set prior to submersion in excess TAE 
running buffer. Samples were mixed with 0.2 volumes of 6X DNA loading buffer, then loaded 
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into individual wells. In each electrophoresis performed, a sample of DNA Smart ladder 
(Eurogentec) was loaded to a separate well and electrophoresed in parallel, allowing estimation 
of the sizes of resolved DNA fragments by extrapolation to the migration of fragments of 
known size. Resolved amplicons were visualised by UV light activated ethidium bromide 
fluorescence using an Autochemi Bioimaging system (UVP) and LabWorks software (Perkin 
Elmer), or a bench-top transluminator (Spectroline). 
 Purification of PCR-amplified DNA 2.4.6
DNA was purified from PCR reactions using the Illustra GFX DNA and Gel Band purification 
Kit (GE Healthcare) according to manufacturer’s instructions. In brief, nucleic acids and other 
macromolecules were first denatured in the presence of a chaotropic buffer (supplied), and then 
non-specifically captured onto silica membranes by centrifugation. Residual salts and other 
impurities were cleared from captured DNA by the addition of wash buffer (supplied) 
supplemented with ethanol, then further centrifugation. Captured and purified DNA was then 
eluted and recovered in an appropriate buffer (supplied) during one further spin. Where target 
amplicons were required to be separated from other non-specific amplicons, they were first 
isolated by agarose gel electrophoresis and then excised directly from gels. Excised gel 
segments were then transferred to sterile 1mL sample tubes, together with an appropriate 
volume of capture buffer, and incubated at 60°C for ~5 mins to melt the gel and release DNA. 
Alternatively, where purity was of little consequences for downstream applications, DNA was 
purified directly from PCR reaction mixtures diluted in capture buffer.  
 Determination of DNA concentration 2.4.7
The concentration of DNA samples was determined using a Nano-drop ND-1000 
spectrophotometer (ThermoScientific). The spectrophotometer was initialised with ddH20 
according to standard operating procedures, then the loading pedestal was wiped using fibre-
less paper. The instrument was then blanked by loading 2 μL of the relevant solvent buffer and 
performance of a measurement. The loading pedestal was again wiped before loading 2 μL of 
analyte sample to be measured.  
2.5 Recombineering of BAC-cloned HCMV and Adenovirus genomes  
 Phage Lambda Red-mediated Homologous Recombination  2.5.1
Recombination mediated genetic engineering (‘Recombineering’) (Warming, Costantino et al. 
2005) of BAC-cloned HCMV genomes and for the insertion of transgenes into the AdZ-5 vector 
was performed as previously described (Stanton, McSharry et al. 2008, Stanton, Baluchova et 
al. 2010). In brief, recombineering was performed in E. coli SW102 cells transduced to express 
phage lambda red recombinant proteins that facilitate recombination between homologous 
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nucleotide sequences as short as 50 bp. Cells containing the ‘recipient’ BAC-cloned genomes to 
be modified were subjected to two successive rounds of transformation. In the first round, a 
DNA construct that encoded selectable characteristics (ampr/sacB/lacZ cassette) was inserted 
into the region to be modified. In the second round of transformation, ‘donor’ sequences were 
inserted in place of the selectable cassette. Details of each recombineering experiment, co-
ordinates to the regions to be modified in the ‘recipient’ genome and sequences/regions to be 
transferred from the ‘donor’ genome, as well as all primers and oligonucleotide used, are 
detailed in Appendix I.  
 Design and preparation of DNA sequences for transformation 2.5.2
To facilitate incorporation by homologous recombination, sequences to be inserted were 
engineered to contain sequence extensions with homology to regions flanking the intended site 
of insertion. The selectable ampr/sacB/lacZ cassette and ‘donor’ sequences were PCR amplified 
and gel-purified prior to use, with primer pairs used designed to contain ~20-nucleotides at their 
3’ end identical to sequences at the termini of the sequence to be inserted (cassette or ‘donor’ 
sequences), and ~80-nucleotide at their 5’ end identical to sequences flanking the insertion site 
in the ‘recipient’ genome. To transfer single ‘donor’ nucleotides, commercially produced 
oligonucleotides of ~100-nucleotide length were used in the second transformation step. 
 ampr/sacB/lacZ cassette amplification  2.5.2.1
The 4.217 Kb ampr/sacB/lacZ cassette was PCR-amplified using the Expand HiFi PCR system 
(Roche), which employs the robust 5’-3’ reading Taq DNA polymerase in combination with a 
3’-5’ proofreading exonuclease for increased amplification fidelity. Amplification was 
performed by a 2-step PCR reaction, under the following thermal-cycling conditions: 
• 95°C - 2 mins;  
• 10 cycles: 95°C - 30 s, 55°C - 30 s and 68°C - 4.5 mins;  
• 25 cycles: 95°C - 30 s, 55°C - 30 s and 68°C - 4.5 mins + 20 s per additional cycle;  
• 68°C - 15 mins. 
  ‘Donor’ sequence amplification 2.5.2.2
‘Donor’ sequences were PCR-amplified using the Phusion High Fidelity kit (New England 
BioLabs) that employs an enzyme that is less robust, though amplifies with greater fidelity, 
compared to Taq DNA polymerase. Amplification was performed as following:  
• 98°C - 1 mins;  
• 35 cycles: 98°C - 30 s, 55°C - 30 s and 72°C - 15-30 s per Kb;  
• 72°C - 10 mins 
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 Preparation and transformation of electro-competent E.coli SW102s  2.5.3
Phage-lambda red homologous recombineering protein expression is temperature-controlled, 
occurring between 37°C and 45°C (optimal 42°C). To limit recombineering protein expression 
prior to transformation, E.coli SW102s were grown at 32°C in a shaking incubator (at 200 
RPM). All bacterial cultures were grown in media based on low-salt LB broth supplemented 
with the anti-biotic chloramphenicol (12.5 μg/mL); this enriched for cells that contained the 
BAC vector encoding a chloramphenicol resistance gene. To generate an abundance of viable 
electro-competent cells, cultures were grown to upper cellular concentration limits whilst 
remaining in ‘log-phase’ of growth. The cellular concentration of cultures was monitored during 
growth by spectrophotometry using an UltraSpec 3000 (Pharmacia Biotech), with bacterial 
culture growth halted when cultures reached a density of 0.6 OD units as detected at 600 wv. 
Phage lambda red homologous recombination protein expression was induced by incubating 
cultures at 42°C for 15 mins, prior to incubation on ice for a further 15 mins to arrest any further 
growth and ensure bacterial cells remained transformation competent. Cells were then washed 
by to clear residual salts by three successive rounds of centrifuging at 3345 x g at 0°C for 5 
mins and re-suspension in ice-cold ddH20. Cells in the final washed pellet were then re-
suspended in ~400-500 μL ice-cold ddH20, with 25 μL aliquots transferred to pre-cooled 0.5 mL 
sample tubes and mixed with 4 μL of DNA to be transfected. Cell-DNA mixes were incubated 
on ice for 5 mins prior to being transferred into a chilled Geneflow 2mm electroporation cuvette 
(Cell Projects), then electroporated using a Micropulser electroporation unit (BioRad) set on 
program EC2 to deliver a voltage of 2.5 KV. Following delivery of the selectable 
ampr/sacB/lacZ cassette, electroporated cells were diluted in 1 mL LB broth, then incubated 
under culture conditions for 1 hr to recover and allow induction of selectable transgene 
expression. Following replacement of the selectable cassette in the second transformation, extra 
time was afforded for the recovery of electroporated cells to ensure that the SacB protein was 
cleared; transformed cells were recovered in 5 mL LB broth during incubation for 4 hrs. 
 Screening for transformants  2.5.4
Following each transformation step, electroporated cells were spread onto LB agar plates 
supplemented with agents to select for, or against, ampr/sacB/lacZ cassette encoded functions, 
and grown at 32°C overnight.  
 Positive selection for ampr/sacB/lacZ cassette following first transformation 2.5.4.1
LB agar was supplemented with ampicillin (50 ng/mL) to select for ampr expression, as well as 
X-gal (80 mg/mL) and IPTG (2 mM) to select for lacZ expression as indicated by the 
development of blue colonies.  
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 Negative selection for ampr/sacB/lacZ cassette following second transformation 2.5.4.2
LB agar was supplemented with 5% (w/v) sucrose, which is metabolised to a toxic product in 
the presence of SacB protein, as well as X-gal (80 mg/mL) and IPTG (2 mM) to identify 
transformants that lack lacZ expression by development of white colonies.  
 Analysis of transformant genome integrity and coding potential 2.5.5
BAC DNA was extracted and purified from screened transformants (see 2.5.6.1.). The integrity 
of ‘recipient’ genomes in selected recombinants was assessed by restriction digest analysis to 
indicate whether recombination had occurred in non-targeted viral genome regions. To ensure 
insertion of DNA into the region to be modified occurred with high fidelity, the nucleotide 
sequence at the site of cassette or ‘donor’ sequence insertion was analysed. 
 Restriction digest 2.5.5.1
Restriction digest reaction mixtures in a final volume of 10 μL were composed of purified 
BAC-DNA mixed with HindIII (10 Units) and associated buffer at working concentration 
(NEB). Digests were performed by incubating reaction mixtures at 37°C for 4 hours, with 
generated fragments resolved over 0.7% (w/v) agarose gels.  
 Sequence analysis 2.5.5.2
Where possible, sequencing reactions were performed using the BigDye Terminator v3.1 cycle 
sequencing kit (Invitrogen/Life Technologies). Reaction mixtures in a final volume of 10 μL 
were composed of BAC DNA (0.5-1.0 μg), primers (3.2 mM) and pre-formed Big Dye mix. 
Reactions were performed under the following thermal cycling conditions:  
• 95°C for 5 mins;  
• 100 cycles: 95°C - 30 s; 55°C - 10 s; - 60°C - 4 mins. 
Reaction products were cleared of excess dye-terminators and other contaminants using 
Performa DTR gel filtration columns (Edge Bio), according to manufacturer’s instructions. 
Initially, columns were centrifuged to dry the gel, with BigDye reaction mixtures loaded 
directly into the gel before repeated centrifuging. The recovered eluate was then analysed using 
an ABI sequencer (Central Biotechnology Services, School of Medicine, Cardiff University). 
Following insertion of the cassette, regions corresponding to the ~80 bp engineered arms of 
homology were analysed using primers that bind at the 3’ termini of the ampr/sacB/lacZ cassette 
and read outwards into the regions flanking the site of insertion: ACG GAA ATG TTA TAC 
TCA TAC TCT and CAC CGT TTT CAT CTG TGC ATA T. Following insertion of ‘donor’ 
sequences, regions corresponding to the engineered arms of homology, as well as the 
transferred ‘donor’ sequence itself, were analysed using primers specific for the  genome region 
modified (Table 2.2.). 
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Figure 2.3. BAC-cloned viral genome recombineering  - overview. (A) E.coli SW102 cells were 
grown to optimum density and the selectable cassette was PCR-amplified; (B) cells were transformed 
with the selectable cassette by electroporation; (C) recovered transformant were screened by growth on 
LB agar containing ampicillin, X-gal, and IPTG for successfully transformed (blue) colonies; (D) 
recombinant BACs were assessed by restriction digest analysis, and PCR-based sequencing at site of 
cassette insertion; (E – I) the same process as in A-D was followed for the replacement of the inserted 
selectable cassette with ‘donor’ sequences, with screening by growth on LB agar supplement with 
sucrose, X-gal, and IPTG for successfully transformed (white) colonies, and PCR-based sequencing to 
analyse the inserted sequence and also site of insertion.  
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  Maintenance of transformed E.coli SW102s as glycerol stocks 2.5.6
E.coli SW102s containing BAC-DNA constructs were stored as plasmid library stocks at -70°C. 
Plasmid library stocks were prepared from bacterial cultures grown over night, with 425 μL of 
bacterial cultures thoroughly mixed with 75 μL of the cryo-preservent glycerol (Fisher), then 
transferred to suitable cryovials before freezing. 
 Extraction and purification of BAC DNA from E.coli SW102s 2.5.7
Extraction and purification of BAC-DNA from E.coli SW102 cells was performed using 
various kits, each based on the release and precipitation of total DNA by alkaline lysis, followed 
by the selective re-naturing of BAC DNA by the addition of acetate in lysis neutralisation 
buffers (Bimboim and Doly 1979). E.coli SW102s grown in LB broth cultures over night were 
harvested by centrifuging under conditions specified by each commercial kit. 
 Small-scale preparation of BAC-DNA 2.5.7.1
Small-scale preparations of purified BAC-DNA were prepared using a Mini-prep Kit (QIAgen). 
Total DNA was extracted by alkaline lysis as previously described. Lysates were cleared of 
precipitated cellular debris by centrifuging at 16,000 x g for 10 mins at room temperature. The 
resulting supernatant was transferred to a fresh tube, with BAC-DNA precipitated and pelleted 
by the addition of room temperature isopropanol and centrifuging at 16,000 x g for 10 mins at 
4°C. Recovered BAC-DNA was retained and washed by the addition of 70% (v/v) ethanol and 
repeated centrifuging. Following drying, the DNA pellet was re-suspended in an appropriate 
volume of TE buffer. 
 Large-scale preparation of transfection grade BAC-DNA 2.5.7.2
Large-scale working stocks of transfection-grade cell-free BAC-DNA constructs were prepared 
by Maxi-prep, using a Nucleobond BAC 100 plasmid DNA purification kit (Machery Nagel), 
according to manufacturer’s instructions for the purification of low-copy number plasmids. In 
this method, silica-based anion exchange resin technology utilising latex beads of exquisite size 
uniformity allowed nucleic acids of different chemistry (e.g. RNA, DNA), structure (single or 
double-stranded), and size, to be resolved within strictly defined elution profiles. In brief, total 
DNA was extracted from E.coli SW102 cells by alkaline lysis, and the resultant flocculate of 
precipitated cellular debris was then cleared by passage of the lysate across a fine filter 
(supplied). The recovered flow-through was then passed across a BAC 100 column by gravity-
flow filtration. Columns containing captured BAC DNA were repeatedly washed by the 
addition of wash buffer (supplied), and all flow-through from these steps was discarded. 
Captured BAC DNA was recovered by addition of pre-warmed (50°C) elution buffer (supplied) 
to the column, with the flow-through from this step recovered. Eluted DNA was precipitated by 
the addition of room temperature isopropanol and pelleted by centrifuging at 15,000 x g for 30 
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mins at 4°C. The resulting DNA pellet was retained and washed by the addition of room 
temperature 70% (v/v) ethanol, and further centrifugation at 15, 000 x g for 10 mins at room 
temperature. The DNA pellet was retained and allowed to air-dry, before being re-suspended in 
appropriate TAE buffer and stored 4°C. 
2.6 Reconstitution, growth and preparation of BAC-derived virus 
 Reconstitution of virus from BAC-cloned HCMV genomes 2.6.1
HCMV viruses were reconstituted from BACs and grown in various fibroblast and epithelial 
cell types. Productive infection in each of these cell types was initiated by transfection of cells 
with BAC DNA. All grown viruses and infected cell-culture supernatant samples were stored at 
-70°C. To minimise the likelihood for the selection of mutants during the production of virus 
stock in cell-culture, no virus was plaque-purified. 
 Transfections of fibroblasts  2.6.1.1
HFFF and HF-tet cells were transfected by electroporation using a Nucleofector II (AMAXA), 
and a basic nucleofector kit (LONZA). In brief, 106 harvested fibroblast cells were collected by 
centrifuging homogenised cellular suspensions at 75 x g for 10 mins at room temperature. The 
pelleted cells were then re-suspended in 100 μL of transfection reagent (supplied), and mixed 
with 2 μg of purified BAC-DNA. The entire transfection reaction mixture was then transferred 
to cuvettes (supplied) and electroporated using Nucleofector II program T-16. Electroporated 
cells were diluted in pre-warmed culture medium and transferred to suitable cell culture vessels, 
then allowed to adhere and recover during overnight incubation. On occasions when cultures 
were <70% confluent after overnight recovery, additional non-transfected cells were added. 
 Transfection of epithelial cells 2.6.1.2
RPE-1 and ARPE-19 cells were transfected by chemical transfection using the Effectene kit 
(QIAGEN), according to instructions for stable transfection of adherent cells. Transfection 
mixtures were generated in two steps. Firstly, 0.4 μg purified BAC DNA was condensed by the 
addition of 3.2 μL enhancer reagent and buffer (supplied) to a final volume of 100 μL, with this 
mixture incubated at room temperature for 2-5 mins. Secondly, transfection complexes were 
formed by the addition of the 10 μL effectene reagent (supplied), and further incubation at room 
temperature for 5-10 mins. The transfection complex mixture was diluted by the addition of pre-
warmed culture medium, and then added to epithelial cell cultures grown to 40-80% confluency 
in the well of a 6-well plate.  
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 Growth of HCMV stocks 2.6.2
Productive infections were initiated in cell cultures grown to near confluency (>90%). Cells 
were either inoculated by the addition of existing infected cells, initially derived from 
transfection, or by the addition of cell-free virus at an approximate MOI of 0.1. To facilitate the 
dissemination of slow growing strains that displayed a tendency towards focal spread and 
formation of discrete plaques, infected cell cultures were disrupted as in ‘splitting’, with the 
entire resultant cellular suspension returned to the flask to allow the monolayer to re-form with 
greater distribution of infectivity. When 70-100% of all cells were infected, infectious 
supernatant containing cell-free virus were collected and replaced with fresh culture medium. 
Infectious supernatants were collected every two days until all cells in infected cell cultures 
were lysed, and stored at -70°C. No virus was plaque purified.  
 Preparation of infected cell culture fractions and sub-fractions 2.6.3
Infected cell-culture supernatant was removed and centrifuged at 470 x g for 5 mins at room 
temperature, with the cleared supernatant recovered to form the cell-released virus (CRV) 
fraction. The pelleted cellular materials were collected and mixed with infected cells recovered 
from culture vessels by trypsinisation. The total infected cell material was re-suspended in fresh 
standard culture medium, forming the cell-associated virus (CAV) fraction.  
 Liberation of CAV infectivity, preparation of Cell-extract and Cell-debris sub-2.6.3.1
fractions 
Infected cells were lysed using a VibraCell sonicator (Sonics), with infected cells subjected to 
30-second pulses of sonication at 100% amplitude. To prevent overheating, samples were 
incubated on ice during sonication. To generate cellular debris and cell-extract sub-fractions, 
lysates were centrifuged at 345 x g for 10 mins at room temperature. The cleared supernatant 
was recovered as the cell-extract CAV sub-fraction, and the pellet was re-suspended in fresh 
standard culture medium to form the Cell-debris CAV sub-fraction.  
 Preparation of concentrated HCMV working stocks  2.6.4
Working stocks of virus were prepared by concentrating cell-free virus contained within 
infected cell culture supernatant ‘bleeds’. Bleeds were initially defrosted and warmed to 37°C in 
a water bath, then cleared of high-mass cellular debris by centrifugation at 470 x g for 5 mins at 
room temperature. Following concentration by various methods, virus was aliquoted to suitable 
cryo-preservent tubes and stored at -70°C.  
  Concentration by high-speed centrifugation 2.6.4.1
Cleared supernatants were pooled and centrifuged at 30,000 x g for 2 hr at 20°C. The pelleted 
infectious virions were then re-suspended in a reduced volume of fresh culture medium. To 
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ensure dissociation of any virion aggregates and generate a homogenous single virion 
suspension, the re-suspended virus was subjected to limited passes (3-5) through a 19 G needle.  
 Concentration by ultra-filtration 2.6.4.2
Virus samples were concentrated by the gradual removal of water using ultrafiltration 
technology. In these methods, virus samples were applied to a polyethersulfone (PES) 
membrane with pores that excluded the passage of particles larger than 1 MDa. 
2.6.4.2.1 Dialysis ultra-filtration 
VivaFlow50 ultra-filtration cartridges (Sartorius) were used according to manufacturer’s 
instruction. In brief, a reservoir of infectious supernatant was stored in a suitable open-necked 
vessel, drawn along an inlet tube connected to the cartridge, circulated through the cartridge 
compartments lined with the PES filtration membrane, then returned to the reservoir through an 
efflux tube. Circulation of supernatant through the efflux tube was restricted by a flow-
restrictor, driving the negative-pressure dialysis of excess media across the PES membrane. 
Circulation of the supernatant was driven by use of a peristaltic pump and occurred at a flow 
rate of 400 mL.min-1. When the final volume was less than 20 mL, the circulation of supernatant 
was stopped. The inlet tube was then transferred to a reservoir containing ~10 mL ddH20 which 
was circulated throughout the cassette and collected to increase recovery of concentrated virus. 
2.6.4.2.2 Centrifugal ultra-filtration 
Cleared supernatants were loaded into the upper chamber of a VivaSpin 20 column (Sartorius), 
with passage of excess water and solutes through the filtration membrane achieved by 
centrifugation at 3000 x g at 25°C.  
 HCMV infectivity quantification 2.6.5
The infectivity in virus samples (not plaque purified) was enumerated by minimal dilution 
assay. Samples were serially diluted to generate a 10-fold dilution series, with cells inoculated 
with 100μL from successive dilutions predicated to contain 1-1000 infectious units. Following 
incubation detectable markers of infection were counted, and titres of original samples, 
expressed as total PFU in 1 mL (PFU.mL-1), were determined by the following calculation: 
plaques per 100 μL inoculum x 10 x inoculum dilution factor  
 Plaque titration 2.6.5.1
Cells were grown to 40-80% confluency in either 6-well, 12-well, or 24-well culture plates. On 
performance of infections, the cell culture media was removed and immediately replaced with 
fresh culture medium (500 μL in 6 well plates; 250 μL in 12-well plates; and 150 μL in 24 well 
plates. Inocula (100 μL) were then added to wells, with infections performed as described. To 
ensure only plaques that were derived from a single infection event were formed, cells were 
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incubated under a semi-solid over-lay. Following sufficient incubation (2-3 weeks, depending 
on cell type), the semi-solid overlay was removed before the infected cultures were washed 
twice in excess PBS and plaques were counted.  
 IE1 immuno-fluorescence titration 2.6.5.2
Cells grown in clear-bottomed 96-well plates were infected under standard conditions. On 
infection, culture media was removed from wells, and 100 μL inocula applied directly to cells. 
Following 12-24 hrs incubation, cells were prepared for staining of nuclear-localised pIE1. 
Infected cell cultures were fixed in 4% (w/v) PFA, permeabilised using immunofluorescence 
buffer (IF buffer) supplemented with 0.1% (w/v) Triton X100, then blocked in excess IF buffer. 
All treatments of cells were performed for 10 mins at room temperature, and followed by three 
washes in excess PBS. The nuclei of infected cells were stained with monoclonal mouse anti-
IE1 antibody (ThermoScientific, MA1-7596) diluted (1:1000) in IF buffer, during incubation 
for 1 hour at 37°C on a rocking platform. Un-bound primary antibody was removed by washing 
in excess PBS, and AlexaFluor 594 conjugated goat anti-mouse antibody F(ab')2 fragment 
(Invitrogen, A11020) diluted (1:500) in IF buffer was applied, with cells further incubated for 
30 mins at 37°C on a rocking platform. Stained cells were then washed in excess PBS, and 
fluorescently stained nuclei were counted.  
 Growth and preparation of Adenovirus vector stocks 2.6.6
Adenovirus vectors were grown in 293-TREx helper cells, with infections initiated by 
transfection using the Effectene chemical transfection kit as described above. Following the 
dissemination of infection throughout the entire 293TREx cell culture, cells were harvested and 
cleared of supernatant by centrifuging at 470 x g for 3 mins at room temperature. Pelleted cells 
were then washed by re-suspension in excess PBS and repeated centrifuging. Cells in the 
resulting pellet were again re-suspended in PBS, then mixed with an equal volume of the 
detergent tetrachloroethylene, before being shaken vigorously to lyse infected cells and liberate 
cell-associated Adenovirus virions. The resulting emulsion was centrifuged at 836 x g for 20 
mins at room temperature, generating three fractions: a low density fraction from which 
extracted Adenovirus virions in PBS were recovered (top layer); a fraction of cellular debris 
(middle layer); and a high-density fraction of tetrachloroethylene (bottom layer). Adenoviruses 
were recovered from the top layer and stored in cryo-preservent tubes at -70°C. 
 Titration of Adenovirus stocks 2.6.7
The infectivity of RAdZ stocks was quantified by titration on 293TREx cells. To prevent 
disturbance of the loosely adhered 293TREx cells, the cell culture supernatant was not removed 
prior to inoculation, with inocula added directly to the cultures. No preliminary incubation on 
the rocker platform was performed. At 48 hours post infection, cell culture supernatant was 
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removed and cells were allowed to air-dry, before being fixed and permeabilised in a cocktail of 
ice-cold acetone and methanol (1:1) at -20°C for 10 mins. Cells were then washed in excess 
blocking buffer composed of PBS supplemented with 0.2% (w/v) BSA, before infected cells 
were stained with polyclonal goat anti-adenovirus primary antibody (Abcam, AB1056) diluted 
(1:5,000) in blocking buffer, during incubation at 37°C for 1 hour on a rocking platform. Un-
bound primary antibody was removed by washing in excess blocking buffer, before HRP-
conjugated polyclonal donkey anti-goat antibody (SantaCruz, 2056) diluted (1:1000) in 
blocking buffer was added and cells, which were further incubated. Cells were again washed in 
excess blocking buffer, before the addition of a colorigenic HRP substrate. DAB substrate 
(Vector Labs, SK100) was used according to manufacturer’s instructions, and prepared by the 
addition of DAB substrate (3, 3’-diaminobenzidine), as well as associated buffers and other 
components (all supplied) to ddH20. Substrate was applied to cells that were then incubated for 
sufficient time for signal development before counting stained cells. 
2.7 HCMV-derived nucleic acid extraction  
 Extraction of viral nucleic acids from infected cells or cell-free virions 2.7.1
Viral nucleic acids were extracted from cells and cell-free virus using various kits of the 
QIAgen product line, according to manufacturer’s instructions. All protocols were based on a 
combination of silica resin anionic binding and microspin technology. In brief, cells and virions 
were disrupted by protease enzymes and lysis buffers to release nucleic acids; cellular and 
virion derived contaminants in lysates were then neutralised by various buffers, or captured 
within spin columns; then nucleic acids were selectively captured on silica membranes by 
centrifugation under binding conditions optimised by the inclusion of salts and alcohols; 
captured nucleic acids were washed by the addition of buffers and/or alcohols and further 
centrifugation, then were recovered by in elution buffers.  
 Extraction of viral RNA from infected cells 2.7.1.1
Total RNA, including virus derived RNA, was extracted from infected cell cultures using an 
RNeasy Plus Universal Kit. Infected cells were harvested and disrupted in lysis buffer, with the 
resulting lysate homogenised by centrifuging through a QIAshredder spin column. DNA was 
removed from the homogenised lysate by centrifuging through a gDNA Eliminator spin 
column. Cleared lysate was mixed with 70% (v/v) ethanol, with RNA then captured onto the 
membrane of an RNeasy spin column, washed and eluted in RNAse-free water. 
 Extraction of viral DNA from infected cells 2.7.1.2
Viral DNA was extracted from infected cells using the DNeasy Blood and Tissue Kit. 
Harvested infected cells were cleared of cell-culture supernatant and re-suspended in PBS, 
before being disrupted by the addition of protease and accompanying lysis buffers and 
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incubation at 56°C for 10 mins. The lysate was mixed with 100% ethanol and loaded into a 
DNeasy mini prep column, with DNA captured onto the membrane then subjected to two 
rounds of washing. Finally, DNA was the recovered in an appropriate volume of elution buffer. 
 Extraction of viral DNA from cell-free virions 2.7.1.3
DNA was extracted from cell-free virions using a MinElute Virus spin Kit. Initially, cell-free 
virions were disrupted by the activity of protease and accompanying lysis buffers, during 
incubation at 56°C for 15 mins. The resultant lysate was mixed with 100% ethanol and 
incubated at room temperature for 5 mins, before viral DNA was captured by centrifugation 
through a spin column. Bound DNA was subjected to three washes, firstly by the addition of 
wash buffers, then by addition of 100% ethanol in the final wash. Washed membranes were 
allowed to air dry, prior to recovery of viral DNA in elution buffer. 
2.8 Nucleic acid sequence analysis 
Details of all primers used for the PCR, RT-PCR, and sequencing reactions, are in Table 2.2. 
 PCR amplification of sequences from HCMV genome regions 2.8.1
 Amplification from virion incorporated genomic DNA  2.8.1.1
When HCMV genome sequences were PCR-amplified directly from virion incorporated 
genomic DNA, the Advantage II PCR system (Clontech) employing the robust Titanium Taq 
dDdP with hot-start PCR technology was used. Cycling conditions included: 
• 95°C - 5 mins (to disrupt virions and release virus genomic DNA) 
• 10 cycles: 95°C - 30 s, 68°C - 60-90 s per Kb  
• 68°C - 4.5 mins, time depending on template size  
• 4°C - indefinite 
 Amplification from extracted and purified viral genomic DNA 2.8.1.2
Amplification of genome regions from extracted and purified HCMV genomic DNA was 
performed using the Expand HiFi PCR kit (Roche) (described above). Amplification was 
performed by one-step PCR under the following thermal cycle conditions: 
• 94°C - 2 mins (to disrupt virions and release virus genomic DNA); 
• 35 cycles: 94°C - 30 s; 65°C - 30 s; 72°C 1 min per Kb  
• 72°C, time depending on template size  
• 4°C – indefinite 
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Table 2.3. Primers used for PCR amplification of genome regions, RT-PCR of transcripts and PCR amplification of cDNAs, and sequencing reactions. 
Genome Region Primer Merlin TR TB40-BAC4 FIX 3301 
UL128L Genome Region amplification primers and co-ordinates in BAC-cloned strain genomes 
Narrow 
PCR Forward: CAG AAA CTC ACA TCG GCG ACA 175,970 - 175,990 
211,709 – 
211,729 
174,763 –
174,783 
52,168 –
52,188  
PCR Reverse: CCA TCA CCT CGC CTA TAC TAT GTG 178,201 –179,013 
213,876 – 
213,899 
176,926 –
176,949 
49,996 –
50,019  
Wide 
PCR Forward: GGC TAA TGG CCA ATA TTG ATT CAA TGT A 175,715 –175,742 
211,456 – 
211,483 
174,510 –
174,537 
52,414 –
52,441  
PCR Reverse: GAG CCC TTA TCA GCG GTT GGA 178,514 –178,515 
214,265 – 
214,286 
177,317 –
177,338 
49,608 –
49,629  
UL128L genome region sequencing primers 
Internal 
Seq 1: TCT TCC AAT ATC GCC ATC TC 176,022 – 176,041 
211,761 – 
211,780 
174,815 – 
174,834 
52,117 – 
52,136  
Seq 2: CGG ATT GTA GTT GCA GCT CG 176,471 – 176,490 
212,210 – 
212,229 
175,260 – 
175,279 
51,666 – 
51,685 
176,621 – 
176,640 
Seq 3: TCT GGT TAT TGG CCT CGG TG 176,971 – 176,990 
212,710 – 
212,729 
175,760 – 
175,779 
51,166 – 
51,185 
177,121 – 
177,140 
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Seq 4: GCG CAC AGA AGC AGG CAG 177,528 – 177,545 
213,267 – 
213,284 
176,317 – 
176,334 
50,611 – 
50,628 
177,678 – 
177,695 
UL131A 5’ – UL132 5’ Region amplification and sequencing primers 
UL131A 5’ - 
UL132 5’ 
PCR Forward + seq: TGT AAC GGG TTT GGT CGG 177,945 – 177,962 
213,684 – 
213,701    
PCR Reverse + seq: TGG GCT CGC GTT TTG ATA 179,117 – 179,134     
Seq: GAA GTC CAT GTG AAG CAG 178,936 – 178,953 
214,675 – 
214,692    
UL128 and UL131A transcript RT-PCR and cDNA amplification primers 
UL128 
PCR Forward + seq: CAT AAA CGT CAA CCA CCC 176,778 – 176,795 
212,517 – 
212,534 
175,567 – 
175,584 
51,361 – 
51,378  
PCR Reverse + seq: CAC TGC AGC ATA TAG CCC 176,136 – 176,153 
211,875 – 
211,892 
174,929 – 
174,946 
52,005 – 
52,022 
 
UL131A 
PCR Forward + seq: GTG TGG CTG TCT GTT TGT 178,063 – 178,080 
 213,802 – 
213,819 
176,852 – 
176,869 
50,076 – 
50,093 
 
PCR Reverse + seq: CGT GGT CCT TTT GTT GGT 177, 670 –177,687 
213,409 – 
213,426 
176,459 – 
176,476 
50,469 – 
50,486 
 
 
a - Primer pairs used to amplify the UL128L genome region of viruses (narrow), and also the UL128L genome plus flanking sequences (wide).  
b - Primers that bound regions internally within the UL128L genome region to generate sufficient contigs for sequencing.  
c - Primer pair used for amplification of virus UL131A 5’ – UL132 5’ genome region and sequencing, and internal primer used for sequencing reactions.  
d - Primer pairs used for the RT-PCR of UL128 and UL131A specified transcripts, PCR-amplification of cDNAs, and also for sequencing reactions.  
 
Nucleotide positions are given relative to sequences of BAC-cloned strains deposited in GenBank: Merlin (GU179001.1); TR (AC146906.1); TB40-BAC4 (EF2999921.1); FIX 
(AC146907.1); strain 3301 (GQ466044.1). 
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 Cloning of PCR products  2.8.2
PCR products were cloned into plasmid vectors using the TOPO TA Cloning Kit 
(Invitrogen/Life technologies). In this kit, a linearised plasmid vector contains 3’ terminal 
deoxythymine overhangs that are bound with Vaccinia virus Topoisomerase I, and this enzyme 
facilitates the incorporation of PCR products that display 3’ deoxyadenosine overhangs. To 
incorporate the necessary 3’ deoxyadenosine overhangs, gel purified PCR products were first 
mixed with dNTPs (New England BioSciences) and Taq polymerase (Invitrogen/Life 
Technologies) that has terminal transferase activity, and incubated for 10 mins at 72°C. Ligation 
reaction mixtures were then prepared from modified PCR products, the linearised plasmid 
vector and salt water (200 mM NaCl, 10 mM MgCl2) (both supplied), and ddH2O. Ligation 
reactions were incubated at room temperature for 30 mins prior to rapid cooling on ice. Electro-
competent One Shot TOP10 E.coli cells (supplied) were grown to competency, transformed by 
electroporation, and recovered as described above in ‘recombineering’. To select for cells 
containing the plasmid that encodes selectable ampicillin resistance (Ampr), recovered cells 
were grown on LB agar plates supplemented with ampicillin (50 μg/mL).  
 RT-PCR of RNA transcripts and production of cDNA libraries  2.8.3
Libraries of cDNAs complimentary to virus-derived mRNAs were generated using a 
NanoScript Precision reverse transcriptase (RT) kit (Primer Design). In the initial annealing 
reaction, total infected cell RNA extracts were mixed with target-specific primers and ddH20, 
then incubated at 65°C for 5 mins before being rapidly cooled by transfer to ice. An extension 
reaction mixture was then prepared from primed mRNAs mixed with the nanoscript RT enzyme 
and associated reaction buffer, as well as dithiotreitol (DTT), dNTPs and RNAse/DNAse free 
water (all supplied). RT extension reactions for the generation of cDNA amplicons was 
performed during incubation at 55°C for 20 mins.  
 DNA sequencing 2.8.4
 Sanger sequencing 2.8.4.1
Sequencing analysis of short genome regions or PCR products was performed by the Sanger 
sequencing services offered by Eurofins (MWG). Genome regions of interest were PCR 
amplified, with DNAs purified as described above. The concentration of DNAs was also 
determined as previously described. All DNAs and primers were sent in volumes and at 
concentrations as required. Primers used for sequencing reactions are listed in Table 2.2.  
 Illumina platform whole-genome sequencing 2.8.4.2
Whole genome sequence analysis, including the detection of mutant populations within grown 
HCMV working stocks, was performed by Illumina platform high-throughput sequencing, 
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conducted by collaborators in the laboratory of Dr Andrew Davison (MRC-Centre for Virology, 
University of Glasgow). Viral genomes were extracted either directly from cell-free virus 
preparations or from within infected cell cultures by methods described above, and delivered as 
frozen samples on dry ice.  
2.9 Biochemical analysis of HCMV particles 
 Purification of virus derived particles 2.9.1
Virus particles were purified from infectious supernatants and concentrated virus preparations 
by ultra-centrifugation over solutions of defined density and viscosity. Ultra-centrifuging was 
performed using an Optima XPN-80 Ultra-centrifuge (Beckman Coulter), using the SW41 rotor 
and compatible thin-walled Ultra-Clear centrifuge tubes (Beckman Coulter). All spins were 
performed at 90465.7 x g for varying times at 20°C. 
 Purification of total virus particles 2.9.1.1
Total virus-derived particles (virions, NIEPs and DBs) were purified from viruses by ultra-
centrifugation over 4 mL ‘cushions’ of various solutions, including PBS containing 20% (w/v) 
sorbitol, and also sodium phosphate buffer containing 15% (w/w) sodium tartrate and 30% 
(w/w) glycerol (gradient ‘light’ solution). Virus derived particles were purified by ultra-
centrifugation over each solution for 1 hr.  
 Purification of virions 2.9.1.2
Virion purification was performed by gravity-flow rate sedimentation of virus-derived particles 
during ultracentrifugation through glycerol-tartrate positive density negative-viscosity 
continuous gradients, as previously described (Talbot and Almeida 1977, Irmiere and Gibson 
1983). In this method, virions are separated from other virus particles and cellular debris as they 
migrate at different rates dictated by differences in particle buoyant density. 
2.9.1.2.1 Forming continuous gradients 
Solutions used to form gradients were made in a sodium-phosphate buffer (pH 7.4): ‘heavy’ 
solution, containing 35% (w/w) sodium tartrate; and ‘light’ solution, containing 15% (w/w) 
sodium tartrate and 30% (w/w) glycerol. Gradients were formed using a SG50 gradient maker 
(Hoefer): the ‘heavy’ and ‘light‘ solutions were loaded to the two separate chambers of the 
gradient maker and allowed to gradually mix as they were released via a single exit tube. 
Gradients were poured into Ultra-clear centrifuge tubes, with the flow of both solutions driven 
by using a peristaltic pump (Pump P1, Pharmacia Fine Chemicals). Gradients were poured 
‘from-the-top’, with ‘heavy’ solution forming the lowest gradient regions, and ‘light’ solution 
forming the upper regions of the gradient.  
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2.9.1.2.2 Isolation of virions 
Virus preparations were gently loaded on top of gradients such that they did not mix, and 
formed a clearly defined bi-layer. Gradients were balanced prior ultra-centrifugation by the 
addition of PBS loaded on top of virus samples. Loaded gradients were ultra-centrifuged for 45 
mins at conditions described above. Banded virus particles were recovered using a syringe and a 
20 G needle. To remove gradient derived salts and other contaminants from the purified virus 
particles, recovered bands were washed by gradual dilution in excess NaPh buffer, and pelleted 
by ultra-centrifugation for 1 hr. The final purified virion pellet was re-suspended in a solvent 
suitable for downstream applications. 
 
 
 
 
 
 
Figure 2.4. Purification of virions over glycerol-tartrate gradients. Glycerol-tartrate gradients were 
poured from the ‘top-up’, to include lower most regions that were composed of gradient heavy solution 
(purple; 35% sodium tartrate in NaPh buffer), and uppermost regions composed of gradient light solution 
(green; 15% sodium tartrate, 30% glycerol, in NaPh buffer). Concentrated virus samples (pink) were 
loaded on top of gradients, with virus particles purified by gravity-flow rate sedimentation during ultra-
centrifugation at conditions described. Bands formed included, ‘cell debris, ‘purified virions, and ‘DBs’ 
(not shown). 
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 Immunoblot detection of proteins 2.9.2
Semi-quantitative detection of proteins was performed by immuno-blot techniques, with 
targeted proteins first resolved and isolated from mixed samples using the NuPage Novex 
protein isolation kit (Invitrogen/Life technologies).  
 Sample preparation 2.9.2.1
Samples were prepared in NuPage LDS sample buffer (supplied), supplemented with 10 mM 
DTT for the reduction of proteins and polypeptides. Where infected cells or virions were re-
suspended directly following pelleting, sample buffer based on NuPage LDS (4x) was first 
diluted to working concentration by the addition of ddH20. When applied to infected cells that 
remained adhered to cell culture vessels, cells were first washed in excess PBS before lysis 
buffer was added, then cells were scraped before lysates were recovered. When infected cells or 
virions were suspended in cell culture supernatant or other media, appropriate volumes of 
NuPage LDS (4x) and DTT were added to achieve final working concentration. Proteins in all 
samples were denatured during incubation at 100°C for 10 mins using a heating block.  
 Resolution and isolation of polypeptides by electrophoresis 2.9.2.2
Proteins and polypeptides present in mixed samples were resolved and isolated based on 
molecular weight by one dimensional polyacrylamide gel electrophoresis, using the XCell 4 
SureLock electrophoresis system and compatible pre-poured gels containing 10% (w/v) 
polyacrylamide in Bis-Tris buffer (supplied). Samples were loaded to individual wells, with a 
separate well also loaded with Novex Sharp Pre-stained Protein Standard for the estimation of 
isolated protein size by extrapolation to the migration of proteins of known size. Gels were 
submersed in MOPs SDS running buffer (supplied) diluted to working concentration, and 
electrophoresed at 150-200 V for 1-2 hrs until sufficient migration had occurred. 
 Western transfer 2.9.2.3
Resolved and isolated proteins/polypeptides were electrophoretically transferred to PVDF (GE) 
or Nitrocellulose (GE) membranes by semi-dry transfer using a TransBlot SD Model 200/2.0 
(BioRad). Initially, gels were gently released from the casings in which they were contained, 
and washed in western transfer buffer. Blotting paper and capture membrane were pre-soaked in 
the relevant western transfer buffers for 5-10 mins, which included NuPage transfer buffer 
(supplied), or carbonate transfer buffer prepared by the user. PVDF was initially soaked in 
methanol for 5 mins. Transfer stacks comprised, from the top down, soaked blotting paper, 
electrophoresed gels, capture membranes and soaked blotting paper. Proteins were transferred 
during electrophoresis at 10-20 V for 1-2 hrs. Following transfer, membranes were rinsed in 
ddH2O, then stored in excess PBS-T at 4°C. 
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 Immuno-staining of captured proteins and polypeptides 2.9.2.4
Two successive rounds of immuno-labelling detected captured proteins, firstly with antibody 
reactive for targeted proteins (Table 2.4), secondly with HRP-conjugated antibody reactive with 
the primary antibody used. All treatments were performed on a rocking platform (10-20 RPM), 
and were followed by washes for 3 mins in excess PBS-T. Membranes were ‘blocked’ in PBS-T 
supplemented with 5% (w/v) milk proteins (Marvel). Blocking was performed either for 1 hr at 
room temperature, or overnight at 4°C.  Target specific primary antibodies were diluted in 
blocking buffer and added to membranes that were again incubated at 4°C overnight, or at room 
temperature for 1 hr. Secondary HRP-conjugated anti-bodies were added to membranes and 
allowed to bind primary antibodies during incubation at room temperature for 1 hr. Primary 
anti-bodies used are detailed in HRP-conjugated secondary anti-bodies used were goat anti-
mouse monoclonal IgG (Bio-Rad; Cat 170-6515) and goat anti-rabbit monoclonal IgG (Bio-
Rad; Cat 170-6516), each used at a 1:2000 dilution. 
 Detection of captured protein 2.9.2.5
As an HRP substrate for the generation of a detectable signal, Super Signal West Pico 
Chemiluminescent Substrate was used (Pierce). Equal volumes of each supplied component 
were added to stained membranes that were then incubated for 3-5 mins at room temperature. 
Chemiluminescent signal was visualised using an Autochemi Bioimaging system (UVP), with 
images analysed using LabWorks software (UVP). 
 Mass spectrometry analysis 2.9.3
The proteome composition of virions derived from several Merlin variants was determined by 
mass spectrometry analysis performed by collaborators in the laboratory of Professor Paul 
Lehner (Cambridge institute for Medical research, University of Cambridge).  
 SILAC labelling virions 2.9.3.1
Proteins incorporated into the virions analysed were differentially labelled by the stable isotope 
labelling by amino acids in cell culture (SILAC) method (Ong, Blagoev et al. 2002).  In brief, 
viruses were grown in SILAC medium supplemented with isotopically labelled amino acids 
arginine, lysine and proline. To ensure only labelled amino acids were available for 
incorporation into virion proteins, cells (HFFFs) grown to >90% confluency were subjected to a 
minimum of 2 passages in SILAC medium prior to infection. To increase the efficiency of virus 
infection, cells were treated over night with the addition of dexamethasone to cell culture 
medium to a final concentration of 10 μM (Tanaka, Ogura et al. 1984). The following day, cells 
were infected at an MOI of 2-4 as previously described, then washed in PBS to remove any 
non-internalised virions. Infections were incubated at standard conditions, with labelled progeny 
virions released into the supernatant recovered every two days until monolayers were destroyed. 
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Table 2.4. Details of primary anti-bodies used in detection of proteins by immuno-blot. 
 
 Target protein Source Product code Host Animal Isotype Clonality Dilution 
Cellular Targets 
Calnexin Millipore MAB3126 Mouse IgG Monoclonal 1:2,000 
S6RP Cell Signaling 5G10 Rabbit IgG Monoclonal 1:2,000 
TGN46 Abcam Ab50595 Rabbit IgG Polyclonal 1:2,000 
Giantin Abcam Ab24586 Rabbit IgG Polyclonal 1:5,000 
Actin Sigma A-2066 Rabbit  Polyclonal 1:10,000 
Viral Targets 
pp28 Abcam Ab6502 Mouse IgG Monoclonal 1:10,000 
gB Abcam Ab6499 Mouse IgG Monoclonal 1:4,000 
gpUL128a G. Gerna SURN   Monoclonal 1:100 
Anti-V5 Serotec MCA1360 Mouse IgG Monoclonal 1:20,000 
a – anti-gpUL128 antibody was kindly donated from the laboratory of Giuseppe Gerna (Servizo di Virologia, Universita di Pavia, Italy). 
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 Virion concentration estimations by total protein concentration determination 2.9.3.2
Total protein concentration of purified virion samples was estimated using a Micro BCA 
Protein Assay Kit (Thermo Scientific), according to manufacturer’s instructions. In brief, total 
protein concentration was estimated by indirect colorigenic reaction, with protein abundance 
resulting in the gradual reduction of Cu2+ to Cu1+, which in turn chelates molecules of 
bicinchoninic acid to generate a purple colour. Working reagent was prepared as instructed, and 
mixed with appropriate volumes of each unknown sample in wells of a 96-well plate, before 
incubation at 37°C for 2 hrs for the colorigenic reaction to occur. The plate was cooled, and the 
intensity of colours formed was read at 562 nm using an Omega Fluostar plate reader (BMG 
Labtech).  Protein concentration was determined by extrapolation of the colour intensity 
readings generated by proteins of known concentration in standard samples.  
 Preparation of samples  2.9.3.3
Purified virion preparations were prepared by suspension in NuPage loading buffer 
supplemented with 10 mM DTT, then loaded to the wells of pre-poured continuous gradient 
gels containing 4-12% (w/v) polyacrylamide in Bis-Tris buffer and electrophoresed such that 
proteins migrated approximately 1-2 cm into the gel. To visualise resolved proteins, the 
Colloidal coomasie blue staining kit (Invitrogen) was used according to manufacturer’s 
instructions. Captured proteins were fixed by submersion in freshly generated fixing solution, 
which contained 50% (v/v) methanol, 40% (v/v) ddH2O and 10% (v/v) acetic acid. Submersed 
gels were incubated on a rocking platform (10-20 RPM) at room temperature for 10 mins. A 
staining solution was generated in two steps, with a final formulation composed of 55% (v/v) 
ddH2O, 20% (v/v) methanol, 20% (v/v) Stainer A (supplied) and 5% (v/v) Stainer B (supplied). 
Captured and fixed proteins were submersed in staining solution minus Stainer B and incubated 
on a rocker (10-20 RPM) from 10 mins. Finally, Stainer B was added and gels were then 
incubated for sufficient time until maximum staining was achieved (3-12 hrs).  Using a sterile 
blade, segments containing migrated proteins were excised from electrophoresed gels and 
sectioned into 6 pieces that were frozen and sent to collaborators for mass spectrometry 
analysis.  
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3 Growth Characteristics of 
Viruses Reconstituted from 
‘Broad-Tropism’ BAC-cloned 
Strains  
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 Initial investigations aimed to directly compare the growth characteristics of viruses 
reconstituted from the TR-BAC, TB40-BAC4 and FIX-BAC clones, to that of viruses from two 
Merlin-BAC variants: Merlin virus that contains wildtype UL128L ORFs and grows to low 
titres; and Merlin virus that contains non-intact UL128L ORFs and grows to higher titres (Table 
3.1). The Merlin-BACs differed at only a single nucleotide position (in UL128 exon 1), yet each 
contained an otherwise full complement of wildtype genes, with the exception of RL13; the 
frame-shifting RL13 mutation selected during the in vitro propagation of the Merlin clinical 
isolate prior to BAC cloning was present in each Merlin-BAC variant used. The RL13 ORFs in 
TB40-BAC4 and FIX also contain lesions, though TR RL13 contained no obvious disruptions. 
However, given that RL13 mutants are consistently selected during the passaging of HCMV 
isolates in vitro, it is likely that the TR RL13 ORF is not expressed, or the encoded gpRL13 is 
non-functional. Thus, no attempts were made to repair RL13 in any strain investigated. To 
provide a detectable marker to monitor infections, all viruses were engineered to express eGFP 
from an IRES inserted downstream from UL122 (encoding the immediate early protein IE2). 
The growth characteristics of viruses were monitored immediately following transfection of 
cells with infectious BAC DNAs: cell-to-cell spread was assessed when transfected cells were 
incubated under semi-solid overlay, and the sizes of plaques formed were compared (plaque 
size comparisons and statistical analyses presented in Appendix III); dissemination kinetics and 
cell-free virus production were assessed from transfected cells incubated without overlay, with 
the proportion of infected cells (i.e. eGFP+) scored at weekly time-points until monolayers were 
destroyed, and supernatant samples collected for enumeration of cell-free virus produced by 
plaque titration on fibroblasts. 
 
Table 3.1. BAC-cloned HCMV strains investigated. 
a – Merlin variant containing UL128 mutation acquired during passage in fibroblast prior to BAC cloning 
b – Merlin variant containing wildtype UL128 following repair of mutation acquired during passage in 
fibroblast prior to BAC cloning 
BAC-clone UL128L status 
Designation in text: 
BAC /Reconstituted Virus 
Merlin-BACa Mutated: G>A (R>stop) in UL128 exon 1 (nt 176,260)  
Merlin-UL128Lmut/RV-Me-UL128Lmut 
Merlin-BACb Wildtype Merlin-UL128L
wt/RV-Me-UL128Lwt 
TR-BAC Intact TR/RV-TR 
TB40-BAC4 Intact TB40-BAC4/RV-TB40-BAC4 
FIX-BAC Intact FIX/RV-FIX 
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3.1 Growth phenotypes of ‘broad-tropism’ HCMV strains in fibroblasts 
The growth characteristics of viruses from each BAC-cloned strain were first 
investigated in fibroblast cells (HFFFs) that are the cell-type most commonly used for the 
propagation of HCMV in vitro.  
 Cell-to-cell spread  3.1.1
 RV-Me-UL128Lmut formed HFFF plaques that were significantly larger than those 
formed by RV-Me-UL128Lwt (p < 0.0001), demonstrating the inhibitory impact of intact 
UL128L ORFs on the cell-to-cell spread of HCMV in fibroblasts (Figure 3.1.A). RV-TR 
formed the smallest HFFF plaques of any virus investigated, even smaller than those formed by 
RV-Me-UL128Lwt (p < 0.05), and therefore displayed the least efficient cell-to-cell spread in 
fibroblasts. RV-TB40-BAC4 and RV-FIX BACs each formed significantly larger HFFF plaques 
than RV-Me-UL128Lwt (p < 0.0001 and p < 0.01, respectively), and therefore displayed a 
greater capacity for cell-to-cell spread in fibroblasts. In fact, HFFF plaques RV-TB40-BAC4 
formed by were almost as large as those formed by RV-Me-UL128Lmut, whilst HFFF plaques 
formed by RV-FIX were of intermediate size compared to those form the Merlin viruses. 
 Dissemination kinetics and cell-free virus production  3.1.2
Transfection of fibroblasts by electroporation is relatively inefficient and results in 
productive infection in only a very low proportion of cells. Furthermore, the dissemination of 
viruses containing intact UL128L ORFs is severely restricted until mutants arise (Stanton, 
Baluchova et al. 2010). Thus, to encourage the early dissemination of each infection, transfected 
HFFF cultures were disrupted by trypsinisation, with all cells (infected and non-infected) re-
seeded to fresh culture vessels where monolayers re-formed with greater distribution of 
infectivity. Infections were treated in this way at weekly intervals until ~10% of all HFFFs were 
infected.  
Consistent with previous work (Stanton, Baluchova et al. 2010), RV-Me-UL128Lmut 
disseminated rapidly (Figure 3.1.B) and produced high peak titres of cell-free virus (Figure 
3.1.C), whereas RV-Me-UL128Lwt disseminated considerably slower and produced peak titres 
of cell free virus that were ~1000-fold lower. Thus, intact UL128L ORFs clearly impeded 
HCMV dissemination and cell-free virus production in fibroblasts. RV-TR initially spread with 
delayed kinetics compared to both Merlin viruses and produced the lowest titres of cell-free 
virus. However this changed dramatically from week 5 post-transfection such that the RV-TR 
infection was completed earlier and produced a peak titre of cell-free virus >100-fold greater 
than the RV-Me-UL128Lwt infection. RV-TB40-BAC4 and RV-FIX each disseminated with 
intermediate kinetics compared to the Merlin viruses, and compared to RV-Me-UL128Lwt, also 
produced greater titres of cell-free virus (~1000-fold, and ~35-fold, respectively).  
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Figure 3.1. Growth characteristics of virus derived from BAC-cloned strains Merlin (UL128Lmut or 
wt), TR, TB40-BAC4 and FIX in fibroblasts.  (A) HFFF cells were transfected with BAC DNA for the 
indicated viruses and incubated under semisolid overlay, with plaque sizes measured 2 weeks post 
transfection. A minimum of 20 plaques per infection was measured. All data from 1 experiment (n = 1). 
Mean plaque sizes and ±SEM are shown. (Where indicated, the mean plaque sizes formed by RV-Me-
UL128Lwt, RV-TR, RV-TB40-BAC4 and RV-FIX were compared to those formed by RV-Me-UL128Lmut 
(black line) and/or RV-Me-UL128Lwt  (grey line): * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 
0.0001). (B) HFFF cells were transfected with BAC DNA for the indicated viruses, and the dissemination 
of infection was allowed to progress until the monolayer was destroyed. At weekly time points post 
transfection (p.t.), the level of infection was estimated by fluorescence microscopy analysis of eGFP-
expressing cells. (C) Supernatant samples collected at weekly time-points from the infections shown in 
panel B were titrated on HFFFs to provide a measure of cell-free virus release throughout the time-course 
of each infection.  
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 Validation of BAC-cloned strain growth phenotypes in fibroblasts 3.1.3
 Since HCMV can undergo adaptation during a single passage in fibroblasts, we sought 
to determine whether any mutations had been selected during the above-described growth 
kinetics assays. The relative order of HFFF plaque sizes formed during titration of supernatant 
samples collected at final time-point in each infection (HFFF-p1) was compared to that formed 
immediately following transfection of HFFFs (p0). The relative order of plaque sizes at p0 was 
closely re-capitulated by all HFFFp1 progeny (Figure 3.2. A+B). However, whereas RV-TR-p0 
formed plaques significantly smaller than RV-Me-UL128Lwt-p0, RV-TR-HFFFp1 formed HFFF 
plaques with more similar size to those produced by RV-Me-UL128Lwt-HFFFp1. This implied 
adaptation was apparently not due to mutations in RV-TR-HFFFp1 UL128L, since PCR-based 
sequencing showed that UL128L in all viruses was equivalent to the parental BAC clone.   
 Conclusion 3.1.4
Compared to the Merlin BAC-derived virus containing wildtype UL128L ORFs, 
viruses derived from the TB40-BAC4 and the FIX-BAC clones spread by the direct cell-to-cell 
route in fibroblasts more efficiently, whilst together with virus from the TR-BAC, they also 
disseminated throughout fibroblast cultures more rapidly and produced greater titres of cell-free 
virus. However, in comparison to virus from the Merlin-BAC variant containing non-intact 
UL128L, none spread in fibroblasts by the cell-to-cell route as efficiently, disseminated as 
rapidly, nor produced greater quantities of cell-free virus. 
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Figure 3.2. Cell-to-cell spread of viruses derived from each BAC-cloned strain in fibroblasts, before and after passage in fibroblasts cells (A) Plaque sizes ±SEM formed 2 
weeks post-transfection (p.t.) of HFFFs with BAC DNA for each indicated virus and incubation under overlay (from Figure 1.A). (B) HFFF plaque sizes and ±SEM of formed by 
HFFF-p1 viruses, at 2 weeks post-infection (p.i.) and incubation under overlay. 
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3.2 Growth phenotype of ‘broad-tropism’ HCMV strains in epithelial cells 
 The growth properties of viruses reconstituted from each BAC-clone were also assessed 
in epithelial cells (RPE-1s), where virus requires an intact UL128L genome region and virion-
incorporated pentameric complex for efficient infection.  
 Cell-to-cell spread  3.2.1
 RV-Me-UL128Lwt formed the largest RPE-1 plaques of any virus investigated, and thus 
displayed the greatest cell-to-cell spread in epithelial cells (Figure 3.3.A). In contrast, RPE-1 
plaques formed by RV-Me-UL128Lmut were significantly smaller than those formed by RV-Me-
UL128Lwt (p < 0.0001); in the vast majority of cases these plaques were represented by single 
cells that were likely infected directly following transfection. This demonstrated the severely 
restricted cell-to-cell spread of virus lacking intact UL128L in epithelial cell culture. Unlike 
RV-Me-UL128Lmut, RV-TR and RV-TB40-BAC4 each consistently formed multi-cellular RPE-
1 plaques, however they were significantly smaller than those formed by RV-Me-UL128Lwt 
(both p < 0.0001). RV-FIX displayed similar epithelial cell-to-cell spread properties as RV-Me-
UL128Lmut and produced RPE-1 plaques significantly smaller than those formed by RV-Me-
UL128Lwt (p < 0.0001). In fact, numerous RPE-1 plaques produced by RV-FIX represented 
single infected cells, yet this occurred less frequently than in the RV-Me-UL128Lmut infection.  
 Dissemination kinetics and cell-free virus production 3.2.2
 The dissemination of infections in epithelial cell culture was monitored by flow 
cytometry; infected RPE-1 monolayers were trypsinised at weekly time-points post-transfection 
and ~1/7th of the total cells were collected for analysis, with the remaining cells seeded into 
fresh flasks for monolayers to reform and for infections to continue.  
 In a contrast to results seen in fibroblasts, RV-Me-UL128Lwt disseminated throughout 
an RPE-1 monolayer with the greatest kinetics of any virus investigated, whilst RV-Me-
UL128Lmut did not spread by any noteworthy degree (Figure 3.3.B). Thus, not only was virus 
lacking intact UL128L unable to spread by the cell-to-cell route in epithelial cells, spread by the 
cell-free supernatant driven route was also severely restricted. RV-TR and RV-TB40-BAC4 did 
spread throughout RPE-1 monolayers, albeit slower than RV-Me-UL128Lwt. Like RV-Me-
UL128Lmut, RV-FIX did not spread throughout an RPE-1 monolayer. In contrast to the direct 
relationship between dissemination kinetics and cell-free virus production seen in fibroblasts, 
the slower spreading RV-TR and RV-TB40-BAC4 infections produced peak titres of cell-free 
virus that were ~85–fold, and ~140–fold greater than that produced by RV-Me-UL128Lwt, 
respectively (Figure 3.3.C). As RV-Me-UL128Lmut and RV-FIX did not establish productive 
infection in RPE-1s, supernatants from these transfected cultures were not analysed.  
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Figure 3.3.  Growth characteristics of virus derived from BAC-cloned strains Merlin (UL128Lmut or 
UL128Lwt), TR, TB40-BAC4 and FIX in epithelial cells.  (A) RPE-1 cells were transfected with BAC 
DNA for the indicated viruses and incubated under semi-solid overlay, with plaque sizes measured 3 
weeks post transfection. Where possible, a minimum of 20 plaques from each infection was measured. 
All data from 1 experiment (n = 1). Means and ±SEM are shown. (Where indicated, the mean plaque 
sizes formed by RV-Me-UL128Lmut, RV-TR, RV-TB40-BAC4 and RV-FIX were compared to those 
formed by RV-Me-UL128Lmut (black line) and RV-Me-UL128Lwt (grey line) by 1-way analysis of 
variance [ANOVA] followed by Dunnett’s posttest: ns – non-significant, * p < 0.05, ** p <0.01, *** p < 
.001, **** p < 0.0001). (B) RPE-1 cells were transfected with BAC DNA for the indicated viruses, and 
the dissemination of infection was allowed to progress until the monolayer was destroyed. At weekly 
time points post transfection (p.t.), the level of infection was estimated by flow cytometry analysis of 
eGFP-expressing cells. (C) Supernatant samples collected at weekly time-points from the infections 
shown in panel B were titrated on HFFFs to provide a measure of cell-free virus release throughout the 
time-course of each infection.  
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 Validation of BAC-cloned strain growth phenotypes in epithelial cells 3.2.3
 As in fibroblasts, HCMV can also undergo rapid adaptation to epithelial cell culture, 
and this could involve mutations in genome regions that are unstable in both cell types (Dargan, 
Douglas et al. 2010). Hence, to assess whether mutations had been selected in the growth 
kinetics assays performed in epithelial cells, the relative HFFF plaque sizes formed during 
titration of progeny virus from each RPE-1 infection (RPE-1p1) were compared to those formed 
immediately following transfection of HFFFs (p0) (Figure 3.4.A+B). The relative HFFF plaque 
sizes formed by TB40-BAC4-RPE-1p1 and RV-Me-UL128Lwt-RPE-1p1 were comparable to 
those formed immediately following transfection, indicating that the TB40-BAC4 BAC-derived 
virus had not undergone any major adaptation. However, whereas RV-TR-p0 formed smaller 
HFFF plaques than RV-Me-UL128Lwt-p0, RV-TR-RPE-1p1 formed slightly larger HFFF 
plaques than RV-Me-UL128Lwt-RPE-1p1. Thus, RV-TR had apparently adapted in RPE-1s. 
Again, PCR-based sequencing indicated that UL128L in all RPE-1-p1 viruses was equivalent to 
that in each parental BAC.  
 Conclusion 3.2.4
Compared to Merlin virus containing wildtype UL128L, virus derived from TR-BAC 
and TB40-BAC4 spread cell-to-cell and disseminated throughout epithelial cultures less 
efficiently, yet produced greater quantities of cell-free virus. Surprisingly, virus reconstituted 
from the FIX-BAC was unable to establish productive infection in RPE-1s and displayed a 
growth phenotype similar to the Merlin virus lacking intact UL128L ORFs. 
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Figure 3.4. Cell-cell spread of viruses derived from each BAC-cloned strain in fibroblasts before and after passage in epithelial cells. (A) Plaque sizes ±SEM formed 2 weeks 
post transfection of HFFFs with BAC DNA and incubation under overlay. (B) HFFF plaque sizes and ±SEM formed by RPE-1-p1 viruses, at 2 weeks post-infection and incubation 
under overlay. 
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3.3 Role of variant UL128L in the differential growth phenotypes of each strain 
 Data from the growth kinetics assays suggested that whilst UL128L was apparently 
intact in each of the TR-BAC and TB40-BAC4 genomes, the inhibitory impact of this genome 
region on the growth of virus in fibroblasts was less severe than in wildtype Merlin virus 
infections. The same consideration applied to FIX, however the assumption that FIX-BAC 
UL128L was intact was based on the reported use of this strain for infections in cell types where 
virus requires UL128L (i.e. endothelial cells). We hypothesised that the distinct growth 
phenotypes of these strains was due to one, or a combination, of three potential circumstances: 
i) each contains natural UL128L variants that are less inhibitory to the growth of virus in 
fibroblasts cells; ii) each contain subtle UL128L mutations, acquired during the fibroblast 
passage of the corresponding parental viruses prior to BAC-cloning, that suppress but not ablate 
pentameric complex functionality; iii) other genome regions in each strain compensate for the 
inhibitory effects of UL128L. Sequencing data for the un-passaged clinical isolates from which 
the TR, TB40-BAC4 and FIX BAC-cloned genomes were captured was not available for 
comparison. We therefore sought to determine the specific impact of each variant UL128L on 
the growth phenotypes of virus. To this end, Merlin BAC variants containing each variant 
UL128L in place of the native UL128L were constructed, and the derived recombinant viruses 
were assessed to see whether the growth characteristics of each donor strain were transferred - 
performed by Dr Richard Stanton (School of Medicine, Cardiff University) (Appendix II). 
 In brief, the Merlin virus expressing TR UL128L displayed an almost identical growth 
phenotype as the parental Merlin virus containing native wildtype UL128L. Thus, UL128L was 
not a major contributing factor to the distinct growth phenotype of TR BAC-derived virus. 
Interestingly, RV-Me-UL128LTR did produce greater titres of cell-free virus at late time-points 
in fibroblast culture infections compared to RV-Me-UL128Lwt. However, this was later shown 
to have occurred following the acquisition of a large deletion encompassing the UL128L ORFs 
(UL128 and UL130), and not due to features inherent to TR UL128L. Transfer of TB40-BAC4 
and FIX UL128L did alter the growth phenotype of Merlin virus. Compared to RV-Me-
UL128Lwt, RV-Me-UL128LTB40 and RV-Me-UL128LFIX each displayed greater cell-to-cell 
spread, more efficient dissemination kinetics, and increased cell-free virus production in 
fibroblasts. Furthermore, both also displayed reduced cell-to-cell spread, yet greater cell-free 
virus production in epithelial cells. The dissemination kinetics of RV-Me-UL128LFIX in 
epithelial cell culture, but not RV-Me-UL128LTB40, also differed to that of RV-Me-UL128Lwt. 
Thus, UL128L contained within the TB40-BAC4 and FIX BACs did contribute, at least 
partially, to the distinct growth phenotypes of virus produced by each corresponding BAC-
cloned strain. Moreover, FIX UL128L was confirmed to be functionally intact when expressed 
in the Merlin genome background.  
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3.4 Comparative nucleotide sequence analysis for the identification of in vitro acquired 
mutations, or other variations that conveyed distinct growth phenotype of each strain 
The UL128L genome region of TB40-BAC4 and FIX contained features that apparently 
altered pentameric complex functionality, ultimately impacting the growth phenotype of virus. 
In contrast, the pentameric complex incorporated into Merlin virions yet composed of TR 
UL128L encoded sub-units was functionally equivalent to the pentameric complex composed of 
wildtype Merlin UL128L encoded sub-units. Therefore, genome regions other than UL128L 
appeared to be responsible for the distinct growth phenotype of TR BAC-derived viruses. To 
identify nucleotides that defined the different growth phenotype of each strain, comparative 
nucleotide sequence analysis of each variant UL128L ORF, and/or other genome regions, was 
performed. 
Initially, the sequences of TR, TB40-BAC4 and FIX UL128L were compared to Merlin 
UL128L (Table 3.2.). Similarly to descriptions of UL128L coding potential in distinct wildtype 
strains (Baldanti, Paolucci et al. 2006, Sun, Ji et al. 2009), each variant UL128L ORF contained 
protein coding nucleotide sequences that were highly homologous: compared to the 
corresponding ORF in Merlin UL128L, each variant UL128 shared between 98.16-98.95% 
nucleotide sequence identity, with variations mostly commonly observed in exon 1; each variant 
UL130, the most variable of the UL128L ORFs, shared between 97.52-98.29% nucleotide 
sequence identity with variations distributed throughout the entire ORF; and each variant 
UL131A shared 98.19-98.39% nucleotide sequence identity, with variations most frequently 
observed in exon 1.  
Of interest were coding nucleotide variations that potentially represented in vitro 
acquired mutations. Given the high degree of homology between UL128L from each strain, the 
primary criteria applied for candidates of ‘in vitro acquired mutations’ were nucleotides that 
were uncommon, or indeed unique to any given strain, and thus unlikely to represent natural 
variations. The common or unique nature of nucleotide variations were then assessed by 
performing BLAST searches against all other HCMV UL128L sequences (~75 either partial or 
complete UL128L sequences) deposited in GenBank, including those derived from both highly-
passaged laboratory-adapted strains, and clinical isolates undergone no passage at all.  
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Table 3.2. Nucleotide variations in UL128L ORFs from TR-BAC, TB40-BAC4, and FIX-BAC compared to the wildtype Merlin-BAC. 
 
BAC clone ORF 
Nucleotide 
Identity to 
Merlin ORFa 
Nucleotide Identity/Variations in coding nucleotidesb,c Amino Acid  Identities/Variation 
TR-BAC 
UL128 
748/759 
(98.55%) 
Exon 1 159/164 (96.95%): A15G, C34T1, G43A, A49G, C75T 
Exon 2 134/135 (99.26%): C325T2 
Exon 3 215/217 (99.08%): T587C, A647G 
168/171 (98.24%): 
A12T1, V77I2 
UL130 
633/645 
(98.14%) 
633/642 (98.86%): G25A1, G79A2, T96C, T99C, T198C, A206G3, C305T4, 
G399A, C351G, T357C, C525T, A540G 
210/214 (98.13%): 
H9Y1, D27S2, L69S3, 
R102K4 
UL131A 
490/498 
(98.39%) 
Exon 1 233/236  (98.73%): C11T1, T69C, C75T 
Exon 2 153/154  (99.35%): T453C 
128/129 (99.22%): 
C4Y1 
TB40-BAC4 
UL128 
745/759 
(98.16%) 
Exon 1 159/164 (96.95 %): C13T1, A15G, G46A, C53T2, C75T 
Exon 2 135/135 (100%) 
Exon 3 215/217 (99.08 %): T587C, A647G 
169/171 (98.83%): 
D5N1, G18D2 
UL130 
634/645 
(98.29%) 
634/642 (98.75%): C6T, C87T, T96C, T99C, G119A1, G178T2, T198C, G233A3, 
C351G T357C, C390T 
211/214 (98.60%): 
L40I1, L60I2, S78L3 
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UL131A 
489/498 
(98.19%) 
Exon 1 234/236 (99.15%): T69C, C75T 
Exon 2 153/154  (99.35%): T453C 
129/129 (100%) 
FIX-BAC 
UL128 
751/759 
(98.95%) 
Exon 1 161/164 (98.78%): C13T1, A15G, C75T 
Exon 2 135/135 (100%) 
Exon 3 215/217 (99.08%): T587C, A647G 
170/171 (99.42%): 
D5N1 
UL130 
629/645 
(97.52%) 
629/642 (97.98%): C6T, G86A1, C87G, T96C, T99C, A139G2, T198C, A206G3, 
A214G4, G399A, C351G, G354A T357C, G480A, C525T, A540G 
210/214 (98.13%): 
S29F1, S47P2, L69S3, S72P4 
UL131A 
490/498 
(98.39%) 
Exon 1 233/236  (98.73%): T69C, C75T, G135A 
Exon 2 153/154  (99.35%): T453A 
129/129 (100%) 
 
a- nucleotide identities through entire corresponding ORF, including coding nucleotides in UL128 and UL131A exons, as well as non-coding nucleotide in the introns of these ORFs.  
b - nucleotide co-ordinates denoted reflect position in Merlin UL128, UL130 and UL131A ORF sequences deposited in GenBank (GU179001).  
c - Bold typeface indicates non-synonymous nucleotide variations; number matches amino acid variation in corresponding glycoprotein product. 
d - amino acid co-ordinates denoted reflect position in Merlin-encoded gpUL128, gpUL130 and gpUL131A glycoproteins. 
    106 
3.5 Genome regions contributing to the growth phenotype of virus from the TR-BAC 
 Compared to Merlin UL128L, each TR UL128L ORF contained non-synonymous 
nucleotide variations. As potential candidates of in vitro acquired mutations, the R102K amino 
acid substitution encoded by TR UL130 was identified only in one further HCMV sequence 
deposited in GenBank, derived from ‘Isolate 39J’ (DQ229947.1), whilst the C4Y amino acid 
substitution encoded by TR UL131A was identified only in ‘Strain AL’ (GQ22015.2) and 
‘Isolate Burns H’ (GU574781.1). However, with few reports regarding the origins and passage 
history of these strains, their relationship to the strain TR viral lineage could not be assessed in 
order to predict whether these features represent uncommon, yet natural sequence variations. 
Furthermore, given the inability of TR UL128L to convey any distinct growth characteristics 
when expressed by Merlin virus, these features were not investigated.  
 Impact of UL131A 5’-UL132 5’ genome region on RV-TR growth phenotype  3.5.1
 TR-BAC derived virus displayed distinct phenotypes in pentameric complex influenced 
activities, yet the TR UL128L ORFs were not responsible for this. We therefore considered 
whether transcriptional regulatory components that govern TR UL128L expression might be 
responsible. Comparative nucleotide sequence analysis was applied to genome regions flanking 
TR UL128L: upstream of UL131A, the promoter from which a polycistronic single read-
through transcript encoding all UL128L glycoproteins is predicted to reside; downstream of 
UL128, the polyadenylation signal common to all UL128L derived transcripts is located. A 
region containing multiple uncommon and unique nucleotide variations was identified 
immediately upstream of UL131A and overlapping UL132 (Figure 3.5.) due to several of these 
nucleotides laying outside of described ORFs, nucleotide co-ordinates are denoted in relation to 
the corresponding position in the Merlin BAC genome sequence (GU179001). Within the TR 
UL131A-UL132 intragenic region were the uncommon nucleotide residues G at nt 178,115 and 
A at nt 178,156, each absent in the vast majority of other HCMV sequences in GenBank. TR 
UL132 also contained uncommon nucleotides, with a G>T at nt 178,618 identified only in 
strains ‘HAN 33’ (GQ221998.1) and ‘HAN 21’ (GQ221987.1), and a G>A at nt 178,861 
identified only in strains ‘NT’ (GQ222016.1) and strain ‘HAN 8’ (GQ221979.1). Unique 
nucleotide variations identified in TR UL132 included a G>A at nt 178,233 and a G>A at nt 
178,750. The variations at nt 178,233 and nt 178,861 were non-synonymous, specifying P261S 
and A51T amino acid substitutions, respectively. Whilst these features possibly impacted the 
UL128L ORF common promoter, they also potentially impacted UL132 that encodes a virion 
envelope glycoprotein (gpUL132) reported to enhance the growth of virus in fibroblasts 
(Spaderna, Kropff et al. 2005).  
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Figure 3.5. Nucleotide sequence identified in TR UL131A 5’ – UL132 5’ genome region. The UL131A 5’ – UL132 5’ genome region of the Merlin and TR BAC-cloned 
genomes is indicated by a single black line; ORFs are depicted in yellow. Nucleotide positions are given relative to the Merlin BAC sequence (GU179001). Dots indicate identical 
nucleotides in comparison sequence. Nucleotide variations highlighted in grey are uncommon amongst all sequences deposited in GenBank, though not unique to TR. In the 
UL131A – UL132 intragenic region, A>G variation at nt 178,115 and G>A at nt 178,156, and in the UL132 ORF, G>A at nt 178,618 and G>A at nt 178,861. Variations highlighted 
in pink are unique to TR, and represent G>A substitutions at positions nt 178,233 and nt 178,750. 
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 The TR UL131A 5’ – UL131 5’ genome region was inserted into the Merlin-UL128Lwt 
BAC genome background to generate the novel BAC variant Merlin-UL132TR, and the growth 
characteristics of the derived recombinant Merlin virus were compared to those of the parental 
viruses containing native UL131A 5’ – UL132 5’ genome regions (Table 3.3). 
 
 
Table 3.3. Viruses containing UL131A 5’ – UL132 5’ from TR or Merlin. 
Genome 
Background 
UL131A 5’- UL132 5’ 
Origin 
Designation in text: 
BAC /Reconstituted Virus 
Merlin Native Merlin-UL128Lwt/RV-Me-UL128Lwt 
Merlin TR Merlin-UL132TR/RV-Me-UL132TR 
TR Native TR /RV-TR 
 
 
 Impact of TR UL131A 5’ – UL132 5’ in fibroblasts  3.5.1.1
 The cell-to-cell spread of each virus was investigated in transfected fibroblasts (Figure 
3.6.A). Consistent with previous results, RV-Me-UL128Lwt formed HFFF plaques that were 
larger than those formed by RV-TR (p < 0.05). RV-Me-UL132TR formed plaques of comparable 
size to those formed by RV-Me-UL128Lwt, and larger than those of RV-TR (p < 0.01).  
 Impact of TR UL131A 5’ – UL132 5’ in epithelial cells 3.5.1.2
 The cell-to-cell spread of RV-Me-UL132TR was also assessed in epithelial cells (3.6.B). 
Again, consistent with previous findings, RV-Me-UL128Lwt produced larger RPE-1 plaques 
compared to RV-TR (p < 0.001). Similar to what was observed in fibroblasts, RV-Me-UL132TR 
displayed cell-to-cell spread in epithelial cells that closely reflected that of the parental Merlin 
virus RV-Me-UL128Lwt, and importantly, formed RPE-1 plaques that were significantly larger 
than those formed by RV-TR (p < 0.0001). The dissemination kinetics of RV-Me-UL132TR in 
RPE-1s were also identical that of RV-Me-UL128Lwt, and dramatically faster than that of RV-
TR (Figure 3.6.C). 
 Conclusion 3.5.2
 The growth characteristics of the recombinant Merlin virus containing the TR UL131A 
5’ – UL132 5’ genome region closely reflected that of the parental Merlin virus and not that of 
the TR BAC-derived virus. Hence, the nucleotide sequence features identified in TR UL131A 
5’ – UL132 5’ were not the cause of the distinct growth phenotype of virus reconstituted from 
the TR-BAC compared to virus from the Merlin-UL128Lwt BAC.  
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Figure 3.6.  Growth characteristics of virus containing TR UL131A 5’ – UL132 5’ genome region in 
fibroblasts and epithelial cells. (A) HFFF cells were transfected with BAC DNA for the indicated 
viruses and incubated under semisolid overlay, with plaque sizes measured 2 weeks post-transfection 
(p.t). (B) RPE-1 cells were transfected with BAC DNA for the indicated viruses and incubated under 
semisolid overlay, with plaque sizes measured 3 weeks post transfection. All data from 1 experiment (n = 
1). A minimum of 20 plaques from each infection was measured, where possible. Means and ±SEM are 
shown. (Where indicated, the mean plaque sizes formed by RV-Me-UL128Lwt, RV-TR, and RV-Me-
UL132TR were compared to those formed by RV-Me-UL128Lwt (grey line) and/or RV-TR (green line) by 
1-way analysis of variance [ANOVA] followed by Dunnett’s posttest: ns – non-significant, * p < 0.05, ** 
p <0.01, *** p < .001, **** p < 0.0001). (C) RPE-1 cells were transfected with BAC DNA for the 
indicated viruses. At weekly time-points post-transfection (p.t.), the level of infection was estimated by 
fluorescence microscopy analysis of eGFP-expressing cells. 
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3.6 Nucleotides contributing to the growth phenotype of viruses from TB40-BAC4  
TB40-BAC4 UL128 and UL130 each contained non-synonymous nucleotide variations 
compared to the corresponding Merlin ORFs, yet none were unique to this strain. TB40-BAC4 
UL131A contained 3 coding nucleotide variations, yet each was synonymous. Thus, TB40-
BAC4 UL128L encoded no amino acid variations that were strong candidates for in vitro 
acquired mutations. The TB40-BAC4 UL128L sequence is highly homologous to that in strain 
‘3301’ (GQ466044.1); this strain has not been passaged in vitro and can be considered to 
contain wildtype UL128L sequence (Cunningham, Gatherer et al. 2010). TB40-BAC4 and 
strain 3301 UL128 ORFs differed at three nucleotide positions, only 1 of which was a coding 
nucleotide but was synonymous. UL131A in these strains differ at only one position in the 
intron. The UL130 ORFs differed at 5 nucleotide positions, 2 of which encoded amino acid 
variations; in comparison to Merlin UL130, TB40-BAC4 encodes an S78L amino acid 
substitution, whilst strain 3301 encodes an A20G amino acid substitution. The fact that TB40-
BAC4 and strain 3301 UL128L ORFs differed to Merlin UL128L ORFs in a near identical way 
provided an opportunity to determine whether natural variations were responsible for the 
distinct growth phenotype impact of TB40-BAC4 UL128L. Thus, the UL128L genome region 
from strain 3301 was inserted into the Merlin-BAC genome to generate Merlin-UL128L3301. 
Interestingly, unique nucleotide variation was identified in TB40-BAC4 UL128 intron 1 (G>T; 
nt 282), 6 nucleotides upstream from the intron 1 splice acceptor site (Figure 3.7). This feature 
was absent in all HCMV sequences deposited in GenBank, including strain 3301. Moreover, 
this variation was also absent in the consensus sequence from the mixed population virus 
‘TB40/E’ from which TB40-BAC4 was cloned, and also sibling clone ‘TB40/E clone Lisa’ 
(KF297339.1). The UL128 intron 1 G>T variation was therefore a candidate for an in vitro 
acquired mutation and inserted into the Merlin-UL128Lwt BAC, generating Merlin-UL128G>T. 
The growth phenotypes of Merlin viruses expressing TB40-BAC4 and strain 3301 UL128L 
sequences were compared to viruses from the original Merlin-BACs variants (Table 3.4). 
 
Table 3.4. Merlin Viruses containing TB40-BAC4, or strain 3301 UL128L sequences. 
 
Genome 
Background 
UL128L Origin / Nucleotide 
features 
Designation in text: 
BAC /Reconstituted Virus 
Merlin 
Native, mutated Merlin-UL128Lmut/RV-Me-UL128Lmut 
Native; wildtype Merlin-UL128Lwt/RV-Me-UL128Lwt 
Strain 3301  Merlin-UL128L3301/RV-Me-UL128L3301 
TB40-BAC4 Merlin-UL128LTB40/RV-Me-UL128LTB40 
Native + UL128 intron 1 G>T Merlin-UL128G>T/RV-Me-UL128G>T 
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Figure 3.7. Unique nucleotide identified in TB40-BAC4 UL128 intron 1. Alignment of UL128 ORFs from Merlin, strain 3301, and TB40-BAC4. ORFs depicted in 5’-‘ 
orientation, inverted to presentation in the HCMV genome. A solid black line depicts the continuous nucleotide sequence. Entire ORFs (blue); coding region (yellow); introns (black 
arch). Nucleotide positions are given relative to the Merlin BAC sequence (GU179001). Dots indicate identical residues in comparison sequences. Purple arrow highlights unique 
TB40-BAC4 UL128 G>T variation (nt 282 in Merlin UL128). 
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 Impact of TB40-BAC4 UL128 G>T variation in fibroblasts 3.6.1
 Cell-to-cell spread 3.6.1.1
RV-Me-UL128L3301 and RV-Me-UL128Lwt produced HFFF plaques with comparable 
size (Figure 3.8.A), demonstrating that wildtype UL128L ORFs of strains 3301 and Merlin 
impeded the cell-to-cell spread of HCMV in fibroblasts by the same degree, regardless of 
natural strain-strain variations. The larger HFFF plaques formed by RV-Me-UL128LTB40 
compared to RV-Me-UL128L3301 (p < 0.01) confirmed that the UL128L nucleotide variations 
common to TB40-BAC4 and strain 3301 were not responsible for the more efficient cell-to-cell 
spread of Merlin virus following transfer of TB40-BAC4 UL128L ORFs. Intriguingly, RV-Me-
UL128G>T produced HFFF plaques with comparable size to those formed by RV-Me-
UL128LTB40, hence the increased cell-to-cell spread in fibroblasts displayed by Merlin virus 
following transfer of TB40-BAC4 UL128L was recapitulated by transfer of the UL128 G>T 
variation alone.  
 Dissemination kinetics and cell-free virus production  3.6.1.2
RV-Me-UL128L3301 disseminated throughout HFFF monolayers with identical kinetics 
compared to RV-Me-UL128Lwt, both being dramatically slower than RV-Me-UL128Lmut 
(Figure 3.8.B). Thus, the wildtype UL128L ORFs of strain 3301 also impeded the dissemination 
of HCMV in fibroblast by a similar degree as Merlin wildtype UL128L ORFs. RV-Me-
UL128LTB40 again spread throughout an HFFF monolayer with kinetics intermediate to that of 
the Merlin viruses containing wildtype or non-intact UL128L ORFs, and crucially, faster than 
RV-Me-UL128L3301. Furthermore, the dissemination kinetics of RV-Me-UL128LTB40 were 
entirely re-capitulated by RV-Me-UL128 G>T.  
The peak titre of cell-free virus produced in the RV-Me-UL128Lwt infection (Figure 
3.8.C) was greater than seen in previous assays – only 10-fold lower than those produced by 
RV-Me-UL128Lmut, whereas previously the difference had been ~1000-fold (see Figure 3.1.C). 
The RV-Me-UL128L3301 infection also produced surprisingly high titres of cell-free virus. In 
later investigations (see section 5.3), RV-Me-UL128Lwt and RV-Me-UL128L3301 viruses derived 
from these infections were shown to have acquired ablating UL128L genome mutations. Based 
on this, the cell-free virus production displayed by RV-Me-UL128Lwt and RV-Me-UL128L3301 
infections were deemed un-suitable for comparison. However, both RV-Me-UL128LTB40 and 
RV-Me-UL128G>T displayed comparable cell-free virus production in fibroblasts, each 
producing peak tires of cell-free virus that were ~30-fold and ~20-fold lower than produced by 
RV-Me-UL128Lmut, respectively. 
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Figure 3.8.  Growth characteristics of virus containing TB40-BAC4 UL128L or strain 3301 UL128L 
nucleotides in fibroblasts. (A) HFFF cells were transfected with BAC DNA for the indicated viruses and 
incubated under semisolid overlay, with plaque sizes measured 2 weeks post-transfection (p.t.). Where 
possible, a minimum of 20 plaques from each infection was measured. All data from 1 experiment (n = 
1). Means and ±SEM are shown. (Where indicated, the mean plaque sizes formed by RV-Me-UL128Lwt, 
RV-Me-UL128L3301, RV-Me-UL128LTB40, RV-Me-UL128G>T were compared to those formed by RV-Me-
UL128Lmut (black line), RV-Me-UL128Lwt (grey line), RV-Me-UL128L3301 (gold line), and/or RV-Me-
UL128LTB40 (purple line) by 1-way analysis of variance [ANOVA] followed by Dunnett’s posttest: ns – 
non-significant, * p < 0.05, ** p <0.01, *** p < .001, **** p < 0.0001). (B) HFFF cells were transfected 
with BAC DNA for the indicated viruses, and the dissemination of infection was allowed to progress until 
the monolayer was destroyed. At weekly time-points post-transfection (p.t.), the level of infection was 
estimated by fluorescence microscopy analysis of eGFP-expressing cells. (C) Supernatant samples 
collected at weekly time-points from the infections shown in panel B were titrated on HFFFs to provide a 
measure of cell-free virus release throughout the time-course of each infection. 
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 Impact of TB40-BAC4 UL128 intron 1 G>T in epithelial cells 3.6.2
 Cell-to-cell spread  3.6.2.1
A similar, but reciprocal, pattern of findings as seen in fibroblasts was observed 
following comparison of RPE-1 plaque sizes formed by the Merlin variants containing UL128L 
sequences from strain 3301 and TB40-BAC4 (Figure 3.9.A). Importantly, RV-Me-UL128L3301 
formed RPE-1 plaques with comparable size to those formed by RV-Me-UL128Lwt, further 
demonstrating that natural strain-strain variations had little impact on the growth phenotype 
influence of wildtype UL128L ORFs. Similar to previous findings, RV-Me-UL128LTB40 again 
formed multi-cellular RPE-1 plaques that were significantly larger than those formed by RV-
Me-UL128Lmut (p < 0.0001), but smaller than those formed by RV-Me-UL128Lwt (p < 0.05). 
Furthermore, RPE-1 plaques formed by RV-Me-UL128LTB40 were also significantly smaller 
than those formed by RV-Me-UL128L3301 (p < 0.05). RV-Me-UL128G>T formed RPE-1 plaques 
with similar size to those formed by RV-Me-UL128LTB40, and these too were smaller than those 
formed by RV-Me-UL128Lwt or RV-Me-UL128L3301 (both p < 0.05). This pattern of results 
indicated that natural variations common to the UL128L genome regions of TB40-BAC4 and 
strain 3301 did not account for the reduced capacity for cell-to-cell spread in epithelial cells 
displayed by RV-Me-UL128LTB40, whilst the UL128 G>T variation unique to TB40-BAC4 was 
responsible. 
 
 Dissemination kinetics and cell-free virus production  3.6.2.2
 Each of RV-Me-UL128Lwt, RV-Me-UL128L3301, RV-Me-UL128LTB40 and RV-Me-
UL128G>T achieved complete infection of epithelial cell cultures within identical time frames 
(Figure 3.9.B). Thus sequence variations amongst the UL128L ORFs in the Merlin-BAC and 
TB40-BAC4 clones or in the UL128L ORFs in strain 3301, whether natural or representative of 
in vitro acquired mutations, had no apparent differential impact on the dissemination of Merlin 
virus in epithelial cell culture. 
 Like RV-Me-UL128Lwt, RV-Me-UL128L3301 produced limited titres of cell-free virus; 
the peak titres produced by these infections differed by only ~ 2-fold (Figure 3.9.C). However, 
RV-Me-UL128LTB40 produced peak titres of cell-free virus that were ~45-fold and ~20-fold 
greater than that produced by RV-Me-UL128Lwt and RV-Me-UL128L3301, respectively, and this 
was entirely re-capitulated by RV-Me-UL128G>T.  
 Thus, similar to the impact on the cell-to-cell spread of HCMV in epithelial cell culture, 
the TB40-BAC4 UL128L genome region and the single and UL128 G>T variation also had an 
identical impact on the dissemination and cell-free virus production of HCMV in this cell-type.
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Figure 3.9.  Growth characteristics of virus containing TB40-BAC4 UL128 intron 1 G>T unique 
nucleotide in epithelial cells. (A) RPE-1 cells were transfected with BAC DNA for the indicated viruses 
and incubated under semisolid overlay, with plaque sizes measured 3 weeks post-transfection (p.t.). 
Means and ±SEM are shown. All data from 1 experiment (n = 1). Means and ±SEM are shown. (Where 
indicated, the mean plaque sizes formed by RV-Me-UL128Lwt, RV-Me-UL128L3301, RV-Me-UL128LTB40, 
RV-Me-UL128G>T were compared to those formed by RV-Me-UL128Lmut (black line), RV-Me-UL128Lwt 
(grey line), RV-Me-UL128L3301 (gold line), and/or RV-Me-UL128LTB40 (purple line) by 1-way analysis of 
variance [ANOVA] followed by Dunnett’s posttest: ns – non-significant, * p < 0.05, ** p <0.01, *** p < 
.001, **** p < 0.0001). (B) RPE-1cells were transfected with BAC DNA for the indicated viruses, and 
the dissemination of infection was allowed to progress until the monolayer was destroyed. At weekly 
time points post transfection (p.t.), the level of infection was estimated by fluorescence microscopy 
analysis of eGFP-expressing cells. (C) Supernatant samples collected at weekly time-points from the 
infections shown in panel B were titrated on HFFFs to provide a measure of cell-free virus release 
throughout the time-course of each infection. 
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 Validation of TB40-BAC4 UL128 intron 1 G>T growth phenotype impact 3.6.3
Again, the relative HFFF plaque sizes formed immediately following transfection with 
BAC DNA for each virus (p0) (Figure 3.10.A) were compared to those formed during titration 
of progeny virus produced in fibroblasts (HFFFp1) (Figure 3.10.B), or in epithelial cell 
infections (RPE-1p1) (Figure 3.10.C). As mentioned, the titres of cell-free virus produced 
during the RV-Me-UL128Lwt and RV-Me-UL128L3301 infections in HFFFs suggested that these 
viruses may have undergone adaptation early following reconstitution, and the sizes of HFFF 
plaques formed by RV-Me-UL128Lwt-HFFFp1 and RV-Me-UL128L3301-HFFFp1 viruses 
reflected this; HFFF plaques formed immediately following transfection with Merlin-UL128Lwt 
and Merlin-UL128L3301 BAC DNA were smaller than those formed immediately following 
transfection with Merlin-UL128LTB40 and Merlin-UL128G>T BAC DNA, whilst the HFFFp1 
progeny from the RV-Me-UL128Lwt and RV-Me-UL128L3301 infections formed larger HFF 
plaques than those formed HFFFp1 progeny from the RV-Me-UL128LTB40 and RV-Me-
UL128G>T infections. However, comparison to the HFFF plaque sizes formed by RV-Me-
UL128Lmut-HFFFp1 gave no indications that either of the Merlin variants containing TB40-
BAC4 UL128L sequence had undergone adaptation in fibroblasts. In addition, there was no 
evidence that any virus had undergone adaptation during passage in epithelial cells.  
 Conclusion 3.6.4
The growth phenotype impact of UL128L ORFs with alternative, but wildtype 
sequences was identical, and apparently not subject to natural strain-strain variation. This was 
apparent in both fibroblasts, where UL128L is inhibitory to virus growth, and also in epithelial 
cells, where virus requires UL128L for efficient infection. The different growth characteristics 
of RV-Me-UL128LTB40 compared to RV-Me-UL128L3301, together with the recapitulation of the 
RV-Me-UL128LTB40 growth phenotype by RV-Me-UL128G>T, indicated that the G>T nucleotide 
variation identified in intron 1 of the TB40-BAC4 UL128 ORF alone, and not natural strain-
strain variations, was the defining difference between TB40-BAC4 UL128L and Merlin 
wildtype UL128L genome regions.  
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Figure 3.10. Fibroblast cell-to-cell spread of recombinant Merlin viruses containing TB40-BAC4 or strain 3301 UL128L nucleotides, before and after passage in fibroblast 
and epithelial cells. (A) Plaque sizes ±SEM formed 2 weeks post-transfection (p.t) of HFFFs with BAC DNA for each indicated virus and incubation under overlay. (B) HFFF 
plaque sizes ±SEM formed during titration of virus in supernatant samples collected at final time-point in growth kinetics assay performed in HFFFs, at 2 weeks post-infection (p.i.) 
and incubation under overlay. (C) HFFF plaque sizes ±SEM of formed during titration of virus in supernatant samples collected at final time-point in growth kinetics assay 
performed in HFFFs, at 2 weeks post-infection (p.i.) and incubation under overlay. 
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3.7 Nucleotides contributing to the growth phenotype of viruses from FIX-BAC  
FIX UL128 contained a single non-synonymous nucleotide variation compared to 
Merlin UL128, however the encoded D5N amino acid substitution was also identified in the 
sequences of several other distinct strains deposited in GenBank. FIX UL131A differed from 
that in Merlin at 4 nucleotide positions, each being synonymous variations and not encoding for 
alternative amino acids. FIX UL130 contained 11 nucleotide variations, four of which were 
non-synonymous. One amino acid variation (L69S) was common to several other strains, and 
potentially represented natural strain-strain variation. However, three amino acid variations 
were less common. The S29F amino acid substitution was identified in sequences from strain 
VR1814 (GU179289.1) (FIX-BAC parental strain), and also from ‘Isolate 20M’ (DQ22943.1). 
The 2 more exclusive nucleotide sequence features were A>G nucleotide variations at nt 140 
and nt 214 in FIX UL130, coding for S47P and S72P amino acid substitutions respectively. The 
S47P amino acid substitution is also present in FIX parental strain VR1814, whilst the S72P 
amino acid substitution was entirely unique to FIX (Figure 3.11). Thus, the S72P variation was 
selected for further investigation and transferred into the Merlin genome to generate Merlin-
UL130A>G.  The contribution of the unique A>G (S72P) nucleotide variation was investigated 
by determining the growth phenotype of Merlin virus engineered to contain this nucleotide 
variation in direct comparison to Merlin virus expressing the entire FIX UL128L, as well as to 
Merlin viruses containing native UL128L sequences (wildtype or non-intact) (Table 3.5). 
 
 
Table 3.5. Merlin BACs/Viruses containing native or FIX UL128L sequence features. 
 
 
 
Genome 
Background 
UL128L Origin / 
Nucleotide feature 
Designation in text: 
BAC /Reconstituted Virus 
Merlin Native, mutated Merlin-UL128Lmut/RV-Me-UL128Lmut 
Merlin Native; wildtype Merlin-UL128Lwt/RV-Me-UL128Lwt 
Merlin FIX Merlin-UL128LFIX/RV-Me-UL128LFIX 
Merlin Native; + FIX UL130 A>G Merlin-UL130A>G /RV-Me-UL130A>G 
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Figure 3.11. Unique nucleotide sequence features identified in FIX UL130. UL130 ORFs from Merlin and FIX, in inverse orientation as to how presented in the HCMV genome. 
A solid black line depicts the continuous nucleotide sequence. Entire ORFs (blue); coding region (yellow). Nucleotide positions are given relative to Merlin UL130 sequences. Dots 
indicate identical residues in comparison sequences. Grey arrow highlights A>G (S47P) variation identified only in FIX and VR1814 at nt 139. Pink arrow highlights A>G (S72P) 
nucleotide variation unique to FIX, at nt 214 (pink).  
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  Impact of FIX UL130 A>G In Fibroblasts 3.7.1
 Cell-to-cell spread   3.7.1.1
As previously demonstrated, RV-Me-UL128LFIX again formed HFFF plaques of 
intermediate size compare to those from RV-Me-UL128Lmut (p < 0.05) and RV-Me-UL128Lwt 
(Figure 3.12.A); the fact this latter difference was deemed non-significant by statistical analysis 
likely reflects that fact that relatively few RV-Me-UL128LFIX plaques were measured. The 
UL130 A>G nucleotide variation was conclusively demonstrated to be a contributing feature of 
the less inhibitory UL128L genome region in the FIX-BAC clone, as RV-Me-UL130A>G formed 
HFFF plaques with comparable size to those produced by RV-Me-UL128LFIX, and significantly 
larger than those formed by RV-Me-UL128Lwt (p < 0.001).  
 Dissemination kinetics and cell-free virus production  3.7.1.2
 RV-Me-UL128LFIX also displayed more rapid dissemination kinetics in fibroblast 
cultures compared to RV-Me-UL128Lwt as had previously been observed, and completed 
infection of an HFFF monolayer was achieved within an a time-frame intermediate to the 
Merlin viruses containing non-intact and wildtype UL128L ORFs (Figure 3.12.B. These 
dissemination kinetics were closely matched by RV-Me-UL130A>G that achieved complete 
infection of the HFFF monolayer 1 week later than RV-Me-UL128LFIX. Thus transfer of the 
UL130 A>G nucleotide variation also alleviated the inhibitory impact of the UL128L genome 
for the dissemination of HCMV in fibroblast culture.  
 As previously stated, RV-Me-UL128Lwt potentially mutated during these assays and 
produced titres of cell-free virus that were deemed unsuitable for comparison. However, 
comparison to the peak titres produced by RV-Me-UL128Lmut provided evidence to suggest that 
the FIX UL128L genome region did not impede cell-free virus production by the same degree 
as previously demonstrated by Merlin wildtype UL128L ORFs, and the UL130 A>G variation 
was a contributing factor (Figure 3.12.C). However, the peak titre of cell-free virus produced by 
RV-Me-UL128LFIX was ~13-fold lower than that from RV-Me-UL128Lmut, whilst the peak titre 
of cell-free virus produced by RV-Me-UL130A>G was ~60-fold lower. Hence, RV-Me-UL130A>G 
produced peak titres ~6-fold lower than those produced by RV-Me-UL128LFIX, suggesting that 
the unique UL130 A>G nucleotide variation alone was not responsible for the increased cell-
free virus production achieved by expression of FIX UL128L ORFs in the Merlin virus. 
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Figure 3.12. Growth characteristics of recombinant Merlin viruses containing FIX UL128L 
nucleotides in fibroblasts. (A) HFFF cells were transfected with BAC DNA for the indicated viruses and 
incubated under semisolid overlay, with plaque sizes measured 2 weeks post transfection. Where 
possible, a minimum of 20 plaques from each infection was counted; an exception to this was the RV-
Me-UL128LFIX infection where only 10 plaques could be measured accurately. All data from 1 
experiment (n = 1). Means and ±SEM are shown. (Where indicated, the mean plaque sizes formed by 
RV-Me-UL128Lwt, RV-Me-UL128LFIX and RV-Me-UL130A>G were compared to those formed by RV-
Me-UL128Lmut (black line), RV-Me-UL128Lwt (grey line) and/or RV-Me-UL130A>G by 1-way analysis of 
variance [ANOVA] followed by Dunnett’s posttest: ns – non-significant, * p < 0.05, ** p <0.01, *** p < 
.001, **** p < 0.0001). (B) HFFF cells were transfected with BAC DNA for the indicated viruses, and 
the dissemination of infection was allowed to progress until the monolayer was destroyed. At weekly 
time points post transfection (p.t.), the level of infection was estimated by fluorescence microscopy 
analysis of eGFP-expressing cells. (C) Supernatant samples collected at weekly time points from the 
infections shown in panel B were titrated on HFFFs to provide a measure of cell-free virus release 
throughout the time-course of each infection. 
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 Impact of FIX UL130 A>G in epithelial cells 3.7.2
 Cell-to-cell spread 3.7.2.1
 The specific impact of FIX UL128L sequences on the cell-to-cell spread of virus in 
epithelial cells was also determined (Figure 3.13.A). Unlike previous findings, RV-Me-
UL128LFIX formed RPE-1 plaques that were significantly larger than those formed by RV-Me-
UL128Lmut (p < 0.0001); previously, RV-Me-UL128LFIX had formed RPE-1 plaques that were 
comparable in size to those formed by RV-Me-UL128Lmut (Appendix II). Nonetheless, the RPE-
1 plaques formed by RV-Me-UL128LFIX in this assay were again significantly smaller than 
those formed by RV-Me-UL128Lwt (p < 0.0001), and thus expression of FIX UL128L ORFs did 
reduce the capacity of Merlin virus for cell-to-cell spread in epithelial cell culture. RV-Merlin-
UL130A>G also formed RPE-1 plaques that were significantly larger than those formed by RV-
Me-UL128Lmut (p < 0.0001), yet significantly smaller than those formed by RV-Me-UL128Lwt 
(p < 0.0001). In fact, RV-Merlin-UL130A>G spread by the cell-to-cell route in epithelial cells 
with similarly reduced efficiency as did the Merlin virus containing the entire FIX UL128L 
genome region.  
 Dissemination kinetics and cell-free virus production  3.7.2.2
 Monitoring the dissemination and cell-free virus production of Merlin variants 
containing either native UL128L or FIX UL128L nucleotides in epithelial cells further revealed 
the impact of the FIX UL130 A>G variation to the growth properties of virus in this cell type 
(3.13.B & C). RV-Me-UL128LFIX again displayed reduced dissemination kinetics in RPE-1s 
compared to RV-Me-UL128Lwt, but the delayed dissemination was more prominent than in 
previous assays; complete infection of an RPE-1 monolayer was achieved by 12 weeks post-
transfection in this assay, whereas in previous assays complete infection had been achieved 
within 9 weeks post-transfection. RV-Me-UL130A>G also spread throughout the RPE-1 
monolayer slower than RV-Me-UL128Lwt, however this infection disseminated considerably 
faster than RV-Me-UL128LFIX.  
 The RV-Me-UL128LFIX infection produced peak titres of cell-free virus that were >150-
fold greater than that produced by RV-Me-UL128Lwt, whereas the peak titre of cell-free virus 
produced by the RV-Me-UL130A>G infection were only ~40-fold greater than that produced by 
RV-Me-UL128Lwt.  
 Ultimately, transfer of the UL130 A>G variation alone impeded the dissemination of 
Merlin virus yet increased the cell-free virus production in epithelial cell culture, though each of 
these effects were less dramatic than transfer of the entire FIX-BAC UL128L genome region. 
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Figure 3.13. Growth characteristics of virus containing FIX UL130 A>G unique nucleotide in 
epithelial cells. (A) RPE-1 cells were transfected with BAC DNA for the indicated viruses and incubated 
under semisolid overlay, with plaque sizes measured 3 weeks post transfection. Where possible, a 
minimum of 20 plaques from each infection was counted. All data from 1 experiment (n = 1). Means and 
±SEM are shown. (Where indicated, the mean plaque sizes formed by RV-Me-UL128LFIX and RV-Me-
UL130A>G were compared to those by RV-Me-UL128Lwt, RV-Me-UL128LFIX and RV-Me-UL130A>G 
were compared to those formed by RV-Me-UL128Lmut (black line), RV-Me-UL128Lwt (grey line) and/or 
RV-Me-UL128LFIX (blue line) by 1-way analysis of variance [ANOVA] followed by Dunnett’s posttest: 
ns – non-significant, * p < 0.05, ** p <0.01, *** p < .001, **** p < 0.0001). (B) RPE-1 cells were 
transfected with BAC DNA for the indicated viruses, and the dissemination of infection was allowed to 
progress until the monolayer was destroyed. At weekly time points post transfection (p.t.), the level of 
infection was estimated by flow cytometry analysis of eGFP-expressing cells. (C) Supernatant samples 
collected at weekly time points from the infections shown in panel B were titrated on HFFFs to provide a 
measure of cell-free virus release throughout the time-course of each infection. 
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 Validation of FIX UL130 A>G growth phenotype impact 3.7.3
 Comparison of the relative plaques sizes formed following transfection of HFFFs with 
BAC DNA for each virus (Figure 3.14.A), to those formed during titration of progeny virus 
produced in fibroblasts (HFFFp1) (Figure 3.14.B), or in epithelial cell infections (RPE-1p1) 
(Figure 3.14.C), gave no indication to suggest recombinant Merlin viruses containing FIX 
UL128L sequence features had undergone adaptation in the growth kinetics assays. The 
apparent adaptation of RV-Me-UL128Lwt in fibroblasts was reflected by the HFFF plaques 
formed by the RV-Me-UL128Lwt-HFFFp1 progeny virus (as described in section 3.6.3.).  
 Conclusion 3.7.4
 The unique A>G nucleotide variation identified in FIX UL130 contributed to the 
differential impact of FIX UL128L compared to wildtype UL128L, in both fibroblasts and 
epithelial cell culture. However, the growth characteristics of the Merlin virus expressing the 
entire FIX UL128L genome region (RV-Me-UL128LFIX) were not entirely re-capitulated by the 
Merlin virus engineered to contain the UL130 A>G variation alone (RV-Me-UL130A>G) in 
either cell-type, most notably the increased cell-free virus production. Therefore, other 
nucleotide features must also contribute to distinct growth phenotype influence of the FIX-BAC 
UL128L genome region. 
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Figure 3.14. Fibroblast cell-to-cell spread of recombinant Merlin viruses containing TB40-BAC4 or strain 3301 UL128L nucleotides, before and after passage in fibroblast 
and epithelial cells. (A) Plaque sizes ±SEM formed 2 weeks post-transfection (p.t) of HFFFs with BAC DNA for each indicated virus and incubation under overlay. (B) HFFF 
plaque sizes ±SEM formed during titration of virus in supernatant samples collected at final time-point in growth kinetics assay performed in HFFFs, at 2 weeks post-infection (p.i.) 
and incubation under overlay. (C) HFFF plaque sizes ±SEM of formed during titration of virus in supernatant samples collected at final time-point in growth kinetics assay 
performed in HFFFs, at 2 weeks post-infection (p.i.) and incubation under overlay. 
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3.8 Summary 
The inhibitory impact of Merlin wildtype UL128L ORFs on the growth of virus in 
fibroblasts was repeatedly demonstrated in 4/4 repeats of each assay: virus from Merlin-
UL128Lmut BAC consistently formed significantly larger HFFF plaques than virus from the 
Merlin-UL128Lwt BAC; virus from the Merlin-UL128Lmut BAC achieved complete infection of 
the HFFF monolayer around twice as fast as virus from the Merlin-UL128Lwt BAC; and virus 
from the Merlin-UL128Lmut consistently produced titres that were ~1000-fold greater than that 
from infections with virus from the Merlin-UL128Lwt BAC (except in assays where this virus 
had apparently undergone adaptation to fibroblast cell culture). Similar consistency was 
observed for the growth phenotype of viruses from the Merlin-UL128Lwt and Merlin-UL128Lmut 
BAC variants in epithelial cell cultures. 
The growth phenotypes of viruses derived from the BAC-cloned versions of strains TR 
(TR-BAC), TB40E (TB40-BAC4), and VR1814 (FIX-BAC) were distinct from that of virus 
from the Merlin BAC containing wildtype UL128L. The UL128L genome regions in the TB40-
BAC4 and FIX-BAC clones contributed to the differential growth phenotype of virus from each 
corresponding strain, and unique single nucleotide variations that were responsible for this 
difference were identified. Importantly, Merlin viruses engineered to contain these unique 
nucleotides (TB40-BAC4 UL128 intron 1 G>T and FIX UL130 A>G [S72P]) remained viable 
in epithelial cells, albeit with slightly compromised fitness in this cell type compared to virus 
from the parental Merlin-BAC variant containing wildtype UL128L ORFs. Thus, these 
nucleotides suppressed, but did not ablate virion pentameric complex functionality. In contrast 
to this, the distinct growth phenotype of TR BAC-derived virus was independent of differences 
in UL128L; TR UL128L conveyed a growth phenotype similar to that conveyed by UL128L 
with wildtype sequence, and TR UL128L mutated within a time frame comparable to that seen 
during the passage of wildtype virus and clinical isolates in fibroblasts, yet this was only 
apparent when expressed from the Merlin genome background. The distinct growth phenotypes 
of TB40-BAC4 and FIX BAC-derived viruses were only partially recapitulated by Merlin 
viruses containing TB40-BAC4 and FIX UL128L sequences. Hence, similar to TR BAC-
derived viruses, other genome regions of TB40-BAC4 and FIX also contributed to the distinct 
growth phenotypes of these viruses.  
 Ultimately, the novel Merlin viruses containing these nucleotides from TB40-BAC4 
UL128 and FIX UL130 could be grown to greater titres than the parental Merlin virus 
containing wildtype UL128L, and this was apparent following infection of fibroblasts, and 
interestingly, also in epithelial cell infections.  
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 The reduced fitness in epithelial cell culture displayed by Merlin viruses engineered to 
contain TB40-BAC4 and FIX UL128L sequences (less efficient cell-to-cell spread and 
dissemination kinetics) suggested that the transferred nucleotides impacted the functionality of 
the pentameric complex. Thus, we next sought to determine the mechanisms, and degree, by 
which the nucleotide sequence variations amongst UL128L genome regions of each strain 
affected the pentameric complex, and also determine the specific impact of these changes on 
activities in the viral replication cycle that are directly or indirectly influenced. 
4.1 Variant UL128L ORF expression efficiency 
 Bioinformatics-based predictions as to the impact of the nucleotide variation identified 
in TB40-BAC4 UL128 intron 1 were made by Dr Gavin Wilkie (MRC-University of Glasgow 
Centre for Virus Research, Glasgow, UK) (Appendix IV). This mutation was predicted to 
disrupt the splicing of UL128 transcripts for the generation of translatable UL128 mRNA, and 
this could ultimately limit the production and availability of gpUL128 for pentameric complex 
assembly. Alternatively, novel UL128 mRNA splice variants could be translated to produce 
distinct gpUL128 isoforms incorporated into functionally deficient complexes. Further 
nucleotide variations were also observed in intron 2 amongst each variant UL128, and also in 
the intron of each variant UL131A (Figure 4.1), however bioinformatics-based predictions as to 
the impact of these sequence variations were not made.  
 
  
 
 
Figure 4.1. Nucleotide variations in UL128 intron 2 and UL131A intron.  (A) Aligned variant UL128 
intron 2. ORF (blue) and protein coding region (yellow) annotations are depicted in solid lines. The solid 
black line under ORF and coding domain annotations depicts the continuous nucleotide sequence. The 
branching line depicts intron sequence regions. Nucleotide variations are depicted in pink arrows; gaps 
are indicated by breaks in solid black lines. (B) Aligned variant UL131A intron. Tables - Locations of 
nucleotide variations are given relative nucleotide positions in Merlin UL128 and UL131A; - indicates 
identical residue. 
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 To assess the impact of the UL128 G>T mutation and other UL128L ORF intronic 
nucleotide variations, the splice patterns of transcripts derived from each variant UL128 and 
UL131A ORF during infection was assessed by RT-PCR. Fibroblasts were the only cell type 
that supported productive infection of each virus, therefore the splice pattern of transcripts were 
analysed following infection of HFFFs. Details of each of virus stocks used for the initiation of 
productive infections are given in Table 4.1. Where possible, virus stocks used were those 
produced in epithelial cell culture; these stocks were chosen, as UL128L mutants were unlikely 
to have been selected during the growth of virus in epithelial cells. Transcripts were analysed at 
72-hrs post-infection when the UL128L ORFs are transcriptionally active (Akter, Cunningham 
et al. 2003, Hahn, Revello et al. 2004, Sun, Ren et al. 2010).  
 
Table 4.1. HCMV virus stocks. 
 
BAC Origin/ 
Reconstituted Virus 
UL128L origin/sequence featuresa,b Cell typec 
Merlin-UL128Lmut/ 
RV-Me-UL128Lmut 
Native; mutated: UL128 G>A at nt 176260 (R> stop) HFFF 
Merlin-UL128Lwt/ 
RV-Me-UL128Lwt 
Native wildtype RPE-1 
TR-BC/ 
RV-TR 
Native RPE-1 
TB40-BAC4/ 
RV-TB40-BAC4 
Native RPE-1 
Merlin-UL128LTB40/ 
RV-Me-UL128LTB40 
TB40-BAC4 RPE-1 
Merlin-UL128G>T/ 
RV-Me-UL128G>T 
Merlin; wildtype + UL128 G>T at nt 176663 (intron 1) RPE-1 
FIX-BAC/ 
RV-FIX 
Native HFFF 
Merlin-UL128LFIX / 
RV-Me-UL128LFIX 
FIX RPE-1 
Merlin-UL130A>G/ 
RV-Me-UL130A>G 
Merlin; wildtype + UL130 A>G at nt 177364 (S72P) RPE-1 
 
a – UL128L genome region sequence features.  
b – Nucleotide positions are given relative to sequence of BAC-cloned strain Merlin (GU179001). 
c – Cell type in which each virus stock was grown.  
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 Variations in coding nucleotide positions, including the FIX A>G (S72P) mutation, 
could also impact the expression of each variant UL128L ORF; these potentially introduced 
codons that reduced the efficiency of ORF transcription, or reduced the efficiency by which 
mRNAs were translated. The expression of each variant UL128L ORF was therefore analysed 
at a translational level following expression from replication deficient recombinant adenovirus 
(RAdZ) vectors (Stanton, McSharry et al. 2008), with the quantities of the glycoproteins 
produced compared. To provide a standard marker for detection, all cloned UL128L ORFs were 
engineered to encode glycoproteins containing a C-terminal V5 epitope tag (~ 3 KDa). Details 
of each RAdZ vector are given in Table 4.2.  
 
 
Table 4.2. RAdZ vectors containing variant UL128L-derived transgenes.  
 
a - Defining sequence features of variant UL128L ORF 
b - Designation of recombinant AdZ vector (RAdZ) containing variant UL128L ORF  
Transgene BAC Origin Sequence featuresa 
Designation in 
Text/Figuresb 
Translation 
product 
UL128 
Merlin-UL128Lwt Wildtype Me-UL128wt 
gpUL128-V5 
TR  TR-UL128 
TB40-BAC4  TB-UL128 
FIX  FIX-UL128 
Merlin-UL128G>T G>T at nt Me-UL128G>T 
UL130 
Merlin-UL128Lwt Wildtype Me-UL130wt 
gpUL130-V5 
TR  TR-UL130 
TB40-BAC4  TB-UL130 
FIX  FIX-UL130 
Merlin-UL130A>G A>G at nt 214 Me-UL130A>G 
UL131A 
Merlin-UL128Lwt  Me-UL131A 
 
gpUL131A-V5 
TR  TR-UL131A 
TB40-BAC4  TB-UL131A 
FIX  FIX-UL131A 
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 TB40-BAC4 intron G>T reduces UL128 mRNA and gpUL128L production 4.1.1
Following RT-PCR, three amplicons corresponding to differently spliced UL128 
transcripts were detected across all infections. Sequencing demonstrated that these transcripts 
corresponded to: i) non-spliced UL128 pre-mRNA (656-662 bp, depending on strain origin); ii) 
partially spliced UL128 pre-mRNA (540 bp transcript; lacking intron 2) pre-mRNAs; iii) fully 
spliced UL128 mRNA (417 bp transcript, lacking introns 1 and 2) (Figure 4.2.A). The quantities 
of non-spliced and partially spliced UL128 pre-mRNAs from each infection were equivalent, 
however all viruses that contained the UL128 intron G>T nucleotide variation (RV-TB40-
BAC4, RV-Me-UL128LTB40, and RV-Me-UL128G>T) produced significantly reduced amounts of 
fully spliced transcripts. Thus, as predicted, the intron 1 G>T nucleotide variation disrupted the 
splicing of exons 1 and 2. Sequencing identified additional amplicons detected in each infection 
as hetero-duplexes of PCR products, and not representative of splice variants. 
 
 
Figure 4.2. Variant UL128 Expression. (A) UL128 transcript splice patterns. HFFFs were infected with 
each indicated virus (MOI 3), and total infected cell RNA was extracted at 72-hrs post-infection. RT-PCR 
was performed using primers that bound conserved regions of exons 1 and 3 of all variant UL128 ORFs. 
cDNAs were resolved over 4% agarose gels. Three PCR products corresponding to the differentially 
spliced UL128 transcripts were detected: (i) non-spliced, (ii) partially spliced (lacking intron), and iii) 
fully spliced (lacking introns 1 and 2). (B) gpUL128 production. HF-hCARs were infected with RAdZ 
vectors (MOI 3) containing each variant UL128 ORF. At 72 hrs post-infection cell lysates were prepared 
and analysed by western blot for actin (upper band) and gpUL128-V5 (lower band). (i) gpUL128-V5 
produced by expression of UL128 from each BAC cloned strain. (ii) gpUL128-V5 produced by 
expression of Merlin UL128 containing intron 1 G>T. 
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Expression of each variant UL128 from RAdZ vectors demonstrated a pattern of 
gpUL128 production similar to that of fully spliced UL128 transcript production (Figure 4.2.B 
(i)). Expression of Merlin wildtype UL128 and TR UL128 produced equivalent levels of 
gpUL128-V5, whilst expression of FIX produced only slightly reduced levels of gpUL128-V5. 
Expression of TB40-BAC4 UL128 produced dramatically reduced levels of gpUL128-V5. 
However, unlike the production of fully spliced mRNA, the reduced levels of gpUL128-V5 
produced from TB40-BAC4 UL128 were not completely re-capitulated by Merlin UL128 
containing the G>T mutation (Figure 4.2.B (ii)).  
 UL130 sequence variations, including FIX UL130 A>G, do not impact gpUL130 4.1.2
production 
 Since the UL130 ORF contains no introns, investigations into the expression of the 
variant UL130 ORFs at a transcriptional level were not pursued. However, no major differences 
in gpUL130-V5 production were observed following expression of each variant UL130 ORF 
from the RAd vector background (Figure 4.3.A). Therefore, nucleotide variations amongst each 
UL130, the most variable of the UL128L ORFs, had no apparent influence on expression. 
Importantly, the A>G (S72P) mutation also had no impact of the expression of UL130 (Figure 
4.3.B).  
 
 
Figure 4.3. Variant UL130 expression. HF-hCARs were infected with RAd vectors (MOI 3) expressing 
each variant UL130, and at 72 hrs post-infection, cell lysates were analysed by western blot for actin 
(upper band) and gpUL130-V5 (lower band). (A) gpUL130-V5 produced by expression of variant UL130 
contained in the each BAC cloned strain. (B) gpUL130-V5 produced by expression of Merlin UL130 
ORF containing FIX UL130 A>G (S72P). 
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 Each variant UL131A is expressed with similar efficiency 4.1.3
 Analysis of UL131A cDNA PCR products identified two amplicons corresponding to 
the differentially spliced UL131A transcripts: (i) non-spliced UL131A pre-mRNA (411 bp); (ii) 
fully spliced UL131A mRNA (303 bp) (See Figure 4.4.A). The levels of UL131A pre-mRNA 
transcripts varied only marginally across infections, whilst the fully spliced UL131 mRNA 
produced by viruses derived from each original BAC-cloned strain were comparable. The only 
exception to this pattern was the reduced levels of fully spliced mRNA produced from by RV-
Me-UL128LFIX, suggesting that FIX UL131A pre-mRNAs are spliced less efficiently when 
contained within transcripts derived from Merlin genome background.   
 Expression of each variant UL131A from the RAd vector background produced 
comparable amounts of gpUL131A-V5, further indicating that each variant UL131A ORF 
contained no nucleotide features that impacted expression (see Figure 4.4.B).  
 
 
 
 
Figure 4.4. Variant UL131A Expression. (A) UL131A transcript splice patterns.  HFFFs were infected 
with each indicated virus (MOI 3), and total RNA was extracted from at 72-hrs post-infection. RT-PCR 
was performed using primers that bound conserved regions in the two exons. cDNAs were resolved over 
4% agarose gels. Two amplicons corresponding to the differentially spliced UL131A transcripts were 
detected: (i) non-spliced, and (ii) fully spliced (lacking intron). (B) gpUL131A production. HF-hCARs 
were infected with RAd vectors (MOI 3) containing each variant UL131A. At 72 hrs post-infection, cell 
lysates were prepared and analysed by western blot for cellular actin (upper band) and gpUL131A-V5 
(lower band).  
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 Conclusion 4.1.4
 Nucleotide variations identified in TR and FIX UL128, as well as those amongst UL130 
and UL131A from each of TR, TB40-BAC4 and FIX, whether natural variations or in vitro 
acquired mutations, did not limit the production of monomeric sub-units for pentameric 
complex assembly. However, the G>T mutation in TB40-BAC4 UL128 affected pre-mRNA 
splicing, and ultimately gpUL128 production. Importantly, no UL128 mRNA splice variant or 
novel gpUL128 isoforms that potentially arose due to the G>T variation was detected. 
4.2 Impact of UL128L coding potential on pentameri complex assembly and/or 
incorporation into virions 
 The fact that the UL128 G>T limited gpUL128 production strongly suggested that 
virions from virus encoding this mutation could contain reduced quantities of pentameric 
complex. Whilst the FIX UL130 A>G (S72P) mutation had no effect on gpUL130 production, 
protein modelling using the Phyre 2 bioinformatics tool (Kelley and Sternberg 2009) predicted 
that this amino acid transition disrupted a beta sheet, and therefore the folding of gpUL130 into 
native conformation. This could impact binding interactions between gpUL130 and other 
pentameric complex sub-units, ultimately impeding the assembly and/or incorporation of the 
pentameric complex into virions. To explore these possibilities, the pentameric complex content 
of virions from each virus was determined. To directly relate pentameric complex content to 
data from investigations into the expression of each variant UL128L, virions analysed were 
those from the same concentrated virus working stocks previously used (Table 4.1). 
 Purification of virions from virus working stocks  4.2.1
 Purification of virus over sorbitol cushions is common practice in HCMV research, 
however does not allow separation of virions from NIEPs or DBs. Greater purification can be 
achieved by rate-velocity sedimentation of virus particles during ultra-centrifugation over 
gradients (Talbot and Almeida 1977). These two approaches are often used in tandem, including 
initial purification of virus over sorbitol cushions prior to gradient purification (Varnum, 
Streblow et al. 2004, Patrone, Secchi et al. 2005, Ryckman, Rainish et al. 2008). We sought to 
determine the most suitable approach (or combination of approaches) for the purification of 
virions from concentrated virus stocks prepared by high-speed centrifugation. To assess the 
degree of purification achieved, recovered viral particles were analysed for the presence of 
contaminating cellular proteins. Markers of contamination were proteins contained in cellular 
structures intimately exposed to virion structural components, or those that localise in close 
proximity with the virion assembly compartment (VAC) (see Table 4.3). Of the markers used, 
only TGN46 has previously been reported to be incorporated into virions (Cepeda, Esteban et 
al. 2010). 
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Table 4.3. Cellular protein markers of virion sample purity. 
 
 
 
 The high-titre RV-Me-UL128Lmut (produced in HFFFs) virus stock was purified over a 
sorbitol cushion, with the levels of co-purified cellular contaminants compared to that in the 
original virus stock, and also infected cell culture supernatant which had undergone no 
concentration at all (Figure 4.5.A). Giantin was detected only in the infected cell culture 
supernatant, indicating that preparation of virus stocks by high-speed centrifugation achieved 
some degree of purification. However, all other markers of contamination detected in the 
original virus stock were also present in the sorbitol cushion purified virus. Thus, ultra-
centrifugation over sorbitol cushions alone did not sufficiently purify virions. 
 To determine the utility of gradients for the purification of virions, the recovery and 
purity of virions isolated from the low-titre RV-Me-UL128Lwt stock (produced in RPE-1 cells) 
was assessed. Virus ultra-centrifuged over glycerol: tartrate gradients produced a distinct 
banding pattern: a band present at the gradient: sample interface, predicted to contain cellular 
and virus derived contaminants; a band 2-3 cm into the gradient predicted to contain purified 
virions; and bands within lower gradient regions predicted to contain dense bodies - this lower 
‘DB’ band was more diffuse less clearly defined. The ‘NIEPs’ band described to localise 
between the gradient: sample interface and the major virion-containing band (Irmiere and 
Gibson 1983) was not observed. Each band was recovered and analysed for markers of 
contamination, and also glycoprotein gB as a marker of virions (Figure 4.5.B). Samples of the 
original virus stock, and virus from this stock purified over a sorbitol cushion were also 
analysed for comparison. As previous, calnexin and TGN46 were each detected in the original 
RV-Me-UL128Lwt virus preparation, and also co-purified with virus over sorbitol cushions. 
From the gradient purified virus, both calnexin and TGN46 were detected in the band derived 
from the gradient: sample interface, whilst calnexin was also detected in the diffuse ‘DB’ band 
recovered from lower regions in the gradient. Importantly, no markers of contamination were 
Protein/ 
Marker 
Cellular 
location 
Comments 
S6RP 40S ribosomal sub-unit  
Exposed to virion structural components during translation 
 
Giantin ER resident Localises in ring-like structure surrounding VAC (Cepeda, Esteban et al. 2010) 
Calnexin ER resident Chaperone specifically implicated in virion envelope glycoprotein folding (Yamashita, Shimokata et al. 1996) 
TGN46 
Trans-Golgi 
network 
resident 
Co-localises with virion materials in structures proximal to the 
VAC (Sanchez, Greis et al. 2000), and also with gB during 
endosome retrieval from the plasma membrane (Crump, Hung 
et al. 2003) 
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observed in the band predicted to contain purified virions. gB was readily detected in all 
gradient samples analysed; each was subsequently shown to contain infectious virus following 
inoculation of HFFFs, however the highest titres were found in the ‘purified virion’ band. Thus 
infectious virions were retained at the gradient: sample interface, and also in the lower band that 
migrated faster than purified virions. However the ‘purified virion’ band contained the greatest 
titres and was free of contamination. 
 
 
 
 
 
Figure 4.5. Purification of virus over sorbitol cushions and Glycerol: Tartrate gradients. (A) Virus 
within the high titre RV-Me-UL128Lmut stocks was ultra-centrifuged over a cushion of 20% solution in 
PBS. Recovered virus was analysed by Western blot for the presence of cellular contamination markers: 
Giantin, TGN46, Calnexin, S6RP. Samples from the original RV-Me-UL128Lmut stock, as well as 
infected cell-culture supernatant undergone no concentration were analysed in parallel. (B) Virus within 
the low titre RV-Me-UL128Lwt stocks were ultra-centrifuged over a glycerol: tartrate gradients, and 
produced a distinct banding pattern. Each band was recovered and materials therein were diluted in NaPh 
buffer, and collected by further ultra-centrifugation. Pelleted materials were analysed by western blot for 
markers of contamination, and also gB as a marker of virions. Samples of the same virus purified over 
sorbitol cushions and a sample undergone no purification at all were analysed in parallel. 
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 Pentameric complex content of virions 4.2.2
 The pentameric gH/gL complex is believed to contain equimolar quantities of each 
glycoprotein sub-unit, and each UL128L sub-unit is absolutely required for assembly and 
incorporation into virions (Wang and Shenk 2005, Ryckman, Rainish et al. 2008). We therefore 
used detection of gpUL128 as surrogate a marker for the entire pentameric complex (Figure 
4.6.A). Samples of virions purified from each virus stock over gradients were normalised 
according to the quantities of envelope glycoprotein gB. 
 Virions purified from virus lacking intact UL128L (RV-Me-UL128Lmut) did not contain 
detectable gpUL128. In contrast, virions purified from virus encoding wildtype UL128L (RV-
Me-UL128Lwt and RV-Me-UL128L3301) contained readily detectable gpUL128, the most 
abundant of any virus analysed. Virions purified from RV-TR stocks contained comparable 
levels of gpUL128 to those detected in RV-Me-UL128Lwt. In contrast, RV-TB40-BAC4 virions 
contained reduced levels of gpUL128, as did virions purified from Merlin variants containing 
the entire TB40-BAC4 UL128L (RV-Me-UL128LTB40), or the single G>T mutation identified in 
TB40-BAC4 UL128 (RV-Me-UL128G>T). RV-FIX virions contained vastly reduced levels of 
gpUL128 that were initially un-detectable, and this too was closely repeated in RV-Me-
UL128LFIX virions. However, whilst RV-Me-UL130A>G virions also contained reduced levels of 
gpUL128, they contained more than virions from viruses expressing the entire FIX UL128L.  
 In a second blot (Figure 4.6.B), the maximum volume of purified virion samples was 
analysed (i.e. without normalisation), facilitating the detection of virion incorporated gpUL128 
even where levels were drastically reduced. This analysis conclusively demonstrated that 
gpUL128 was present in virions from RV-TB40-BAC4, RV-Me-UL128LTB40, RV-Me-
UL128G>T, RV-FIX and RV-Me-UL128LFIX.  
 Conclusion 4.2.3
 The pentameric complex content of virions from Merlin viruses containing alternative 
wildtype UL128L ORFs (native, or from strain 3301) was comparable. Thus, pentameric 
complex assembly and/or incorporation did not vary due to natural inter-strain differences in 
UL128L. TR UL128L ORFs, which are expressed with similar efficiency compared to Merlin 
wildtype UL128L, also contain no features that convey different complex assembly and/or 
incorporation into virions. Virions from the Merlin viruses expressing TB40-BAC4 UL128L or 
the single UL128 G>T variation alone displayed similar pentameric complex content, thus the 
reduced gpUL128 production due to the UL128 G>T variation appeared entirely responsible for 
this effect. In contrast to this, observation that virions from Merlin virus containing FIX 
UL128L displayed lower pentameric complex content compared to those from the Merlin virus 
modified by the UL130 A>G variation alone indicated that FIX UL128L contains other features 
that impede complex assembly and/or incorporation into virions.  
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Figure 4.6. gpUL128 content of virions. (A) Virions were purified from working stocks of each virus indicated on glycerol-tartrate gradients, and analysed by western blot. 
Samples loads were normalised to gB content (upper panel) and stained for gpU128 (lower panel). (B) The gpUL128 content in the maximised loads of samples analysed in A that 
were not non-normalised to gB content.  
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4.3 Impact of virion gH/gL/gpUL128/gpUL130/gpUL131A content on epitheliotropism 
 The pentameric complex content of virions had the potential to impact the efficiency by 
which the virus infects cell types where the complex is required. Therefore, the epitheliotropism 
of the different viruses investigated was assessed: the same virus stocks in which pentameric 
complex content was analysed (Table 4.1.) were titrated onto fibroblasts (HFFFs) and epithelial 
cells (RPE-1s and ARPE-19s) in parallel, and titres reported on the different epithelial cell types 
were normalised to that reported on fibroblasts. Thus, the ability of each virus to infect 
epithelial cells was quantified relative to its ability to infect fibroblasts.  
 RV-Me-UL128Lmut infected ARPE-19s with ~5,000–fold reduced efficiency, and RPE-
1s with ~100–fold reduced efficiency, than in HFFFs (Figure 4.7.A). Hence the lack of 
pentameric complex in virions from this virus resulted in significantly reduced tropism for both 
epithelial cell types (both p < 0.0001). In contrast to this, viruses that produce virions with the 
greatest pentameric complex content (RV-Me-UL128Lwt, RV-Me-UL128L3301, and RV-TR) 
displayed similar tropism for fibroblasts and epithelial cells. 
 RV-TB40-BAC4 infected ARPE-19s with comparable efficiency to HFFFs, but 
infected RPE-1s with ~9-fold lower efficiency (p < 0.05) (Figure 4.7.B). RV-Me-UL128LTB40 
and RV-Me-UL128G>T each infected ARPE-19s with ~4-fold reduced efficiency than HFFFs (p 
< 0.001 and p < 0.0001, respectively), and RPE-1s 8-10-fold less efficiently (both p < 0.0001). 
Thus, the similarly reduced pentameric complex content of virions from the Merlin variants 
resulted in a near identical reduction in relative epitheliotropism.  
 RV-FIX infected ARPE-19s and RPE-1s with ~75-fold and >180-fold reduced 
efficiency compared to HFFFs, respectively (both p < 0.0001) (Figure 4.7.C). RV-Me-
UL128LFIX, the Merlin variant containing FIX UL128L that produced virions with vastly 
reduced pentamer content, infected ARPE-19s with ~25-fold reduced efficiency and RPE-1s 
with ~50-fold reduced efficiency (both p < 0.0001), thus displaying severely reduced 
epitheliotropism. This was only partially recapitulated by RV-Me-UL130A>G that infected 
ARPE-19s and RPE-1s with ~2-fold and ~6.5–fold reduced efficiency, respectively (p < 0.05).  
 Conclusion 4.3.1
 The relative epitheliotropism of viruses, particularly the Merlin variants, correlated with 
the pentameric complex content of virions: as pentameric complex content pentamer decreased, 
so did epitheliotropism. However, whilst the epitheliotropism of the novel Merlin viruses 
containing TB40-BAC4 and FIX single unique nucleotides was reduced, these Merlin variants 
displayed at most 10-fold reduced relative epitheliotropism, as compared to the 100-5000-fold 
reduced relative epitheliotropism of Merlin virus completely lacking the pentameric complex. 
    141 
 
Figure 4.7. Impact of virion pentameric complex content on epitheliotropism. Virus working stocks 
were plaque titrated onto HFFFs, ARPE-19s and RPE-1s in parallel, with all titres normalised to the titres 
of the same virus on HFFFs. Data are based on 2-3 independent experiments (n = 2-3). ±SD is shown. (A) 
Relative epitheliotropism of viruses containing undetectable or the greatest levels of pentameric complex. 
(B) Relative epitheliotropism of viruses containing reduced pentameric complex due to expression of 
TB40-BAC4 UL128L sequence features. (C) Relative epitheliotropism of viruses containing reduced 
pentameric complex levels due to expression of FIX UL128L sequence features. (Where indicated, the 
fibroblast infection efficiency of each virus was compared to the epithelial cell infection efficiency by 1-
way analysis of variance [ANOVA] followed by Dunnett’s posttest: ns – non-significant, * p < 0.05, ** p 
<0.01, *** p < .001, **** p < 0.0001). 
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4.4 Impact of UL128L coding potential on progeny virion production and/or release 
from epithelial cells 
 The pentameric complex content of virions could be inversely correlated with cell-free 
virus production displayed during the growth kinetics assays. However it was unclear whether 
the expression of UL128L limited the formation, or alternatively the release, of progeny virions. 
Furthermore, it has been reported that TB40-BAC4 BAC-derived virus produced two distinct 
progeny sub-populations in endothelial cells, each varying in virion-incorporated pentameric 
complex content and tropism: progeny released into the supernatant contain lower levels of 
pentameric complex, and in turn display reduced endotheliotropism, whilst progeny retained 
associated with cells contain greater levels of pentameric complex, and display the greatest 
endotheliotropism (Scrivano, Sinzger et al. 2011). Thus, it was considered possible that a major 
source ‘broad-tropism’ virus could be retained within producer cells. To explore this possibility, 
the production of cell-free released virus (CRV) or cell-association virus (CAV) sub-
populations during infection of epithelial cells was assessed, as was the tropism of any 
recovered sub-populations. RPE-1s were infected at low MOI with RV-Me-UL128Lwt, and 
CRV and CAV fractions prepared 4 days after all cells were productively infected (i.e. GFP+): 
the CRV fraction was prepared from the infectious supernatants that was cleared of cellular 
materials by centrifugation; the CAV fraction was prepared from cells that remained intact, and 
also the pelleted cellular material cleared from the CRV fraction.  
 Relative CRV and CAV infectivity produced during infection of epithelial cells 4.4.1
 Sonication was explored as a method to disrupt cells and liberate CAV infectivity. To 
determine whether this treatment had an impact on virion integrity, infectious supernatant was 
sonicated under conditions required to achieve total cell lysis, with the infectivity that could be 
recovered quantified by plaque titration in parallel to supernatants that had undergone no 
treatment at all (Figure 4.8.A). The near complete recovery of infectivity from the sonicated 
supernatant sample indicated that this treatment did not disrupt virions. 
 Following sonication of the infected cellular materials (intact cells and cellular debris), 
lysates were centrifuged to generate two further CAV sub-fractions: the cell-extract 
compartment (cleared supernatant), and the cell-debris compartment (pelleted cellular material). 
For comparison of the relative quantities of progeny virus located to either the CRV or CAV 
fractions, the ‘CAV total’ was estimated as the sum of infectivity reported in the cell-extract and 
cell-debris sub-fractions. The CAV fraction was a considerable site of infectivity, and contained 
similar levels of total infectivity to the CRV fraction (Figure 4.8.B). However the relative virus 
titres from the CRV and CAV (total) sub-populations were of different magnitudes on the 
different cell types used. Interestingly, the CAV ‘total’ infectivity was ~ 4-fold higher than the 
CRV fraction on HFFFs (p < 0.05), but ~3.5-fold lower than in the CRV fraction on ARPE-19s 
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(p < 0.01). The infectivity within each infected cell-culture fraction was reported with similar 
titres on RPE-1s.   
 
 
Figure 4.8. CRV and CAV sub-populations produced in epithelial cells. RPE-1 cells were infected at 
low MOI with Merlin virus containing wildtype UL128L ORFs (RV-Me-UL128Lwt). 4 days after all cells 
were productively infected, cell-released virus (CRV) and cell-associated virus (CAV) populations were 
analysed. All data is based on 1 experiment (n = 1). ±SEM are shown. (A) To assess the effect of 
sonication on virions, treated (sonicated) or untreated infectious supernatants were analysed in parallel by 
plaque titration onto HFFFs, ARPE-19s, and RPE-1s in duplicate. (B) Infectivity recovered from the 
CRV sub-population and CAV fractions was quantified by plaque titration onto HFFFs, ARPE-19s, and 
RPE-1 in parallel. The ‘CAV total’ infectivity was estimated as the sum of infectivity recovered from 
both the Cell-extract and Cell-debris fractions. To account for the preparation of CRV and CAV sub-
populations in different volumes (6 mL and 7 mL, respectively), the total infectivity in each sample was 
calculated from the determined titres. (C) Titres of virus recovered from Cell-extract and Cell-debris 
fractions, reported on each different cell type. (D) Relative epitheliotropism of virus recovered from the 
CRV and CAV sub-fractions was determined by normalising infectivity reported in all infected-cell 
culture fractions (and sub-fractions) on ARPE-19s and RPE-1s to titres of the same samples reported on 
HFFFs. (Where indicated, titres of virus progeny recovered from the stated infected cell culture sub-
population and sub-fraction were compared by paired 1-tailed t-test: ns – non-significant, * p < 0.05, ** p 
<0.01, *** p < .001, **** p < 0.0001). 
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 Within the CAV sub-population, the Cell-extract sub-fraction was the major site of 
infectivity and contained greater titres of virus than that in the cell debris sub-fraction. As 
reported on HFFFs, the cell-extract fraction contained ~9-fold greater titres compared to the cell 
debris fraction (p < 0.05), whilst on RPE-1s the cell-extract fraction was also reported to contain 
~5-fold greater titres (p < 0.05). Furthermore, the titres of the cell-extract fraction were also 
greater than in the cell-debris fraction on ARPE-19s, but this was not significant. Thus the 
majority of the virus progeny that remained associated with producer cells could be separated 
from cellular materials.  
 Relative epitheliotropism of CRV and CAV populations produced during infection 4.4.2
of epithelial cells  
 The relative epitheliotropism of progeny contained within the CRV and CAV sub-
fractions was quantitated by normalising titres of each sample reported on epithelial cells to 
those of the same sample reported on fibroblasts (see Figure 4.8.C). Virus within the CRV 
fraction infected ARPE-19s slightly more efficiently than HFFFs, though infected RPE-1s with 
~5-fold reduced efficiency compared to HFFFs. Interestingly, infectivity in the ‘CAV total’ 
fraction displayed reduced epitheliotropism compared to the CRV infectivity. Whilst the 
epithelial cell infection efficiency of virus in the cell-debris compartment was also reduced 
compared to that of the CRV, the infectivity contained within the cell-debris compartment 
displayed greater epitheliotropism than that in the cell-extract compartment. 
  Conclusion 4.4.3
 The CAV fraction produced during infection of epithelial cell cultures was a major 
source of infectious virus. However the total infectivity recovered from both CRV and CAV 
fractions of epithelial cells infected with virus containing wildtype UL128L (RV-Me-
UL128Lwt) was still lower than CRV infectivity produced during previous infections with 
viruses engineered to contain UL128L adaptations (i.e. RV-Me-UL128LTB40, RV-Me-UL128G>T, 
RV-Me-UL128LFIX, RV-Me-UL130A>G). Therefore, expression of wildtype UL128L apparently 
inhibits the production of infectious virus during infection in epithelial cells. Furthermore, virus 
localised to the CAV fraction of infected epithelial cell cultures displayed reduced 
epitheliotropism compared to that of the CRV fraction, and presumably included virions with 
reduced pentameric complex content.  
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4.5 Impact of UL128L coding potential on progeny virion production and/or release 
from fibroblast cells 
 We next sought to determine whether pentameric complex impeded the morphogenesis 
or cell-free release of progeny virions produced in fibroblasts. In the previously mentioned 
report, it was suggested that CRV and CAV progeny sub-populations are produced in 
fibroblasts, with the CAV displaying the more restricted tropism compared to the CRV sub-
population (Scrivano, Sinzger et al. 2011). Thus, the tropism of any sub-population recovered 
from fibroblasts was also assessed. One-step growth curve assays were performed, with the 
CRV and CAV produced over the time-course of each infection compared. Viruses used in 
these assays are those described in Table 4.1, except for an alternative version of the Merlin 
virus containing wildtype UL128L; the titre of the previous RV-Me-UL128Lwt stock grown in 
RPE-1s was not sufficient for the performance of high MOI Infections. Instead, an alternative 
version of this virus was grown to high titres by alleviating the inhibitory impact of UL128L in 
a tetracycline repression culture system (Stanton, McSharry et al. 2008, Stanton, Baluchova et 
al. 2010). This virus, RV-Me-tet-UL128Lwt, differed at only two genetic loci compared to RV-
Me-UL128Lwt: at UL122, no eGFP expression cassette was inserted; in the UL131A-UL132 
inter-genic region, a binding sequence for the tetracycline operator was inserted.  
 HFFF monolayers infected with all Merlin viruses were almost entirely obliterated by 
the final time-point, (day 10 p.i.) however RV-TR, RV-TB40-BAC4 and RV-FIX infected 
HFFFs displayed delayed degradation. CRV samples were collected every two days post 
infection, and cellular materials cleared by low-speed centrifugation were returned to each 
infection. Total CAV samples were prepared at the final time-point of each infection as 
previously mentioned, with CAV infectivity released by sonication.  
 Relative CRV and CAV infectivity produced by viruses containing non-intact or 4.5.1
wildtype UL128L ORFs 
 The inhibitory impact of Merlin UL128L on cell-free virus production was again 
demonstrated, with the total estimated CRV produced by RV-Me-UL128Lmut ~900-fold greater 
than that produced by RV-Me-tet-UL128Lwt (Figure 4.9.A). The CAV sub-population 
represented <1% of the total infectivity produced by RV-Me-UL128Lmut, thus the vast majority 
of progeny virus produced in this infection had egressed producer cells. Surprisingly, no CAV 
infectivity was recovered from the RV-Me-tet-UL128Lwt infection, providing strong evidence 
that the pentameric complex was inhibitory to the production of progeny virions, and not simply        
cell-free release. Surprisingly, RV-TR produced the least CRV infectivity of any infection. In 
fact, cell-free virus was un-detectable other than at day 2 or day 10 post-infection. The vast 
majority of the RV-TR infected HFFFs (>80%) remained intact at day 10 post-infection, with 
~98% of the total infectivity recovered located in the CAV fraction. 
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Figure 4.9. CRV and CAV sub-populations produced in fibroblast infections. HFFFs were infected 
(MOI 3) with each indicated virus, and supernatant samples were collected every two days and cleared of 
cellular materials by centrifugation. Pelleted cellular materials were returned to each original infection. At 
day 10 post-infection, the total cellular material was sonicated to release CAV infectivity. All CRV and 
CAV samples were analysed by plaque titration onto HFFFs. Plotted on the left Y-axis, infectivity 
contained within each CRV samples collected over time-course of infections. On the right Y-axis, total 
CRV and CAV infectivity. Total CRV infectivity was estimated as the sum of infectivity produced at 
each time-point over the time-course of infections. All data based on 1 experiment (n = 1). ±SEM are 
shown. Plotted (A) CRV and CAV subpopulations produced by virus containing greatest/least pentamer. 
(B) CRV and CAV subpopulations produced by virus containing pentamer levels dictated by TB40-
BAC4 UL128L nucleotides. (C) CRV and CAV subpopulations produced by virus containing pentamer 
levels dictated FIX UL128L nucleotides.   
    147 
 Relative CRV and CAV produced by viruses containing TB40-BAC4 UL128L 4.5.2
sequence features 
 The RV-TB40-BAC4 infection produced the most cell-free virus, with total CRV 
infectivity >2500-fold more than produced by RV-Me-tet-UL128Lwt and also more than twice 
that produced by RV-Merlin-UL128Lmut (Figure 4.9.B). However, this infection also produced 
the greatest quantities of CAV infectivity; this may reflect the fact that more cells remained 
intact at the final infection time point (day 10 p.i.). Merlin viruses expressing TB40-BAC4 
UL128L or the single UL128 intron 1 G>T variation (RV-Me-UL128LTB40 and RV-Me-
UL128G>T) again displayed almost identical cell-free virus production that was intermediate to 
the Merlin control virus infections. They also produced similar levels of CAV infectivity, which 
compared to RV-Me-UL128Lmut infection, represented a greater proportion of the total 
infectivity produced (~14% and ~16%, respectively). However, the CAV produced in each 
infection could not account for the deficit in CRV production compared to RV-Merlin-
UL128Lmut. Thus, TB40-BAC4 UL128L was also inhibitory to infectious virus production, 
although less so than Merlin wildtype UL128L. Furthermore, the UL128 intron 1 G>T 
nucleotide variation was solely responsible for this difference. 
 Relative CRV and CAV produced by viruses containing FIX-BAC UL128L 4.5.3
sequence features 
 The total CRV produced by the RV-FIX infection was >120-fold greater than that 
produced by RV-Me-tet-UL128Lwt, though ~7.5-fold less than that produced by RV-Me-
UL128Lmut (Figure 4.9.C). This was almost re-capitulated by the Merlin virus containing FIX 
UL128L, which produced total CRV that was ~100-fold greater than that produced by RV-Me-
UL128Lwt. The CAV from each of these infections was broadly equivalent, representing 2-3% 
of the total infectivity produced. Thus, as in the RV-Me-UL128Lmut infection, the vast majority 
of RV-FIX and RV-Me-UL128LFIX progeny virions that also display dramatically reduced 
pentameric complex content had successfully egressed producer cells. The total CRV produced 
by RV-Me-UL130A>G was >13-fold greater than that produced by RV-Me-UL128Lwt, and thus 
lower than that produced by each of RV-Me-UL128Lmut, RV-FIX, or RV-Me-UL128LFIX. The 
titres of CAV produced by RV-Me-UL130A>G were similar to that produced by RV-FIX or RV-
Me-UL128LFIX; this represented a greater source of the total progeny virus produced (~17%), 
however could not account for the lower CRV produced.   
 Tropism of CRV and CAV sub-populations produced in fibroblasts 4.5.4
 The tropism of CRV and CAV sub-populations produced in fibroblasts were assessed 
from separate infections. In the previous one-step growth curve assays, peak titres of cell–free 
virus were consistently produced at day 6 post-infection, other than in the RV-TR infection. 
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Furthermore, HFFFs infected with Merlin viruses were almost completely degraded by day 10 
post-infection, whereas more HFFFs infected with viruses from TR-BAC, TB40-BAC4, and to 
a lesser extent FIX-BAC, remained intact. Thus, to assess progeny derived from a comparable 
number of intact cells across all infections, CRV and CAV fractions were produced from 
infected HFFFs at day 8 post-infection. CRV and CAV samples were then titrated onto 
fibroblasts (HFFFs) and epithelial cells (RPE-1s) in parallel, with titres of each sample reported 
on epithelial cells normalised to that for the same sample reported on fibroblasts. 
 CRV from the RV-Me-UL128Lmut infection displayed ~100-fold reduced infection 
efficiency in RPE-1s compared to HFFFs, similar to that previously demonstrated for stocks of 
RV-Me-UL128Lmut grown in HFFFs (Figure 4.10.A). Interestingly, RV-Me-tet-UL128Lwt CRV 
infected RPE-1s with >10-fold reduced efficiency than HFFFs, whilst RV-TR CRV infected 
RPE-1s with >100-fold reduced efficiency. This was in contrast to the comparable fibroblast 
and epithelial cell infection efficiency by counterpart viruses that had been produced in 
epithelial cells. Similarly, CRV from infections with viruses expressing TB40-BAC4 UL128L 
sequence features infected RPE-1s 15-30-fold less efficiently than they did HFFFs, whereas 
versions of each corresponding virus grown in epithelial cells had previously displayed 8-10-
fold reduced RPE-1 cell infection efficiency. CRV from the RV-FIX infection again displayed 
~100-fold reduced epitheliotropism, similarly to the RV-FIX stock produced in HFFFs. CRV 
from infections with Merlin viruses expressing FIX UL128L sequence features infected 
epithelial cells in a similar pattern to that seen previously: RV-Me-UL128LFIX displayed the 
most reduced (~40-fold) epitheliotropism, and RV-Me-UL130A>G displayed the least reduced 
(~14-fold) epitheliotropism. The epithelial infection efficiency of each virus was however 
slightly lower than previously demonstrated for counterpart virus stocks produced in epithelial 
cell culture. A similar pattern of results was seen in the reported infectivity in the CAV fractions 
of each infection (Figure 4.10.B). 
 Conclusion 4.5.5
 Increasing levels of pentameric complex in virions inversely correlated with progeny 
virion production, and not simply the cell-free release, from producer fibroblast cells. Whilst 
increasing pentameric complex levels could be correlated with greater relative proportions of 
CAV produced several infections in this cell type, this compartment did not contain any source 
of infectious virions that could account for differences in CRV production. The tropism of 
viruses containing intact UL128L and produced in fibroblast was different to that of the same 
virus produced in epithelial cells; viruses produced in fibroblasts consistently displayed reduced 
epitheliotropism compared to counterparts grown in epithelial cells. Furthermore, unlike 
progeny sub-populations produced in epithelial cell infections, the CRV and CAV sub-
populations displayed no observable differences in tropism.  
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Figure 4.10. Tropism of CRV and CAV Sub-populations produced in Fibroblasts. HFFFs were infected with each stated virus (MOI 3), and at day 8 post-infection, CRV and 
CAV fractions were prepared as previously described. CRV and CAV fractions were prepared in identical final volumes, and analysed by titration onto HFFFs and RPE-1s in 
parallel. Titres reported on RPE-1s were normalized to those reported on HFFFs, giving the relative epithelial cell infection efficiency (epitheliotropism). All data based on one 
experiment (n=1). (A) The relative epithelial cell infection efficiency of CRV fraction infectivity from each infection. (B) The relative epithelial cell infection efficiency of CAV 
fraction infectivity from each infection. 
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4.6 Summary 
 An investigation as to how the TB40-BAC4 UL128 G>T and FIX UL130 A>G (S72P) 
mutations impacted pentameric complex functionality revealed that they each reduced the 
assembly and/or incorporation of the pentameric complex into virions. However, these effects 
were brought about by different mechanisms: the UL128 intron 1 G>T nucleotide variation 
reduced the efficiency by which UL128 pre-mRNAs were spliced, in turn reducing the 
production and availability of gpUL128 for pentameric complex assembly; the UL130 A>G 
(S72P) nucleotide variation did not impact UL130 expression, and it is most likely that the 
gpUL130 structural changes that were introduced impacted peptides that facilitate binding 
interactions with other pentameric complex sub-units.   
  Except for the TB40-BAC4 UL128 G>T mutation, the UL128L ORFs of each strain 
investigated contained no further nucleotide sequence variations that impacted expression at 
either the transcriptional or translational levels. The similar expression efficiency of TR 
UL128L to that of Merlin UL128L resulted in RV-TR virions containing pentameric complex 
levels that were equivalent to that of the Merlin virus containing wildtype UL128L sequences. 
The reduced levels of pentameric complex in TB40-BAC4 virions appeared to be heavily 
contributed to by the UL128 G>T mutation, whilst the reduced pentameric complex content of 
FIX virions was only partially due to the UL130 A>G (S72P) mutation; virions from the 
recombinant Merlin virus containing the A>G (A72P) mutation contained greater pentameric 
complex levels than the recombinant Merlin virus containing the entire FIX UL128L genome 
region.  
 The pentameric complex content impacted various activities in the viral replication 
cycle, offering some explanation to the previously determined distinct growth phenotypes of the 
viruses assessed. Reduced pentameric complex content in virions in turn reduced the ability of 
virus to gain entry into epithelial cells relative to fibroblasts, however the relative 
epitheliotropism of Merlin viruses containing the single UL128 G>T and UL130 A>G 
mutations was only slightly compromised (≤10-fold) in comparison to virus completely lacking 
the pentameric complex (100-5000-fold). Greater cell-free virus production of strains also 
correlated with reduced pentameric complex content. Data from infections performed in 
epithelial cells and fibroblasts suggested that whilst the pentameric complex may promote cell-
association and impede the release of progeny virions, its main effect was to inhibit infectious 
virion morphogenesis. Furthermore, any progeny virus recovered from cellular sites displayed 
reduced epitheliotropism, and thus likely contained less pentameric complex. Importantly, 
viruses derived from the same BAC-clone though produced in different cell-types display 
differences in tropism; cell-free released virus produced during infection of epithelial cell 
culture displayed greater epitheliotropism than counterparts produced in fibroblasts. 
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5 Genetic Stability of Virus from 
BAC-cloned Strains and Novel 
Merlin-BAC Variants in vitro 
 
    152 
 
  
    153 
 As previously mentioned, viruses from the TR, TB40-BAC4 and FIX BACs appear to 
retain broad tropism when propagated in fibroblast cell culture. We hypothesised that the 
apparent greater stability of UL128L in these strains, compared to that contained within clinical 
isolates, was directly related to the more efficient growth phenotype of the viruses they 
produced. Encouragingly, the transfer of TB40-BAC4 UL128 and FIX UL128L sequences also 
conveyed a greater fitness to Merlin viruses in fibroblasts, and we this potentially alleviated the 
selective pressures normally encountered during passage in cell culture. However, the 
adaptation of TR BAC-derived viruses in the previous growth kinetics assays had apparently 
occurred without mutation in UL128L, suggesting that other genome regions may have also 
contributed to the greater stability of TR UL128L. This potentially applied to the apparent 
greater stability of TB40-BAC4 and FIX UL128L genome regions too.  
5.1 Adaptation of TR-BAC-derived viruses during previous growth kinetics assays  
 Virus reconstituted from the TR-BAC adapted during a single passage in HFFFs 5.1.1
 Initially, the RV-TR-HFFFp1 virus (section 3.1) was further passaged in fibroblasts to 
enrich any UL128L mutant population that may not have been detected by PCR-based 
sequencing. The resultant RV-TR-HFFFp2 virus displayed further increased HFFF plaque 
formation (Figure 5.1.), yet PCR-based sequencing again suggested that UL128L appeared 
unchanged.  
` 
 
 
Figure 5.1. Adaptation of RV-TR to fibroblasts. The cell-to-cell spread of TR BAC-derived virus in 
fibroblast following sequential passage in the same cell type. Where possible, a minimum of 20 plaques 
following 2 weeks incubation under overlay was measured. Mean and ±SEM are shown. (A) HFFFs 
plaques formed following transfection of HFFFs with BAC DNA for each virus (p0). (B) HFFF plaques 
sizes following 1 passage in HFFFs. (C) HFFF plaques formed by RV-TR-HFFFp2, compared to that of 
RV-Me-UL128Lmut-HFFFp1 and RV-Me-UL128Lwt-HFFFp1. 
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 The RV-TR-HFFFp2 virus was assessed by whole genome sequencing, performed by 
Dr Andrew Davison and Dr Gavin Wilkie (MRC-University of Glasgow Centre for Virus 
Research, Glasgow, UK) (Appendix V). To generate sufficient quantities of viral genomic DNA 
for analysis, HFFFs were infected at high MOI with RV-TR-HFFFp2, and viral genomic DNA 
was extracted at 72-hr post-infection. Whole genome sequencing confirmed that the RV-TR-
HFFFp2 virus contained UL128L genome regions that were unchanged. Furthermore, RL13 
that is apparently intact in TR also remained unchanged. However, a significant population 
(~30%) in the RV-TR-HFFFp2 virus contained a large deletion encompassing sequence 
originating from the a’ genome region terminus, and ending in the BAC vector sequence 
(Figure 5.2.). Thus, TR BAC-derived virus had lost ORFs IRS1 and US1, along with the 
remainder of US2 and part of the BAC vector, within as few as 2 passages in fibroblasts. 
 
 
 
 
 
Figure 5.2. TR–BAC derived virus acquired a large deletion at the site of BAC vector insertion 
during passage in fibroblasts. Schematic of the BAC-cloned HCMV strain TR genome; black star 
indicates the site of BAC vector insertion. (A) TR-BAC a’ – US6 genome region. (B) TR-HFFFp2 a’ – 
US6 genome region. Sequence deleted (green) originated from the a’ region termini (red) and spanned 
ORFs (yellow) up to and including part of the BAC vector (grey). Average coverage depth = 478 nt. 
 
 
 
 Virus reconstituted from the TR-BAC adapted during a single passage in RPE-1s  5.1.2
 We next examined the TR BAC-derived virus from RPE-1 cells (RV-TR-RPE-1p1) that 
had also apparently undergone adaptation during the growth kinetics assays (section 3.2). 
Genomic DNA was again prepared from HFFFs infected at high MOI with RV-TR-RPE-1p1, 
and analysed by whole genome sequencing (Figure 5.3.). The UL128L genome region in this 
TR-BAC-derived virus contained identical sequence to that of the parental BAC, as did RL13. 
The majority population was that of virus containing mutations at two genomic loci: a frame-
shifting mutation in UL84, following the insertion of an additional T into a tract of 8 T residues; 
and a deletion from within US9 and encompassing ORFs up to and including part of US16.  
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Figure 5.3. TR–BAC derived virus acquired a large deletion proximal to the site of BAC vector 
insertion during passage in epithelial cells.  Schematic of the TR-BAC genome as previously 
described; the black star indicates the site of BAC vector insertion. (A) TR-BAC US9-US16 genome 
region. (B) RV-TR-RPE-1p1 US9-US16 genome region Sequence deleted (green) originated from within 
US9 and spanned all ORFs (yellow) up to and including part of US16. Bases with coverage = 99.945%.  
Average coverage depth = 207.117 nt. 
 
 
 Conclusion 5.1.3
 TR BAC-derived virus had mutated within a single passage following reconstitution in 
both fibroblasts (HFFF) and epithelial cells (RPE-1s), and in both instances, this involved the 
deletion of sequences that included, or were proximal to, the site of the stably incorporated 
BAC vector sequence insertion.   
5.2 Genetic stability of viruses in epithelial cell culture 
 The demonstration that TR BAC-derived virus underwent adaptation as early as the first 
passage following reconstitution in RPE-1s invoked the question as to whether other viruses 
were also prone to rapid mutation in this cell type. To answer this question, we examined the 
virus stocks grown in RPE-1 epithelial cells and used in previous investigations (Table 4.1). An 
exact assessment of the number of passages each virus had undergone was not possible, 
however each was subjected to the minimal passage history required for the growth of a stock 
from a BAC; productive infections from which each stock was prepared were initiated by 
inoculating RPE-1s in T25 culture flasks with RPE-1p1 viruses produced in the growth kinetics 
assays. When all cells were infected (i.e. eGFP+), harvested cells were diluted ~1:5 with fresh 
RPE-1s before being seeded to new culture flasks (firstly to T75 culture flasks, then to single 
T150 culture flasks, and finally to 5 T150 culture flasks).  
Genomic DNA from each virus stock was again prepared from high MOI infection of 
HFFFs, other than that from the RV-Me-UL128Lwt and RV-Me-UL128L3301 stocks. The low 
titre of these stocks were sufficient only for the performance of low MOI HFFF infections, and 
the multiple rounds of lytic virus replication that would be required to generate a sufficient 
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abundance of genomes could result in the selection of mutated progeny at population levels that 
were not representative of the virus stock. Thus, we attempted sequencing of viral genomic 
DNA extracted directly from these virus stocks.  
 Viruses containing stably-incorporated BAC-vector sequences rapidly adapt 5.2.1
during propagation in epithelial cell culture, involving mutation at the site of BAC-
vector insertion 
 Stocks of RV-TR were prepared from the same virus lineage that contained the UL84 
mutation and deletion of US9-US16 described above; these mutations were identified in ~80% 
of all genomes derived from the RV-TR-RPE-1 stock (Table 5.1). However, no further genetic 
changes had occurred during the additional passaging in RPE-1s prior to stock preparation. Like 
strain TR, TB40-BAC4 also contains a stably incorporated BAC vector in US genome region: 
the left hand end of the BAC interrupts US2 that is fused to the a’ sequence; the right hand end 
of the BAC replaces sequence within the US6-US7 intergenic region (Sinzger, Hahn et al. 
2008). RV-TB40-BAC4-RPE-1 stocks contained similar de novo mutant populations to those 
identified in the RV-TR-RPE-1 stocks. The majority population (~80%) had undergone a large 
deletion resulting in the loss of the entire BAC vector sequence, as well as ORFs in flanking 
genome regions (to the left of the BAC vector, the loss of the US2 fragment; to the right of 
BAC vector, loss of US7, US8 and part of US9) (Figure 5.4.). Also similar to the RV-TR-RPE-
1 stock, ~1/2 of all genomes in the RV-TB40-BAC4-RPE-1 stock contained a premature stop 
codon in UL84.  
 
 
 
 
 
Figure 5.4. TB40-BAC4 BAC derived virus acquired a large deletion at the site of BAC vector 
insertion during passage in epithelial cells. Schematic of the TB40-BAC4 genome; repeated sequence 
regions (red box); unique sequence regions depicted by arrows (UL, dark blue; US light blue) in relative 
orientation of ORF blocks; site of stably incorporated BAC at US2 to US6-US7 intergenic region (black 
star). (A) TB40-BAC4 a’-US9 genome region. (B) RV-TB40-BAC4-RPE-1p5 genome region. Sequence 
deleted (green) originated from the a’ (red) terminus that overlapped the remainder of the ORF US2, and 
spanned the entire BAC vector (grey) as well as ORFs (yellow) up to and including part of US9. Bases 
with coverage = 99.907%.  Average coverage depth = 383.475 nt. 
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 Viruses from the Merlin-BAC variants rapidly adapt during propagation in 5.2.2
epithelial cell culture, involving mutation in the UL/b’ genome region 
 Unlike the TR and TB40-BAC4 BAC clones, the BAC vector inserted into the Merlin 
genome (at the US28-US29 intergenic region) is excised following reconstitution of virus in 
eukaryotic cells, with the only remnant being a single 40 bp LoxP binding site. In turn, the 
genome region in which the BAC vector sequence was inserted remained intact in all Merlin 
viruses propagated in epithelial cells. However, stocks of all but one of the Merlin viruses (RV-
Me-UL130A>G-RPE-1) grown in RPE-1s contained de novo mutant populations, predominantly 
affecting the UL/b’ genome region.  
 In the stock of the Merlin virus containing native wildtype UL128L (RV-Me-
UL128Lwt-RPE-1), a minority population (<3%) contained a deletion from within UL128 and 
extending into UL136 (Figure 5.5.). This deletion occurred with a concomitant insertion of an 
11895 bp fragment of DNA that contained sequence from the HCMV ORF US20 flanked by 
sequences from E.coli.   
 
 
 
 
Figure 5.5. Minority mutant population present in RV-Me-UL128Lwt–RPE-1 stocks. Schematic of 
the BAC-cloned wildtype Merlin genome; repeated sequence regions (red box); unique sequence regions 
depicted by arrows (UL, dark blue; US light blue) in relative orientation of ORF blocks; site of self-
excising BAC vector at US28-US29 intergenic region (black line). (A) ORFs (yellow) UL128-UL136 in 
the Merlin BAC UL/b’ genome region. (B) Sequence deleted (green) in RV-Me-UL128Lwt, spanning 
UL128-UL138, and part of UL136, occurring with concomitant insertion of E.coli DNA (dark grey) and 
duplication of part of US20. Bases with coverage = 99.994%.  Average coverage depth = 138.897 nt. 
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 Stocks of recombinant Merlin viruses containing UL128L sequence from other strains 
each contained more significant mutant populations (Figure 5.6.). The UL141 ORF was 
consistently compromised across all Merlin viruses grown in epithelial cells, either due to large 
deletions encompassing multiple ORFs in the UL/b’ genome, or by the acquisition of mutations 
affecting this ORF alone. In RV-Me-UL128L3301-RPE-1 stocks, deletion of ORFs UL147–
UL150 occurred with the concomitant insertion of duplicated sequence from UL/b genome 
region (TRL/b sequence-RL12) (Figure 5.6.B). RV-Me-UL128LTB40–RPE-1 stocks contained 
two mutant populations: the major population contained a deletion of sequence from within 
UL145 and spanning all ORFs up to, and including UL148C, with concomitant insertion of 
E.coli DNA (Figure 5.6.C.i); the minor population had acquired a deletion of sequence 
commencing from within UL142 and spanning all ORFs up to, and including, part of UL139 
(Figure 5.5.6.ii). Each of RV-Me-UL128G>T and RV-Me-UL128LFIX contained majority 
populations in which UL141 alone was compromised (Figure 5.6.D & E).  
 Mutations outside of the UL/b’ genome region were identified in the Merlin virus 
containing the UL128 G>T mutation (RV-Me-UL128G>T-RPE-1), with amino acid substitutions 
affecting UL26 and also UL75 in ~1/2 of all genomes. A population containing US8 
compromised by an amino acid substitution was also identified in this virus, though this 
represented relatively few of the genomes analysed.  
  Conclusion 5.2.3
When passaged in epithelial cells, viruses that contained stably incorporated BAC 
vector sequences consistently acquired large deletions in genome regions that included, or were 
proximal too, the site of BAC vector insertion. Mutations affecting UL84 were also identified in 
these viruses. In contrast, the passage of various Merlin viruses resulted in the rapid selection of 
mutations affecting ORFs in the UL/b’ genome region, as well as occasional mutations at other 
genomic loci. 
 
    159 
 
Figure 5.6. Mutation in UL/b’ genome region of Merlin viruses grown in epithelial cells. Schematic 
of the BAC-cloned wildtype Merlin genome, as previous. (A) ORFs UL147-UL150 in the Merlin-BAC 
variants in the UL/b’ genome region. Mutated regions in each passaged virus are aligned to corresponding 
region in UL/b’ region, though not to scale. Deleted regions are depicted in green. (B) Deletion of 
sequence from within RV-Me-UL128L3301 UL147 and spanning ORFs up to and including UL150, 
occurring with concomitant insertion of duplicated sequence (pink) (UL to RL12). Bases with coverage = 
99.956%.  Average coverage depth = 179.172 nt. (C) Deletion of UL/b’ ORFs in RV-Me-UL128LTB40 (i) 
Major population – loss of part of UL145 and ORFs up to and including UL148B, with concomitant 
insertion of E.coli DNA; (ii) minor population – loss of part of UL142 and ORFs up to and including part 
of UL139. Bases with coverage = 99.855%.  Average coverage depth = 769.865 nt. (D) Acquisition of 
amino acid substitution encoding SNP (purple) in RV-Me-UL128G>T UL141. Bases with coverage = 
99.975%.  Average coverage depth = 396.27 nt. (E) In frame deletion of RV-Me-UL128LFIX UL141. 
Bases with coverage = 99.919%.  Average coverage depth = 546.484 nt. 
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Table 5.1. Mutant populations in virus stocks prepared in RPE-1 epithelial cells. 
 
 
a Location/Nucleotide co-ordinates in TR BAC (AC146906), TB40-BAC4 BAC (EF29999), and Merlin BAC (GU179001) genome sequences deposited in GenBank. The sequences 
of strains TR and TB40-BAC4 deposited in GenBank commence immediately following the site of BAC vector insertion. The positions of deletions in viruses derived from these 
clones are described to include sequence at each end of the deposited sequences. 
b Mutation and coding effect: Δ indicates deletion; bp – base pairs. Numbers enclosed in [] detail the origin of HCMV sequences duplicated in mutant virus genomes. 
 
Virus Stock Location (nt)a ORFs affected Mutation/(Coding Effect)b Population (%) 
RV-TR-RPE-1-RPE-1 
3,687-9,738 US9-US16 Δ 6052 bp 80 
159,574-159,581 UL84 Frame-shifting insertion: TTTTTTTT>TTTTTTTTT 80 
RV-TB40-BAC4-RPE-1 
228,878 – 1973 a'-US9 Δ 173 bp of US2, BAC vector, and 1,973 bp over-lapping US7, US8 and part US9 80 
155,174 UL84 G>A (Q>Stop) 46 
RV-Me-UL128Lwt-RPE-1 176,129-188,023 UL128-UL136 Δ 11,895 bp; insertion 1,217 bp (E.coli DNA-UL20 [25,726-26,006]-E.coli DNA) < 3 
RV-Me-UL128L3301-RPE-1 180,563-194,029 UL147-UL150 Δ ~13,750 bp; insertion 10,300 bp from UL-RL12 [1-10,300] 45 
RV-Me-UL128LTB40-RPE-1 
183,591-186,632 UL145-UL148C Δ 3,042 bp  90 
181,910-191,511 UL142-UL139 Δ 9,602 bp; insertion 3733 bp E.coli DNA 9 
RV-Me-UL128G>T-RPE-1 
32,652 UL26 G>T (R>S) 50 
110,792 UL75 G>C (L>M) 50 
185,141 UL141 C>T (W>Stop) 65 
204,004 US8 A>C (V>G) low 
RV-Me-UL128LFIX-RPE-1 184,459-184,914 UL141 Δ 456 bp (In-frame Deletion) 100 
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5.3 Genetic stability of viruses in fibroblast cells 
 In contrast to viruses grown in epithelial cells, whole genome sequencing of the RV-
Me-UL128Lmut and RV-FIX stocks grown in fibroblasts identified no populations that had 
acquired de novo mutations. These stocks were prepared by a similar method as stocks 
produced in RPE-1s, though were subjected to 1 fewer passage; productive infections were 
initiated by transfection of HFFFs with BAC DNA, and not infection of cells with virus derived 
from the growth kinetics assays. Despite this, the lack of any mutants in either of these stocks 
suggested that either the selection of mutants occurred less rapidly in fibroblasts, or the lack (or 
reduced levels) of pentameric complex and increased fitness of virus in this cell type (greater 
cell-to-cell spread, cell-free virus production, and dissemination kinetics) reduced the chance of 
mutation.  
 To investigate these possibilities, the genetic stability of all viruses following 
successive passages in HFFFs was assessed. Where possible, the passage series of each virus 
was a continuation of infections from the previously described growth kinetics assays. Each 
successive infection was initiated by inoculating fresh HFFFs with cell-free virus collected 
when the previous passage was completed (i.e. when mono-layers were destroyed). Infectivity 
in supernatants was quantified by immunofluorescence titration, and all new infections were 
performed at an approximate MOI of 0.05-0.1. Viral genomic DNA was extracted directly from 
virions released into the supernatant at the end of passage 5, and assessed by whole genome 
sequencing. 
 Viruses containing stably-incorporated BAC-vector sequences rapidly adapt 5.3.1
during sequential passage in fibroblasts, involving mutation at the site of BAC-
vector insertion 
 TR BAC-derived virus had previously undergone adaptation within a single passage in 
fibroblasts, involving the deletion of sequences at the site of BAC vector insertion. The RV-TR-
HFFFp5 assessed in this investigation was derived from a separate transfection of HFFFs, yet 
contained populations with near identical mutations to that of the previous RV-TR-HFFFp2 
virus. Two distinct populations were detected, each containing deletions from the a’ genome 
region terminus to within the BAC vector, and differing only as to the size of the deletion: the 
major population lost 6087 bp, whilst the minor population lost 4306 bp (Table 5.2). The RV-
TB40-BAC4-HFFFp5 virus also contained a major population that lacked sequence originating 
from with the a’ genome region, spanning the entire BAC vector sequence, and also part of 
US7.  
 
 The FIX BAC-clone also contains a stably incorporated BAC vector in the US genome 
region (Hahn, Khan et al. 2002), with the BAC vector interrupting the US2 ORF that is fused to 
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the end of the a sequence at the outermost US genome segment terminus. RV-FIX-HFFFp5 
virus contained a mutant population in which a large deletion had removed sequence 
commencing immediately outside of the terminal a sequence, spanning the entire BAC vector 
sequence, and removing part of the remaining US2 ORF (Figure 5.7.). Thus like viruses 
produced from TR and TB40-BAC4, FIX BAC-derived virus is prone to mutation involving the 
site of the stably incorporated BAC insertion. 
 
 
 
 
Figure 5.7. Deletion of BAC vector in RV-FIX-HFFFp5. Schematic of the FIX-BAC genome; repeated 
sequence regions (red box); unique sequence regions depicted by arrows (UL, dark blue; US light blue) in 
relative orientation of ORF blocks; site of stably incorporated BAC vector at US2 to US6-US7 intergenic 
region (black star). ORFs in the US segment in reverse orientation relative to that of the UL genome 
segment. The FIX BAC clone lacks any IRS genome region at the UL/US junction, which instead contains 
the single inverted copy of the TRS sequence. (A) FIX-BAC genome region spanning from US8 to the 
terminal a sequence. (B) RV-FIX-HFFFp5 US8 to terminal a sequence region. Sequence deleted (green) 
originated from the a (red) terminus fused with the remainder of the ORF US2, and spanned the entire 
BAC vector (grey), as well as 7 bp in the US6-US7 intergenic region.  Bases with coverage = 99.481%.  
Average coverage depth = 562.065 nt. 
 
 
 Virus from the Merlin-BAC variant lacking intact UL128L is stable in fibroblasts; 5.3.2
virus from the Merlin-BAC variants containing wildtype UL128L are prone to 
rapid mutation in this genome region, and others, during sequential passage in 
fibroblasts  
 No mutant populations were detected in the sequentially passaged Merlin virus lacking 
UL128L (RV-Me-UL128Lmut-HFFFp5). In contrast, Merlin viruses containing wildtype 
UL128L each contained mutations in the encompassing this genome region (Figure 5.8.). The 
vast majority of genomes (~92%) in the RV-Me-UL128Lwt–HFFFp5 virus contained a deletion 
of sequence originating from within UL128 up to, and including UL139, as well as sequence 
from within the U139-UL138 intergenic region (Figure 5.8.Bi). A smaller population (~6%) 
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also contained a deletion of 4 bp within UL131A (Figure 5.8.Bii). RV-Me-UL128L3301–HFFFp5 
virus contained a mutant population that had acquired a frame-shifting single nucleotide 
insertion adjacent to a nucleotide substitution in UL128 exon 1 (Figure 5.8.C). Each of these 
stocks was derived from HFFFp1 progenitor viruses produced during growth kinetics assays. In 
these assays, each of the Merlin viruses containing wildtype UL128L had apparently undergone 
adaptation during the first passage in fibroblasts, as evidenced by the production of 
unexpectedly high titres of cell-free virus, and unusually large HFFF plaques formed during 
titration of supernatants. The RV-Me-UL128L3301–HFFFp5 virus also contained a G>A 
nucleotide substitution located in the intergenic region between UL54 and UL55. 
 
 
 
 
 
Figure 5.8. Mutation in UL/b’ genome region of Merlin containing wildtype UL128L when grown in 
fibroblasts. Schematic of the Merlin genome, as previous. (A) ORFs UL128-UL138 in the Merlin-BAC 
variants in the UL/b’ genome region. Mutated regions in each passaged virus are aligned to corresponding 
region in UL/b’ region, though not to scale. Deleted regions are depicted in green. (B) Deletion of 
sequence from within RV-Me-UL128Lwt  (i) major population – loss of sequence commencing from 
within UL128 and spanning ORFs up to and including UL139, and ending in the UL139-UL138 
intergenic region; (ii) small deletion of 4 bp within UL131A exon 1. Bases with coverage = 100%.  
Average coverage depth = 594.686 nt. (C) Single nucleotide substitution and frame-sifting nucleotide 
insertion in RV-Me-UL128L3301 UL128 exon 1. Bases with coverage = 100%.  Average coverage depth = 
533.51 nt. 
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 TB40-BAC4 UL128L is not stable when expressed in the Merlin genome 5.3.3
background in fibroblasts, yet the unique UL128 intron 1 G>T variation does 
stabilise Merlin UL128L ORFs in fibroblasts 
 Whole genome sequencing of the sequentially passaged Merlin virus containing TB40-
BAC4 UL128L (RV-Me-UL128LTB40-HFFFp5) identified a population (~60%) in which a 
deletion had occurred in the UL/b’ genome region, resulting in the loss of sequence from within 
UL130 up to and including part of UL148 (Figure 5.9.). In contrast, Merlin virus containing the 
G>T mutation identified in TB40-BAC4 UL128 contained no mutations in the UL/b’ genome 
region. In fact, the RV-Me-UL128LG>T–HFFFp5 virus contained relatively few mutations at all, 
with amino acid substitution encoding SNPs in just ORFs UL47 and UL55.  
 
 
 
 
 
Figure 5.9. Mutation in UL/b’ genome region of Merlin containing TB40-BAC4 UL128L when 
grown in fibroblasts. Schematic of the Merlin genome, as previous. (A) ORFs UL128-UL148 in the 
Merlin-BAC variants in the UL/b’ genome region. Mutated regions in each passaged virus are aligned to 
corresponding region in UL/b’ region, though not to scale. Deleted regions are depicted in green. (B) 
Deletion of sequence from within RV-Me-UL128LTB40 originating from within UL130, and spanning 
ORFs up to, and partially including UL148. Bases with coverage = 99.966%.  Average coverage depth = 
463.882 nt. 
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 FIX-BAC UL128L is stable when expressed in the Merlin genome background in 5.3.4
fibroblasts, and the unique UL130 A>G variation also stabilises Merlin UL128L 
ORFs in fibroblasts 
 All genomes detected in the RV-Me-UL128LFIX-HFFFp5 virus contained sequence that 
was identical to the parental BAC, and therefore de novo mutations had not been acquired 
during the passage of this virus. This result was closely matched by that of the Merlin virus 
containing the UL130 A>G mutation identified in FIX UL128L, with the only mutation 
identified in RV-Me-UL130A>G-HFFFp5 being a deletion within the synthetic eGFP cassette 
inserted upstream of UL122. 
 Conclusion 5.3.5
 As in epithelial cell culture, viruses containing stably incorporated BAC vector 
sequences were prone to the acquisition of large deletions surrounding the site of BAC vector 
insertion. Wildtype UL128L was rapidly mutated following growth of virus in fibroblasts, 
regardless of natural strain-strain sequence variation. Like TR UL128L (see Appendix II), 
TB40-BAC4 UL128L was stable in the TB40-BAC4 background, but was prone to mutation in 
when expressed in the Merlin genome. However, the FIX UL128L genome region that is more 
severely compromised than UL128L from other strains was not prone to mutation, whether 
expressed in the native FIX genome background, or in the Merlin genome background. The 
UL128L genome region of Merlin viruses engineered to contain mutations from TB40-BAC4 
UL128 or FIX UL130 were more stable than wildtype UL128L in the parental Merlin virus in 
fibroblasts, although point mutations were occasionally acquired elsewhere in these genomes of 
these viruses. 
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Table 5.2. Mutant populations in viruses produced following by sequential passage in fibroblasts (HFFFp5). 
 
 
a Location/Nucleotide co-ordinates in TR BAC (AC146906), TB40-BAC4 BAC (EF29999), and Merlin BAC (GU179001) genome sequences deposited in GenBank. The sequences 
of strains TR and TB40-BAC4 deposited in GenBank commence immediately following the site of BAC vector insertion. The positions of deletions in viruses derived from these 
clones are described to include sequence at each end of the deposited sequences. 
b Mutation and coding effect: Δ indicates deletion; bp – base pairs. Numbers enclosed in [] detail the origin of HCMV sequences duplicated in mutant virus genomes.
Virus Stock Location (nt)a ORFs affected Mutation/(Coding Effect)b Population (%) 
RV-TR-HFFFp5 194,202-BAC  a’-US3 
Δ 6,087 bp: 3,899 bp from a’- to BAC vector, + 2,188 BAC nt > 
Δ 4,306 bp: 3,899 bp from a’- to BAC vector, + 407 BAC nt < 
RV-TB40-BAC4-HFFFp5 228,878-446 US7 Δ173 bp: a’- BAC vector, entire BAC vector, 446 bp into US7  
RV-FIX-HFFFp5 228,002-60  Δ 7,650 bp: Sequence from a’ to BAC vector + 7 bp  
RV-Me-UL128Lwt-HFFFp5 
176,320-187,358 UL128 – UL139 Δ 11,039 bp 92 
178,063-178,066 UL131A Δ 4 bp; Frame-shift 6 
RV-Me-UL128L3301-HFFFp5 
176,827-176,828 
UL128 exon 1 
Insertion: G; Frame-shift  
176,827 Substitution: C>T  
RV-Me-UL128LTB40-HFFFp5 
177,130-179,950 UL130 – UL148 Δ 2,807 bp 60 
n/a eGFP Substitution: T>A  
RV-Me-UL128G>T-HFFFp5 61,647 UL47 Substitution: G>C (D>H)  
83,915 UL55 Substitution: T>A (D>V) 
RV-Me-UL130A>G-HFFFp5 n/a eGFP Δ 720 bp 99 
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5.4 Stabilisation of genomes by repression of ORFs most inhibitory to virus 
propagation in vitro 
Previous work demonstrated the utility of the tetracycline repressor culture system for 
the growth of virus containing wildtype RL13 and UL128L ORFs to high titres, comparable to 
that of virus containing ablation mutations in these genome regions (Stanton, McSharry et al. 
2008). We speculated that tet-repression might stabilise these ORFs that are normally rapidly 
mutated when virus is passaged in fibroblasts, and as suggested by the exquisite stability of the 
Merlin virus lacking intact RL13 and UL128L (RV-Me-UL128Lmut) in fibroblasts, other 
genome regions that are prone to mutation in this cell type.  
 Genetic stability of virus produced in tetracycline repression culture system  5.4.1
 Alternative versions of Merlin-UL128G>T and Merlin-UL130A>G BACs were 
constructed, and similarly to the alternative version of Merlin-UL128Lmut that was used in 
previous 1-step growth curve assays (see section 4.5), each differed from previously used 
counterparts at only two genomic loci: at UL122, no eGFP expression cassette was inserted; in 
the UL131A-UL132 inter-genic region, binding sequences for the tetracycline operator were 
inserted. One further virus was analysed, containing wildtype RL13 as well as wildtype 
UL128L (RV-Me-RL13wt/UL128Lwt). This virus contained no eGFP cassette, and binding 
sequences for tetracycline operators inserted were inserted both upstream of RL13, and in the 
UL131A-UL132 inter-genic region. Details of all viruses investigated are listed in Table 5.3. 
Stocks of each virus were grown in cells expressing tetracycline (HFFF-Tet), and virus genomic 
DNA was extracted directly from each stock and analysed by whole genome sequencing. No de 
novo mutant populations were identified in any stock, with all viruses displaying coding 
potential equivalent to the parental BACs. 
 
Table 5.3. HCMV stocks grown in HF-tets. 
a –  FS-ins – frame-shifting insertion. 
b – Nucleotide positions are given relative to sequence of BAC-cloned strain Merlin (GU179001). 
Recombinant Merlin 
Virus RL13 UL128L 
RV-Me-tet-UL128Lwt Mutated; FS-insa - A at nt  226 b   Wildtype 
RV-Me-tet-UL128G>T Mutated; FS-insa - A at nt 226b Wildtype + UL128 G>T  
RV-Me-tet-UL130A>G Mutated; FS-insa - A at nt 226 b   Wildtype + UL130 A>G (S72P) 
RV-Me-tet-RL13wt-tet- 
UL128Lwt 
Wildtype  Wildtype 
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 Growth phenotype of virus produced during subsequent infection wioth virus 5.4.2
stocks produced in tetracycline repression culture system  
 It was important to determine whether viruses produced in the tetracycline repression 
system could efficiently express RL13 and UL128L in subsequent infection of cell types where 
these ORFs were not repressed, ultimately producing progeny that contained gpRL13 and the 
pentameric complex. To explore this, one-step growth curve assays were performed to assess 
the growth phenotype of progeny produced following infection of ‘normal’ fibroblasts with 
viruses produced in the tetracycline repression culture system (Table 5.3.). The growth 
properties of the Merlin virus containing existing mutations in RL13 and UL128L (RV-Me-
UL128Lmut) were also determined for comparison.   
 In previous assays, investigation into the relative CRV and CAV sub-populations relied 
on the collection of supernatant samples throughout the time-course of infection, but total 
cellular materials at the final time-point of infections. Surprisingly, no RV-Me-tet-UL128Lwt 
progeny sub-population was detected. This was potentially due to: i) the vast majority of cells 
being lysed at the time of CAV fraction preparation, and any progeny that was originally 
retained within cells may have ultimately been released; ii) virions are thermo-labile at standard 
culture conditions with a half-life of 24-48hrs (Christian Sinzger – Pers Comm.), and CAV 
infectivity that was retained at these conditions for extended times compared to CRV infectivity 
may have been subjected to greater decay. To more accurately reflect the relative CRV and 
CAV infectivity produced by infections in this this repeat analysis, cellular materials cleared 
from supernatant samples collected every two days were stored for later analysis, rather than 
being returned to the original infection.   
 The Merlin virus containing wildtype UL128L ORFs again produced the lowest titres of 
cell-free virus, with the total CRV infectivity produced by RV-Me-tet-UL128Lwt 750-800-fold 
lower than that produced by RV-Me-UL128Lmut (Figure 5.10. – left axis). Merlin viruses 
encoding the single nucleotide variations identified in TB40-BAC4 UL128 intron 1 (RV-Me-
tet-UL128G>T) and FIX UL130 (RV-Me-tet-UL130A>G) again produced greater total CRV titres 
compared to RV-Me-tet-UL128Lwt, yet less than produced by RV-Me-UL128Lmut. In 
comparison to previous assays, greater CAV infectivity was recovered from the infection with 
virus completely lacking the pentameric complex (RV-Me-UL128Lmut), representing ~55% of 
the total infectivity produced (Figure 5.10. – right axis); this difference likely reflects the 
different approach to CAV sample preparation between the repeat analyses. Furthermore, CAV 
infectivity recovered from the RV-Me-tet-UL128Lwt infection represented ~70% of the total 
infectivity produced, whereas the counterpart to this virus used in previous assays produced no 
detectable CAV. Importantly, the CAV produced by RV-Me-UL128Lmut was >380-fold greater 
than that produced by RV-Me-tet-UL128Lwt, providing further evidence to suggest that the 
difference in CRV production by these infections was not simply due to the pentameric complex 
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impeding the cell-free release of progeny. Merlin viruses encoding TB40-BAC4 and FIX 
UL128L mutational features, and containing intermediate quantities of virion-incorporated 
pentameric complex, each produced CAV infectivity that represented ~60% and 75% of the 
total infectivity produced in each corresponding infection respectively.  
 Consistent with a prior report (Stanton, Baluchova et al. 2010), the Merlin virus 
containing wildtype RL13 and UL128L ORFs (RV-Me-tet-UL128Lwt-tet-RL13wt) produced the 
least cell-free virus; total CRV from this infection was >2500-fold lower that that produced by 
RV-Me-UL128Lmut, and also ~3.5-fold lower than produced RV-Me-tet-UL128Lwt. The CAV 
produced by the Merlin virus containing wildtype UL128L and RL13 was also the lowest of any 
virus assessed, however this represented ~80% of the total infectivity produced in this infection. 
 
 
 
Figure 5.10. Growth phenotype of progeny produced by viruses grown in tetracycline repression 
culture system. HFFFs were infected (MOI 5) with each indicated virus. Supernatants were collected 
every two days and centrifuged at low speed to collect cellular materials that were stored for later 
analysis. Infectivity within each sample was enumerated by IE1 immuno-fluorescence titration on HFFFs. 
Cellular Left Y-axis: Infectivity within CRV supernatant samples collected over the time course of 
infection. Right Y-axis: CAV infectivity was investigated from pooled and sonicated cellular material 
samples, in parallel to pooled and sonicated CRV samples. To account for differences in the volumes of 
these reported the CRV and CAV sub-populations, total CRV infectivity was calculated from the titres of 
each sample. 
 
 Conclusion 5.4.3
 Repression of genome regions most inhibitory to the growth of virus in fibroblasts 
allowed the stable propagation of virus without the selection of de novo mutations in any 
genome region, i.e. the normally rapidly mutated RL13 and UL128L ORFs were stabilised, as 
were other genome regions prone to mutation in fibroblasts when virus contains intact UL128L. 
Furthermore, as judged by growth phenotypes, virus produced in the tetracycline repression 
culture system still retained the ability to express RL13 and UL128L in subsequent infection of 
cell types where these ORFs were not repressed. 
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5.5 Summary 
 Whilst phenotype analysis provided indications that viruses had undergone adaptation 
to cell culture, the genome regions in which mutations were selected was not easily predicted. 
High-throughput whole-genome sequencing analysis provided a reliable assessment of the 
coding potential of viruses studied. Assuming random sampling of genomes, the average 
nucleotide covergae depth (at lowest, 138.897-fold for sequencing data directly the low-titre 
stock of RV-Me-UL128Lwt produced in RPE-1s) was sufficient to reliably depict the genetic 
diversity of each virus assessed. The incomplete genome sequences reported (ie nucleotides 
with coverage <100%) reflect the lack of data in high-G+C or repetitive regions (eg in UL57, 
OriLyt, or b/b'), or regions deleted from major genome populations. 
 Viruses derived from each of the TR-BAC, TB40-BAC4 and FIX-BAC clones 
repeatedly underwent rapid adaptation following reconstitution in both fibroblasts and epithelial 
cells, and this consistently involved the loss of sequence at, or proximal to, the site of BAC 
vector insertion. Moreover, this occurred within the minimum passaging required to generate 
virus stocks of each strain.  
  Merlin viruses were prone to adaptation when passaged in epithelial cells, most 
commonly involving the selection of mutants in the UL/b’ genome region, as well as 
occasionally at other genetic loci. In fibroblasts, Merlin viruses containing wildtype UL128L 
(whether native or from strain 3301) rapidly acquired ablating mutations in this genome region. 
In contrast, Merlin viruses containing TB40-BAC4 and FIX-BAC UL128L sequences were 
generally more stable in fibroblasts, compared to the parental Merlin viruses containing 
wildtype UL128L sequences. Importantly, incorporation of the TB40-BAC4 UL128 G>T or 
FIX UL130 A>G (S72P) single nucleotide variations stabilised the Merlin UL128L genome 
region. Thus, the more efficient growth properties that correlated with reduced virion 
pentameric complex content apparently alleviated the selective pressures for the acquisition of 
further UL128L mutations. However, these viruses often acquired mutations affecting other 
genome regions. Taken together, these data suggest that the stable passage of HCMV in cell 
culture may be best achieved in fibroblasts when UL128L is modified such that the growth 
inhibition of this genome region is less severe.  
 The Merlin virus containing existing ablating mutations in RL13 and UL128L remained 
stable in all genome regions following successive passaging in fibroblasts – this has been 
recapitulated in seven independent virus stocks derived from the Merlin-UL128Lmut BAC 
variant. Similarly, tet-repression of wildtype RL13 and UL128L ORFs permitted the 
propagation of viruses from the Merlin-BAC without selection of any de novo mutations. 
Growth phenotype analysis of progeny from viruses produced in this repression culture system 
indicated that RL13 and UL128L were unchanged and again expressed in normal fibroblasts.  
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 Conditional repression of wildtype RL13 and UL128L ORFs allowed the growth of 
genetically intact virus from the Merlin-BAC- to high titres. The growth phenotype of viruses 
following subsequent infection of fibroblasts where RL13 and UL128L are not repressed 
suggested that progeny virions that were produced contained gpRL13 and the pentameric 
complex. Importantly, the limited number of lytic replication cycles virus was subjected to 
following high MOI infection in ‘regular’ fibroblasts reduced the likelihood of the selection of 
de novo mutations. Ultimately, virions containing the full array of viral proteins encoded by the 
wildtype Merlin-BAC could be produced, and this provided an opportunity to gain valuable 
insights into the composition of wildtype HCMV virions. To investigate the full range of virus-
derived proteins that are incorporated into virions, virions derived from Merlin viruses produced 
by this two-step propagation method were analysed by mass spectrometry. 
 
 The reduced pentameric complex content in the novel Merlin viruses containing 
UL128L sequences from TB40-BAC4 and FIX potentially impacted the composition of virions. 
Based on previous demonstration that a gO-null mutant that does not assemble the trimeric 
gH/gL complex (gH/gL/gO) produces virions with increased pentameric complex content 
(Wille, Knoche et al. 2010), I hypothesised that reduced pentameric complex content may occur 
with concomitant increase in trimeric complex (gH/gL/gO). Similarly, the presence or absence 
of gpRL13 in virions potentially affected the incorporation of other components, and it was also 
important to determine how our most commonly used variants (RL13mut) differ from fully 
wildtype virus. Thus, as well as determining the absolute composition of virions, the relative 
abundances of viral proteins incorporated into virions different Merlin viruses. To this end, 
quantitative stable isotope labelling by amino acid mass spectrometry (SILAC-MS) was 
employed (Ong, Blagoev et al. 2002).  
6.1 Optimising recovery of virions purified over gradients 
 Mass spectrometry analysis required a suitable abundance of purified virions. However, 
previous investigations demonstrated that gradient purification of concentrated virus stocks 
prepared by high-speed ultra-centrifugation resulted in limited recovery of purified virions 
(Section 4.5). This was at least partially due to virions localising with cellular debris at the 
sample: gradient interface, and also in lower bands predicted to contain DBs. The detection of 
cellular contaminants in the ‘DB’ gradient bands suggested that viral particles and 
contaminating cellular proteins were incorporated into aggregates that may have segregated 
virions from the ‘purified virion’ band, to lower regions of the gradient. One potential reason 
for this was the method of virus concentration; the compaction of cellular contaminants along 
with virus particles into a pellet during high-speed ultra-centrifugation of supernatants may have 
promoted aggregate formation. Therefore, alternative methods for the preparation of 
concentrated virus stocks were explored. 
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 Concentration of virus by high-speed centrifugation (HSC) or Ultrafiltration (UF) 6.1.1
 Ultra-filtration of infected cell-culture supernatants has been described as a suitable 
method for the preparation of concentrated herpesvirus stocks (Smith and De Harven 1973) In 
this approach, excess media is removed from infectious supernatants via membranes with pores 
that allow the passage of water and other small molecules (<1 MDa), but not macromolecular 
structures (e.g. HCMV particles). The elimination of small molecules via membranes can be 
driven by negative pressure dialysis (for larger volumes), or low-speed centrifugation (for 
smaller volumes). Initially, the recovery of infectivity in virus stocks concentrated by virus 
stocks prepared by high-speed centrifugation (as performed previously; HSC) or by dialysis 
ultra-filtration (dUF) was compared. Neither method resulted in any significant loss in 
infectivity (Figure 6.1.A). 
 Recovery and purification of virions following ultra-centrifugation of HSC and 6.1.2
dUF concentrated viruses over gradients 
 HSC and dUF concentrated viruses were then purified over gradients, and the 
infectivity that localised to the ‘purified virion’ band and the lower ‘DB’ band of the different 
gradients compared (Figure 6.1.B). The ‘purified virion’ band from the HSC virus gradient 
contained as little as 3.5% of the total infectivity loaded, with ~1.75% localised to the ‘DB’ 
band. In contrast, the ‘purified virion’ band from the dUF virus gradient contained ~20% of the 
total infectivity loaded, whilst the ‘DB’ band contained <1% of the infectivity.  
 The purity of virions recovered following ultra-centrifugation of HSC and dUF 
concentrated viruses over gradients was also assessed (Figure 6.2.B). As a marker of virions and 
contaminating proteins, ‘purified virion’ and ‘DB’ band samples were analysed for the virion 
tegument protein pp28 and calnexin, respectively. Interestingly, whilst concentrated virus stocks 
prepared by either method each contained calnexin (Figure 6.2.C lanes 1 & 6), the levels were 
markedly reduced in the dUF concentrated virus. Thus, ultra-filtration of supernatants resulted 
in elimination of some contaminating proteins. The ‘purified virion’ band from both HSC and 
dUF concentrated virus gradients contained pp28, but not calnexin (Figure 6.2.C lanes 2 & 7), 
indicating that virions had been successfully purified from both concentrated stocks. 
Significantly, whilst the ‘DB’ band from the HSC virus contained readily detectable levels of 
pp28, the ‘DB’ band from dUF virus was completely devoid of pp28 (Figure 6.2.C lanes 3 & 8). 
 HSC and dUF viruses were also purified over sorbitol cushions (Figure 6.2.C lanes 4 & 
9), or the ‘light solution’ used to form the uppermost region of gradients (Figure 6.2.C lanes 5  
& 10); it was unclear whether the previously observed impurity of virus particles ultra-
centrifuged over sorbitol was due to aggregate formation that occurred during concentration by 
high-speed centrifugation. However, calnexin co-purified with viral particles following ultra-
centrifugation of both concentrated virus stocks over these solutions.  
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Figure 6.1. Recovery of infectivity following concentration of virus by high-speed centrifugation 
(HSC) or dialysis ultra-filtration (dUF), and subsequent purification over glycerol-tartrate 
gradients. RV-Me-UL128Lmut was grown in HFFFs according to standard virus propagation procedures. 
Supernatants collected over the time-course of infection were initially cleared of large cellular debris by 
low-speed centrifugation. Aliquots were then concentrated ~40-fold by high-speed centrifugation (HSC), 
or ~20-fold by dialysis ultra-filtration (dUF), before being ultra-centrifuged over glycerol tartrate 
gradients. (A) The original (un-concentrated) supernatant, as well as HSC and dUF concentrated viruses 
were titrated onto HFFFs in singlicate. To reflect differences in the volume of infectious supernatants 
concentrated by either method, and also the reduced volume of the concentrated virus stocks that were 
prepared, the total infectivity was estimated from the titres of each sample as reported on HFFFs. (B) 
Following recovery from gradients, infectivity in ‘purified virion’ and ‘DB’ bands was enumerated by 
plaque titration onto HFFFs. Total infectivity loaded to gradients and recovered from each band are 
reported. (C) Immunoblot analysis of gradient purified HSC or dUF concentrated viruses: 1 – HSC virus 
stock; 2 – HSC virus ‘purified virion’ band; 3 – HSC virus ‘DB’ band; 4 – HSC virus over gradient light 
solution; 5 – HSC virus over sorbitol cushion; 6 – dUF virus stock; 7 – dUF virus ‘purified virion’ band; 
8 – dUF virus ‘DB’ band; 9 – dUF virus over gradient light solution; 10 – dUF virus over sorbitol 
cushion. 
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 Conclusion 6.1.3
 Whilst neither method of virus concentration resulted in significant loss of infectivity, 
5-6-fold greater infectious-virion recovery was achieved following gradient purification of virus 
stocks concentrated by dialysis ultra-filtration compared to high-speed centrifugation. Taken 
together with the banding patterns of virions and contaminants from HSC and dUF concentrated 
viruses over gradients, the improved recovery of virions from gradient purified dUF virus was 
likely due to reduced aggregate formation during concentration by ultra-filtration. 
6.2 Production and preparation of virions for mass spectrometry analysis 
 The panel of Merlin viruses analysed included 2 variants that contained ablating 
mutations in both RL13 and UL128L: RV-Me-UL128Lmut, and a derived virus that was also 
deleted for the ORF UL141 (RV-Me-UL128Lmut/ΔUL141). Stocks of each of these viruses were 
produced in ‘regular’ HFFFs. The remaining 4 viruses each contained intact, but tet-regulated 
UL128L genome regions, whilst one also contained wildtype tet-regulated RL13 (RV-Me-tet-
RL13wt/UL128Lwt). Stocks of these viruses were produced in the tetracycline repression culture 
system (HFFF-tet). All virus stocks used to initiate productive infections were assessed by 
whole genome sequencing and shown to be equivalent to the parental BACs. Quantitative 
SILAC-MS is performed by the simultaneous analysis of proteins labelled with different 
isotopes. Virions containing differently labelled proteins were produced following infection of 
HFFFs at high MOI (2-4), with each virus grown in SILAC media supplemented with ‘light’, 
‘medium’ or ‘heavy’ amino acids (See Table 6.1.).  
  
 
Table 6.1. Merlin virions analysed by mass spectrometry. 
 
a – Δ denotes deleted gene 
  
  
BAC Origin Reconstituted Virus SILAC label 
Merlin-UL128Lmut RV-Me-UL128Lmut Medium 
Merlin-tet-UL128Lwt RV-Me-tet-UL128Lwt Light 
Merlin-tet-RL13wt/tet-UL128Lwt RV-Me-tet-RL13wt/-tet-UL128Lwt Heavy 
Merlin-tet-UL128G>T RV-Me-tet-UL128G>T Heavy 
Merlin-tet-UL130A>G RV-Me-tet-UL130A>G Heavy 
Merlin-UL128Lmut/Δ UL141a RV-Me-UL128Lmut/Δ UL141 Light 
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 Supernatants collected over the time-course of each productive infection were first 
cleared of large cellular debris by low-speed centrifugation, then concentrated by ultra-
filtration: firstly by dialysis ultra-filtration (dUF), and subsequently by low-speed centrifugal 
ultra-filtration (cUF). Preliminary experiments demonstrated that viruses in SILAC media 
concentrated >15-fold were too dense to be layered onto glycerol: tartrate gradients, therefore 
all samples were concentrated 10-fold. Virions were purified over gradients and re-suspended in 
lysis buffer lacking DTT, and the total protein concentrations of samples determined by Micro 
BCA assay. 
 Two mixed virion preparations (MVP) containing equal protein loads from 3 different 
purified virion samples were analysed. To assess the impact of gpRL13 and pentameric 
complex incorporation on the composition of virions, the mixed virion preparation MVP-1 
contained ‘light’ virions from RV-Me-tet-UL128Lwt, ‘medium’ virions from RV-Me-
UL128Lmut, and ‘heavy’ virions from RV-Me-tet-RL13wt/-tet-UL128Lwt; to assess the specific 
impact of variations in pentameric complex content, the mixed virion preparation MVP-2 
contained the same ‘light’ and ‘medium’ virions, but with ‘heavy’ virions from RV-Me-tet-
UL128G>T. Virions purified from each virus were also analysed separately. Samples were 
prepared as in Methods and Materials, then analysed by mass spectrometry analysis at the 
laboratory of Professor Paul Lehner (Cambridge institute for Medical research, University of 
Cambridge) under procedures as previously reported (Weekes et al, 2014), according to the 
protocol described in Appendix VI.  
6.3 Merlin virion proteome  
 Mass spectrometry analysis is limited in its ability to identify all proteins in complex 
mixtures on each independent run. Whilst the Merlin viruses analysed differed in coding 
potential, they did so only in a small sub-set of ORFs (i.e. RL13, UL128, UL130, UL131A, 
UL141). Analysis of each virus individually, along with the two mixed samples, provided a 
total of 8 independent analyses of near identical Merlin virions. The absolute Merlin virion 
proteome was determined as the consensus of proteins identified across all virion preparations. 
Proteins were designated as being identified with ‘high confidence’ according to the following 
criteria: when a minimum of 2 peptides unique to that protein were detected, and when the 
peptides were present in at least half of all virus preparations analysed. An exception was made 
for gpRL13, gpUL128, gpUL130, gpUL131A and gpUL141, where ‘high confidence’ 
identification was based on identification of these proteins in at least half of the preparations 
containing virions from viruses in which the relevant ORFs were intact. 
 Virion proteins identified with high-confidence 6.3.1
  70 HCMV proteins were identified with high confidence (Table 6.2.A). Of these, 51 
were previously identified by mass spectrometry analysis of AD169 virions, including all 5 
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recognised capsid components, as well as the capsid maturational protease and capsid assembly 
protein pre-cursor (pUL80/PR-AP) fusion protein; 25 known tegument proteins; 8 proteins yet 
to be assigned to any virion compartment; and 12 proteins either known, or predicted to be 
incorporated into the envelope due to the presence of membrane anchors. A further 6 proteins 
not identified by mass spectrometry analysis of AD169 virions, but recognised as HCVM virion 
components following assessment of virions from other strains by alternative approaches, were 
also detected with high confidence (UL36x1, gpRL13, gpUL128, gpUL130, gpUL131A and 
gpUS28).  
 A further 13 proteins identified with high confidence have not been previously 
described as virion components. Of these, 5 are implicated in viral genome 
transcription/replication and virion assembly (pUL52, pUL34, pUL70, pUL98, and ppUL114). 
The viral CXC chemokine homologue encoded by UL146/vCXC-1 was also identified with 
high confidence. 7 integral membrane bound proteins (gpRL12, gpUL116, gpUL141, gpUL148, 
pUS12, pUS14 and pUS20), likely incorporated into the virion envelope were also identified. In 
support of these novel proteins being virion components, homologous proteins to pUL52 
(Rh83), gpUL116 (Rh148), gpUL141 (Rh164), pUS12 (Rh190) have been identified in RhCMV 
virions, whilst homologous proteins of pUL70 (M70) and pUL116 (M116) have also been 
identified in MCMV virions.  
 Proteins identified with low confidence  6.3.2
 Criteria applied for the identification of proteins with low confidence included the 
detection of a minimum of 2 peptides unique to that protein in at least one virion preparation. A 
further 22 proteins were identified across the virion preparations analysed that met this criteria 
(Table 6.2.B). Of these, two were previously identified during mass spectrometry analysis of 
AD169 virions (pUL54, and pUL56). Homologues for each of these proteins were identified in 
MCMV virions (M54 and M56, respectively), suggesting that they may represent bona fide 
virion components. Two further proteins identified with low confidence have previously been 
described as virion components, though were not detected in AD169 virions (pUL28/UL29, and 
gpUL78). Homologous proteins to pUL28/pUL29 were also previously identified in MCMV 
virions (M28). 
 No reports exist of the remaining 17 proteins as being HCMV virion components. 
Proteins homologous to pUL102 and pUL105 were identified in RhCMV virions (Rh138), and 
also in MCMV virions (M102 and M105). The major immediate early protein pUL123 and the 
viral chemokine homologue pUL147/vCXC-2 were both also detected. Novel integral 
membrane proteins identified include gpUL16, gpUL74A, gpUL139 and pUL140, gpUS9 (US6 
family members), and pUS13 and pUS18 (US12 family members). A further 6 proteins were 
detected with low confidence, none of which are characterised biochemically or functionally: 
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pRL1, pUL31 (a DURP family member), pUL145, pUL150A, pUS1 (US1 family member) and 
pUS26 (US22 family member). Homologues of pUL31 (M31) have been identified in MCMV, 
whilst homologues of pUS1 (Rh181) and pUS26 (Rh211) have been identified in RhCMV.   
 Proteins previously identified in HCMV virions, or homologous proteins identified 6.3.3
virions of other CMVs, but not on MS analysis of Merlin virions 
 Several proteins that have previously been described as HCMV virion components were 
not detected by MS analysis of Merlin virions. This includes 6 proteins previously identified by 
MS analysis of AD169 virions (although these were only identified by a second, more sensitive 
methodology in this previous study), including the tegument proteins pUL38, pUL72; the 
envelope proteins gpRL14 and gpUL5; the late gene transactivator protein pUL79; and also the 
virion associated glycoprotein gpUL22A (Varnum, Streblow et al. 2004). Of these proteins, 
only homologues of pUL72 have also been identified in other CMV virions (Kattenhorn, Mills 
et al. 2004). Unidentified proteins previously detected in HCMV virions, though by alternative 
approaches to mass spectrometry analysis include the tegument protein pUL23 (Dunn, 
Chalupny et al. 2003), virion envelope components gpUL1 (Shikhagaie, Mercé-Maldonado et 
al. 2012) and gpUL4 (Bhushan, Meyer et al. 2010), as well as the virion associated protein 
gpUL76 (Wang, Duh et al. 2004). Further HCMV protein homologues were also identified in 
virions other CMVs, though have yet to be identified in HCMV by any analytical approach: in 
RhCMV, homologues of UL13 (Rh31), UL111a (Rh143) and US30 (Rh223) have been 
identified (Malouli, Nakayasu et al. 2012), whilst in MCMV, homologies of proteins UL51 
(M51), UL87 (M87), UL95 (M95), UL121 and (M121) have been identified (Kattenhorn, Mills 
et al. 2004). In consideration of theses undetected components, single peptides corresponding to 
pUL13 (1/8 preparations), gpUL22A (3/8 preparations), pUL23 (4/8 preparations) and gpUL76 
(2/8 preparations), and pUL95 (3/8 preparations) were detected across the Merlin virion 
preparations. 
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Table 6.2. Virus encoded proteins identified by MS-analysis of Merlin virions. 
ORFa IDb Protein/Functionc AD169d RhCMVe MCVMf 
A- Proteins identified with high confidence  
Capsid: 
UL46 8/8 pUL46/mCBP (minor capsid protein binding protein); interacts with mCP to form capsid triplex    
UL48A 8/8 pUL48A/SCP (smallest capsid protein); decorates capsid hexons    
UL80 7/8 pUL80/PR-AP (assembly protein) precursor; scaffold for capsid assembly    
UL85 8/8 pUL85/mCP (minor capsid protein); interacts with mCBP to form capsid triplex    
UL86 8/8 pUL86/MCP (major capsid protein); forms capsid walls and faces    
UL104 8/8 pUL104/PORT; forms specialized portal capsomere for genome insertion/release    
Known Tegument: 
UL24 8/8 pUL24; US22 family member; enhances replication in endothelial cells    
UL25 8/8 pUL25; UL25 family member    
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UL26 7/8 pUL26; US22 family member, MIEP transcription transactivator, tegument material phosphorylation, stabilises virion    
UL32 8/8 pp150 / NSP (nucleocapsid-proximal stabilization protein); virion maturation    
UL35 8/8 pUL35; UL25 family member, virion morphogenesis    
UL36x1 6/8 pUL36x1; US22 family member, vICA (viral inhibitor of caspase-8-induced apoptosis)    
UL43 8/8 pUL43; US22 family member    
UL45 8/8 pUL45/RR1 (Ribonucleotide reductase homologue sub-unit)    
UL47 8/8 pUL47/LTPbp (Largest tegument protein binding protein); interacts with ppUL48 intra-cellular transport of nucleocapsid    
UL48 8/8 pUL48/LTP (Largest tegument protein); interacts with ppUL47 intra-cellular transport of nucleocapsid    
UL50 8/8 pUL50/NEC1 (nuclear egress complex membrane anchoring component 1); interacts with pUL53 (NEC2) to orchestrate nuclear egress of nucleocapsids    
UL52 8/8 pUL52; DNA encapsidation, nucleocapsid formation    
UL69 8/8 ppUL69; MRP (multiple regulatory protein)    
UL71 8/8 pUL71; Secondary envelopment, virion egress    
 
  ORFa              IDb                                                                     Protein/Functionc                                                                    AD169d      RhCMVe      MCMVf 
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UL82 7/8 ppUL82/pp71/UMP (upper matrix protein); secondary envelopment, relieves DAXX-mediated repression    
UL83 8/8 ppUL83/pp65/LMP (lower matrix protein); phosphorylase, innate and adaptive immune response evasion    
UL88 8/8 pUL88; Putative cytoplasmic egress function    
UL94 8/8 pUL94; interacts with pp28 to facilitate secondary envelopment    
UL96 6/8 pUL96; interacts with pp150 to stabilise nucleocapsid during cytoplasmic egress    
UL97 8/8 ppUL97/VPK (viral protein kinase); phosphorylates viral and cellular proteins    
UL99 7/8 ppUL99/pp28; myristylated protein, secondary envelopment    
UL103 7/8 pUL103; VEP (Virion and DB egress protein); orchestrates release from producer cells    
IRS1 8/8 pIRS1; US22 family member, PKR (Protein kinase R) inhibitor, Transcriptional activator    
US22 8/8 pUS22; US22 family member    
US23 6/8 pUS23; US22 family member    
US24 5/8 pUS24; US22 family member; enhances early infection    
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TRS1 8/8 pTRS1; US22 family member, PKR (Protein kinase R) inhibitor, Transcriptional activator, capsid assembly    
Transcription/replication machinery, yet to be assigned to virion compartment: 
UL34 7/8 pUL34; Represses US3 transcription    
UL44 8/8 ppUL44/PPS (Viral DNA polymerase processivity sub-unit); DNA synthesis    
UL57 8/8 ppUL57/SSB (single-stranded DNA binding protein); DNA synthesis    
UL70 5/8 pUL70/HP2 (DNA helicase-primase sub-unit 2); DNA synthesis    
UL77 8/8 pUL77/CVC1 (putative capsid vertex-specific component 1); DNA encapsidation    
UL84 8/8 ppUL84/Viral DNA replication accessory; DURP family member, DNA synthesis    
UL89 6/8 pUL89/TER1 (terminase sub-unit 1); DNA encapsidation    
UL93 7//8 pUL93/CVC2 (putative capsid vertex-specific component 2); DNA encapsidation    
UL98 7/8 pUL98/NUC (deoxyribonuclease)    
UL112-UL113 8/8 pUL112/UL113; Orchestrates DNA synthesis, transcriptional activator    
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UL114 4/8 ppUL114; DNA synthesis UNG (Uracil-DNA glycosylase), control DNA synthesis    
UL122 8/8 pUL122; IE2; transactivator or host-cell transcription machinery    
UL146 7/8 gpUL146; vCXC chemokine homologue family, putative chemokine    
Envelope: 
RL10 7/8 gpRL10    
RL12 7/8 gpRL12/gp95;  RL11 family member, IgG Fc binding    
RL13 ½ gpRL13;  RL11 family member, putative IgG Fc binding, impedes replication in fibroblasts and epithelial cells    
UL33x1 8/8 pUL33x1; GPCR homologue family member, constitutive signalling GPCR   
 
UL41A 6/8     
UL55 8/8 gB; gCI subunit, virion binding and entry    
UL73 8/8 gN; gCII sub-unit, virion binding, progeny virion secondary envelopment    
UL74 8/8 gO; gCIII sub-unit, fibroblast cell entry, release of progeny virions from producer cells    
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UL75 8/8 gH; gCIII/pentameric complex sub-unit, entry into cells    
UL100 8/8 gM; gCII sub-unit, virion binding, progeny virion secondary envelopment    
UL115 7/8 gL; gCIII/pentameric complex sub-unit, entry into cells    
UL116 7/8 gpUL116; putative membrane glycoprotein    
UL118-UL119 8/8 gpUL118-UL119/gp68; IgG Fc binding    
UL128 4/6 gpUL128,; pentameric complex, entry into non-fibroblasts    
UL130 4/6 gpUL130; pentameric complex, entry into non-fibroblasts    
UL131A 4/6 gpUL131A; pentameric complex, entry into non-fibroblasts    
UL132 8/8 gpUL132; enhances replication in fibroblasts    
UL141 7/7 gpUL141; UL14 family member, NK evasion, down regulates CD155 and CD112    
UL148 8/8 gpUL148, putative membrane glycoprotein    
US12 7/8 pUS12; US12 family member, 7TM protein    
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US14 8/8 pUS14;  US12 family member, 7TM protein    
US20 6/8 pUS20;  US12 family member, 7TM protein    
US27 8/8 gpUS27;  GPCR homologue family member, 7TM protein, enhances virion release    
US28 8/8 gpUS28;  GPCR homologue family member, 7TM protein, CC and CXC3 chemokine receptor    
B- Proteins identified with low confidence 
Tegument 
UL28/UL29 1/8 pUL28/UL29; US22 family member, Stimulates IE gene expression    
Transcription/replication machinery, immune evasions, yet assigned to virion compartment: 
UL54 1/8 pUL54; POL; catalytic DNA polymerase sub-unit    
UL56 3/8 pUL56; TER2 (terminase sub-unit 2); DNA encapsidation    
UL102 1/8 pUL102/HP3 (helicase primase sub-unit 3); DNA synthesis    
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UL105 2/8 pUL105; HP1 (helicase-primase sub-unit 1), DNA synthesis    
UL123 2/8 ppUL123/IE1 (major IE protein); promotes transcription cascade, enhances IE2 activation    
UL147 3/8 pUL147; vCXC-2 chemokine homologue family, putative chemokine    
Envelope: 
RL11 3/8 gpRL11/gp34; RL11 family member, IgG Fc binding    
UL16 3/8 gpUL16; membrane glycoprotein, NK cell evasion, blocks NKG2D ligands MICB, ULBP1 and ULBP2    
UL74A 1/8 gpUL74A; putative membrane glycoprotein    
UL78 2/8 gpUL78; GPCR homologue family member; putative chemokine receptor    
UL139 1/8 gpUL139; putative membrane glycoprotein    
UL140 3/8 pUL140; putative membrane protein    
US9 2/8 gpUS9; US6 family member, membrane glycoprotein    
US13 3/8 pUS13; US12 family member, 7TM protein    
 
    ORFa              IDb                                                                     Protein/Functionc                                                                   AD169d      RhCMVe      MCMVf 
 
188 
 
 
 
a ORFs encoding proteins identified in Merlin virions. Highlighted in purple are proteins identified in HCMV virions by approaches other than mass spectrometry, in yellow are 
novel HCMV virions components; 
b identities depict the number of virion preparations in which proteins were detected; 
c - comments as to the biochemistry and function of proteins identified, as described in Field’s Virology {Mocarski, 2007 #511} 
d - proteins previously identified during mass spectrometry analysis of AD169 virions (pink) {Varnum, 2004 #65};  
e - homologous proteins identified during mass spectrometry analysis of RhCMV virions {Malouli, 2012 #991};  
f - homologous proteins identified during mass spectrometry analysis of MCMV virions {Kattenhorn, 2004 #992}.  
(A) Proteins identified with high confidence.  
(B) Proteins identified with low confidence.  
US18 1/8 pUS18; US12 family member, 7TM protein    
Uncharacterised: 
RL1 1/8 pRL1; RL1 family member    
UL31 1/8 pUL31; DURP family member    
UL145 3/8     
UL150A 3/8 Putative secreted protein    
US1 3/8 US1 family member    
US26 3/8 pUS26; US22 family member    
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6.4 Relative abundance of proteins in virions from Merlin variants 
In the quantitative SILAC-MS analysis approach, the relative abundance of a given 
protein incorporated into the different virions is inferred from the ratio of differently labelled 
versions of that protein identified in the mixed virion preparation. Since the capsid is 
structurally constrained and the virion compartment with greatest homogeneity between strains, 
accurate comparison of protein levels in an equal number of different virions will include capsid 
protein rations approximating the value 1. Based on this, SILAC-MS raw data were corrected 
by normalising the ratios of all identified proteins within a sample to the ratios of the major 
capsid protein (pUL86/MCP) in that same sample.  
 Inter-assay variation 6.4.1
 To compare the relative abundance of components incorporated into the different 
virions in each mixed virion preparation, it was important to assess the precision of the MS 
analysis. The composition of RV-Me-tet-UL128Lwt and RV-Me-UL128Lmut virions were 
compared during analysis of both the MVP-1 and MVP-2 preparations, and the reproducibility 
of the SILAC-MS data was assessed by comparing the relative abundances of proteins as 
reported in these duplicate analyses (See figure 6.3.A). 68 HCMV virion components were 
identified in both MVP-1 and MVP-2, and the ratios of 61 of these proteins were reported with 
<1.3-fold variation in the duplicate analyses to demonstrate the high precision of the SILAC-
MS technique. The reported ratios of 7 proteins were more variable (See Figure 6.3.B). The 
ratios of pUL34, pUL50 and pUL89 showed 1.5-2.2-fold variation on repeat analyses. The 
reported ratios of pUS24 were widely contrasting in the two assays: on analysis of the MVP-1 
preparation, RV-Me-tet-UL128Lwt virions contained ~8.4-fold more pUS24 than RV-Me-
UL128Lmut virions, whilst on analysis of the MVP-2 preparation, RV-Me-tet-UL128Lwt virions 
contained ~2.5-fold less pUS24 than RV-Me-UL128Lmut virions. The remaining virion proteins 
reported with great variation were the UL128L encoded glycoproteins (see section .6.4.3.2)  
 Impact of variations in gpRL13 content  6.4.2
 In the MVP-1 preparation, RV-Me-tet-RL13wt/-tet-UL128Lwt virions contained 
significantly greater levels of the vast majority of proteins compared to virions from both RV-
Me-tet-UL128Lwt (68/73 proteins) and RV-Me-UL128Lmut (56/73 proteins), suggesting a major 
impact of gpRL13 on virion composition. However, pUL86/MCP ratios in the raw data 
indicated that approximately ~10-fold fewer RV-Me-tet-RL13wt/UL128Lwt virions were loaded 
compared to those of the other viruses, potentially affecting the accuracy of quantitation. Thus, 
a repeat of this experiment will be required before firm conclusions can be drawn. 
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Figure 6.3. SILAC-MS inter-assay variation and outlier proteins. (A) Tukey Box-plot displaying variation in ‘light’/‘medium’ ratios of all 68 proteins identified during analysis 
of MVP-1 and MVP-2 preparations. pUL34, pUL50, pUL89, gpUL128, gpUL130, gpUL131A and pUS24 showed the greatest variation between runs. Of the remaining 61 proteins, 
median variance = 1.013. (B) ‘Light’ / ‘Medium’ ratios of pUL34, pUL50, pUL89, and pUS24 as detected in the MVP-1 and MVP-2 duplicate analyses. 
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 Impact of variations in pentameric complex content   6.4.3
 Heterogeneity amongst capsid proteins as a measure of the accuracy of the assay 6.4.3.1
 Following normalisation to pUL86/MCP ratios, the ratios of all other known capsid 
proteins closely approximated the value 1 (Figure 6.4.) to indicate a high level of accuracy in 
the SILAC-MS assay. One protein (pUL80/PR-AP) tentatively assigned to the capsid 
compartment was identified with greater abundance in RV-Me-tet-UL128Lwt and RV-Me-tet-
UL128LG>T virions compared to those of RV-Me-UL128Lmut. However the current model of 
herpesvirion assembly includes homologues of this protein being eliminated from nascent 
nucleocapsids during maturation (Yu, Trang et al. 2005). It is therefore possible that residual 
pUL86 was detected at differing levels that did not reflect the heterogeneity of the virion capsid 
compartment. The most variable bona fide capsid protein between the different virions was 
pUL48A/SCP, varying at most by 1.1665-fold; given that the capsid proteins should be present 
in different virions at equimolar amounts, ±1.1665-fold variation was assumed to represent the 
accuracy range of the SILAC-MS technique. A threshold of ±1.5-fold variation was applied to 
distinguish proteins that varied between virions with confidence; this figure was calculated as 2 
standard deviations (2 S.D.) from the ‘accuracy range’ of the assay [accuracy range (±1.1665-
fold) + 2 S.D. (0.122) = confidence threshold (± 1.4108-fold; rounded to 1.5-fold)].  
  
 
 
Figure 6.4. Relative abundance of capsid proteins in RV-Me-tet-UL128Lwt (L) RV-Me-UL128Lmut 
(M), RV-Me-tet-UL128G>T (H) virions. Highlighted (grey) is the degree of acceptable variation within 
the accuracy range of the SILAC-MS technique. Broken lines (dark grey) shows the variance threshold 
applied (± 1.5-fold) to highlight proteins that differed between virions with confidence. 
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 Relative abundance of gH/L complexes (pentameric complex and (gH/gL/gO) 6.4.3.2
 SILAC-MS analysis of both MVP-1 and MVP-2 preparations detected the UL128L-
encoded glycoproteins with greater abundance in virions from RV-Me-tet-UL128Lwt compared 
to RV-Me-UL128Lmut (Figure 6.5.A). As previously mentioned, the relative abundance of these 
glycoproteins in RV-Me-tet-UL128Lwt and RV-Me-UL128Lmut virions was reported with 
different magnitudes between each independent analysis. Furthermore, relative abundances of 
each of gpUL128, gpUL130, and gpUL131A also differed within each independent analysis; 
this was surprising given that the UL128L-encoded glycoproteins are believed to be 
incorporated into the pentameric complex (and therefore virions) at equimolar quantities. These 
discrepancies were likely due to the complete absence of these components in RV-Me-
UL128Lmut virions, with the relative abundance compared to RV-Me-tet-UL128Lwt virions 
reported against background noise of the SILAC-MS analysis. Conversely, glycoprotein gO was 
detected with reduced abundance in virions from RV-Me-tet-UL128Lwt compared to those from 
RV-Me-UL128Lmut, yet this variation was reported with similar magnitude on duplicate 
analyses. Importantly, glycoproteins gH and gL (that are common to the pentameric complex 
and gH/gL/gO) were detected with comparable abundance in virions from RV-Me-tet-
UL128Lwt and RV-Me-UL128Lmut. Thus, the inverse relative abundances of the UL128L-
encoded glycoproteins and glycoprotein gO likely reflect the contrasting pentameric and 
trimeric complex content of RV-Me-tet-UL128Lwt and RV-Me-UL128Lmut virions.  
 Virions from the Merlin virus engineered to express the UL128 intron 1 G>T variation 
(RV-Me-tet-UL128G>T) contained intermediate quantities of the UL128L-encoded glycoprotein 
compared to virions from RV-Me-tet-UL128Lwt and RV-Me-UL128Lmut (Figure 6.5.B). The 
greater abundance of these glycoproteins in virions from RV-Me-tet-UL128G>T compared to 
those from RV-Me-UL128Lmut was clear, although the reduced abundance of gpUL128 and 
gpUL131A in comparison to RV-Me-tet-UL128Lwt virions did not exceed the confidence 
threshold. Each of gpUL128, gpUL130, and gpUL131A were however detected with similar 
relative abundance between RV-Me-tet-UL128Lwt and RV-Me-tet-UL128G>T virions, consistent 
with being incorporated into pentameric complexes at equimolar quantities. Glycoprotein gO 
was also detected in RV-Me-tet-UL128G>T virions with intermediate abundance compared to 
virions from RV-Me-tet-UL128Lwt and RV-Me-tet-UL128Lmut, and these variations did exceed 
the threshold for confidence. Furthermore, glycoproteins gH and gL were detected in RV-Me-
tet-UL128G>T virions at similar abundance as in virions from both RV-Me-tet-UL128Lwt and 
RV-Me-tet-UL128Lmut. These latter results provide further evidence for an inverse linear 
correlation between pentameric and trimeric complex content in virions, and support the 
hypothesis that reduce pentameric complex content occurs with a concomitant increase trimer 
complex content.  
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Figure 6.5. Pentameric complex and gCIII (gH/gL/gO) content in virions from Merlin viruses 
differing in UL128L coding potential. Highlighted (grey) is the acceptable degree of intra-assay 
variation (±1.1.665-fold). Broken lines (dark grey) show the threshold (± 1.5-fold) to highlight proteins 
that differed between virions with confidence. (A) Relative abundance of proteins in RV-Me-tet-
UL128Lwt (L) compared to RV-Me-UL128Lmut (M) virions. (B) Relative abundance of proteins in RV-
Me-tet-UL128G>T (H) compared to RV-Me-tet-UL128Lwt (L) and RV-Me-UL128Lmut (M).  
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 Variations in tegument compartment materials 6.4.3.3
 All tegument proteins with variance exceeding the threshold for confidence were 
detected at greater abundance in RV-Me-tet-UL128Lwt virions compared to those from RV-Me-
UL128Lmut (Figure 6.6.A). One protein (pUL36) was dramatically more abundant in RV-Me-
tet-UL128Lwt virions, identified at ~3.7-fold greater levels than in RV-Me-UL128Lmut virions. A 
further 9 tegument proteins (pUL52, ppUL69, ppUL82, pUL96, ppUL97, pIRS1, pUS22, pUS2, 
pTRS1) were moderately more abundant. Only 6 tegument proteins (ppUL32, pUL45, pUL47, 
pUL83, ppUL99, pUL103) were detected with comparable abundance in RV-Me-tet-UL128Lwt 
and RV-Me-UL128Lmut virions, whilst 9 proteins (pUL24, pUL25, pUL26, pUL35, pUL43, 
pUL48, pUL71, pUL88, pUL94) were slightly more abundant in RV-Me-tet-UL128Lwt virions, 
but did not exceed the threshold of variance applied for confidence.  
 Virions from RV-Me-tet-UL128G>T that contained intermediate pentamer/trimer ratios 
displayed a tegument protein profile with similarities to virions from both RV-Me-tet-UL128Lwt 
and RV-Me-UL128Lmut (Figure 6.6.B). The most variable tegument protein, pUL36x1, was 
dramatically more abundant (> 3-fold) in RV-Me-tet-UL128G>T virions compared to those from 
RV-Me-UL128Lmut, but also slightly more abundant than in RV-Me-tet-UL128Lwt virions. 
Hence, the incorporation of this virion component did not correlate with increasing pentameric 
complex content, but rather the presence of the pentamer at any level. 10 tegument proteins 
varied moderately (< 3-fold) between RV-Me-tet-UL128LG>T virions and those of the 
comparison viruses. Three tegument proteins (pUL25, pUL26 and ppUL97) more closely 
matched that in RV-Me-UL128Lmut virions and were less abundant than in RV-Me-tet-
UL128Lwt virions, whilst 6 proteins (pUL52, ppUL69, ppUL82, pIRS1, pUS22 and pTRS1) 
closely matched RV-Me-tet-UL128Lwt virions with greater abundance than in RV-Me-
UL128Lmut virions. Incorporation of pUL96 into virions potentially correlated with increasing 
pentameric complex levels, with RV-Me-tet-UL128LG>T containing more than virions from RV-
Me-UL128Lmut, but less than in RV-Me-tet-UL128Lmut virions. However the ratios of this 
protein between RV-Me-tet-UL128LG>T and RV-Me-tet-UL128Lwt virions did not exceed the 
applied threshold for confidence.  
A further 9 tegument proteins varied between virions from RV-Me-tet-UL128LG>T and 
the comparison viruses, and whilst none exceeded the threshold for confidence, a trend 
suggestive of a correlation between their incorporation and the pentamer/trimer ratios of virions 
was apparent. These included 4 proteins (pUL24, pUL43, ppUL83, and pUL94) that closely 
matched RV-Me-UL128Lmut virions (low pentamer, high trimer), and 5 proteins (e.g. pUL47, 
pUL48, pUL71, pUL88 and pUS23) more closely matched those in RV-Me-tet-UL128Lwt 
virions (high pentamer, low trimer). Only 5 tegument proteins (ppUL32, pUL35, pUL45, 
ppUL99, pUL103) were detected in RV-Me-tet-UL128LG>T virions at comparable levels to those 
from both comparison viruses (RV-Me-UL128Lmut and RV-Me-tet-UL128Lwt).  
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Figure 6.6. Tegument protein content of virions with contrasting pentameric/trimeric complex 
ratios. Highlighted (grey) is the degree of acceptable intra-assay variation (±1.1.665-fold). Broken lines 
(dark grey) show the threshold (± 1.5-fold) to highlight proteins that differed between virions with 
confidence. (A) Relative abundance of proteins in RV-Me-tet-UL128Lwt (L) compared to RV-Me-
UL128Lmut (M) virions. (B) Relative abundance of proteins in RV-Me-tet-UL128G>T (H) compared to 
RV-Me-tet-UL128Lwt (L) and RV-Me-UL128Lmut (M).  
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 Variation in proteins yet to be assigned to any particular virion compartment  6.4.3.4
 Similarly to the tegument proteins, the majority of the variable viral proteins that are yet 
assigned to any virion compartment were more abundant in virions containing the pentameric 
complex (RV-Me-tet-UL128Lwt) than those lacking the pentameric complex (RV-Me-tet-
UL128Lmut) (Figure 6.7.A). Amongst the most variable proteins in this category were the novel 
virion components pUL70 and pUL147, detected in RV-Me-tet-UL128Lwt virions with 
dramatically greater abundance (~6.4-fold and ~6.7-fold greater, respectively) than in RV-Me-
UL128Lmut virions. A further 6 proteins (ppUL44, ppUL57, ppUL84, pUL98, pUL112-113, 
pUL122) were moderately more abundant in RV-Me-tet-UL128Lwt virions. In contrast, the 
novel virion component gpUL146 was identified with dramatically reduced abundance (~4.25-
fold) in virions from RV-Me-tet-UL128Lwt compared to those from RV-Me-tet-UL128Lwt. The 
remaining proteins in this category (pUL77 and pUL93) were detected with comparable 
abundance in RV-Me-tet-UL128Lwt and RV-Me-tet-UL128Lmut virions; each of these proteins 
are sub-units of a capsid vertex complex, and similar to the known capsid proteins, will likely 
be heterogeneous amongst different strains and strain variants. Proteins pUL102 and pUL114 
were not detected on SILAC-MS analysis of the MVP-2 preparation. However in the MVP-1 
preparation, pUL102 was present at greater levels in RV-Me-tet-UL128Lwt virions but not by a 
degree that exceeded the threshold of confidence, whereas pUL114 was confidently detected at 
greater abundance than in RV-Me-tet-UL128Lmut virions.  
 In RV-Me-tet-UL128LG>T virions, the abundance of these viral proteins (those yet 
assigned to any virion compartment) more closely resembled that in RV-Me-tet-UL128Lwt 
virions (Figure 6.7.B). This included the proteins that varied the most between virions 
containing or lacking the pentameric complex, with RV-Me-tet-UL128LG>T virions containing 
comparable levels of pUL70 and gpUL147 to virions from RV-Me-tet-UL128Lwt, and therefore 
dramatically more than in virions from RV-Me-UL128Lmut. Furthermore, RV-Me-tet-
UL128LG>T virions also contained comparable levels of gpUL146 as in those from RV-Me-tet-
UL128Lwt, and therefore dramatically less than in RV-Me-UL128Lmut. Interestingly, RV-Me-tet-
UL128G>T virions contained ppUL57 at greater levels than in RV-Me-UL128Lmut and RV-Me-
UL128Lwt virions. This was also apparent for proteins pUL98 and pUL122, but the variance in 
these components between RV-Me-tet-UL128LG>T and RV-Me-tet-UL128Lwt virions did not 
exceed the threshold for confidence. Thus, incorporation of ppUL57, pUL98, and pUL122 into 
virions did not correlate with increasing pentameric complex content, but simply the presence of 
the pentameric complex at any level. The 5 remaining variable proteins (pUL44, pUL84, 
pUL98, pUL112-113, pUL122) were present at similar levels to RV-Me-tet-UL128Lwt virions, 
yet were greater than in RV-Me-UL128Lmut virions. The capsid-vertex complex proteins pUL77 
and pUL93 were present at levels similar to that in both RV-Me-UL128Lmut and RV-Me-tet-
UL128Lmut virions.  
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Figure 6.7. Relative abundance of proteins ‘yet to be assigned’ to any compartment in virions with 
contrasting pentameric/trimeric complex ratios. Highlighted (grey) is the degree of acceptable intra-
assay variation (±1.1.665-fold). Broken lines (dark grey) show the threshold (± 1.5-fold) to highlight 
proteins that differed between virions with confidence. (A) Relative abundance of proteins in RV-Me-tet-
UL128Lwt (L) compared to RV-Me-UL128Lmut (M) virions. (B) Relative abundance of proteins in RV-
Me-tet-UL128G>T (H) compared to RV-Me-tet-UL128Lwt (L) and RV-Me-UL128Lmut (M). * denotes 
protein detected in MVP-1 preparation only. 
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 Variation in envelope incorporated glycoproteins/proteins 6.4.3.5
 Incorporation of several virion envelope components was apparently influenced by 
incorporation of the pentameric complex (Figure 6.8.A). The envelope proteins that varied in 
relative abundance most dramatically were the novel virion components gpUL16 and gpUL148, 
each identified with ~3.3-, and ~6-fold greater abundance in RV-Me-tet-UL128Lwt virions 
compared to those from RV-Me-UL128Lmut. A further 8 envelope proteins  (gpRL12, pUL33x1, 
gpUL78, gpUL132, pUS12, pU13, pUS14 and pUS20) were also more abundant in RV-Me-tet-
UL128Lwt virions. Conversely, RV-Me-tet-UL128Lwt virions contained less gpUL118-UL119. 
Only 4 (gpRL10, gpUL55, gpUL116, and gpUS28) of the 21 identified envelope components 
were detected at comparable levels in the virions from RV-Me-tet-UL128Lwt and RV-Me-
UL128Lmut. The relative abundance of the remaining 6 envelope components that were 
identified in the MVP-2 preparation varied between virions with contrasting pentamer/trimer 
ratios, but did not exceed the threshold for confidence; RV-Me-tet-UL128Lwt virions contained 
marginally greater levels of gpUL141 and gpUS27, yet less pUL41A, gpUL73, gpUL100, and 
pUL140. Of particular interest were gpUL73 (gN) and gpUL100 (gM) that are components of 
glycoprotein complex family gCII members. The identification of these envelope components 
with similar relative abundance between RV-Me-tet-UL128Lwt and RV-Me-UL128Lmut virions 
likely reflects the inclusion gM and gN in the different virions at similar stoichiometry. 
Furthermore, the fact that each was less abundant in RV-Me-tet-UL128Lwt virions compared to 
and RV-Me-UL128Lmut virions may indicate that pentameric complex incorporation may 
impede the incorporation of gM/gN complexes.  
 
 Ten of the 21 identified envelope proteins were present at comparable levels in virions 
from RV-Me-tet-UL128G>T and RV-Me-tet-UL128Lwt virions, whilst the ratios of a further 9 
envelope proteins were below the threshold of confidence (i.e. < ±1.5-fold) (Figure 6.8.B). 
Interestingly, RV-Me-tet-UL128LG>T virions contained the greatest abundance of 8 envelope 
proteins (gpRL12, gpUL16, gpUL141, pUS12, pUS13, pUS20, gpUS28, gpUL148). Since these 
proteins were more abundant in RV-Me-tet-UL128G>T compared to RV-Me-tet-UL128Lwt 
virions, their incorporation was not correlated with increasing pentameric complex content of 
virions. In fact, incorporation of only 2 of the 21 identified envelope components correlated 
with increasing pentameric complex content, with RV-Me-tet-UL128G>T virions potentially 
containing less gpUL78 and pUS14 than RV-Me-tet-UL128wt virions, yet more than in RV-Me-
UL128mut virions. Furthermore, whilst variation in the levels gpUL73 (gN) and gpUL100 (gM) 
between virions from RV-Me-tet-UL128G>T and the comparison viruses did not exceed the 
threshold of confidence, a trend to further suggest that pentameric complex assembly may 
impede the incorporation of gM/gN complexes was observed. 
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Figure 6.8. Relative abundance of membrane proteins in virions with contrasting 
pentameric/trimeric complex ratios. Highlighted (grey) is the degree of normal intra-assay variation 
(±1.1.665-fold). Broken lines (dark grey) show the threshold (± 1.5-fold) to highlight proteins that 
differed between virions with confidence. (A) Relative abundance of proteins in RV-Me-tet-UL128Lwt 
(L) compared to RV-Me-UL128Lmut (M) virions. (B) Relative abundance of proteins in RV-Me-tet-
UL128G>T (H) compared to RV-Me-tet-UL128Lwt (L) and RV-Me-UL128Lmut (M).  
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 Variation in uncharacterised proteins 6.4.3.6
 Of the viral proteins yet to be characterised biochemically or functionally, only two 
were detected during SILAC-MS analysis of the MVP-2 preparation. Compared to RV-Me-
UL128Lmut virions, RV-Me-tet-UL128Lwt virions contained moderately greater abundance of 
pUL31, yet a dramatically greater abundance of pUL145 (Figure 6.9.). Interestingly, RV-Me-
tet-UL128G>T virions contained the greatest abundance of these proteins. However, only pUL31 
was detected with different abundance between virions from RV-Me-tet-UL128G>T and RV-Me-
tet-UL128Lwt virions above the confidence threshold. Thus, whilst virus containing non-intact 
UL128L ORFs and producing virions that lacked the pentameric complex contained the lowest 
abundance of these proteins, their incorporation could not be correlated with the 
pentameric/trimeric complex ratio of virions. One uncharacterised viral protein was detected 
only during SILAC-MS analysis of the MVP-1 preparation, with pUL150A identified with 
moderately greater abundance in RV-Me-tet-UL128Lwt virions compared to RV-Me-UL128Lmut 
virions. 
 
 
 
 
 
Figure 6.9. Relative abundance of uncharacterised viral proteins in virions with contrasting 
pentameric/trimeric complex ratios. Highlighted (grey) is the degree of acceptable intra-assay variation 
(±1.1.665-fold). Broken lines (dark grey) show the threshold (± 1.5-fold) to highlight proteins that 
differed between virions with confidence. (A) Relative abundance of proteins in RV-Me-tet-UL128Lwt 
(L) compared to RV-Me-UL128Lmut (M) virions. (B) Relative abundance of proteins in RV-Me-tet-
UL128G>T (H) compared to RV-Me-tet-UL128Lwt (L) and RV-Me-UL128Lmut (M). * denotes protein 
detected in MVP-1 preparation only. 
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6.5 Summary 
 Preliminary investigations demonstrated that the method of virus concentration prior to 
purification over gradients is an important consideration for any investigation of viral particles. 
Concentration of virus by high-speed centrifugation likely promotes aggregate formation 
between virus particles and contaminating proteins. This limits the recovery virus particles over 
gradients, and also potentially the degree of purification that can be achieved. In contratst, the 
reduced aggregate formation in virus stocks concentrated by dialysis ultra-filtration improves 
virus particle segregation and recovery over gradients, and may also limit the co-purification of 
contaminating proteins. Thus proteins detected in virions purified from viruses concentrated by 
ultra-filtration can be more confidently assumed to represent bona fide components. 
 Mass spectrometry analysis of purified Merlin virions identified a total of 92 virus-
encoded proteins. This included 39 proteins that were not identified during previous by MS 
analysis of AD169 virions; 19 identified with high confidence, and 20 identified with low 
confidence. Furthermore, 13 of these proteins identified with high confidence were novel and 
have not been identified as HCMV virion components by any previous approach, whilst 17 of 
the proteins identified with low confidence were also novel components. 10 proteins previously 
reported to be components of HCMV virions were not identified by MS analysis of Merlin 
virions.  
 SILAC-MS analysis was validated to be a reliable approach for the comparison of 
virions from distinct Merlin variants; a high degree of precision in this technique was 
demonstrated by the reproducibility of data generated on repeat analyses, and the high degree of 
accuracy was demonstrated by the fact that components that should be heterogeneous amongst 
distinct HCMV strains and strain variants (capsid proteins) were detected with near identical 
abundance in the different virions. In agreement with the original hypothesis, reduced 
pentameric complex content of virions occurred with a concomitant increase in the abundance 
of the alternative gH/gL complex (gH/gL/gO) The pentamer/trimer ratio of virions also 
correlated with incorporation of various other virion components, and in general, virions with 
high pentamer/low trimer content contained increased quantities of numerous envelope 
components, tegument materials, and also proteins that have yet to be assigned to any particular 
virion compartment. Thus, viruses that have undergone adaptation to cell culture involving the 
selection of ablating UL128L mutations produce virions that are biochemically dissimilar to 
wildtype HCMV virions beyond differences in pentameric complex content.  
 Importantly, virions from the novel Merlin variant containing the UL128 G>T 
mutation, that can be propagated more efficiently and with greater stability, displayed a 
proteome profile that most closely matched that of Merlin virus containing wildtype UL128L, 
and not that of the Merlin variant lacking intact UL128L.  
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 Data described in this thesis demonstrate significant advances in addressing a major 
challenge in HCMV research – the efficient in vitro propagation of virus that closely represents 
the causative agent of disease. The isolation of HCMV from clinical samples has by necessity 
been performed on cultured fibroblasts, yet a number of functions encoded by wildtype strains 
inhibit the propagation of virus in this cell type. The ORFs that are most inhibitory are RL13 
with unknown function, and the UL128L ORFs that encode tropism factors required for 
efficient infection of a wide range of other naturally targeted cell types. The passage of HCMV 
in cell culture (fibroblasts) invariably results in the selection of ablating mutations in these 
genome regions, giving rise to viruses that can be propagated more efficiently, but display 
restricted tropism. The cloning of the HCMV strain Merlin genome as a BAC construct and 
repair of all in vitro acquired mutations represented an important milestone in addressing these 
problems, providing for the first time a stable source of virus with coding potential equivalent to 
that of wildtype virus in vivo (Stanton, Baluchova et al. 2010). However, prior to this work, 
efficient propagation of ‘broad-tropism’ viruses (UL128Lwt) from the Merlin-BAC remained a 
technical challenge; similar to recent clinical isolates, the wildtype UL128L ORFs of Merlin 
impeded the dissemination and cell-free virus production of infections, and propagation in 
fibroblasts resulted in the selection of de novo UL128L mutations. Addressing these issues, the 
work detailed in this thesis concerns the production of novel Merlin-BAC variants engineered to 
contain subtle non-ablating UL128L mutations, with the ‘broad-tropism’ viruses produced 
growing more efficiently in fibroblasts, thereby alleviating the selective pressure imposed 
against the UL128L ORFs. In addition, the composition of virions from a range of Merlin 
variants was determined, highlighting an array of previously un-recognised virus encoded 
protein components that are likely to be incorporated into virions from wildtype virus in vivo.  
7.1 The need to develop the Merlin BAC – why not use other ‘broad tropism’ strains? 
 The fact that the BAC-cloned Merlin genome displays coding potential equivalent to 
that of wildtype virus in vivo makes it an ideal strain for HCMV research. However, the 
difficulties associated with the in vitro propagation of the Merlin-BAC derived viruses have to 
date prevented the use of this strain by many laboratories. Data presented in thesis offer some 
explanation for the preference of the most commonly used ‘broad tropism’ BAC-cloned strains 
(TR-BAC, TB40-BAC4, and FIX-BAC). These strains do not suffer the above-described 
problems: each contains intact UL128L genome regions and produce viruses that display broad 
tropism, yet these viruses can be grown to high titres without the selection of de novo UL128L 
mutations. However, whilst these qualities are clearly desirable, none of these strains contain 
the full complement of wildtype HCMV genes. TR was cloned from a multi-drug resistant 
isolate and contains GCV-resistance associated mutations in UL97, and cifodovir-resistance 
associated mutations in UL54 (Smith, Taskintuna et al. 1998). TB40-BAC4 contains mutations 
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in RL5A, RL6, UL141, and UL40 (Sinzger, Hahn et al. 2008, Magri, Muntasell et al. 2011). 
TR-BAC, TB40-BAC4 and FIX-BAC may also contain further genetic lesions that are yet to be 
identified; this is particularly evident for FIX-BAC, as data in this thesis and also previous 
reports (Dargan, Douglas et al. 2010) indicates that this strain lacks intact copies of ORFs 
required for efficient infection of epithelial cells. 
 A major site of heterogeneity between the genomes of the TR, TB40-BAC4 and FIX 
BACs and wildtype virus is in the US region. The capture of the TB40-BAC4 and FIX genomes 
involved the sacrifice of ORFs US2-US5 in order to accommodate stably incorporated BAC 
vector sequences, however recombination events that occurred during cloning resulted in the 
loss of additional sequences flanking the intended site of BAC insertion (Hahn, Khan et al. 
2002, Sinzger, Hahn et al. 2008). No report detailing the construction of the TR BAC is 
available, yet it is believed to have involved the replacement of ORFs US2-US5, similar to the 
construction of TB40-BAC4 and FIX (Murphy, Yu et al. 2003). Nucleotide sequence analysis 
of TR-BAC derived viruses produced in this work revealed discrepancies at the intended site of 
BAC vector insertion, prompting the re-analysis of the TR BAC coding potential; the BAC 
vector sequence was identified as starting from within the 5’ region of US2, and ending within 
the 3’ region in US6 (performed by Andrew Davison). Ultimately, each of TR-BAC, TB40-
BAC4 and FIX-BAC lacks intact copies of US2, US3 and US6 (US4 and US5 have since been 
deemed non- coding; Andrew Davison – Pers. Comm.). These ORFs encode immuno-
modulatory functions that impede MHC complex presentation of viral antigens at the infected 
cell surface, and are therefore important virulence factors in natural infection (Jones, Wiertz et 
al. 1996, Ahn, Gruhler et al. 1997, Jones and Sun 1997, Lehner, Karttunen et al. 1997). 
Furthermore, both TB40-BAC4 and FIX have lost sequence close to the BAC vector insertion 
site, such that the a’/a sequences present at the US genome segment termini are fused with a 
portion of US2. As a result, TB40-BAC4 and FIX also lack copies of IRS1 that encodes a multi-
functional protein involved in viral gene transcription transactivation (Romanowski and Shenk 
1997), viral genome synthesis (Pari, Kacica et al. 1993), and subversion of intrinsic anti-viral 
responses (Child, Hakki et al. 2004), as well as US1 with unknown function.  
As demonstrated in this work, viruses from each of the BAC-cloned versions of strains 
TR (TR-BAC), TB40E (TB40-BAC4) and VR1814 (FIX-BAC) are prone to rapid mutation 
following reconstitution in both fibroblasts and epithelial cells. This repeatedly involved the 
deletion of sequence at, or close to, the site of BAC vector insertion in the US genome region. 
Importantly, this occurred within the very first passage of viruses from the TR-BAC, but also in 
the minimum number of passages required to grow stocks of virus derived from TB40-BAC4 
and FIX-BAC. The selective pressure for these mutations is likely due to the increase in genome 
size that occurred following insertion of BAC vector sequences, coupled with genome size 
restrictions during virion morphogenesis (Yu, Smith et al. 2002, Cui, McGregor et al. 2009). 
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However, if genome size constraints alone were responsible, compensating deletion mutations 
may be expected to occur in any genome region that contains multiple dispensable ORFs in 
tandem. Whilst the US ORFs involved in these mutations are clearly dispensable, there are no 
reports to suggest that the functions they encode are inhibitory to the growth of virus. Therefore, 
it seems that the BAC vector sequences in these strains itself may contain features that impede 
virus replication, making the US genome region prone to mutation.   
Hence, whilst viruses from the TR, TB40-BAC4 and FIX BAC do not suffer the same 
growth restriction and UL128L instability seen with viruses from the wildtype Merlin-BAC, 
they are genetically and phenotypically dissimilar to wildtype virus, and are also prone to rapid 
mutation when propagated in cell culture. These limitations with the most commonly used 
‘broad-tropism’ strains underpin the need for the development of the wildtype BAC-cloned 
strain Merlin. 
7.2 Wildtype UL128L is inhibitory to growth of virus – but is Merlin UL128L 
unusual? 
 Data presented in this work recapitulate that of previous findings to clearly demonstrate 
the inhibitory impact of the wildtype UL128L of BAC-cloned strain Merlin (Stanton, 
Baluchova et al. 2010). However, no investigations directly comparing the UL128L genomes 
regions from distinct wildtype strains have previously been reported, and it remained to be 
determined whether natural strain-strain variations made Merlin UL128L more inhibitory to the 
growth of virus in cell culture. The high nucleotide sequence homology of this genome region 
amongst distinct wildtype strains (Baldanti, Paolucci et al. 2006, Sun, Ji et al. 2009) suggested 
that the growth phenotype impact would be similar, and this is now confirmed experimentally; 
the UL128L genome region of the un-passaged strain 3301 contained natural sequence 
variations compared to Merlin UL128L, yet conveyed an identical growth phenotype. The 
growth phenotype influence of TR UL128L (when expressed form the Merlin genome 
background) was also identical to that of Merlin UL128L; together with the absence of unique 
nucleotide variations, these observations make a strong case that TR UL128L contains fully 
wildtype sequence.  
 The inhibitory impact of TB40-BAC4 and FIX UL128L genome regions was less 
severe compared to Merlin wildtype UL128L due to nucleotide sequence variations in these 
genome regions. Whilst it is not possible to entirely discount that the nucleotides concerned are 
natural strain-strain variations, several lines of evidence indicate that they represent mutations, 
most likely acquired during the passage of each virus in cell-culture prior to BAC-cloning: they 
conveyed a strikingly altered growth phenotype when expressed by Merlin viruses, whereas 
natural variations had little to no differential impact; they reduced the fitness of virus in 
epithelial cells, an important cell type in natural infection; and they were unique to each strain, 
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and absent even in closely related or even parental strains. These subtle ‘mutations’ suppress, 
but do not ablate pentameric complex functionality. As a result, TB40-BAC4 and FIX BAC-
derived viruses display a broad tropism phenotype, and these strains are classified as ‘clinical 
strains’ that are considered a close representation of wildtype virus. However, the identification 
of these ‘mutations’ highlight important considerations when using these, or other BAC cloned 
strains: i) the phenotypes of BAC-cloned strains cannot be assumed to accurately represent that 
of wildtype virus; ii) it is essential to compare BAC-captured genomes to that of viruses 
undergone no passage at all in order to determine whether genome regions of interest are 
wildtype in sequence.  
7.3 The alternative gH/gL complex content of virions is a major factor dictating the 
virus growth phenotype 
 The effect of the non-ablating UL128L ‘mutations’ was to impede the assembly and/or 
incorporation of pentameric complex (gH/gL/gpUL128/gpUL130/gpUL131A) into Merlin 
virions, and particularly for the UL128 G>T mutation, this occurred with a concomitant 
increase in trimeric complex (gH/gL/gO) content. Based on this, there appears to be competition 
between the UL128L-encoded glycoproteins and gO for available gH/gL and the assembly of 
either glycoprotein complex variant. This model is supported by a similar but reciprocal 
observation, where a gO-null mutant that does not assemble the trimeric complex produced 
virions with increased pentameric complex content (Wille, Knoche et al. 2010). The relative 
abundance of the pentamer or trimer incorporated into virions is a major factor that dictates the 
growth phenotype of virus in cell culture. Both complexes are implicated in core activities 
during the viral replication cycle (e.g. entry of cell-free virus into cells, cell-to-cell spread, and 
cell-free virus production), yet there is a different requirement for each complex in different cell 
types. In fibroblasts, the trimeric complex is necessary for all of these activities, whilst the 
pentameric complex is inhibitory to cell-to-cell spread and cell-free release; hence the selective 
pressure imposed against UL128L. In epithelial cells, the pentameric complex is required for 
cell entry and cell-to-cell spread, while the role of the trimeric complex is unclear. Whilst an 
inverse relationship between the pentamer/trimer content of virions was shown for only a select 
panel of viruses grown in fibroblasts, the growth phenotypes of all Merlin variants correlated 
with the projected pentamer/trimer ratios of virions. In summary, high pentamer/low timer 
viruses displayed reduced cell-to-cell spread, dissemination kinetics, and cell-free virus 
production in fibroblasts. In epithelial cells, high pentamer/low timer viruses displayed greater 
cell-to-cell spread and dissemination kinetics, but reduced cell-free virus production. 
 The role of the trimer and its impact on titration data 7.3.1
Analyses of the virion production and tropism of the different Merlin variants were 
based on plaque titration data to enumerate the virion of load of various samples. However, 
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special consideration should be given to the proposed roles of the trimer when interpreting this 
data. The role of trimer in cell entry is widely accepted (Vanarsdall and Johnson 2012), yet 
there are conflicting reports regarding a role in the production and/or cell-free release of 
progeny virions (Jiang, Adler et al. 2008, Wille, Knoche et al. 2010). If the trimer promotes 
cell-free virus production, then the ranging titres reported on analysis of the different samples 
correlate well with the projected pentamer/trimer content of virions, i.e. titres of low 
pentamer/high trimer virus samples were consistently higher than in high pentamer/low trimer 
virus samples. Alternatively, it is possible that the trimer content of virions influences the 
efficiency by which virus infects cells (see section 7.3.2). Thus, the plaque titration assay may 
detect virions with different pentamer/trimer ratios with different degrees of sensitivity. 
Ultimately this may result in the virion loads in samples from the different Merlin viruses being 
reported with varying degrees of accuracy.  
 Several lines of indirect evidence from this work support the model where the trimer 
contributes to the production of cell-free virus. Firstly, gradient purification of UL128L-null 
Merlin viruses containing the highest trimer content produced noticeably stronger ‘purified 
virion’ bands, and this occurred without any noticeable difference in ‘DB’ band strength that 
may indicate the pentamer contributes to the formation of aggregates that would limit the 
recovery of virions. These observations indicate a greater number of virions were released into 
the supernatant from infections with high trimer virus. Secondly, SILAC-MS analysis revealed 
that high pentamer/low trimer Merlin virions contained greater quantities of the vast majority of 
all other incorporated HCMV proteins. There is no evidence to suggest that UL128L or the 
encoded glycoproteins regulate the expression of other HCMV ORFs, and it is hard to imagine 
that the pentamer directly facilitates the incorporation of all other virion components by direct 
protein-protein interactions. Thus, the differing composition of virions most likely represents 
equivalent quantities of proteins being produced by the Merlin variants that are distributed 
between different numbers of progeny virions. Whilst this does not exclude the possibility that 
the virion trimer content impacts the efficiency by which virus enters cells, it supports the 
interpretation of titration data as reflecting different virion loads in samples.  
 Impact of pentamer/trimer ratios on cell-free virus entry  7.3.2
The Merlin variants clearly displayed differences in tropism. However it is not easy to 
determine whether this was solely due to variations in the pentamer content of virions alone, 
whether variations in trimer content also contributed, or whether variations in both complexes 
played a role but possibly with contrasting effects. It should be noted that the virions with the 
lowest trimer content were those produced by the Merlin variant containing wildtype UL128L; 
this variant can be considered a close representative of wildtype virus in vivo, and likely 
produces virions with a similar pentamer/trimer content. It would be seemingly counterintuitive 
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for wildtype virus to produce virions with a trimer content that did not allow efficient infection 
of naturally targeted cell types, particularly in epithelial cells that are first encountered 
following intra-host transmission of virus; the requirement for the pentameric complex for 
efficient entry into this cell type would mean that by default virions would contain a relatively 
low trimer content. Based on this, the different epitheliotropism displayed by the Merlin 
variants was likely dictated by the pentameric complex content of virions, and not trimeric 
complex content. If the virion trimer content does impact the efficiency of cell entry, then this 
may be most apparent in fibroblasts where the trimer but not the pentamer is required. To 
accurately determine the impact of varying pentamer/trimer ratios on the absolute tropism of 
virus for each cell type, the viruses assessed in this thesis will be need to be quantified by 
methods independent of the biological characteristics (e.g. EM analysis and HCMV particle 
counts, qPCR genome copy estimation) in parallel to plaque titration assays. 
 Aside from these uncertainties, the projected pentamer/trimer content of virions 
correlated with the relative abilities of virus to infect epithelial cells compared to fibroblasts. 
This was best demonstrated by comparison of viruses produced in epithelial cells: Merlin 
viruses containing wildtype UL128L (greatest quantities of pentameric complex, and lowest 
quantities of trimer) infected epithelial cells with equivalent, if not greater efficiency, than 
fibroblasts, whilst the novel Merlin viruses containing subtle UL128L mutations (medium 
pentamer, medium trimer) infected epithelial cells with reduced efficiency than fibroblasts. The 
efficiency by which viruses infected different epithelial cell types followed an interesting, and 
consistent pattern: virus lacking the pentameric complex was able to infect RPE-1s much more 
efficiently than ARPE19’s, whilst viruses containing the complex, at any abundance, infected 
ARPE-19s with greater efficiency than RPE-1s. One explanation for this includes ARPE-19s 
being more permissive to HCMV infection than RPE-1s, but with a stricter requirement for the 
pentameric complex. This observation underpins the need for further investigations into the 
tropism of viruses in a greater range of cell types, particularly primary cells such as endothelial 
cells and DCs.  
 Interestingly, cell-free viruses produced in fibroblasts did not show the same relative 
epitheliotropism as their counterparts produced in epithelial cells; differences were most 
striking for Merlin viruses predicted to contain the greatest levels of pentameric complex 
(UL128Lwt, UL128LTR). This may reflect the fact that the levels of pentameric complex 
incorporated into virions produced in either epithelial cells or fibroblasts differs. Indeed, 
analysis of the gpUL128 content in virions from the Merlin-UL128Lwt and Merlin-UL128G>T 
Merlin-BAC variants and produced in epithelial cells was dramatic (by immunoblot), whilst the 
difference in the gpUL128 content of virions from the same BACs but produced in fibroblasts 
was <1.5-fold (shown by SILAC-MS). Clearly further characterisation of the novel Merlin 
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viruses produced in this work will require an assessment of tropism when produced in different 
cell types.  
 Impact of pentamer/trimer on cell-free virus production  7.3.3
 Important clues as to how the pentameric complex impedes cell-free virus production 
came from investigation into the cell-free released virus (CRV) and cell-associated virus (CAV) 
sub-populations produced in fibroblast infections. For viruses with increasing predicted virion 
pentamer content, the CAV sub-population represented a greater proportion of the total progeny 
produced, suggesting that the pentamer may promote cell-association and/or impede the release 
of progeny virions. However, the CAV titres across all infections were broadly equivalent, and 
also considerably lower than the CRV titres from the same infections. Importantly, the CAV 
produced by high pentamer virus infections was unable to account for the differences in CRV 
infectivity produced by infections with low pentamer virus. Thus, whilst it cannot be 
conclusively discounted that the pentameric complex actively promotes the cell-association 
and/or impedes the cell-free release of virus, the major effect appears to be reducing the 
production of infectious virions. Furthermore, the CAV sub-populations displayed reduced 
epitheliotropism compared to the CRV sub-populations produced in infections, suggesting that 
virions retained within the cell contained reduced pentamer content. These data corroborate 
previous reports based on strain TB40-BAC4 where the CAV sub-populations produced in 
fibroblasts showed reduced endotheliotropism compared to the CRV sub-population (Scrivano, 
Sinzger et al. 2011), and further support a role of the trimer in progeny virion morphogenesis 
(Jiang, Adler et al. 2008).  
 Similar findings were evident on analysis of the CRV and CAV sub-populations 
produced in epithelial cell infections, with the progeny that remained cell-associated displaying 
reduced epitheliotropism compared to the cell-free released progeny. However this investigation 
was based only on the Merlin variant containing wildtype UL128L, and therefore firm 
conclusions regarding the impact of varying pentamer/trimer ratios cannot be drawn. The fact 
that the CAV sub-population from this infection represented a more significant site for the total 
progeny produced compared to that in fibroblasts infected with the same Merlin variant likely 
reflects the analysis of CRV and CAV sub-populations at a different time point post infection. 
The demonstration that UL128L inhibits cell-free virus production during infection of epithelial 
cells was unexpected, and conflicts with previous findings; in an early investigation, 
complementation of a ‘broad tropism’ strain with additional copies of UL128L ORFs (UL131A) 
did not reduce cell-free virus production during infection of endothelial cells (Adler 2006). 
However the ‘broad-tropism’ strain used was VR1814, the parental virus of the FIX BAC.  
VR1814 also contains a unique UL128L nucleotide (UL130 A>G that encodes an S42P amino 
acid substitution (discussed in section 7.4.2). This nucleotide likely represents an in vitro 
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acquired mutation that could impact the pentameric complex that may not have been overcome 
by complementation with UL131A. However, data presented in this thesis conclusively 
demonstrate that, like in fibroblasts, pentameric complex assembly impedes the production of 
cell-free virus in cell types where it is required by the virus for efficient infection. 
 Impact of pentamer/trimer ratio on cell-to-cell spread 7.3.4
 The mechanisms of direct virus cell-to-cell spread are not well described. One proposed 
mechanism includes the same virion envelope glycoproteins that orchestrate the entry of cell-
free herpesviruses being presented at the infected cell surface (Cocchi, Menotti et al. 2000, 
Kinzler and Compton 2005), and these induce microfusion events between the plasma 
membranes of adjacent cells to form pores through which virus migrates (Gerna, Percivalle et 
al. 2000). Recent work has confirmed the presence of all three trimer sub-units (gH, gL, gO) on 
the surface of fibroblasts infected with HCMV strain Merlin (Weekes, Tomasec et al. 2014). 
Indications that the pentameric complex is presented at the cell-surface in HCMV-infected 
fibroblasts, and also the pentamer and trimer are presented at the cell-surface in HCMV-infected 
epithelial cells, have come from experiments using recombinant expression systems (Ryckman, 
Rainish et al. 2008, Vanarsdall, Chase et al. 2011). However there may be different 
glycoprotein requirements for cell-to-cell and cell-free spread, as the trimer has been reported to 
be required for entry of cell-free virus into epithelial cells, yet a gO-null virus displayed no 
compromise in cell-to-cell spread in this cell type (Jiang, Adler et al. 2008, Wille, Knoche et al. 
2010). It should also be considered that HCMV might spread cell-to-cell by alternative routes 
than via intracellular pores. One further possibility includes the dissemination of cell-free virus 
between closely opposed cells, such that infectious virions encounter a new cell immediately 
following egress from a producer cell. 
 None-the-less, data in this thesis demonstrate a direct correlation between the projected 
pentamer/trimer ratios of the viruses assessed and their abilities to spread by the cell-to-cell 
route in both fibroblasts and epithelial cells. Again, data generated in this thesis complement the 
reciprocal observations made from work on the gO-null mutant. This offers some explanation to 
the apparently conflicting ideas that UL128L expression inhibits the cell-to-cell spread of 
viruses in fibroblasts (Stanton, Baluchova et al. 2010), yet the pentameric complex has been 
reported to participate in the cell-to-cell spread of HCMV in fibroblasts; a gO-null mutant 
remained capable of cell-to-cell in fibroblasts, albeit displaying a small plaque phenotype, 
whereas a gO-null/UL128L-null double mutant was completely non-viable (Jiang, Adler et al. 
2008, Wille, Knoche et al. 2010). The inhibitory impact of UL128L expression on the cell-to-
cell spread of virus in fibroblasts may therefore be simply due to the reduced trimer assembly 
that occurs with pentamer assembly. Conversely, the previously described greater cell-to-cell 
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spread of gO-null viruses in epithelial cells is likely due to an increase in pentameric complex 
assembly (Wille, Knoche et al. 2010).  
 Impact of pentamer/trimer ratio on wildtype virus during natural infection 7.3.5
 It is possible that the pentamer/trimer content of virions also impacts HCMV-host 
interactions during natural infection. Intra-host dissemination of HCMV is heavily dependent on 
the direct cell-to-cell transfer of virus; an obvious benefit for this mode of dissemination 
includes avoiding components of the humoral immune system. Data in this thesis make the case 
that the reduced cell-free virus production that occurs with increasing pentamer assembly is not 
simply due to infectious virions remaining cell-associated, but is instead due to lower infectious 
progeny virion production. This invokes the question as to how such a virus could disseminate 
throughout an infected host. Direct cell-to-cell transfer can be significantly more efficient than 
cell-free virus dissemination, with relatively few virions required to infect neighbouring cells 
(Sattentau 2008). Furthermore cell-to-cell spread may not require fully formed virions to be 
produced; a UL99-null mutant does not produce the tegument protein ppUL28 that orchestrates 
secondary envelopment for the production of enveloped virions, but is still capable of cell-to-
cell spread in fibroblasts (Silva, Schroer et al. 2005). Thus, immature non-enveloped virus 
particles may represent one form of infectivity that disseminates by direct cell-to-cell transfer.  
 Based on the above described possibilities, the pentamer could have two effects to 
promote the cell-to-cell spread of virus: i) when expressed at the surface, it could contribute to 
the formation of intra-cellular pores through which virus migrates; ii) the limited trimer 
assembly could impede morphogenesis of progeny virions destined to egress the cell by 
exocytosis, with the accumulated sub-viral particles instead driven to disseminate by the direct 
cell-to-cell route. In this model, pentamer assembly would have different effects on the cell-to-
cell spread of virus in fibroblasts: reduced progeny virion morphogenesis could drive cell-to-
cell dissemination of immature viral particles, yet reduced trimer assembly could impede 
intracellular pore formation. It would be interesting to determine whether UL128L-null mutants 
arise in infected fibroblast tissues in vivo. The structure of fibroblast tissues in the host includes 
densely packed cells that are arranged in close proximity, and dissemination of HCMV 
throughout these tissues will most likely be heavily dependent on direct cell-to-cell transfer. The 
increased cell-free release of any UL128L-null mutants that arose during natural infection 
would result in exposure to humoral components of the immune system, selecting against these 
mutants. However, cell-associated UL128L-null progeny would not be exposed to the humoral 
immune system, and the more efficient cell-to-cell spread in fibroblasts could allow these 
mutants to persist.  
Despite these comments concerning intra-host spread, cell-free virus must be produced 
for inter-host transmission. It is becoming increasingly recognised that clinical samples from an 
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infected individual often contain variants derived from a single strain. Following acquisition 
and intra-host dissemination, distinct quasi-species may arise within a host due to the selective 
pressures imposed during infection of different tissues (Renzette, Gibson et al. 2013). Following 
inter-host transmission (which occurs at epithelial tissues, and would thus require UL128L), a 
bottleneck process occurs, presumably with the selection of virus containing the full set of 
wildtype ORFs required to initiate new infection. Both wildtype UL128L and mutated UL128L 
populations could arise in the host, and these distinct variants may simultaneously infect 
glandular epithelial tissues from where virus is secreted. Genomes containing intact UL128L 
ORFs could complement genomes in which the UL128L genome region is mutated, and the net 
effect of this could be the production of progeny virions with reduced pentamer content, yet 
increased trimer content. These hypothetical virions would be biochemically similar to those of 
the novel Merlin viruses produced in this work, with greater production and release, yet still 
displaying epitheliotropism. Such a process was observed experimentally with the generation of 
UL128L mutant populations when passaging wildtype Merlin virus in epithelial cells (described 
below). However, arguing against this possibility, when the genomes of un-passaged virus are 
sequenced directly from clinical samples, they have been invariably reported to contain intact 
UL128L genome regions. This could indicate that a more complex process of active gene 
regulation may be occurring in secretory cells to suppress, but not ablate, UL128L ORF 
expression, or alternatively increase UL74 (gO) expression.  
7.4 Novel Merlin BAC reagents: assessment, propagation and utility  
 The preference for cell-to-cell dissemination displayed by wildtype virus in natural 
infection is an important consideration, and future investigations into this method of spread are 
essential. However, the requirement for infectious cell-free virus preparations for experimental 
applications, including studies on inter-host transmission, remains equally important.  
 Merlin viruses containing TB40-BAC4 UL128L sequences 7.4.1
 The UL128 G>T ‘mutation’ impacted pentameric complex assembly by impeding 
UL128 pre-mRNA splicing for the formation of translatable mRNA, and ultimately the 
production of gpUL128. Importantly, there was no evidence to suggest that a distinct gpUL128 
isoform was produced. Several important assumptions regarding the pentameric complex 
assembled in the Merlin viruses containing the G>T mutation can be made: pentameric 
complexes are composed of UL128L encoded sub-units with wildtype amino acid sequence; 
thus they are arranged with normal conformation; and they are functionally equivalent to 
complexes composed of Merlin wildtype UL128L encoded sub-units. This also holds true for 
the Merlin virus containing the entire TB40-BAC4 UL128L genome region - no unique coding 
nucleotide variations were identified in TB40-BAC4 UL128L and all but one of the acid 
variations identified were also identified in the un-passaged strain 3301, and therefore likely 
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represented natural variations. There was discrepancy in the levels of gpUL128 production 
following expression of UL128 in isolation from the recombinant adenovirus vectors, with 
Merlin UL128 containing the G>T mutation producing more gpUL128 than TB40-BAC4 
UL128. The reasons for this are unclear, but may include TB40-BAC4 UL128 mRNAs 
containing codons that are translated less efficiently, or have reduced thermo-stability, or 
produce a protein with reduced thermo-stability. If this is the case, these limitations must only 
be apparent in isolation from other pentamer sub-units, as virions purified from these viruses 
contained similar levels of gpUL128. Each of the novel Merlin viruses containing either the 
entire TB40-BAC4 UL128L genome region or the G>T mutation alone grew to significantly 
greater titres than the Merlin virus containing wildtype UL128L (in both fibroblasts and 
epithelial cells), yet displayed only moderately reduced relative epitheliotropism (≤10-fold) 
compared to the severely reduced relative epitheliotropism of virus lacking intact UL128L (100-
5000-fold). Therefore, each of these Merlin variants can be considered valuable reagents for 
future research into the biology of HCMV in cell-types where the pentameric complex for 
efficient infection.    
 Merlin viruses containing FIX UL128L sequences 7.4.2
 The FIX UL130 A>G (S72P) mutation did not impact the expression of UL130, but 
potentially disrupted the folding of gpUL130 into native conformation. All three members of 
UL128L are required for egress of the complex from the ER, explaining why modification in 
one component would affect the entire complex. In support of the prediction that this impacted 
pentameric complex sub-unit binding interactions, gpUL130 has been demonstrated to play a 
central role in complex assembly via interactions with both gH and gpUL131A (Ryckman, 
Rainish et al. 2008). In addition to affecting the amounts of UL128L components in the virion, 
this may also have affected the functionality of the pentameric complex that was assembled; the 
FIX S72P mutation resulted in virions containing significantly more pentameric complex than 
those containing the TB40-BAC G>A mutation, yet the relative epitheliotropism of the Merlin 
virus containing the S72P mutation was only marginally higher. 
Unlike the TB40-BAC4 mutation, the FIX UL130 A>G (S72P) mutation contributed 
only partially to the distinct growth phenotypes influence of the FIX UL128L genome region. A 
candidate for an additional contributing feature is the FIX UL130 A>G (S42P) variation that 
was present only in FIX and the parental strain VR1814.  Being unique to the FIX virus lineage, 
this variation also likely represent an in vitro acquired mutation. The S42P mutation may only 
have a modest impact on pentameric complex functionality; it did not apparently alleviate the 
selective pressures of fibroblast cell culture passage since the S72P mutation was acquired later. 
However, given that Merlin virus containing both mutations (in the entire FIX UL128L) was 
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severely restricted in epithelial cells, a Merlin double mutant containing both of these features 
would most likely be of limited utility.  
 Propagation of novel Merlin virus stocks 7.4.3
 The choice of cell culture system used for the propagation of viruses is an important 
consideration. Several observations from this work suggest that viruses produced in different 
cell types are phenotypically distinct. As previously mentioned, viruses produced in epithelial 
cells displayed greater relative epitheliotropism than counterparts from the same Merlin BAC 
variant that were produced in fibroblasts. Furthermore, the pentameric complex content of 
virions from Merlin viruses containing wildtype UL128L compared to virus containing the 
UL128 G>T mutation differed by different degrees when produced from epithelial cells or 
fibroblasts. These producer cell-type specific variations may occur due to the different 
capacities of cell types to translate, modify, and process the pentameric complex sub-units, as 
has been reported when comparing the processing of viral encoded glycoproteins in fibroblasts 
and astrocytoma cells (Kari, Radeke et al. 1992). An assessment of the composition of virions 
produced in different cell types would directly answer these questions. Nonetheless, the choice 
of cell type used for the production of virus stocks should likely be guided by the intended 
experimental use. 
 In epithelial cells 7.4.3.1
 In experiments where virus containing the greatest pentameric complex content possible 
is desirable, it should be advantageous to grow viruses in epithelial cell culture. Furthermore, 
the UL128L genome region of viruses should be more stable in this cell type as opposed to 
fibroblasts. However, similar to observations made in previous studies (Dargan, Douglas et al. 
2010), viruses were prone to rapid mutation during propagation in this cell type. Importantly, 
this occurred within the minimal passage history required to grow virus stocks, and occurred in 
similar timeframes across the panel of Merlin viruses. Most strikingly, the wildtype UL128L 
genome region of Merlin was observed to mutate on one occasion, and this occurred with 
concomitant insertion of E.coli DNA. The source of contaminating DNA was most likely 
derived from the bacterial cells from which BAC-DNA was prepared prior to transfection – 
deep sequencing of maxipreps identified bacterial DNA in some preparations, indicating that 
recombination could have occurred following transfection into mammalian cells. Alternatively 
recombination could have occurred within the bacterial cells. The expansion of this UL128L 
mutant population that occurred on further propagation in epithelial cells was likely due to 
complementation of mutated genomes with pentameric complexes derived from UL128L intact 
genomes present in the same cell. Whilst this virus was not used for further experimentation, it 
demonstrated a growth phenotype similar to viruses containing UL128L sequences from TB40-
BAC4 i.e. it grew to higher titres than the parental virus, yet showed slightly reduced relative 
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epitheliotropism. This observation underpins the crucial importance of assessing the genetic 
integrity of any virus stock prior to use in experiments.  
 The UL/b’ genome region consistently mutated when Merlin viruses were propagated in 
epithelial cells, and this always involved the UL141 ORF. Given that this ORF often acquired 
mutations independently from the surrounding ORFs in this genome region, UL141 may be 
inhibitory to the growth of virus in epithelial cell culture. UL141 encodes an NK-cell evasion 
function that sequesters multiple NK activating ligands in the ER (Tomasec, Wang et al. 2005, 
Prod'homme, Sugrue et al. 2010), and is therefore an important virulence factor in natural 
infection. ORFs flanking UL141 that were frequently also lost in the Merlin viruses passaged in 
epithelial cells, including UL145, UL144, UL142, and UL140, have previously been shown to 
mutate during passage of virus in epithelial cells (Dargan, Douglas et al. 2010). In one Merlin 
virus (containing wildtype UL128L from strain 3301), all ORFs in the UL/b’ genome region 
(UL148-UL150) were lost during growth in epithelial cells. This resembled the mutation of 
strains AD169 and Towne following extensive passage in fibroblasts (Cha, Tom et al. 1996), 
although data presented in this work suggest that loss of UL/b’ occurs more rapidly during 
propagation of virus in epithelial cell culture. It remains to be determined whether all ORFs in 
this genome region encode temperance factors, or whether the deletion of some ORFs occurred 
co-incidentally with the deletion of UL141. In light of this data, it may be worth identifying the 
ORFs in this region that encode functions which are inhibitory to virus growth, as Merlin 
viruses deleted (or inhibited) for these ORFs (e.g. UL141) could be significantly more stable 
during passage in epithelial cell culture.  
 In fibroblasts 7.4.3.2
 In contrast to the growth of viruses in epithelial cells, Merlin viruses were generally 
more stable during propagation in fibroblasts. Thus, virus stocks produced in this cell type may 
be desirable where the inclusion of the pentameric complex at any level is sufficient, yet 
genome wide integrity is essential. Unlike in epithelial cells where all Merlin variants mutated 
genetic stability in fibroblasts correlated with the fitness of virus in fibroblasts; the reduced 
fitness conveyed by expression of wildtype UL128L ORFs resulted in their rapid mutation as 
has previously been reported (Dolan, Cunningham et al. 2004, Dargan, Douglas et al. 2010, 
Stanton, Baluchova et al. 2010), whilst Merlin virus containing an ablating mutation in UL128L 
was exquisitely stable. Recapitulation of this genome-wide stability by repression of UL128L 
and RL13 demonstrated that without the inhibitory impact of these genome regions, the 
selective pressure against other genome regions in fibroblast culture is less severe. Thus, 
repression of the genome regions most inhibitory to the growth of virus in cell culture is an 
attractive option for the production of virus retaining the coding potential of the wildtype 
Merlin-BAC. An obvious limitation to this approach includes any virus produced in this 
repression culture system being restricted in tropism and suited only for infection in fibroblasts. 
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‘Broad-tropism’ progeny that contain all encoded virion components (gpRL13 and the 
pentameric complex) can be produced in subsequent infection of fibroblasts that do not 
endogenously express tetracycline, however expression of RL13 and UL128L would severely 
impede cell-free virus production. Thus, the titres of genetically stable, ‘broad-tropism’ virus 
stocks produced in this two-step culture system may be limiting for infections in large numbers 
of endothelial/epithelial cells.  
 Crucially, the reduced pentameric complex content of the novel Merlin viruses also 
conveyed a growth phenotype that alleviated the selective pressures for de novo UL128L 
mutations, and relatively few mutations were acquired at other loci in the genomes of these 
viruses. Mutations acquired by the Merlin virus containing the G>T mutation include non-
synonymous substitutions acquired in UL47 that encoded the capsid-proximal tegument protein 
HMWPbp, and UL55 that encodes glycoprotein gB. Whilst the impact of these mutations was 
not assessed, they are unlikely to be ablating since these ORFs either enhance virus growth 
(UL47), or are essential to virus growth (UL55), in cell culture (Dunn, Chou et al. 2003). 
Surprisingly, TB40-BAC4 UL128L mutated when expressed in the Merlin genome; this mutant 
population accounted ~60% of all genomes present. It remains to be determined at what passage 
this mutation was acquired and became dominant, and also whether this was an unusual 
occurrence. Neither of the Merlin viruses containing FIX UL128L nucleotides acquired 
mutation in any HCMV ORF, although Merlin virus containing the UL130 A>G mutation did 
acquire an ablating deletion in the eGFP cassette, demonstrating that mutations can be acquired 
even in the absence of obvious selective pressure.  
 Utility of the novel Merlin reagents  7.4.4
 With the exception of an ablating mutation in RL13 and modified UL128L ORFs, the 
novel viruses produced in this work display coding potential equivalent to wildtype virus in 
vivo. Hence, the composition of virions from these viruses can be considered to more accurately 
represent that of the causative agent of disease than other strains previously used. It can be 
envisaged that these qualities will aid more reliable HCMV research, including investigations 
into HCMV pathogenesis; HCMV tissue tropism in vivo; and the mechanisms of binding and 
entry, as well as cell-to-cell spread. A greater understanding in these aspects in HCMV biology 
will likely herald the development of novel therapeutic strategies.  
 An example of the utility of these novel reagents may include the development of 
vaccine strategies based on the pentameric complex sub-units. This is currently an area of great 
interest, and preliminary studies to assess the immunogenicity of the pentameric complex or 
UL128L encoded glycoproteins, as well as the homologues encoded by other animal CMVs, has 
been encouraging (Saccoccio, Sauer et al. 2011, Auerbach, Yan et al. 2013, Freed, Tang et al. 
2013, Gnanandarajah, Gillis et al. 2014, Wen, Monroe et al. 2014). Since the novel Merlin 
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viruses containing TB40-BAC4 and FIX nucleotides can be propagated to higher titres without 
loss of UL128L genome region integrity, they may be of utility in vaccine development. The 
Merlin virus containing the entire TB40-BAC4 UL128L genome region may also be valuable 
here, providing a virus that assembles pentameric complexes complex containing natural 
epitope variations. Merlin viruses containing wildtype UL128L (native or derived from strain 
3301) and producing virions with the greatest levels of pentameric complex may be of use as 
challenge strains to assess the efficacy of any vaccine produced. Further utility of these novel 
variants includes investigations into the alternative roles of the UL128L-encoded glycoproteins 
when in monomeric form, particularly gpUL128. It has recently been reported that this 
glycoprotein may have an additional function as a soluble chemokine homologue, and facilitates 
the attraction of PBMCs, and stimulates expression of TNF-alpha and IL-6 (Zheng, Tao et al. 
2012, Tao, Xu et al. 2014). The novel Merlin viruses containing the UL130 A>G mutation may 
be of particular use here; since UL128 in this virus is expressed efficiently, but is not as 
efficiently incorporated into pentameric complexes, it may be secreted at greater levels. The 
array of novel virus-encoded components identified in Merlin virions may also include 
important virulence factors that are either ideal targets for novel therapies, or be responsible for 
the limited efficacy of existing therapies, and warrant further investigation.  
7.5 Scope for further Merlin BAC development 
Genome regions other than UL128L clearly contributed to the distinct growth 
phenotype of TR, TB40-BAC4 and FIX BAC-derived viruses. These may include features that 
could be exploited to further increase the efficiency by which Merlin virus is propagated in cell 
culture. The most obvious candidates for this include the other glycoproteins that are present in 
the virion envelope and contribute to the mechanisms employed during the binding and entry of 
virions in cells, and also the morphogenesis of progeny virions. Glycoproteins gB, gM and gN 
are major contributors to these processes, and each exists as multiple genotypes. Alignment of 
ORFs encoding these virion envelope glycoproteins to those of other strains deposited in 
GenBank identified no unique nucleotide features that could represent in vitro acquired 
mutations. However, the different gB genotypes have been correlated with different tropism and 
tissue invasiveness (Meyer‐König, Vogelberg et al. 1998). Thus it could be worthwhile 
investigating the impact of natural variations in these glycoproteins.   
Asides from the UL128L encoded glycoproteins, variations in the gH, gL, and gO could 
also influence assembly of either the pentamer or trimer, or alternatively the functionality of 
these complexes. The glycoproteins common to the pentamer and trimer, gH and gL, exist in 2 
and 4 major genotypes, respectively (Chou 1992, Rasmussen, Geissler et al. 2002). 
Comparative nucleotide sequence analysis revealed sequence variations in the UL75 (gH) and 
UL115 (gL) ORFs amongst each BAC-cloned strain, indicating that each of the alternative 
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genotypes was represented. Glycoprotein gO displays extraordinary amino acid sequence 
diversity amongst strains, and exists as 8 genotypes (Rasmussen, Geissler et al. 2002). Analysis 
of UL74 (gO) sequences amongst the strains investigated revealed that each was of a distinct 
genotype; this could explain the distinct growth phenotype of some of the viruses, particularly 
TR BAC-derived virus that did not fit the pentamer/trimer ratio patterns displayed by all other 
viruses. During the time of this work, independent investigations were performed by another 
group to assess and compare levels of pentameric and trimeric gH/gL complexes incorporated 
into virions from different HCMV strains, including those derived from the Merlin and TR 
BACs (Zhou, Yu et al. 2013). The findings of this study potentially contradicted data presented 
in this thesis. Unlike in this work, virions from Merlin-BAC-derived virus contained greater 
levels of the pentameric complex than virions from TR-BAC-derived virus, whilst conversely, 
virions from the TR-BAC-derived virus contained greater levels of trimer compared to those 
from Merlin. This discrepancy may be explained by the fact that virions compared in this thesis 
were produced from epithelial cells, whilst virions compared in this alternative report were 
produced from fibroblasts, underlining that the producer cell can influence the relative virion 
composition. Data in this thesis suggest that the differences between TR and Merlin were 
clearly not due to UL128L, and alternatively ORFs UL75 (gH), UL115 (gL) or UL74 (gO) may 
be responsible. An interesting observation is the apparent chimeric gH encoded by the TR BAC, 
which contains sequence motifs of gH group 1 in N-terminal most domain, and sequence motifs 
of the gH group 2 within the internal region. It is therefore possible that the chimeric gH of TR 
displays greater affinity for gO than the UL128L-encoded glycoproteins. These observations 
open up exciting avenues of exploration and suggest that other components of the gH/gL 
complexes may be manipulated to the optimise the growth phenotype of HCMV in vitro.  
Assessment of the TB40-BAC4 and TR BAC-derived viruses propagated in epithelial 
cells suggested that the UL84 ORF might be manipulated to increase the Merlin virus progeny 
turnover. This ORF encodes a multi-functional protein involved in DNA synthesis initiation at 
the origin of lytic replication (OriLyt) via interactions with the viral DNA polymerase (UL44), 
and also as a transdominant inhibitor of IE2 (ppUL123) that is the major transactivator of early 
gene expression (Gebert, Schmolke et al. 1997). Interactions between pUL84 and ppUL123 
increase the autologous repression of ppUL123, and suppress the cascade of viral gene 
transcription that precedes genome replication. Thus, UL84 has conflicting activities to both 
promote and impede virus replication. UL84 was initially deemed essential for virus growth 
(Sarisky and Hayward 1996), yet it has since been reported that a UL84-null mutant of TB40-
BAC4 remained viable in HFFFs (Spector and Yetming 2010). Domains that facilitate the 
interactions with pUL44 required for genome replication and nucleocapsid translocation are 
located within N-terminal residues 1-68 (Strang, Bender et al. 2012), whilst domains that are 
involved in the transcriptional repression interaction with ppUL123 are found in both the N-
terminal and C-terminal regions (Gebert, Schmolke et al. 1997). The UL84 mutations acquired 
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by TR and TB40-BAC4 derived viruses in epithelial cells each resulted in the production of 
truncated pUL84 lacking C-terminal residues, and were dominant in each of these viruses 
(~80% population size). Thus it appears that domains specifically implicated in the IE2-
mediated repression activity of UL84 are dispensable, and may result in a growth advantage in 
vitro.  
7.6 Composition of Merlin virions – a closer reflection of wildtype virus in vivo 
 By far the most comprehensive description of the HCMV virion composition to date 
was that based on mass-spectrometry analysis of AD169 virions (Varnum, Streblow et al. 
2004). However, given that this strain is a multiple mutant, it is not surprising that as many as 
40 novel virus-encoded components (21 high confidence, 19 low confidence) were identified in 
wildtype Merlin virions. The MS technique is limited in its ability to detect proteins that may 
present at low levels within a complex mixture, as well as those that are small and release few 
signature peptides following trypsinisation. As previously mentioned, increasing virion 
production appears to result in virions containing lower levels of almost all incorporated 
components. AD169 displays virion production that is greater even than that of the Merlin virus 
containing non-intact UL128L, and the abundance of virus encoded proteins incorporated into 
AD169 virion may be further reduced. Thus, several of the novel proteins identified in Merlin 
virions could in fact be incorporated into AD169 virions, though at levels undetectable by MS. 
Recent advances in mass spectrometers may also account for the detection of a greater number 
of proteins in the present study. Furthermore, on MS analysis, protein identification is achieved 
by comparing peptide detection events to a database of predicted peptide signatures. 
Interpretation of ORFs within the HCMV genome have been subject to many revisions since 
MS analysis of AD169 virions, and the more comprehensive database used in this thesis may 
have facilitated the more reliable identification of proteins. For example gpRL14 was detected 
in AD169 virions, though not in Merlin virions, since RL14 has been deemed non-coding in 
more recent interpretations. On this note it should be appreciated that the database used to 
identify proteins included in the Merlin virions did not account for the 700+ distinct ORFs as 
are predicted by ribosome profiling (Stern-Ginossar, Weisburd et al. 2012). Thus it is likely that 
HCMV virions contain further components that were not identified during this work. An 
alternative reason for the differences between Merlin and AD169 virions may also include the 
different preparation protocols used. Purification of AD169 virions involved an initial 
centrifugation of virus over glycerol prior to gradients. However, data presented in this thesis 
demonstrated the centrifugation of virus over glycerol could result in significant aggregate 
formation, potentially explaining detection of gpUL22A in AD169 but not Merlin virions.  
 Of the novel HCMV virion components identified, several are implicated in viral 
genome transcription, replication and encapsidation. This includes, pUL70, the helicase-primase 
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sub-unit 2 that was identified with high confidence, as well as pUL102 and pUL105, helicase-
primase sub-units 3 and 1 respectively that were identified with low confidence (McMahon and 
Anders 2002). Further participants in viral genome replication are pUL98, an alkaline 
deoxyribonuclease (Kuchta, Parikh et al. 2012), and ppUL114, a Uracil-DNA glycosylase 
(Courcelle, Courcelle et al. 2001), each implicated in the repair of viral genomic DNA during 
synthesis and identified with high confidence. Others are involved in the transcription of the 
viral genome, including pUL34 that suppresses expression of US3 (LaPierre and Biegalke 
2001), and pUL123/IE1 protein that is enhances activation of IE2 (the major transactivator of 
viral gene expression) (Malone, Vesole et al. 1990). pUL52 orchestrates DNA encapsidation 
and nucleocapsid maturation/formation (Borst, Wagner et al. 2008). The significance of these 
novel virion components is hard to predict, however their identification may simply reflect the 
sensitive detection of components that remain in association with the genome or capsid at 
residual levels of following virion morphogenesis. Alternatively, the detection of these proteins 
may also reflect limitation in the purity that can be achieved when isolating virions, together 
with the highly sensitive detection by MS-analysis. It would be interesting to determine the 
virion compartment to which the viral chemokine homologues pUL146/vCXC-1 and 
pUL147/vCXC-2 localise. pUL146/vCXC-1 has been shown to be an agonistic ligand for 
cellular chemokine receptors CXCR1 and CXCR2 to attract neutrophils and DCs to sites of 
infected endothelial cells (Luttichau 2010). However, this has been demonstrated for soluble 
pUL146/vCXC-1, and the role of this protein when contained in virions is unclear. Most 
interestingly, up to 14 novel envelope components (7 with high confidence, and 7 with low 
confidence) were also identified. These may be involved in the binding, docking and entry of 
virus in permissive cells, and potentially represent targets to block intra-host virus 
dissemination and inter-host transmission. Like the RL11 family members gpRL1 and gpRL13, 
gpRL12 has possesses anti-body Fc binding and sequestration activities, though this has only 
been demonstrated when expressed from a recombinant expression system (Cortese, Calo et al. 
2012, Cortese 2013). None of pUS9, pUS12, pUS13, pUS14, are described functionally, 
however by homology to US16 (another US12 family member) (Bronzini, Luganini et al. 2012), 
these novel proteins could be tropism factors for epithelial and endothelial cells. US18 and 
US20 are also members of the US12 family and have recently been described to encode NK-cell 
evasion functions by promoting the lysosomal degradation of MIC A, an activating ligand for 
the NK cell receptor NKG2D (Fielding, Aicheler et al. 2014). However it is hard to see how this 
activity would be significant in the virion. Similarly, none of gpUL148, pUL140, or gpUL139, 
are well described functionally, but the ORFs encoding these envelope components are situated 
in the UL/b’ region where multiple proteins are immuno-modulatory, or virulence factors. The 
novel component gpUL141 is another example of an immuno-modulatory protein encoded in 
this genome region. This glycoprotein binds CD155 that is also found at the junctions of 
adjacent epithelial cells (Ogita and Takai 2006), and has been described as a receptor for 
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poliovirus entry (Mendelsohn, Wimmer et al. 1989). Thus, when presented in the virion, 
gpUL141 may be implicated in the entry of virus in this cell type, or perhaps cell-to-cell spread. 
Conversely, gpUL16 also impairs NK activity, but has been reported to impair the replication of 
virus in epithelial cells (Mocarski, Shenk et al. 2007). The roles of gpUL74A and gpUL116 in 
the virion are unknown. Peptides from >2000 cellular proteins were detected by MS analysis of 
Merlin virions, though the number that met the criteria for high confidence identification would 
likely be much lower. However the significance of these proteins is not easily predicted, as the 
cellular proteins incorporated into virions produced in cell culture may be significantly different 
to those incorporated in vivo. To validate proteins identified in Merlin virions as bona fide 
HCMV virion components, and also identify cellular proteins that are incorporated into 
wildtype virions during natural infection, analysis of virions directly from clinical samples will 
need to be performed. 
As previously mentioned, virions containing greater levels of pentamer and lower levels 
of trimer, or low production of virions, generally contained greater levels of all other 
components. In fact, only 5 virus-encoded proteins were present at reduced levels as pentamer 
levels increased: pUL146/vCXC-1, and envelope components gp41A, gpUL118-gpUL119, 
gN/gpUL73 and pUL140. Of these, the levels of only pUL146/vCXC-1 and gpUL118-gpUL119 
varied by a significant degree, potentially indicating direct interaction with the trimer. In 
contrast to this, proteins that were significantly more abundant with increasing pentamer levels 
included tegument protein pUL36x1, pUL147/vCXC-1, as well as the envelope glycoproteins 
gpUL16 and gpUL148. The biological significance of these variations cannot simply be inferred 
from the difference in relative abundance, but it should be appreciated that experiments 
performed with UL128L-null virus may not accurately reflect the true magnitude of observed 
biological effects. It is of interest that whilst the majority viral proteins did vary between the 
different virions assessed by SILAC-MS analysis, others were present at comparable 
abundance. Since the capsid vertex complex sub-units pUL77 and pUL93 will likely be 
incorporated into different virions with at equimolar quantities, the equivalent relative 
abundance of these proteins amongst the different virions potentially offers a further 
demonstration of the high degree of accuracy in these assays. The other proteins that did not 
apparently vary in abundance between virions may be expressed with efficiency such that they 
are not limiting for the assembly of virions. 
 In summary, the Merlin virion proteome data presented in this thesis provides a more 
comprehensive picture of the composition of wildtype HCMV virions in vivo, and highlights a 
range of components that may be important as tropism determinants, or even immune evasion 
functions. Moreover, virions from the newly produced Merlin variants were found to contain a 
proteome that closely reflected those of the parental wildtype Merlin-BAC, further 
demonstrating the suitability of these reagents for future research.  
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A.I.1. Recombineering of BAC-cloned HCMV genomes (Tables A.I.1-4) 
• Designation of the novel BAC-cloned HCMV genome construct.  
• Co-ordinates for the region in the ‘recipient’ genome to be modified. 
• Primers used for the amplification of the selectable cassette that was inserted into the 
genome region to be modified during the first round of recombineering; primers designated 
SacBF or SacBR are the forward and reverse reading primers, respectively. Primers 
included ~80bp in the 5’ region with sequence homologous to 'recipient’ genome regions 
flanking the intended site of insertion (bold, underlined), and ~20bp in the 3’ region with 
sequence homologous to the termini of the selectable cassette. 
• Co-ordinates within the ‘donor’ genome for regions/sequences to be transferred into the 
‘recipient’ genome in the second recombineering step. 
• Primers used for the amplification of ‘donor’ genome regions/sequences, or 
oligonucleotides used for the delivery of short ‘donor’ sequences. Primers were designed to 
bind and amplify regions with identical sequence across all strains. For the amplification of 
each variant UL128L genome region, short ~20bp primers that bound ~80bp outside of 
UL128 and UL131A were used (Table A.I.1.). Primers used for the amplification of other 
‘donor’ genome regions included: ~80bp in the 5’ region with sequence homologous to 
'recipient’ genome regions flanking the intended site of insertion (bold, underlined): ~20bp 
in the 3’ region with sequence homologous to the termini of the ‘donor’ genome 
region/sequence (italic). Oligonucleotides used for the transfer of single ‘donor’ nucleotides 
or small sequences (red, italic) into recipient genomes contained flanking ~50bp sequences 
homologous to the intended site of insertion in the ‘recipient’ genome (bold, underlined).  
 
A.I.2. Recombineering of AdZ expression vectors (Table A.I.5) 
• V5-tagged transgene inserted into AdZ expression vector construct. 
• Transgene co-ordinates in ‘donor’ strain. 
• Primers used for amplification of variant UL128L ORF transgenes: Primers were designed 
to bind and amplify regions with identical sequence across all strains. Primers were 
designed to contain ~80bp in the 5’ region with sequence homologous to intended site of 
insertion in the AdZ vector construct (bold, underlined), and ~20bp in the 3’ region with 
sequence homologous to the termini of each variant UL128L ORF (italic). Reverse reading 
primers were designed to exclude natural stop codons in each variant UL128L ORF, and 
include sequence encoding a 3’ V5 tag. 
 
All denoted nucleotide positions refer to sequences of each BAC-cloned strain deposited in 
GenBank: Merlin - GU179001; TR AC146906; TB40-BAC4 - EF999921; and FIX - AC146907 
and 3301 - GQ466044.1. 
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Table A.I.1. Recombinant Merlin BACs containing UL128L from other strains in place of the native UL128L in Merlin. 
 
 
 
Recombinant Merlin 
BAC 
Merlin Genome 
Region Modified Primers for cassette amplification 
‘Donor’ genome 
Co-ordinates 
Primers for amplification of sequence 
to be transferred 
Merlin-UL128LTR 
Merlin 
nt 176135-178095 
 
SacBF into Merlin UL128L: 
ATC CAG CCG TTT GTG TTT CTT 
AAC GCT CTC CAG GTA CTG ATC 
CAG GCC CAC GAT CCG GGT TAT 
CTT GTC GTA TTC CAG CCT GTG ACG 
GAA GAT CAC TTC G 
 
SacBR into Merlin UL128L: 
CAG TCT GCA ACA TGC GGC TGT 
GTC GGG TGT GGC TGT CTG TTT 
GTC TGT GCG CCG TGG TGC TGG 
GTC AGT GCC AGC GGG ACT GAG 
GTT CTT ATG GCT CTT G 
 
TR 
nt 211874-213834 
UL128L F: 
GCG TAT TTC GGA CAA ACA CAC A 
 
UL128L R: 
CGC ATG TTG CAG ACT GAG AAA GA 
Merlin-UL128LTB40 
TB40-BAC4 
nt 208578-210534 
Merlin-UL128LFIX 
FIX 
nt 50061-52023 
Merlin-UL128L3301 
3301 
nt 176289-178245 
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Table A.I.2. Recombinant Merlin BACs containing unique mutations identified in TB40-BAC4 UL128 (G>T) and FIX UL130 (A>G). 
 
Recombinant 
Merlin BAC 
Merlin Genome 
Region Modified Primers for cassette amplification 
‘Donor’ 
Sequence 
Oligonucleotide for delivery of 
SNPs 
Merlin-UL128G>T 
Merlin   
 
nt 176612 
SacBF into Merlin UL128 intron 1: 
GGT GGT GAC GAT CCC GCG AAT CTC AGC CGT TTT 
CTC GGG ACT GTA GCA GAC TTC GCC GTC CGG ACA 
CCG CAG CCT GTG CCT GTG ACG GAA GAT CAC TTC G 
SacBR into Merlin UL128 intron 1: 
CTG GAT CTG TCT CTC GAC GTT TCT GAT AGC CAT 
GTT CCA TCG ACG ATC CTC GGG AAT GCC AGA GTA 
GAT TTT CAT GAA TCT GAG GTT CTT ATG GCT CTT G 
TB40-BAC4 
  
nt 209051  
UL128 G>T insert oligo: 
GTT TTC TCG GGA CTG TAG 
CAG ACT TCG CCG TCC GGA 
CAC CGC AGC CTG TGT ATT 
CAT GAA AAT CTA CTC TGG 
CAT TCC CGA GGA TCG TCG 
ATG GAA CAT G  
  
Merlin-UL130A>G 
Merlin   
 
nt 177372 
SacBF into Merlin UL130 CDS: 
GTC TGG CCT TCC CGG TTG TAC AGC AGA TAC AGG 
GTC TCG TTG CGA CAC TCG GGA CCC GTT GAT ACC 
CGC TGG AAC CCC CCT GTG ACG GAA GAT CAC TTC G 
SacBR into Merlin UL130 CDS: 
TAT#TCC#AAA#CCG#CAT#GAC#GCG#GCG#ACG#TTT#TAC#TGT#CCT#
TTT#CTC#TAT#CCC#TCG#CCC#CCA#CGA#TCC#CCC#TTG#CAA#TTC!
CCT#GAG#GTT#CTT#ATG#GCT#CTT#G 
FIX  
 
nt 50792 
UL130 A>G insert oligo: 
CAG GGT CTC GTT GCG ACA 
CTC GGG ACC CGT TGA TAC 
CCG CTG GAA CCC CGG GAA 
TTG CAA GGG GGA TCG 
TGG GGG CGA GGG ATA 
GAG AAA AGG ACA GTA A 
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Table A.I.3. Recombinant Merlin BAC containing TR UL131A 5’ – UL132 5’ genome region 
 
 
  
Recombinant Merlin 
BAC 
Merlin Genome 
Region Modified Primers for cassette amplification 
‘Donor’ genome 
Co-ordinates 
Primers for amplification of 
sequence to be transferred  
Merlin-UL132TR 
Merlin  
nt 178096-179013 
  
 
 
SacBF-into Merlin UL131A-132: 
 
TTC CGC GGT TTC CCG CTG GCA CTG 
ACC CAG CAC CAC GGC GCA CAG ACA 
AAC AGA CAG CCA CAC CCG ACA CAG 
CCG CAT CCT GTG ACG GAA GAT CAC TTC G 
 
 
 
SacBR- into Merlin UL131A-132: 
 
TAG AGG CTT GCG GAA ACC ACG TCC 
TCG TCA CAC GTC GTT CGC GGA CAT 
AGC AAG AA ATC CAC GTC GCC ACG TCT 
CGA GAC TGA GGT TCTT ATG GCT CTT G 
 
TR   
nt 213835-214752 
 
 
 
UL131A-132F: 
 
TTT TCCG CGG TTT CCC GCT 
GGC ACT GAC CCA GCA CCA CGG 
CGC ACA GAC AAA CAG ACA GCC 
ACA CCC GAC ACA GCC GCA TGT 
TGC AGA CTG AGA AAG AGA 
 
 
 
UL131A-132R: 
 
GTA GAG GCT TGC GGA AAC CAC 
GTC CTC GTC ACA CGT CGT TCG 
CGG ACA TAG CAA GAA ATC CAC 
GTC GCC ACG TCT CGA GAA TGC 
CGG CCC CGC GGG GT 
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Table A.I.4. Recombinant Merlin BACs containing tetracycline-binding sequences upstream of UL131A. 
 
 
 
Recombinant 
Merlin BAC 
‘Recipient’ Genome Region 
Modified 
Primers for amplification of selectable 
cassette 
‘Donor’ 
Sequence  
Oligonucleotide for delivery of tet-
binding sequence 
Merlin-tet-UL128L 
Merlin 
nt: 178128 
  
SacB F into Merlin UL131A region: 
ACA GCC ACA CCC GAC ACA GCC 
GCA TGT TGC AGA CTG AGA AAG 
AAA GCT TTA TTA TGA GTC TCT ATC 
ACT GAT AGG GAG CCT GTG ACG GAA 
GAT CAC TTC G 
SacB R into Merlin UL131A region: 
TCT TTC GGT TCC AAC TCT TTC CCC 
GCC CCA TCA CCT CGC CTA TAC 
TAT GTG TAT GAT GTT CCC TAT 
CAG TGA TAG AGA TCT GAG GTT CTT 
ATG GCT CTT G 
Tetracycline 
binding operator 
site 
GCA GAC TGA GAA AGA AAG 
CTT TAT TAT GAG GCA GAC TGA 
GAA AGA AAG CTT TAT TAT GAG 
TCT CTA TCA CTG ATA GGG AGA 
TCT CTA TCA CTG AGG GAC ATC 
ATA CAC ATA GTA TAG GCG 
AGG TGA T 
Merlin-tet-UL128G>T 
Merlin-tet-UL130A>G 
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Table A.I.5. Recombinant AdZ vectors (RAdZ) for the expression of variant UL128L transgenes. 
RAdZ Construct Transgene   Co-ordinates in ‘Donor’ 
genome  
Primers for amplification of sequence to be transferred  
RAdZ-Me-UL128wt Merlin-UL128Lwt - nt: 176,138 – 176,901 UL128 insert F: 
AAC CGT CAG ATC GCC TGG AGA CGC CAT CCA CGC TGT TTT GAC CTC CAT AGA 
AGA CAC CGG GAC CGA TCC AGC CTG GAT CCC GCG CGT CAT GA G TCC CAA A 
UL128 insert R: 
ATA GAG TAT ACA ATA GTG ACG TGG GAT CCT TAC GTA GAA TCA AGA CCT AGG 
AGC GGG TTA GGG ATT GGC TTA CCA GCG CTC TGC AGC ATA TAG CCC ATT T 
RAdZ-TR-UL128 TR - nt: 211,877 – 212,640 
RAdZ-TB-UL128 TB40-BAC4 - nt: 174,931 – 175,690 
RAdZ-FIX-UL128 FIX - nt: 51,263 – 52,020 
RAdZ-Me-UL128G>T Merlin-UL128 G>T - nt: 176,138 – 176,901 
RAdZ-Me-UL130wt Merlin- UL128Lwt - nt: 176,936 – 177,598 UL130 insert F: 
AAC CGT CAG ATC GCC TGG AGA CGC CAT CCA CGC TGT TTT GAC CTC CAT AGA 
AGA CAC CGG GAC CGA TCC AGC CTG GAT CCG CCT GCG TCA CGG GAA ATA A 
UL130 insert R: 
ATA GAG TAT ACA ATA GTG ACG TGG GAT CCT TAC GTA GAA TCA AGA CCT AGG 
AGC GGG TTA GGG ATT GGC TTA CCA GCG CTA ACG ATG AGA TTG GGA TGG G 
RAdZ-TR-UL130 TR nt: 212,675 – 213,337 
RAdZ-TB-UL130 TB40-BAC4 - nt: 175,25 – 176,387 
RAdZ-FIX-UL130 FIX - nt: 50,579 – 51,220 
RAdZ-Me-UL130A>G Merlin-UL130 A>G  - nt: 176,936 – 177,598 
RAdZ-Me-UL131A Merlin  - nt 177,601 – 178,109 UL131A insert F: 
AAC CGT CAG ATC GCC TGG AGA CGC CAT CCA CGC TGT TTT GAC CTC CAT AGA 
AGA CAC CGG GAC CGA TCC AGC CTG GAT CCT CTC AGT CTG CAA CAT GCG G 
UL131A insert R: 
ATA GAG TAT ACA ATA GTG ACG TGG GAT CCT TAC GTA GAA TCA AGA CCT AGG 
AGC GGG TTA GGG ATT GGC TTA CCA GCG CTG TTG GCA AAG AGC CGC ACG C 
RAdZ-TR-UL131A TR  - nt 213,340 – 213,848 
RAdZ-TB-UL131A TB40-BAC4  - nt: 176,390 – 176,898 
RAdZ-FIX-UL131A FIX  - nt: 50,047– 50,536 
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 To determine the contribution of TR, TB40-BAC4 and FIX UL128L genome regions to 
the distinct growth phenotypes of virus, each variant UL128L was inserted into Merlin genome 
in place of the native UL128L genome region, to assess whether the growth phenotype of the 
donor virus was also transferred (Table A.II.1.). 
 
 
 
Table A.II.1. Recombinant Merlin BAC variants containing UL128L from TR, TB40-
BAC4 and FIX 
 
 
 
 
Genome 
Background 
UL128L origin 
Designation in text: 
BAC /Reconstituted Virus 
Merlin 
Native; mutated: G>A in UL128 
at nt 176260 (R>stop) 
Merlin-UL128Lmut/RV-Me-UL128Lmut 
Native; wildtype Merlin-UL128Lwt/RV-Me-UL128Lwt 
TR Merlin-UL128LFIX /RV-Me-UL128LTR 
TB40-BAC4 Merlin-UL128LTB40 /RV-Me-UL128LTB40 
FIX Merlin-UL128LFIX /RV-Me-UL128LFIX 
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A.II.1 Impact of variant UL128L in fibroblasts 
A.II.1.1 Cell-to-cell spread 
Fibroblasts (HFFFs) were again transfected with BAC DNA for the recombinant Merlin 
viruses to assess the specific impact of each variant UL128L genome region on the cell-to-cell 
spread of virus in this cell-type (Figure A.II.1.A). As previously demonstrated, the Merlin virus 
lacking intact UL128L (RV-Me-UL128Lmut) displayed the greatest capacity for cell-to-cell 
spread in fibroblasts and formed HFFF plaques that were significantly larger than any other 
virus assessed (p < 0.0001). However, whereas RV-TR had formed HFFF plaques that were 
smaller than those produced by RV-Me-UL128Lwt, RV-Me-UL128LTR formed HFFF plaques 
with comparable size to those formed by RV-Me-UL128Lwt. RV-Me-UL128LTB40 and RV-
Merlin-UL128LFIX each formed larger HFFFs plaques than RV-Me-UL128Lwt (p < 0.001 and p 
< 0.01, respectively), mirroring the previously observed greater cell-to-cell spread displayed by 
both RV-TB40-BAC4 and RV-FIX compared to RV-Me-UL128Lwt. 
A.II.1.2 Dissemination kinetics and cell-free virus production 
 RV-Me-UL128Lmut again spread the most efficiently (Figure A.II.1.B) and produced the 
greatest peak titres of cell-free virus (Figure A.II.1.C), whilst dissemination of RV-Me-
UL128Lwt was again delayed and produced the lowest peak titre of cell-free virus. However, in 
this assay, the peak titre of cell-free virus produced by RV-Me-UL128Lwt was only ~ 270-fold 
lower than that produced by RV-Me-UL128Lmut, whereas the difference had previously been 
~1000-fold. The dissemination kinetics of RV-Me-UL128LTR resembled that of RV-Me-
UL128Lwt at all time points through the infection time-course, yet similar to what was 
demonstrated by RV-TR, cell-free virus production by RV-Me-UL128LTR rapidly increased at 
later time points, and the peak titre of cell-free virus produced was ~100-fold greater that than 
produced by RV-Me-UL128Lwt. Merlin viruses expressing TB40-BAC4 and FIX UL128L each 
displayed dissemination kinetics and cell-free virus production that was intermediate compared 
to the Merlin control infections. RV-Me-UL128LTB40 produced peak titres of cell free virus ~4-
fold greater than that produced by RV-Me-UL128Lwt, whilst Me-UL128LFIX produced a peak 
titre of cell- free virus ~7.5-fold greater than that produced by RV-Me-UL128Lwt.  
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Figure A.II.1 Growth phenotype impact of variant UL128L in fibroblasts. (A) HFFF cells were 
transfected with BAC DNA for the indicated viruses and incubated under semisolid overlay, with plaque 
sizes measured 2 weeks post transfection. Means and ±SEM are shown. (Where indicated, the mean 
plaque sizes formed by RV-Me-UL128Lwt, RV-Me-UL128LTR, RV-Me-UL128LTB40, RV-Me-UL128LFIX 
were compared to those formed by RV-Me-UL128Lmut (black line) and/or RV-Me-UL128Lwt (grey line) 
by 1-way analysis of variance [ANOVA] followed by Dunnett’s posttest: * p < 0.05, ** p <0.01, *** p < 
.001, **** p < 0.0001). (B) HFFF cells were transfected with BAC DNA for the indicated viruses, and 
the dissemination of infection was allowed to progress until the monolayer was destroyed. At weekly 
time points post transfection (p.t.), the level of infection was estimated by fluorescence microscopy 
analysis of eGFP-expressing cells. (C) Supernatant samples collected at weekly time points from the 
infections shown in panel B were titrated on HFFFs to provide a measure of cell-free virus release 
throughout the time-course of each infection.  
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A.II.1.3. Validation of variant UL128L impact in fibroblasts 
 To determine whether the growth phenotypes of the recombinant Merlin viruses were 
an accurate reflection of the impact of each variant UL128L, we again sought to determine 
whether any virus had undergone adaptation during the growth kinetics assays in HFFFs. The 
relative plaque sizes formed following transfection of HFFFs with BAC DNA for each virus (p0 
virus) (Figure A.II.2.A) were again compared to those formed during titration of progeny virus 
produced at the latest time-points in each infection (HFFFp1 virus) (Figure A.II.2.B). With the 
exception of RV-Me-UL128LTR—HFFFp1, no other progeny displayed any signs of adaptation. 
Furthermore, PCR-based sequencing confirmed UL128L in these viruses to be equivalent to 
each parental BAC clone. Whereas transfection of HFFFs with Merlin-UL128LTR BAC DNA 
resulted in the formation in smallest plaques of any virus investigated, HFFF plaques formed 
during titration of the progeny produced in the RV-Me-UL128LTR-HFFFp1 of comparable size 
to those formed by progeny of the Merlin virus lacking intact UL128L (RV-Me-UL128Lmut-
HFFFp1). PCR-based sequencing analysis revealed the RV-Me-UL128LTR-HFFFp1 to contain a 
major mutant population that acquired a 507 bp deletion affecting ORFs UL128 and UL130 (nt 
176,742-177,249, as well as a premature stop coding SNP (Q>Stop) in UL130 (nt 177,355). 
Thus, the dramatic increase in cell-free virus production by the RV-Me-UL128LTR infection 
occurred secondarily to mutation in UL128L.  
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Figure A.II.2 Cell-to-cell spread of viruses derived from Merlin-BAC variants containing UL128L from other strains in fibroblasts, before and after passage in fibroblasts. 
(A) Plaque size (±SEM) formed 2 weeks post-transfection of HFFFs with BAC DNA (p0) for each indicated virus, and incubation under overlay. (B) HFFF plaque sizes (±SEM) 
formed 2 weeks post-infection of HFFFs with viruses in supernatants collected at final time-point of growth kinetics assays performed in fibroblasts (HFFF-p1), and incubation 
overlay. 
  276 
A.II.2.1 Impact of variant UL128L in epithelial cells 
A.II.2.2 Cell-to-cell spread  
 The specific contribution of each variant UL128L to cell-to-cell spread of virus in 
epithelial cells (RPE-1s) was assessed (Figure A.II.3.A). As previously demonstrated, RV-Me-
UL128Lwt again formed the largest RPE-1 plaques, whilst RV-Me-UL128Lmut was unable to 
form multi-cellular RPE-1 plaques. RV-Me-UL128LTR formed RPE-1 plaques with mean size 
that did not differ from those produced by RV-Me-UL128Lwt by any significant degree. In 
contrast to this, whilst RV-Me-UL128LTB40 formed multi-cellular RPE-1 plaques that were 
significantly larger than those formed by RV-Me-UL128Lmut (p < 0.0001), these were still 
smaller than those formed by RV-Me-UL128Lwt (p < 0.01). Similar to RF-FIX, RV-Me-
UL128LFIX formed RPE-1 plaques with comparable size to those formed by RV-Me-UL128Lmut 
and significantly smaller compared to those formed by RV-Me-UL128Lwt (p < 0.0001), the 
smallest of any virus investigated. However unlike the majority of RPE-1 plaques formed by 
RV-FIX, multi-cellular plaques formed by RV-Me-UL128LFIX were consistently observed.  
A.II.2.3 Dissemination kinetics and cell-free virus production 
 An assessment of the dissemination kinetics and cell-free virus production of each 
recombinant Merlin virus was also performed in epithelial cell (Figure A.II.3.B+C). RV-Me-
UL128Lwt spread the fastest in RPE-1s, and similar to findings in fibroblasts, RV-Me-UL128LTR 
spread with identical kinetics. Furthermore the peak titre of cell-free virus produced by RV-Me-
UL128LTR was also comparable to that produced by RV-Me-UL128Lwt. RV-Me-UL128LTB40 
also displayed identical dissemination kinetics to RV-Me-UL128Lwt, unlike the parental virus 
RV-TB40-BAC4 that displayed delayed dissemination kinetics in this cell type. However, like 
RV-TB40-BAC4, RV-Me-UL128LTB40 did produce greater peak titres of cell-free virus that 
were ~18-fold greater than that produced by RV-Me-UL128Lwt. Interestingly, RV-Me-
UL128LFIX was able to establish productive infection in RPE-1s, whereas RV-FIX previously 
could not. Nonetheless, transfer of FIX UL128L did reduce the dissemination kinetics of Merlin 
virus in RPE-1s, and also increased the productivity of cell-free virus in this cell type such that 
the peak titre of cell-free virus produced was ~12-fold greater than that produced by RV-Me-
UL128Lwt.  
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Figure A.II.2 Growth phenotype impact of variant UL128L in Epithelial cells. (A) RPE-1 cells were 
transfected with BAC DNA for the indicated viruses and incubated under semisolid overlay, with plaque 
sizes measured 3 weeks post transfection. Means and ±SEM are shown. (Where indicated, the mean 
plaque sizes formed by RV-Me-UL128Lwt, RV-Me-UL128LTR, RV-Me-UL128LTB40, RV-Me-UL128LFIX 
were compared to those formed by RV-Me-UL128Lmut (black line) and/or RV-Me-UL128Lwt (grey line) 
by 1-way analysis of variance [ANOVA] followed by Dunnett’s posttest: * p < 0.05, ** p <0.01, *** p < 
.001, **** p < 0.0001). (B) RPE-1 cells were transfected with BAC DNA for the indicated viruses, and 
the dissemination of infection was allowed to progress until the monolayer was destroyed. At weekly 
time points post transfection (p.t.), the level of infection was estimated by fluorescence microscopy 
analysis of eGFP-expressing cells. (C) Supernatant samples collected at weekly time points from the 
infections shown in panel B were titrated on HFFFs to provide a measure of cell-free virus release 
throughout the time-course of each infection.  
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A.II.2.4. Validation of variant UL128L impact in epithelial cells 
 Comparison of HFFF plaque sizes formed immediately following transfection (Figure 
A.II.4.A), to those produced during titration of progeny virus produced in RPE-1 epithelial cells 
(Figure A.II.4.B), gave no indication that any virus had undergone adaptation in epithelial cell 
culture. PCR-based sequencing confirmed UL128L in these viruses to be equivalent to each 
parental BAC clone. Hence, the impact of each variant UL128L on the growth phenotype of 
virus in epithelial cells was accurately represented. 
A.II.2.5. Conclusion 
 In summary, TR UL128L was not the major difference responsible for the distinct 
growth phenotype of RV-TR in epithelial cell culture compared to RV-Me-UL128Lwt. In fact, in 
all investigations performed, TR UL128L was functionally equivalent to that of wildtype 
UL128L. However, TB40-BAC4 and FIX UL128L were responsible, at least partially for the 
distinct growth phenotypes of RV-TB40-BAC4 and RV-FIX in epithelial cell culture. 
Interestingly, RV-FIX was non-viable in RPE-1s, yet RV-Me-UL128LFIX was, albeit with 
dramatically reduced fitness compared to RV-Me-UL128Lwt. It was therefore confirmed that 
FIX UL128L is indeed functionally intact, and sequence features in other genome regions must 
dictate the incompatibility of FIX in RPE-1s. 
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Figure A.II.4 Cell-to-cell spread of viruses derived from Merlin-BAC variants containing UL128L from other strains in fibroblasts, before and after passage in epithelial 
cells. (A) Plaque size (±SEM) formed 2 weeks post-transfection of HFFFs with BAC DNA (p0) for each indicated virus, and incubation under overlay. (B) HFFF plaque sizes 
(±SEM) formed 2 weeks post-infection of HFFFs with viruses in supernatants collected at final time-point of growth kinetics assays performed in epithelial cells (RPE-1-p1), and 
incubation overlay. 
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Plaque size comparisons were performed as follows: 
• Plaque sizes formed by each virus in either fibroblast (HFFFs) or epithelial cells    
(RPE-1s and ARPE-19s) were first logged, thus normalising each data set. 
• Normalized plaque size data sets were then analysed by one-way analysis of variance 
(ANOVA) and Dunnett’s post-test.  
• In the tables below, the mean plaque size formed by each infection is noted, as are the 
fold-differences in plaque sizes between infections, and the significance (p) of any 
difference observed (as determined by Dunnett’s post-test). 
• Mean plaque sizes formed by each infection that differed by a significant degree are 
highlighted: where the mean plaque sizes formed by any given virus were larger than 
those formed the comparison virus, in green; where smaller than those formed by the 
comparison virus, in pink. 
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Table A.III.1. Comparison of mean HFFF and RPE-1 plaque sizes formed immediately following transfection with BAC DNA for each strain investigated. 
 
Virus 
HFFFs RPE-1s 
Mean Plaque 
Size (μm2) Compared to RV-Me-UL128Lmut 
Compared to 
RV-Me-UL128Lwt 
Mean Plaque 
Size (μm2) Compared to RV-Me-UL128Lmut 
Compared to 
RV-Me-UL128Lwt 
RV-Me-UL128Lmut 627681.875  + 8.75x (p < 0.0001) 
1886.625  - 32.25x (p < 0.0001) 
RV-Me-UL128Lwt 70942.625 - 8.75x (p < 0.0001)  
60977.625 + 32.25x 
(p < 0.0001)  
RV-TR 29882.25 - 21x (p < 0.0001) 
- 2.5x 
(p < 0.05) 
9897.625 + 5.25x 
(p < 0.001) 
- 6.25x 
(p < 0.0001) 
RV-TB40-BAC4 285380.125 - 2.25x (ns) 
+ 4x 
(p < 0.0001) 
11497.25 + 6x 
(p < 0.0001) 
- 5.25x 
(p < 0.0001) 
RV-FIX 188327.50 - 3.25x (p < 0.0001) 
+ 2.75x 
(p < 0. 01) 
2306.00 + 1.25x 
(ns) 
- 26.5x 
(p < 0.0001) 
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Table A.III.2. Comparison of mean HFFF and RPE-1 plaque sizes formed immediately following transfection with BAC DNA for recombinant Merlin 
viruses containing variant UL128L genome regions from other strains. 
 
Virus 
HFFFs RPE-1s 
Mean Plaque 
Size (μm2) 
Compared to 
RV-Me-UL128Lmut 
Compared to 
RV-Me-UL128Lwt 
Mean Plaque 
Size (μm2) 
Compared to 
RV-Me-UL128Lmut 
Compared to 
RV-Me-UL128Lwt 
RV-Me-UL128Lmut 317676.00  + 8.5x (p < 0.0001) 
6945.625  -9.5x (p < 0.0001) 
RV-Me-UL128Lwt 37989.50 - 8.25x (p < 0.0001)  
65130.50 + 9.5x 
(p < 0.0001)  
RV-TR 30536.50 - 10.5x (p < 0.0001) 
- 1.25x 
(ns) 
55584.125 + 8x 
(p < 0.0001) 
- 1.25x 
(ns) 
RV-TB40-BAC4 94620.50 - 3.25x (p < 0.0001) 
+ 2.5x 
(p < 0.001) 
25579.25 + 3.75x 
(p < 0.0001) 
- 2.5x 
(p < 0.01) 
RV-FIX 114900.125 - 2.75x (p < 0.0001) 
+ 3x 
(p < 0.01) 
9476.92 + 1.25x 
(ns) 
- 6.75x 
(p < 0.0001) 
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Table A.III.3. Comparison of HFFF and RPE-1 plaques formed immediately following transfection with BAC DNA for recombinant Merlin viruses 
containing TR UL131A 5’ – UL132 5’ genome region. 
 
Virus 
HFFFs RPE-1s 
Mean Plaque 
Size (μm2) 
Compared to 
RV-Me-UL128Lwt 
Compared to 
RV-TR 
Mean Plaque 
Size (μm2) 
Compared to 
RV-Me-UL128Lwt 
Compared to 
RV-TR 
RV-Me-UL128Lwt 40302.375  + 2x (p < 0.05) 
54918.375  + 2.5x (p < 0.001) 
RV-TR 20798.25 - 2x (p < 0.05)  
22072.125 - 2.5x 
(p < 0.001)  
RV-Me-UL132TR 66365.50 +1.75x (ns) 
+ 3.25x 
(p < 0.01) 
63939.75 + 1.25x 
(ns) 
+ 3x 
(p < 0.0001) 
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Table A.III.4.a Comparison of mean HFFF plaque sizes formed immediately following transfection with BAC DNA for recombinant Merlin viruses 
containing UL128L genome regions from strain 3301 or TB40-BAC4, as well as the unique nucleotide identified in TB40-BAC4 UL128. 
 
Virus 
HFFFs  
Mean Plaque Size (μm2) Compared to  
RV-Me-UL128Lmut 
Compared to  
RV-Me-UL128Lwt 
Compared to  
RV-Me-UL128L3301 
Compared to  
RV-Me-UL128LTB40 
RV-Me-UL128Lmut 336104.75     
RV-Me-UL128Lwt 63658.50 - 5.25x (p < 0.0001)    
RV-Me-UL128L3301 50859.50 - 6.5x (p < 0.0001)    
RV-Me-UL128LTB40 112035.875 - 3x (p < 0.0001) 
+ 1.75x 
(p < 0.05) 
+ 2.25x 
(p < 0.01)  
RV-Me-UL128G>T 
112027.625 
 
- 3x 
(p < 0.0001) 
+ 1.75x 
(p < 0.05) 
+ 2.25x 
(p < 0.01) 
+/-1x 
ns 
 
 
 288  
 
Table A.III.4.b Comparison of mean RPE-1 plaque sizes formed immediately following transfection with BAC DNA for recombinant Merlin viruses 
containing UL128L genome regions from strain 3301 or TB40-BAC4, as well as the unique nucleotide identified in TB40-BAC4 UL128. 
 
Virus 
RPE-1s  
Mean Plaque Size (μm2) Compared to  
RV-Me-UL128Lmut 
Compared to  
RV-Me-UL128Lwt 
Compared to  
RV-Me-UL128L3301 
Compared to  
RV-Me-UL128LTB40 
RV-Me-UL128Lmut 3841.625     
RV-Me-UL128Lwt 109047.00 + 28.5x (p < 0.0001)    
RV-Me-UL128L3301 46353.25 + 24x (p < 0.0001) 
- 1.25x 
(ns)   
RV-Me-UL128LTB40 50317.25 + 12x (p < 0.0001) 
- 2.25x 
(p < 0.05) 
- 2x 
(p < 0.05)  
RV-Me-UL128G>T 91813.125 + 13x (p < 0.0001) 
- 2.25x 
(p < 0.05) 
- 2x 
(p < 0.05) 
+/- 1x 
(ns) 
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Table A.III.5.a Comparison of mean HFFF plaque sizes formed immediately following transfection with BAC DNA for recombinant Merlin viruses 
containing UL128L genome regions from strain FIX, as well as the unique nucleotide identified in FIX UL130. 
 
Virus 
HFFFs 
Mean Plaque Size (μm2) Compared to 
RV-Me-UL128Lmut 
Compared to 
RV-Me-UL128Lwt 
Compared to 
RV-Me-UL128LFIX 
RV-Me-UL128Lmut 336104.75    
RV-Me-UL128Lwt 63658.50 - 5.25x (p < 0.0001)   
RV-Me-UL128LFIX 122350.375 - 2.75x (p < 0.05) 
+ 2x 
(ns)  
RV-Me-UL130A>G 128950.125 - 2.5x (p < 0.001) 
+ 2x 
(p < 0.001) 
+/-1x 
(ns) 
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Table A.III.5.b Comparison of mean RPE-1 plaque sizes formed immediately following transfection with BAC DNA for recombinant Merlin viruses 
containing UL128L genome regions from strain FIX, as well as the unique nucleotide identified in FIX UL130. 
 
Virus 
 
RPE-1s 
Mean Plaque Size (μm2) Compared to 
RV-Me-UL128Lmut 
Compared to 
RV-Me-UL128Lwt 
Compared to 
RV-Me-UL128LFIX 
RV-Me-UL128Lmut 3915.50    
RV-Me-UL128Lwt 104883.625 + 26.75x (p < 0.0001)   
RV-Me-UL128LFIX 26572.125 + 6.75x (p < 0.0001) 
-4x 
(p < 0.0001)  
RV-Me-UL130A>G 35727.125 + 9x (p < 0.0001) 
-3x 
(p < 0.0001) 
+ 1.25x 
(ns) 
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 The unique G>T identified in TB40-BAC4 UL128 lay 6 nucleotides in from the intron 
1 splice acceptor site determined by mRNA mapping experiments (Akter, Cunningham et al. 
2003). Given the location of this nucleotide variation, the splicing of UL128 pre-mRNA 
transcripts could be interrupted by this mutation. Thus, investigations into the impact of the 
G>T mutation commenced with the mapping of splice donor and acceptor sites in Merlin 
wildtype UL128, and also in Merlin UL128 containing the G>T mutation using three alternative 
predictive tools: SplicePort (Dogan, Getoor et al. 2007), NNSplice v.0.9 (Reese, Eeckman et al. 
1997) and NetGene2 (Brunak, Engelbrecht et al. 1991). Predicted splice donor and acceptor 
sites are listed in Table A.IV.1. 
 The splice donor and acceptor sites were initially mapped in Merlin wildtype UL128L. 
In all analyses, the intron 1 splice donor site was predicted to reside at nucleotide position 164, 
corresponding to the splice donor site in established UL128 ORF interpretations. An alternative 
splice donor site was proposed at nucleotide position 196 using NNsplice v.0.9, however 
previous mRNA mapping experiments have generated no data to suggest the authenticity of this 
position. Various UL128 intron 1 splice acceptor sites were predicted, including nucleotide 
position 287 that corresponded to the splice acceptor site in current UL128 ORF interpretations. 
Alternative splice acceptor sites were predicted at nucleotide position 231, using SplicePort and 
NetGene2, at positions 320 and 327 using NetGene2 alone, and also at position 385 using 
NNsplice v.0.9 alone. Though like the alternative splice donor sites predicted by NNsplice 0.9, 
no data from UL128 mRNA mapping experiments support these proposed positions as authentic 
splice acceptor sites. Various candidate intron 2 splice donor and acceptor sites donor sites that 
were predicted by each analysis, including those determined to be authentic by mRNA mapping 
experiments at positions 422 and 542 respectively.  
 Splice donor/acceptor mapping of Merlin UL128 containing the unique G>T nucleotide 
substitution differed only in the prediction of intron 1 splice acceptor sites. The alternative 
splice acceptor sites were again proposed, whilst no analysis predicted the authentic splice 
acceptor site at nucleotide position 287. Therefore the unique G>T nucleotide feature identified 
in TB40-BAC4 UL128 intron 1 had the potential to disrupt the splice acceptor function at 
nucleotide position 287.  
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Figure A.IV.1. Potential UL128 intron 1 and intron 2 splice donor/acceptor sites (A) Splice donor/acceptor sites predicted for intron 1 and intron 2 of HCMV ORF UL128. 
Arrows pointing rightwards indicate splice donor sites; arrows pointing leftwards indicate splice acceptor sites. Positions highlighted in pink arrows are authentic donor/acceptor 
sites determined by mRNA mapping experiments; in dark blue are cryptic sites predicted by NNSplice 0.9; in grey are cryptic sites predicted by Spliceport; in green are cryptic sites 
predicted by NetGene. (B) Effect of exon 2 skipping with intron 1 splice donor site using intron 2 splice acceptor site. (C) Effect of activating cryptic splice site at position 21 – 
premature stop codon is highlighted by light blue arrow. (D) Effect of activating cryptic splice acceptor site at position 385 – premature stop codon is highlighted by light blue arrow. 
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Table A.IV.1. Predicted splice ‘donor’ and ‘acceptor’ sites for UL128 introns 1 and 2. 
 
UL128 intron 
Splice 
Donor/Acceptor 
Site 
SplicePort NNSplice 0.9 NetGene 
Intron 1 
Donor 
164 164 164 
 196  
Acceptor 
287* 287* 287* 
231 385 231 
  320 
  327 
Intron 2 
Donor 422 422 422 
Acceptor 
542 542 542 
556  556 
623  583 
  594 
  600 
 
Nucleotide positions are given relative to the sequence of the UL128 ORF in Merlin BAC-cloned genome 
deposited in GenBank (GU179001). In bold are splice ‘donor’ and ‘acceptor’ sites shown to be authentic 
by mRNA mapping experiments. In italics are novel ‘donor’ and ‘acceptor’ sites predicted in the 
corresponding predictive tool. * - denotes intron 1 acceptor site predicted in Merlin UL128 with wildtype 
sequence, though absent in Merlin UL128 containing the unique G>T nucleotide.   
 
 
This loss of the intron 1 splice acceptor site at nucleotide position 287 would potentially 
manifest in a range of possible effects that included, but were not limited to: 
• The splicing of intron 1 donor and intron 2 splice acceptor site at position 542, 
resulting in the skipping of exon 2. In this scenario, exon 3 was predicted to remain in 
frame, but the amino acids encoded by sequence in exon 2 would be absent from 
gpUL128.  
• The use of cryptic splice acceptor site at position 231, resulting in the inclusion of 56 
nucleotides from intron 1. This would cause a frame-shift in exons 2 and 3, resulting in 
the inclusion of 43 abnormal amino acids and introduce a premature stop codon that 
truncated gpUL128 after 98 amino acids.  
• The use of cryptic splice acceptor site at position 385 within exon 2. This was also 
predicted that causes a frame shift in the remainder of exon 2 sequences, resulting in 
the inclusion of 5 abnormal amino acids and the truncation of gpuL128 after 60 
residues.  
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 All virus stocks were sequenced following reconstitution from BAC DNA to ensure 
they had not undergone mutation during passage.  All matched the original BAC sequence 
perfectly. Sequence data sets were generated using either a Genome Analyzer IIx or MiSeq 
instrument (Illumina, San Diego, CA, USA). 1000ng of DNA from each sample was sheared by 
sonication and DNA fragments were purified and size-selected using AMPure XP beads 
(Beckman-Coulter, High Wycombe, UK). Purified DNA fragments were end-repaired, 3’-
adenylated, ligated to paired-end multiplexing adapters and amplified by PCR using standard 
methods (Illumina). Sequence read data sets were filtered to remove bases less than phred 
quality 30 and processed for adapter removal using Trim Galore v. 0.2.2, which is a wrapper for 
Cutadapt and FastQC  (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore). 
Filtered reads were aligned against reference genomes using BWA v0.6.2-r126 (Li and Durbin 
2009). Indexed Bam files were generated from the alignments using Samtools v. 0.1.18 (Li, 
Handsaker et al. 2009) and viewed using Tablet 1.12.12.05 (Milne, Bayer et al. 2010).
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Solutions 
• MS solvent; 3% (V/V) MeCN, 0.1% (V/V) TFA 
• In-gel destain solution; 1:1 (V/V) H2O: acetonitrile 
• In-gel reduction solution; 10 mM DTT, 100 mM NH4HCO3 
• In-gel alkylation solution; 55 mM iodoacetamide, 100 mM NH4HCO3 
• In-gel digestion solution; 12.5 ng/µL modified trypsin, 50 mM NH4HCO3 
• In-gel peptide extraction solution 1; 1:1 (V/V) 50 mM NH4HCO3/acetonitrile 
• In-gel peptide extraction solution 2; 1:1 (V/V) 5% (V/V) formic acid/acetonitrile 
 
In-gel digestion: 
• Gel pieces are destained at room temperature for 15 min with shaking at 800 rpm using 
In-gel destain solution.  Multiple washes may be necessary to fully destain samples. 
• Destained samples are equilibrated in 100 mM NH4HCO3, after 5 min equilibration an 
equal volume of acetonitrile is added and incubated at room temperature for 15 min 
with shaking at 800 rpm. 
• Equilibration solution is removed and replaced with In-gel reduction solution. Samples 
are reduced at 56°C for 45 min with shaking at 800 rpm. 
• In-gel reduction solution is removed and replaced with an equal volume of In-gel 
alkylation solution. Samples are alkylated for 30 min at room temperature in the dark 
with shaking at 800 rpm. 
• Samples are washed twice with 100 mM NH4HCO3 followed by equal volumes of 
acetonitrile as in step 2. Following washes, gel pieces are dehydrated and dried using 
acetonitrile and a vacuum centrifuge. 
• Sufficient In-gel digestion solution is added to cover the gel pieces and samples are 
incubated for 30 min on ice to allow gel pieces to rehydrate. Excess In-gel digestion 
solution is removed from the rehydrated gel pieces and replaced with fresh 50 mM 
NH4HCO3. Samples are digested overnight at room temperature.  
• Digested peptides are extracted once with In-gel peptide extraction solution 1 and twice 
with In-gel peptide extraction solution 2. All extraction steps are performed at room 
temperature with shaking at 800 rpm. The three washes are pooled in a 0.6 mL 
Maxymum Recovery microtube (Axygen, #MCT-060-L-C) and dried almost to 
completion using a vacuum centrifuge. 
• Re-suspend sample in 10 µL MS solvent. 
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LC-MSMS 
LC-MSMS data were generated using a RSLC3000 (Dionex) coupled to a Q Exactive mass 
spectrometer with an EASY-spray source (Thermo). Peptides were trapped on a 5 mm PepMap 
5µm C18 µ-Precolumn and eluted to a 50 cm, 2 µm PepMap column (Dionex).  Data were 
acquired in a Top 10 DDA fashion with MS scans in the Orbitrap at 70,000 (fwhm at 200 m/z), 
a target value of 1e6 and a maximum ion accumulation time of 250ms. The 10 most intense 
peaks with charges ≥2 were fragmented in the HCD collision cell with normalized collision 
energy of 28%. Tandem mass spectra were acquired in the Orbitrap at 17,500 (fwhm at 200 
m/z), a target value of 5e4 and a maximum accumulation time of 200 ms. Raw files were 
processed using MaxQuant 1.3.0.5 and searched against a concatenated human/HCMV 
database. Data were searched allowing a MSMS tolerance of 20 ppm and a protein and peptide 
FDR of 0.01. CAM cysteine was defined as a fixed modification while oxidized methionine, 
acetyl (protein N-terminus), and deamidated N/Q were defined as potential variable 
modifications. 
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 Raw data from the SILAC-MS analysis of Merlin virion preparations described the 
ratios of ‘heavy’-‘medium’, ‘medium’-light’, and ‘heavy’-‘light’ versions of all proteins 
identified, according to a log2 scale. Data from the MV-P2 mixed virion preparation were 
corrected to accurately reflect the relative abundance of proteins in an equivalent number of 
different virions, by normalising the ratios of all proteins in each comparison by the reported 
ratios of differently labelled pUL86 (MCP). Corrected raw SILAC-MS data are included in 
Table A.VI.1. 
 
Table A.VI.1 SILAC-MS raw data.  
 
ORF 
RV-Me-UL128Lmut 
Vs. 
RV-Me-UL128Lwt 
RV-Me-UL128G>T 
Vs. 
RV-Me-UL128Lwt 
RV-Me-UL128G>T 
Vs. 
RV-Me-UL128Lmut 
Ratio 
(Log2) 
Fold - 
difference 
Ratio 
(Log2) 
Fold - 
difference 
Ratio 
(Log2) 
Fold - 
difference 
Capsid: 
UL46 - 0.0359 1.0252 - 0.0312 1.0219 - 0.0084 1.0058 
UL48A - 0.1374 1.1000 - 0.2222 1.1665 - 0.0547 1.0387 
UL80 - 0.9882 1.9837 - 0.2104 1.1570   0.9148 1.8853 
UL85  0.0240 1.0168 - 0.0152 1.0106 - 0.0187 1.0131 
UL86 - 1.0000 - 1.0000 - 1.0000 
UL104 - 0.0209 1.0146  0.0889 1.0636  0.0118 1.0082 
Tegument: 
UL24 - 0.3143 1.2434 - 0.5243 1.4383 - 0.2025 1.1507 
UL25 - 0.5177 1.4317 - 0.8973 1.8626 - 0.2202 1.1649 
UL26 - 0.5018 1.4159 - 0.8334 1.7819 - 0.3335 1.2600 
UL28/UL29 - - - - - - 
UL32 - 0.1200 1.0868 - 0.0748 1.0532  0.0536 1.0379 
UL35 - 0.2423 1.1828 - 0.1785 1.1317  0.0544 1.0384 
UL36x1 - 1.8800 3.6807  0.4680 1.3832  2.1753 4.5168 
UL43 -0.4949 1.4092 -0.4798 1.3945 0.0523 1.3945 
UL45 -0.0066 1.0046 -0.1019 1.0732 -0.0611 1.0432 
    308 
UL47 -0.1680 1.1235 0.0432 1.0304 0.2235 1.1676 
UL48 -0.2408 1.1817 0.1038 1.0746 0.3166 1.2454 
UL50 -0.5637 1.4780 0.7703 1.7056 0.9588 1.9437 
UL52 -1.0296 2.0414 0.1814 1.1340 1.3314 2.5165 
UL69 -1.2121 2.3167 -0.0894 1.0640 0.9762 1.9673 
UL71 -0.3189 1.2473 -0.0078 1.0054 0.2943 1.2263 
UL82 -0.8067 1.7492 -0.1260 1.0912 0.6360 1.5540 
UL83 -0.2037 1.1517 -0.5461 1.4601 -0.3500 1.2745 
UL88 -0.2473 1.1870 0.1158 1.0836 0.3462 1.2712 
UL94 -0.4347 1.3516 -0.3294 1.2565 0.0082 1.0057 
UL96 -1.3074 2.4750 -0.4311 1.3482 0.8750 1.8340 
UL97 -1.0396 2.0557 -0.6395 1.5578 0.1683 1.1237 
UL99 0.0477 1.0336 -0.0535 1.0378 -0.1862 1.1378 
UL103 -0.0740 1.0526 -0.1949 1.1447 0.0938 1.0672 
IRS1 -1.2251 2.3377 -0.0455 1.0321 1.3804 2.6034 
US22 -1.0256 2.0359 0.2853 1.2187 1.3462 2.5425 
US23 -0.7245 1.6524 -0.0235 1.0164 0.4894 1.4039 
US24 1.1675 2.2462 1.1049 2.1508 0.9019 1.8685 
TRS1 -1.0583 2.0825 0.0589 1.0416 0.9272 1.9016 
Proteins yet assigned to any virion compartment: 
UL34 -0.8632 1.8190 0.5081 1.4222 1.3833 2.6087 
UL44 -0.7416 1.6720 0.2268 1.1703 0.9343 1.9110 
UL54 - - - - - - 
UL56 - - - - - - 
UL57 -1.0152 2.0212 0.7459 1.6770 1.6652 3.1717 
UL70 -2.6732 6.3784 -0.0435 1.0306 2.5879 6.0123 
UL77 0.1294 1.0938 0.0892 1.0638 -0.0613 1.0434 
UL84 -1.4501 2.7323 0.1392 1.1013 1.4389 2.7111 
UL89 -1.2479 2.3749 -0.4749 1.3898 0.7396 1.6698 
UL93 -0.0597 1.0422 0.0922 1.0660 0.0704 1.0500 
UL98 -0.9679 1.9560 0.2966 1.2282 1.2485 2.3760 
UL102* - 0.4435 1.3599 - - - - 
UL105 - - - - - - 
    309 
UL112-UL113 - 1.2906 2.4462   0.1602 1.1175   1.9507 3.8657 
UL114* -  0.7805 1.7178 - - - - 
UL122 - 0.9112 1.8806   0.3139 1.2430   1.1671 2.2456 
UL123 - - - - - - 
UL146   2.0872 4.2493   0.1527 1.1117 - 1.7744 3.4210 
UL147 - 2.7470 6.7131 - 0.4411 1.3576   2.2612 4.7938 
Envelope: 
RL10   0.0577 1.0408 -0.1261 1.0913 -0.1265 1.0916 
RL11 - - - - - - 
RL12 - 0.7738 1.7098 0.4515 1.3675 1.1123 2.1619 
UL16 - 1.7176 3.2888 0.6025 1.5184 2.3578 5.1259 
UL33x1 - 0.6340 1.5519 -0.1656 1.1216 0.4572 1.3729 
UL41A   0.3420 1.2675 0.2251 1.1688 -0.0434 1.0306 
UL55   0.1167 1.0842 0.0583 1.0412 -0.0603 1.0427 
UL73   0.3914 1.3117 -0.0651 1.0461 -0.2499 1.1892 
UL74   1.6496 3.1374 0.8920 1.8558 -0.6439 1.5625 
UL74A - - - - - - 
UL75 - 0.0679 1.0482 0.1208 1.0873 0.1123 1.0810 
UL78 - 1.3477 2.5451 -0.3420 1.2675 0.9781 1.9699 
UL100 0.2464 1.1862 -0.0575 1.0406 -0.2729 1.2083 
UL115 0.1165 1.0841 0.1609 1.1180 -0.0791 1.0564 
UL116 0.1616 1.1185 0.2160 1.1615 -0.0614 1.0435 
UL118/UL119 0.6278 1.5452 -0.0701 1.0498 -0.7847 1.7228 
UL128 -1.7007 3.2505 -0.5242 1.4381 0.9592 1.9442 
UL130 -3.1677 8.9860 -0.7144 1.6408 2.4085 5.3092 
UL131A -2.3270 5.0176 -0.3358 1.2621 2.3913 5.2463 
UL132 -0.9072 1.8754 -0.0229 1.0160 0.7117 1.6377 
UL139 - - - - - - 
UL140 0.3068 1.2370 -0.1319 1.0958 -0.4835 1.3981 
UL141 -0.4235 1.3412 0.3657 1.2885 0.8060 1.7483 
UL148 -2.5699 5.9377 1.4249 2.6850 3.7576 13.5251 
US9       
US12 -0.8126 1.7564 0.3122 1.2416 0.9777 1.9694 
    310 
US13 -1.2570 2.3900 0.5247 1.4387 1.6178 3.0690 
US14 -0.8727 1.8311 -0.2201 1.1648 0.6077 1.5238 
US18 - - - - - - 
US20 -0.6888 1.6120 0.4755 1.3904 1.3908 2.6223 
US27 -0.3294 1.2565 -0.3922 1.3124 -0.1286 1.0932 
US28 0.0539 1.0381 0.4218 1.3396 0.4487 1.3648 
Uncharacterised: 
RL1 - - - - - - 
UL31 -1.5535 2.9352 0.8880 1.8506 2.2549 4.7729 
UL145 -1.8333 3.5636 0.4933 1.4077 2.2864 4.8785 
UL150A* - 0.9295 1.9046     
US1 - - - - - - 
US26 - - - - - - 
 
Where log2 ratios are preceded by (-), virions contained lower levels of the corresponding protein than 
virions from the comparison virus.  
In italics are ORFs encoding proteins identified as Merlin virion components, though not in the MVP-1 or 
MVP-2 mixed virion preparations.  
* - Denotes ORFs whose proteins were detected in the MVP-1 mixed virion preparation, but not the 
MVP-2 preparation 
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Impact of Sequence Variation in the UL128 Locus on Production of
Human Cytomegalovirus in Fibroblast and Epithelial Cells
Isa Murrell,a Peter Tomasec,a Gavin S. Wilkie,b Derrick J. Dargan,b Andrew J. Davison,b Richard J. Stantona
Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdoma; MRC–University of Glasgow Centre for Virus Research, Glasgow,
United Kingdomb
The human cytomegalovirus (HCMV) virion envelope contains a complex consisting of glycoproteins gH and gL plus proteins
encoded by the UL128 locus (UL128L): pUL128, pUL130, and pUL131A. UL128L is necessary for efficient infection of myeloid,
epithelial, and endothelial cells but limits replication in fibroblasts. Consequently, disrupting mutations in UL128L are rapidly
selected when clinical isolates are cultured in fibroblasts. In contrast, bacterial artificial chromosome (BAC)-cloned strains
TB40-BAC4, FIX, and TR do not contain overt disruptions in UL128L, yet no virus reconstituted from them has been reported to
acquire mutations in UL128L in vitro. We performed BACmutagenesis and reconstitution experiments to test the hypothesis
that these strains contain subtle mutations in UL128L that were acquired during passage prior to BAC cloning. Compared to
strainMerlin containing wild-type UL128L, all three strains produced higher yields of cell-free virus. Moreover, TB40-BAC4 and
FIX spread cell to cell more rapidly than wild-typeMerlin in fibroblasts but more slowly in epithelial cells. The differential
growth properties of TB40-BAC4 and FIX (but not TR) were mapped to single-nucleotide substitutions in UL128L. The substitu-
tion in TB40-BAC4 reduced the splicing efficiency of UL128, and that in FIX resulted in an amino acid substitution in UL130.
Introduction of these substitutions intoMerlin dramatically increased yields of cell-free virus and increased cell-to-cell spread in
fibroblasts but reduced the abundance of pUL128 in the virion and the efficiency of epithelial cell infection. These substitutions
appear to represent mutations in UL128L that permit virus to be propagated in fibroblasts while retaining epithelial cell tropism.
Human cytomegalovirus (HCMV) is ubiquitous throughoutpopulations worldwide and represents a significant public
health challenge in both developed and developing countries (1).
Like other herpesviruses, HCMV establishes life-long persistent
infections with periodic episodes of reactivation that require con-
stant immunosurveillance. Productive infection is commonly
asymptomatic in an immunocompetent host, but the virus re-
mains a leading infectious cause of congenital malformation and
is responsible for a broad spectrum of pathological consequences
in immunocompromised (e.g., AIDS patients) or immunosup-
pressed individuals (e.g., transplant recipients). HCMV displays
tropism for a broad range of cell types and tissues in vivo, with
disease being associated with most major organs. For example,
initial infection occurs in mucosal epithelial tissues, infection of
endothelial tissues can result in transfer of virus to solid organs
and leukocytes for dissemination, and CD34! bone marrow pro-
genitor cells and monocytes are sites of latency (1–3). Thus, stud-
ies of HCMV pathogenesis require the use of virus with the ability
to infect a wide range of cell types in vitro. However, there are
significant challenges associated with in vitro propagation of virus
that exhibits the broad tropism characteristic of clinical virus.
Classically, three distinct virion envelope glycoprotein com-
plexes, designated gCI, gCII, and gCIII, have been implicated in
recognition and uptake of HCMV by the cell. gCI, composed of
glycoprotein gB, and gCII, composed of glycoproteins gMand gN,
mediate the initial attachment of virions. Both are capable of bind-
ing to heparin sulfate proteoglycans (4–7), while gB is also capable
of binding to integrins, epidermal growth factor receptor (EGFR),
and platelet-derived growth factor receptor " (PDGFR"). All of
thesemolecules have been reported to be important for virus entry
(8–11), although the roles of EGFR and PDGFR" have been dis-
puted (12, 13). Following initial binding, fusion with cellular
membranes is orchestrated by gB and gCIII, which is formed of
glycoproteins gH, gL, and gO (14–18). More recently it has be-
come apparent that gH and gL also form a second glycoprotein
complex, and that infection of different cell types occurs by differ-
ent mechanisms involving these two different complexes.
Infection of fibroblasts occurs by direct fusion of the virion
envelope with the plasmamembrane, whereas in epithelial, endo-
thelial, and myeloid cells, membrane fusion takes place in vesicles
following internalization by endocytosis ormicropinocytosis (19–
22). gH/gL/gO is required for infection, virionmaturation, egress,
and cell-to-cell spread in fibroblasts, as well as for infection of
epithelial and endothelial cells (6, 23, 24). A second complex, gH/
gL/UL128L, is formed by gH/gL along with the products of the
UL128 locus (UL128L), pUL128, pUL130, and pUL131A. gH/gL/
UL128L is required for efficient infection and cell-to-cell spread in
epithelial, endothelial, and myeloid cells (22, 25–35), either by
binding to cell surface receptors (22, 27, 28) or by promoting
nuclear translocation of virions (21, 32, 36). Infection of fibro-
blasts does not require gH/gL/UL128L; in fact, virus containing
gH/gL/UL128L displays reduced cell-to-cell spread and cell-free
release in fibroblasts in vitro (37, 38). As a result, there is consid-
erable selection pressure against UL128L in this cell type. Thus,
routine isolation of HCMV strains from clinical material in fibro-
blasts is associated with rapid acquisition of disabling mutations
in UL128L, which are usually apparent as frameshifts caused by
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insertion or deletion of one or more nucleotides, in-frame termi-
nation codons caused by single-nucleotide substitutions, or dele-
tions (37–44). This results in the generation of laboratory-adapted
viruses that display efficient growth in fibroblasts but limited
growth in other cell types.
To provide a genetically stable source of HCMV, the genome
can be cloned into a bacterial artificial chromosome (BAC) and
virus recovered by transfection (38, 45–47). However, HCMV is
invariably subjected to some degree of passaging in vitro prior to
BAC cloning, and as a result, BAC-cloned strains exhibit various
degrees of in vitro adaptation. We have previously described the
cloning of the complete HCMV strain Merlin genome into a self-
excising BAC following five passages in fibroblasts (38). In vitro-
acquired mutations were identified by reference to the original
clinical material and repaired, with the resulting BAC having the
genetic competence of wild-type virus. However, as with clinical
HCMV strains, the presence of wild-typeUL128L in reconstituted
virus results in the production of very low titers of cell-free virus in
vitro, and the virus is prone to mutation when passaged in fibro-
blasts (38).
Several HCMV strains in addition to Merlin have been BAC
cloned. These include TB40-BAC4, which was cloned from a
mixed population of TB40/E following five passages in fibroblasts
and 22 passages in endothelial cells (48), FIX, which was derived
from strain VR1814 following 46 passages in fibroblasts (49, 50),
and TR, which was isolated from an ocular swab from an AIDS
patient (51, 52). Strains TB40-BAC4, FIX, and TR were cloned by
replacing sequences in one region of the genome (at the left end of
Us) with a nonexcising BAC vector. UL128L in each BAC is ap-
parently intact, and reconstituted virus is able to infect epithelial
and endothelial cells. However, unlike strains isolated from clini-
cal material, there are no reports of viruses reconstituted from
these BACs acquiring mutations in UL128L during passage in
vitro. This raised the hypothesis that these viruses contain subtle
mutations in UL128L that were acquired during passage of the
clinical isolates prior to BAC cloning. Indeed, our study identifies
single-nucleotide substitutions in strains TB40-BAC4 and FIX
that impact UL128 andUL130, respectively. Introduction of these
substitutions into wild-type UL128L in strainMerlin dramatically
increased yields of cell-free virus and increased cell-cell spread in
fibroblasts but reduced both the abundance of pUL128 in the
virion and the efficiency of infection in epithelial cells.
MATERIALS AND METHODS
Cells and viruses. Primary human fetal foreskin fibroblast (HFFF) cells
and human telomerase reverse transcriptase (hTERT)-immortalized ret-
inal pigmented epithelial (RPE-1) cells were grown in Dulbecco’s modi-
fied Eaglemedium (DMEM) (Life Technologies) supplemented with fetal
bovine serum (10%, vol/vol), penicillin (500 U/ml), and streptomycin
(500 !g/ml) at 37°C in 5% CO2. Two variants of the Merlin BAC were
used and have been described previously (38). Merlin-UL128Lmut (previ-
ously called pAL1158) contains a premature stop codon in UL128, while
Merlin-UL128Lwt (previously called pAL1160) containswild-typeUL128.
Both BACs contain a frameshift in RL13 and an internal ribosomal entry
site (IRES) followed by enhanced green fluorescent protein (EGFP) after
UL122. TB40-BAC4was kindly donated by Christian Sinzger (48), FIX by
Gabi Hahn (50), and TR by Jay Nelson (51). For these BACs, recom-
bineering was used to insert an IRES followed by EGFP after UL122 as
described previously (38). HCMV strain 3301 DNA had been extracted
previously from the urine of a congenitally infected infant (40).
Infections were performed at 37°C for 2 h on a rocker, followed by
removal of the inoculum and addition of fresh medium (53). In titrations
and assays to investigate cell-to-cell spread, supernatant-driven spread
was limited by use of a 1%Avicel semisolid overlay (54). After incubation
for 14 days (for fibroblasts) or 21 days (for epithelial cells), the overlay was
removed and cells were washed in phosphate-buffered saline (PBS). Un-
less otherwise stated, quantitation of cell-free virus produced during in-
fection of both fibroblast and epithelial cells was performed using HFFF,
since this is the only cell type in which all viruses could infect and spread.
Plaques were identified based on EGFP expression and imaged using an
ORCA-ER camera and Leica DMIRBE microscope. Plaque sizes were de-
termined using OpenLab 3 software.
Preparation of BACs. Stocks of each BAC-cloned genome were pre-
pared using a Nucleobond plasmid purification kit (Macherey-Nagel) ac-
cording to themanufacturer’s instructions. The concentration of purified
plasmid DNA was determined by use of an ND1000 spectrophotometer
(Nanodrop).
Transfections. BACs were transfected into HFFF cells by electropora-
tion using a Nucleofector (Amaxa) and basic fibroblast kit (Lonza) and
programT-16 according to themanufacturer’s instructions.Onoccasions
when themonolayer formedwas less than 70% confluent on the following
day, additional cells were added. The number of plaques formed following
electroporation varied only marginally, ranging from 20 to 35 per trans-
fection. RPE-1 cells were transfected using Effectene (Qiagen) according
to themanufacturer’s instructions. The number of plaques formed varied
only minimally, with 50 to 70 plaques generated per transfection. These
variations were not observed to have amajor impact on the relative rate of
virus spread through the monolayer in experimental repeats.
FACS analysis. At weekly time points posttransfection, infected
RPE-1 cultures were trypsinized and reseeded into fresh flasks. An aliquot
of cells was kept for fluorescence-activated cell sorter (FACS) analysis
using an Accuri C6 and CFlow software for the detection of EGFP" cells.
Recombineering. All recombineering was performed as described
previously (38, 55, 56), using E. coli SW102 cells containing the BAC to be
modified. A selectable amp/sacB/lacZ cassette was PCR amplified and in-
serted into the region to be modified, followed by positive selection for
expression of ampicillin resistance on medium supplemented with ampi-
cillin (50 !g/ml). In a second round of recombineering, the selection
cassette was swapped with the DNA sequence to be inserted, followed by
negative selection onmedium supplemented with sucrose (5%, wt/vol) to
select against sacB expression and 5-bromo-4-chloro-3-indolyl-#-d-ga-
lactopyranoside (X-Gal) and isopropyl #-d-1-thiogalactopyranoside
(IPTG) to identify white colonies lacking lacZ expression. Amplification
of the selectable cassette was performed using the Expand HiFi system
(Roche) under the following conditions: 95°C for 2min; 10 cycles at 95°C
for 30 s, 55°C for 30 s, and 68°C for 4.5min; 25 cycles at 95°C for 30 s, 55°C
for 30 s, and 68°C for 4.5 min; and 68°C for 15 min. Primer pairs were
designed with approximately 20 bp of identity to the selectable cassette at
each 3= end and approximately 80 bp of identity to sequences adjacent to
the insertion site at the 5= end. In the primer sequences shown below,
regions identical to sequences immediately up- and downstream from the
insertion site are underlined. Primers were designed to cover regions with
100% identity in all strains.
Insertion of UL128L sequences into the Merlin genome. For inser-
tion of the complete UL128L from strains TR, TB40-BAC4, FIX, and 3301
in place of the wild-type Merlin UL128L, the amp/sacB/lacZ cassette was
amplified using primers SacBR-131A (CAG TCT GCA ACA TGC GGC
TGT GTC GGG TGT GGC TGT CTG TTT GTC TGT GCG CCG TGG
TGC TGG GTC AGT GCC AGC GGG ACT GAG GTT CTT ATG GCT
CTT G) and SacBF-128 (ATC CAG CCG TTT GTG TTT CTT AAC GCT
CTC CAG GTA CTG ATC CAG GCC CAC GAT CCG GGT TAT CTT
GTC GTA TTC CAG CCT GTG ACG GAA GAT CAC TTC G). UL128L
from each strain was amplified using a Phusion high-fidelity kit (New
EnglandBioLabs) and primersUL128LF (GCGTATTTCGGACAAACA
CAC A) and UL128LR (CGC ATG TTG CAG ACT GAG AAA GA). PCR
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was performed under the following conditions: 98°C for 1 min; 35 cycles
at 98°C for 30 s, 55°C for 30 s, and 72°C for 1 min; and 72°C for 10 min.
Insertion of the unique TB40-BAC4 nucleotide into the Merlin ge-
nome. The amp/sacB/lacZ selection cassette was amplified using primers
SacBF (GGT GGT GAC GAT CCC GCG AAT CTC AGC CGT TTT CTC
GGG ACT GTA GCA GAC TTC GCC GTC CGG ACA CCG CAG CCT
GTG CCT GTG ACG GAA GAT CAC TTC G) and SacBR (CTG GAT
CTG TCT CTC GAC GTT TCT GAT AGC CAT GTT CCA TCG ACG
ATC CTC GGG AAT GCC AGA GTA GAT TTT CAT GAA TCT GAG
GTT CTT ATG GCT CTT G). The following oligonucleotide was used to
insert the TB40-BAC4 UL128 nucleotide (underlined): GTT TTC TCG
GGA CTG TAG CAG ACT TCG CCG TCC GGA CAC CGC AGC CTG
TTG ATT CAT GAA AAT CTA CTC TGG CAT TCC CGA GGA TCG
TCG ATG GAA CAT G.
Insertion of unique FIX UL130 nucleotide into the Merlin genome.
The amp/sacB/lacZ selection cassette was amplified using primers SacBF-
FIX (GTC TGG CCT TCC CGG TTG TAC AGC AGA TAC AGG GTC
TCG TTG CGA CAC TCG GGA CCC GTT GAT ACC CGC TGG AAC
CCCCCTGTGACGGAAGATCACTTCG) and SacBR-FIX (TATTCC
AAA CCG CAT GAC GCG GCG ACG TTT TAC TGT CCT TTT CTC
TAT CCC TCG CCC CCA CGA TCC CCC TTG CAA TTC CCT GAG
GTT CTT ATG GCT CTT G). The following oligonucleotide was used to
insert the FIXUL130 nucleotide (underlined): AGGGTCTCGTTGCGA
CAC TCG GGA CCC GTT GAT ACC CGC TGG AAC CCC GAT AAT
TGC AAG GGG GAT CGT GGG GGC GAG GGA TAG AGA AAA GGA
CAG TAA A.
Sanger DNA sequencing.UL128L was amplified by PCR using prim-
ers UL128LF (GCG TAT TTC GGA CAA ACA CAC A) and UL128LR
(CGC ATG TTG CAG ACT GAG AAA GA). UL128L was amplified from
all viruses during time courses (e.g., from infected cell culture superna-
tants) to determine whether it retained its original sequence. The Advan-
tage II PCR system (Clontech) was used according to the manufacturer’s
instructions under the following conditions: 95° for 10 min; 35 cycles at
95°C for 30 s, 55°C for 30 s, and 68°C for 3 min; and 68°C for 10 min.
When UL128L was amplified from a BAC, the HiFi expand PCR system
(Roche) was used according to the manufacturer’s instructions under the
following conditions: 94°C for 2min; 30 cycles at 94°C for 15 s, 68°C for 30
s, and 72°C for 2 min; and 72°C for 7 min. PCR products were purified
from agarose gels by using an Illustra GFX PCR DNA gel band purifica-
tion kit (GE Healthcare) and then sequenced (EurofinsMWG) using the
primers CGG ATT GTA GTT GCA GCT CG, TCT GGT TAT TGG CCT
CGG TG, TCT TCC AAT ATC GCC ATC TC, and GCG CAC AGA AGC
AGG CAG. Sequence alignments, BLAST searches, and other analyses
were performed by using CLC MAIN 6 software.
Generation of cDNA libraries of UL128 transcripts. Total cell RNA
samples from HFFF cultures infected at a multiplicity of infection (MOI)
of 3 were extracted 72 h postinfection by using an RNeasy plus universal
kit (Qiagen) according to the manufacturer’s instructions. cDNAs were
generated using a NanoScript Precision reverse transcriptase kit (Primer
Design). cDNAs were then amplified using primers UL128F (CATAAAC
GTCAACCACCC) and UL128R (CACTGCAGCATATAGCCC) with the
HiFi expand PCR system (Roche) under the conditions stated above.
Bioinformatics analysis.Analysis ofUL128 splice siteswas carried out
by using NNsplice v. 0.9 (57), NetGene2 (58), SplicePort (59), and Hu-
man Splicing Finder v. 2.4.1 (60). Protein structure prediction was per-
formed using Phyre 2 (61).
Preparation of virus stocks.Where feasible, virus stocks were gener-
ated in RPE-1 cells to prevent the selection of mutations in UL128L. Mer-
lin strainsmutated inUL128L and FIXwere grown inHFFF cells owing to
their inability to spread productively in RPE-1 cells. Supernatant from
infected cell cultures was collected and centrifuged at 470! g for 5 min at
room temperature to pellet cellular debris. Cleared supernatants were
centrifuged at 30,000 ! g for 2 h at 20°C. Pelleted virions were resus-
pended in DMEM containing 10% fetal bovine serum (FBS) and stored at
"80°C.
Gradient purification of virions. Virions were purified from nonin-
fectious enveloped particles, dense bodies, and cellular debris by ultracen-
trifugation through glycerol-tartrate positive-density, negative-viscosity
gradients, as described previously (62, 63). The gradients were centrifuged
at 90,465.7! g for 45min at 20°C. Virions were recovered by piercing the
tubes using a 20-gauge needle and syringe, diluted in 0.04 M sodium-
phosphate buffer (pH 7.4), and pelleted by centrifugation at 90,465.7! g
for 1 h at 20°C. The virion pellet was resuspended in amedium suitable for
downstream applications (see below).
Western blot analysis. Purified virions were resuspended in Nu-Page
LDS sample buffer, and proteins were separated by using a Nu-page Tris-
acetate gel system (Invitrogen) according to the manufacturer’s instruc-
tions. Electrophoresed proteins were subsequently transferred to Hy-
bond-P polyvinylidene difluoride (PVDF) membranes (GE Healthcare)
by semidry transfer at 10 V for 1 h using carbonate transfer buffer. The
membranes were incubated for 1 h at room temperature in blocking buf-
fer (PBS containing 0.1% Tween 20 [PBST] plus 5% [wt/vol] fat-free
milk). They were then incubated with primary antibody for 1 h at room
temperature, washed three times with PBST, and incubated with second-
ary antibody for 1 h at room temperature. Antibody was detected by
SuperSignal West Pico (Thermo) using an AutoChemi imaging system
and Labworks software (UVP Bioimaging). Primary antibodies were
mouse-anti pUL128 antibody SURN, provided by Giueseppe Gerna (1:
100), and mouse anti-gB (1:4,000; Abcam). The secondary antibody was
goat anti-mouse horseradish peroxidase (HRP; 1:1,000; GE Healthcare).
RESULTS
Growth properties of HCMV strains FIX, Merlin, TB40-BAC4,
and TR in fibroblast cells.Clinical isolates of HCMV consistently
replicate inefficiently in fibroblast cultures until mutations arise
and are selected, first in RL13 and then in UL128L (37, 38). A
defect in any of UL128, UL130, or UL131A suppresses formation
of the pentameric glycoprotein complex (gH/gL/UL128L) in the
virion (37). To establish the growth characteristics of virus lacking
or containing gH/gL/UL128L, viruses derived from two Merlin
BAC variants were used in this study.Merlin-UL128Lmut contains
a premature stop codonmutation inUL128 that was selected dur-
ing growth of Merlin in fibroblasts prior to BAC cloning. This
mutation was repaired in Merlin-UL128Lwt. In addition, because
the FIX and TB40-BAC4 clones contain mutations in RL13 (38),
which invariably mutates upon passage in fibroblast or epithelial
cells (37, 38), a preexisting RL13 frameshift mutation present in
these Merlin BACs was not repaired. TR contains an intact RL13,
which could contribute to the growth characteristics of this virus.
However, given the speed with which mutants are consistently
selected in RL13 when clinical virus is grown in vitro (37, 38), it
seems likely that RL13 is either not expressed or is nonfunctional
in virus derived from TR.
Interestingly, all three protein-coding regions in UL128L ap-
pear to be intact in the TB40-BAC4, FIX, and TR BACs, yet recon-
stituted viruses have not been reported to acquire obvious muta-
tions during passage in fibroblasts. It is possible that these three
BACs contain natural variants of UL128L that are stable in fibro-
blasts, or that subtle UL128L mutations have been selected that
preserve the integrity of the protein-coding regions but suppress
their functions. Unfortunately, the clinical samples from which
these strainswere derived are not available for comparison. There-
fore, we compared the growth properties of TB40-BAC4, FIX, and
TR to those of Merlin-UL128Lwt and Merlin-UL128Lmut. To
monitor infection, all viruses were engineered to express EGFP
from an IRES inserted downstream from UL122 (encoding IE2)
(Table 1).
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UL128L mutants can arise within a single passage of wild-
type HCMV in fibroblasts (43). To ensure that the experiments
were initiated using genetically homogenous virus prepara-
tions, HFFF cells were transfected with infectious BAC clones
of each virus. The capacity of virus infection to progress by
cell-to-cell spread was assessed by direct measurement of
plaque sizes formed under a semisolid overlay (Fig. 1A). In this
assay, Merlin-UL128Lmut consistently generated the largest
plaques, whereas TB40-BAC4 and FIX plaques were smaller
than those of Merlin-UL128Lmut but were 4- to 2.5-fold larger,
respectively, than those of Merlin-UL128Lwt. TR produced the
smallest plaques of all viruses tested.
Consistentwith previouswork (38),Merlin-UL128Lmut spread
through the HFFF monolayer the fastest (Fig. 1B) and produced
the greatest amounts of cell-free virus (Fig. 1C), whereas Merlin-
UL128Lwt spread the slowest and produced the lowest cell-free
titers (approximately 1,000-fold less than Merlin-UL128Lmut).
Compared toMerlin-UL128Lwt, TB40-BAC4 and FIX each spread
through the HFFF monolayer faster and produced much higher
yields (1,000- and 50-fold, respectively) of cell-free virus. Indeed,
the amount of cell-free TB40-BAC4 release was similar to that of
Merlin-UL128Lmut. The TR infections spread very slowly at first,
but the rate increased from week 5. Like TB40-BAC4 and FIX, TR
also produced peak titers of cell-free virus that exceeded those of
Merlin-UL128Lwt by more than 100-fold.
Thus, TB40-BAC4 and FIX displayedmore efficient cell-to-cell
spread in fibroblasts and produced greater yields of cell-free virus
than Merlin containing wild-type UL128L. Cell-to-cell spread of
TR in fibroblasts was reduced compared to that ofMerlin contain-
ing wild-type UL128L, yet peak cell-free titers were significantly
higher.
TABLE 1 BAC-cloned and recombinant HCMV strains used in this study
Strain Reference UL128L origina
GenBank
accession no. Designation in text
BAC cloned
Merlinb 38 Mutated: G!A in UL128 at nt
176260 (R!stop)
GU179001.1 Merlin-UL128Lmut
Merlinb 38 Native GU179001.1 Merlin-UL128Lwt
TRb 51 Native AC146906.1 TR
TB40-BAC4 48 Native EF999921.1 TB40-BAC4
FIXb 50 Native AC146907.1 FIX
Clinical sample (nonpassaged)
3301 40 Native GQ466044.1 3301
Recombinant Merlin containing variant UL128L
Merlin 3301 Merlin-UL128L3301
Merlin TR Merlin-UL128LTR
Merlin TB40-BAC4 Merlin-UL128LTB40
Merlin FIX Merlin-UL128LFIX
Recombinant Merlin strains containing unique substitutions in UL128L
Merlin TB40-BAC4: G!T in UL128
at nt 176663 (near splice
acceptor site)
Merlin-UL128G!T
Merlin FIX: A!G in UL130 at nt
177364 (S72P)
Merlin-UL130A!G
a Nucleotide positions are relative to the sequence of BAC-cloned HCMV strain Merlin (GU179001).
b GenBank accession numbers for parental viruses are NC_006273 (Merlin), GU179289 (VR1814; parental virus of FIX), and KF021605 (TR).
FIG 1 Growth characteristics of BAC-cloned strains in fibroblasts. (A) HFFF
cells were transfected with BACDNA for the indicated viruses and then placed
under semisolid overlay. Plaque sizes were measured 2 weeks later. Means and
standard deviations are shown. (B) HFFF cells were transfected with BAC
DNA for the indicated viruses, and infection was allowed to progress until the
monolayer was destroyed. At weekly time points posttransfection (p.t.), the
level of infectionwas estimated by FACS analysis of EGFP-expressing cells. (C)
Supernatants from the infections shown in panel B were retained at weekly
intervals and titrated on HFFFs to provide a measure of cell-free virus release.
(Where indicated, samples were compared by 1-way analysis of variance
[ANOVA] followed by Dunnett’s posttest to compare each sample to Merlin-
UL128wt. *, P" 0.05; **, P" 0.01; ***, P" 0.001).
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Growth properties of HCMV strains FIX, Merlin, TB40-
BAC4, and TR in epithelial cells. In order to investigate the
growth characteristics of FIX, Merlin, TB40-BAC4, and TR in an
epithelial cell line (which requires UL128L for efficient infection),
RPE-1 cells were transfected with the infectious BAC clones. In
marked contrast to the findings for fibroblasts, Merlin-UL128Lwt
displayed much more efficient plaque formation than Merlin-
UL128Lmut (Fig. 2A). TB40-BAC4 and TR plaques were of an
intermediate size (approximately 6 times smaller than Merlin-
UL128wt), while FIX formed plaques that were 25 times smaller,
similar to those produced byMerlin-UL128Lmut. TB40-BAC4 and
TR each spread throughout the RPE-1 monolayer much more
slowly than Merlin-UL128Lwt (Fig. 2B and C) yet produced 100-
to 150-fold higher titers of cell-free virus. Neither FIX norMerlin-
UL128Lmut supported significant spread through RPE-1 mono-
layers.
Thus, the growth phenotypes displayed by TB40-BAC4, FIX,
and TR in fibroblasts and epithelial cells were distinct from those
of Merlin containing wild-type UL128L. Cell-to-cell spread of
TB40-BAC4 and FIX was more efficient in fibroblasts but less
efficient (along with TR) in epithelial cells. TB40-BAC4, TR, and
FIX all produced significantly higher cell-free titers than Merlin-
UL128Lwt in both cell types.
The differential growth characteristics of TB40-BAC4 and
FIX are determined by UL128L. To assess whether the growth
characteristics of each strain could be attributed to UL128L, we
replaced UL128L in Merlin with that from TB40-BAC4, FIX, or
TR, thereby generating the recombinant viruses Merlin-
UL128LTB40, Merlin-UL128LFIX, and Merlin-UL128LTR, respec-
tively (Table 1). Compared to Merlin-UL128Lwt, acquisition of
TB40-BAC4or FIXUL128Lwas consistently associatedwith a 2.5-
to 3-fold increased plaque size in fibroblasts (Fig. 3A), an in-
creased rate of cell-free spread (Fig. 3B), and approximately 10-
fold increased yields of cell-free virus (Fig. 3C). In contrast, TR
UL128L did not alter the rate of cell-to-cell spread of strainMerlin
and produced titers of cell-free virus that were comparable to
those of Merlin-UL128Lwt, at least until week 6 posttransfection.
However, production of cell-free virus by Merlin-UL128LTR in-
creased dramatically by week 7. DNA sequencing of UL128L from
cell-free virus during the final time point revealed that all viruses
retained their original sequence in UL128L, with the exception of
Merlin-UL128LTR. Merlin-UL128LTR harbored a deletion (nt
176742 to 177247) affecting both UL130 and UL128, as well as a
G-to-A mutation at nt 177355 that resulted in a premature stop
codon in UL130. Thus, the rapid increase in cell-free virus pro-
duction by Merlin-UL128LTR was correlated with mutation of
UL128L.
Measurement of the size of plaques formed by these recombi-
nant viruses in RPE-1 cells (Fig. 3D) revealed that expression of
TB40-BAC4 and FIX UL128L reduced the epithelial cell-to-cell
spread ofMerlin, with plaques 2.5 to 7 times smaller, respectively.
However, TR UL128L did not affect the growth characteristics of
Merlin. Likewise, time course experiments in epithelial cells
showed that transfer of FIX UL128L resulted in reduced speed of
dissemination, and transfer of FIX and TB40-BAC4, but not TR,
UL128L resulted in 10- to 20-fold increased production of cell-
free virus (Fig. 3E and F). Thus, compared to Merlin-UL128Lwt,
the ability of TB40-BAC4 and FIX to produce larger plaques in
fibroblasts but smaller plaques in epithelial cells, as well as to pro-
duce higher titers of cell-free virus in both cell types, appears to be
attributable at least in part to genetic differences inUL128L.How-
ever, the differential growth characteristics between TR and Mer-
lin-UL128Lwt appear to be independent of UL128L.
A single-nucleotide difference in a UL128 intron increases
cell-free virus production. TB40-BAC4 infection produced sig-
nificantly higher titers of cell-free virus than Merlin-UL128Lwt in
both epithelial and fibroblast cells. Since UL128L clearly makes a
major contribution to the differential growth characteristics of
TB40-BAC4, we hypothesized that UL128L had acquired a muta-
tion during passage that is compatible with growth in fibroblasts
yet permits the virus to retain a degree of epithelial cell tropism. If
this were the case, any such mutation would be expected to be
unique to TB40-BAC4. UL128L sequences from different strains
exhibit a high level of sequence conservation (!92.3% at the nu-
cleotide level [64, 65]); however, BLAST searches revealed that
TB40-BAC4 had a unique G-to-T (G!T) substitution at nt
176612 (with reference to the equivalent location in the Merlin
BAC genome). The G residue is conserved in 50 other HCMV
strains and is located in the first of the two UL128 introns, 6 nt
from the splice acceptor site. To determine whether this substitu-
tion affects the growth properties of TB40-BAC4, it was intro-
duced into Merlin-UL128Lwt to generate Merlin-UL128G!T (Ta-
ble 1). As an additional control, UL128L from strain 3301 was
inserted intoMerlin (generatingMerlin-UL128L3301). Strain 3301
had not been subjected to in vitro passage prior to sequencing and
FIG 2 Growth characteristics of BAC-cloned strains in epithelial cells. (A)
RPE-1 cells were transfected with BACDNA for the indicated viruses and then
placed under semisolid overlay. Plaque sizes were measured 3 weeks later.
Means and standard deviations are shown. (B) RPE-1 cells were transfected
with BACDNA for the indicated viruses, and infectionwas allowed to progress
until the monolayer was destroyed. At weekly time points, cells were
trypsinized and the level of infection wasmeasured by FACS analysis of EGFP-
expressing cells. (C) Supernatants from the infections shown in panel B were
retained at weekly intervals and titrated on HFFFs to provide a measure of
cell-free virus release. (Where indicated, samples were compared by 1-way
ANOVA followed by Dunnett’s posttest to compare each sample to Merlin-
UL128wt. *, P" 0.05; **, P" 0.01; ***, P" 0.001).
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was thus representative of a UL128L sequence that was different
from that of Merlin but that was known to be wild type. UL128L
from 3301 was also highly homologous to UL128L from TB40-
BAC4 (99.49%at the nucleotide level); however, it did not contain
the G!T nucleotide difference identified in the intron of UL128.
Therefore, it was useful to determine whether the G!T substitu-
tion, as opposed to natural strain variation elsewhere, contributed
to the different characteristics of UL128L from TB40-BAC4 com-
pared to that from Merlin.
Merlin-UL128Lwt and Merlin-UL128L3301 displayed similar
cell-cell spread properties in RPE-1 cells. Transfer of the substitu-
tion identified in TB40-BAC4 UL128 was sufficient to reduce
epithelial cell-to-cell spread ofMerlin to the same degree (approx-
imately 2-fold) as transfer of the entire TB40-BAC4 UL128L (Fig.
4A). Investigations of infection kinetics (Fig. 4B) and production
of cell-free virus in epithelial cell culture (Fig. 4C) also showed that
Merlin-UL128L3301 had growth characteristics similar to those of
Merlin-UL128Lwt. Transfer of theG!T substitution toMerlin did
not alter the rate of spread through the monolayer, but it did
increase the production of cell-free virus by Merlin by the same
degree as transfer of the entire TB40-BAC4 UL128L (approxi-
mately 50-fold). When plaque sizes were measured in fibroblasts
(Fig. 4D), Merlin-UL128L3301 again formed plaques of sizes com-
parable to those ofMerlin-UL128Lwt, whereas the plaques formed
byMerlin-UL128G!T were similar in size to those formed byMer-
lin-UL128LTB40 and were consistently 2-fold larger than those
formed by Merlin-UL128Lwt and Merlin-UL128L3301.
A single-nucleotide difference in a TB40 UL128 intron re-
duces splicing efficiency. The proximity of the G!T substitution
in TB40-BAC4 UL128 to the splice acceptor site in intron 1 sug-
gested that it had the potential to disrupt splicing of UL128
mRNA. Indeed, bioinformatics analysis predicted that this would
be the case (Fig. 5A). Total infected cell RNA was extracted 72 h
postinfection, and RT-PCR was performed across both introns of
UL128 (Fig. 5B). Three differently spliced products were detected,
and DNA sequencing demonstrated that they corresponded to (i)
an unspliced transcript (656 to 662 bp, depending on the strain),
(ii) a transcript with intron 2 excised (540 bp), and (iii) a tran-
script with both introns 1 and 2 excised (417 bp). All three UL128
products were detected in all strains tested; however, in the con-
structs containing the G!T substitution (TB40-BAC4, Merlin-
UL128LTB40, and Merlin-UL128G!T), the cDNAs corresponding
to the fully spliced transcript were present at significantly lower
abundance.
Thus, the G!T substitution identified in TB40-BAC4 reduced
the efficiency of UL128 mRNA splicing and appeared to be en-
tirely responsible for the different growth characteristics con-
ferred by TB40-BAC4 UL128L compared to those of Merlin
UL128L.
A single-nucleotide difference in FIX UL130 increases virus
production. BLAST searches of UL128L sequences also revealed a
unique A-to-G (A!G) substitution in FIX UL130 at nt 177364
(with reference to the Merlin BAC sequence). This difference
manifests as a serine-to-proline amino acid change (S72P), and
according to protein structure prediction, it disrupts a beta sheet
within the protein. The alteration was introduced into Merlin-
UL128Lwt (generating Merlin-UL130A!G) (Table 1). Merlin-
UL130A!G produced plaques in RPE-1 cells approximately 3-fold
smaller than those ofMerlin-UL128Lwt but similar in size to those
formed by Merlin-UL128LFIX (Fig. 6A). The effects of this substi-
tution on dissemination during infection (Fig. 6B) and cell-free
virus production (Fig. 6C) in epithelial cell culture were also in-
vestigated. It reduced the rate of dissemination through the epi-
thelial cell monolayer compared to that of Merlin-UL128Lwt, al-
though not as much as transfer of the entire FIX UL128L. It also
FIG 3 Growth characteristics of recombinant Merlin viruses containing
UL128L from other strains. HFFF (A) or RPE-1 (D) cells were transfected with
BAC DNA for the indicated viruses and then placed under semisolid overlay.
Plaque sizes were measured 2 (A) or 3 (D) weeks later. Means and standard
deviations are shown. HFFF (B) or RPE-1 (E) cells were transfected with BAC
DNA for the indicated viruses, and infection was allowed to progress until the
monolayer was destroyed. At weekly time points, the level of infection was
estimated from EGFP expression (B), or cells were trypsinized and the level of
infection wasmeasured by FACS analysis of EGFP-expressing cells (E). (C and
F) Supernatants from the infections shown in panels B and E were retained at
weekly intervals and titrated on HFFFs to provide a measure of cell-free virus
release. (Where indicated, samples were compared by 1-wayANOVA followed
byDunnett’s posttest to compare each sample toMerlin-UL128wt. *, P" 0.05;
**, P" 0.01; ***, P" 0.001.)
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increased the production of cell-free virus approximately 50-fold
compared to that of Merlin-UL128Lwt. As with the rate of spread
through the monolayer, the increase in cell-free release was not as
dramatic as that achieved by transfer of the entire FIX UL128L
(approximately 150-fold). When cell-to-cell spread ability was
tested in HFFFs (Fig. 6D), Merlin-UL130A!G and Merlin-
UL128LFIX formed plaques of comparable size, and the plaques
were consistently twice as large as those formed by Merlin-
UL128Lwt.
Thus, the A!G substitution in FIX UL130 contributed signif-
icantly to the different growth characteristics of FIXUL128L com-
pared to those of Merlin UL128L.
pUL128 is reduced in TB40-BAC4 and FIX virions. The sub-
stitutions in TB40-BAC4 and FIX UL128L identified above have
the potential to influence the function of gH/gL/UL128L by vari-
ous mechanisms. Impairing the efficiency of RNA splicing in
TB40-BAC4 would be expected to limit expression of full-length
pUL128, and the S72P substitution in pUL130 might reduce the
stable incorporation of pUL130 into gH/gL/UL128L or affect a
functional domain of the complex. Since all five subunits are re-
quired for stable incorporation of gH/gL/UL128L into the virion
(28, 66), alteration of the amounts or structural attributes of any
one component has the potential to affect the levels of the entire
complex incorporated into the virion. To investigate this, levels of
pUL128 were analyzed in HCMV virions purified on glycerol-
tartrate gradients (Fig. 7A), with sample loading normalized to
that of gB. Note that although the epitope recognized by the anti-
UL128 antibody used in this assay is not mapped, any differences
in detection are unlikely to be due to different antibody affinities
for pUL128 from different strains; compared toMerlin, UL128 in
the other strains differed by only one (FIX) or two (TB40-BAC4
and TR) amino acids, while in Merlin viruses containing the sin-
gle-nucleotide substitutions from FIX or TB40-BAC4, pUL128 is
identical to Merlin.
pUL128 was undetectable in Merlin-UL128Lmut but was read-
ily detected in viruses having wild-type UL128L sequences
(Merlin-UL128Lwt and Merlin-UL128L3301). Consistent with TR
UL128L having a similar influence on growth kinetics compared
toMerlin UL128L, TR contained levels of pUL128 that were com-
parable to those in Merlin-UL128Lwt and Merlin-UL128L3301.
FIG 4 Characteristics of virus containing TB40-BAC4 UL128 G!T unique
nucleotide. (A) RPE-1 cells were transfected with BAC DNA for the indicated
viruses and then incubated under semisolid overlay. Three weeks later plaque
sizes were measured. Means and standard deviations are shown. (B) RPE-1
cells were transfected with BAC DNA for the indicated viruses, and infection
was allowed to progress until the monolayer was destroyed. At weekly time
points, cells were trypsinized and the level of infection was measured using
FACS analysis of EGFP-expressing cells. (C) Also at weekly time points, super-
natants were kept and titrated onHFFFs to provide ameasure of cell-free virus
release. (D) HFFF cells were transfected with BAC DNA for the indicated
viruses and then placed under semisolid overlay. Two weeks later, plaque sizes
were measured. Means and standard deviations are shown. (Where indicated,
samples were compared by 1-way ANOVA followed by Dunnett’s posttest to
compare each sample to Merlin-UL128wt. *, P" 0.05; **, P" 0.01; ***, P"
0.001.)
FIG 5 UL128 gene map and transcripts. (A) The position of the unique A
residue identified in TB40-BAC4 UL128 intron 1, in place of the C residue
present in all other strains, is indicated. Protein-coding exons are shaded. (B)
HFFF cells were infected with the indicated virus, and total RNAwas extracted
at 72 h postinfection. RT-PCR was performed using primers binding in the
first and third exons of UL128. The bands correspond to transcripts that are (i)
unspliced, (ii) lacking intron 2, or (iii) lacking both intron 1 and intron 2.
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However, TB40-BAC4 contained reduced levels of pUL128, as did
Merlin containing either the entire TB40-BAC4 UL128L region
(Merlin-UL128LTB40) or only the G!T substitution (Merlin-
UL128G!T). pUL128 was undetectable in FIX and Merlin-
UL128LFIX, while Merlin-UL130A!G contained reduced, though
detectable, levels of pUL128.
Based on the spread of these viruses in epithelial cells, it seemed
likely that all exceptMerlin-UL128Lmut contained gH/gL/UL128L
in the virion, and that lack of detection of pUL128 in somewas due
to the small amounts of virus loaded in order to keep sample
loading comparable to that of the low-titer viruses Merlin-
UL128Lwt and Merlin-UL128L3301. In a separate blot where the
virion load was not normalized, pUL128L was detectable in all
virions except Merlin-UL128Lmut (Fig. 7B).
Thus, all virions except Merlin-UL128mut contain pUL128;
however, the substitutions identified in UL128L of TB40-BAC4
and FIX resulted in reduced levels of gH/gL/UL128L being incor-
porated into the virion.
TB40-BAC4 and FIXUL128L bestow impaired epithelial cell
tropism. Since gH/gL/UL128L is required for efficient infection of
epithelial cells, its reduced incorporation into virions would be
expected to restrict epithelial cell tropism. Viruses derived from
each BAC-cloned strain were plaque titrated on HFFF and RPE-1
cells in parallel (Fig. 8A). For each virus, the titer reported in
RPE-1 cells was normalized to that reported for HFFF cells for the
same virus, thereby quantitating the ability of each virus to infect
epithelial cells relative to its ability to infect fibroblasts. Merlin-
UL128Lmut infected RPE-1 cells approximately 100-fold less effi-
ciently than HFFFs; however, the majority of plaques were repre-
sented by single cells, indicating that cell-to-cell spread was
strongly inhibited. Viruses containingwild-typeUL128L (Merlin-
UL128Lwt and Merlin-UL128L3301) infected RPE-1 cells with
comparable or slightly greater efficiency than they didHFFFs. Like
Merlin-UL128Lwt and Merlin-UL128L3301, TR infected RPE-1
and HFFF cells with similar efficiencies, consistent with these vi-
ruses containing comparable levels of gH/gL/UL128L in virions.
However, infection of RPE-1 cells by TB40-BAC4 was approxi-
FIG 6 Growth characteristics of virus containing the FIX UL130 A!G sub-
stitution. (A) RPE-1 cells were transfected with BAC DNA for the indicated
viruses and incubated under semisolid overlay. Plaque sizes were measured 3
weeks later. Means and standard deviations are shown. (B) RPE-1 cells were
transfectedwith BACDNA for the indicated viruses, and infectionwas allowed
to progress until the monolayer was destroyed. At weekly time points, cells
were trypsinized and the level of infection was measured by FACS analysis of
EGFP-expressing cells. (C) Supernatants from the infections shown in panel B
were retained atweekly intervals and titrated onHFFFs to provide ameasure of
cell-free virus release. (D) HFFF cells were transfected with BAC DNA for the
indicated viruses and then placed under semisolid overlay. Plaque sizes were
measured 2 weeks later. Means and standard deviations are shown. (Where
indicated, samples were compared by 1-way ANOVA followed by Dunnett’s
posttest to compare each sample toMerlin-UL128wt. *, P" 0.05; **, P" 0.01;
***, P" 0.001.)
FIG7 Virion pUL128 content of BAC-cloned strains and recombinantMerlin
viruses. (A) Stocks of the indicated viruses were grown, and infectious virions
were purified on glycerol-tartrate gradients before being analyzed by Western
blotting. Loading was normalized to gB levels (upper panel) and stained for
pUL128 (lower panel). (B) The same samples as those used for panel A were
analyzed by Western blotting. However, rather than being normalized to gB
content, virion loads weremaximized to facilitate detection of pUL128 in each
strain.
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mately 10-fold less efficient than infection of HFFFs, whereas the
efficiency of infection of RPE-1 cells by FIX was approximately
100-fold less than that of HFFFs and comparable to a virus lacking
gH/gL/UL128L (Merlin-UL128Lmut).
Like TB40-BAC4, Merlin-UL128LTB40 and Merlin-UL128G!T
infected RPE-1 cells approximately 10-fold less efficiently than
HFFFs (Fig. 8B), displaying a lower infection efficiency thanMer-
lin-UL128Lwt, Merlin-UL128L3301, and TR.
FIX infected epithelial cells with approximately 100-fold less
efficiency than fibroblasts, and this was closely recapitulated by
Merlin containing FIX UL128L (Fig. 8C). The A!G substitution
in FIX UL130 also reduced the ability of Merlin to infect RPE-1
cells, although only by approximately 10-fold.
In summary, the unique nucleotide differences identified in
TB40-BAC4 UL128 and FIX UL130 resulted in a reduction in the
amounts of gH/gL/UL128L incorporated into the virion and a
concomitant reduction in the relative ability of virus to infect ep-
ithelial cells.
DISCUSSION
Previous attempts to propagate wild-type HCMV from clinical
material by passage in vitro in fibroblasts have shown that muta-
tions invariably occur in the viral genome. RL13 mutates first,
followed by UL128L, and following these steps virus grows to
much higher cell-free titers (37, 38). However, the adapted virus
lacks gH/gL/UL128L in the virion envelope; therefore, it does not
efficiently infect cells other than fibroblasts. The single-nucleotide
substitutions identified in UL128L of TB40-BAC4 and FIX may
explain the apparently conflicting fact that these strains retain the
ability to infect endothelial and epithelial cells when passaged on
fibroblasts. gH/gL/UL128L is expressed and is present in virions of
these strains, but the level is reduced. This permits greater release
of cell-free virus and potentially reduces the selective pressure for
further mutations in UL128L.
It is important to determine whether these substitutions rep-
resent natural strain variation or mutations acquired in vitro. The
clinical material from which the strains were derived is not avail-
able; therefore, it is not possible to answer this question directly.
However, the S72P substitution in FIX UL130 is absent from the
passaged parental strain VR1814 (37); thus, it probably occurred
during further passage of VR1814 prior to BAC cloning. Similarly,
the fact that the G!T substitution in intron 1 of TB40-BAC4 is
unique to TB40-BAC4 strongly suggests that it was acquired dur-
ing passage in fibroblasts prior to BAC cloning. This mutation is
also absent from the consensus sequence of the parental strain
(TB40/E), which instead contains a unique C207S variation in
UL130. TB40/E is known to comprise a mixture of genomes (48),
and the G!T mutation may be present at low levels in this mix-
ture. Nevertheless, the identification of the substitutions in FIX
and TB40-BAC4 demonstrates the importance of comparing viral
genomes to unpassaged virus when determining whether a gene is
wild type in sequence and whether (by extension) the phenotype
of a virus can be assumed to be the same as the clinical virus.
The effect of these substitutions was a reduction in levels of
gH/gL/UL128L in the virion. This manifested in impaired effi-
ciency of epithelial cell entry, an increase in cell-to-cell spread in
fibroblasts but a decrease in cell-to-cell spread in epithelial cells,
and an increase in cell-free release in both cell types. Taken to-
gether, these observations indicate that the level of gH/gL/UL128L
in the virion is directly related to its ability to inhibit replication in
fibroblasts and to promote entry and cell-to-cell spread in epithe-
lial cells. Surprisingly, it also suggests that wild-type UL128L in-
hibits the production of cell-free virus in both epithelial and fibro-
blast cells. Themechanismbywhich this occurs is unclear butmay
be related to the fact that gH and gL are common to two glycopro-
FIG 8 Relative infection efficiency of fibroblast and epithelial cells. Stocks of
the indicated viruses were simultaneously titrated onto HFFF or RPE-1 cells.
Titers for each virus on RPE-1 cells were then normalized to the titer of the
same virus on HFFF cells, which was arbitrarily set to 1, giving the relative
efficiency of infection of epithelial cells for each strain. The data are based on
two independent experiments. (A) Relative infection efficiencies of TR, TB40-
BAC4, and FIX compared to various Merlin viruses. (B) Relative infection
efficiencies of Merlin containing either the entire UL128L or the substitution
fromTB40-BAC4 compared to TB40-BAC4 andMerlin. (C) Relative infection
efficiencies of Merlin containing either the entire UL128L or the single nucle-
otide from FIX compared to FIX and Merlin.
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tein complexes (gH/gL/UL128L and gH/gL/gO). Greater amounts
of gH/gL/UL128L may result in there being less gH/gL available
for the formation of gH/gL/gO. gH/gL/gO may be important for
secondary envelopment of progeny virions and egress into the
supernatant (23) and for subsequent infection by cell-free released
virus (24, 67), explaining the increased titers of cell-free virus as
the level of gH/gL/UL128L is reduced. This model is supported by
the observation that expression of wild-type UL128L reduces lev-
els of both cell-free and cell-associated virus (37), and that loss of
gO results in greater accumulation of gH/gL/UL128L in the virion
with a concomitant increase in cell-to-cell spread in epithelial and
endothelial cells (24).
Although the mutations identified in FIX and TB40-BAC4
strongly contributed to the greater production of cell-free virus
and differences in cell-to-cell spread, it is clear that they are not the
sole reason for the growth differences seen in TB40-BAC4 and FIX
compared to Merlin-UL128Lwt. TB40-BAC4 grew to approxi-
mately 1,000-fold higher cell-free titers than Merlin-UL128Lwt,
whereas transfer of the G!T mutation in TB40-BAC4 UL128 re-
sulted in an increase of only 50-fold. Likewise, FIX was unable to
spread cell to cell in RPE-1 epithelial cells, yet Merlin-UL128LFIX
was able to spread, albeit more slowly than Merlin-UL130A!G,
which itself spread more slowly than Merlin-UL128Lwt. Similar
considerations apply to TR. Despite containing levels of gH/gL/
UL128L similar to those in Merlin-UL128Lwt, TR generated
higher cell-free titers yet displayed lower efficiency of cell-to-cell
spread in both fibroblast and epithelial cells. The observation that
Merlin-UL128LTR behaved the same as Merlin-UL128Lwt and
Merlin-UL1283301, and that TR UL128L readily mutated when
expressed in the Merlin genome during growth in fibroblasts but
not when expressed within the TR genome, underlines the con-
clusion that the differential growth characteristics of TR were in-
dependent of UL128L yet are sufficient to enhance the stability of
UL128L in vitro. These differences may be due to a number of
other genome regions that can influence growth in a cell type-
specific manner (37, 68–70). Sequence differences in other glyco-
proteins might also be responsible, with gO being a particularly
prominent candidate because it exists in several highly divergent,
yet stable, genotypes (43, 71–73). Alignments of the protein-cod-
ing regions of gH, gL, gM, gN, gO, and gB of TR, TB40-BAC4, and
FIX with those of other strains did not reveal any unique substi-
tutions that could represent in vitro adaptations, although all 3
viruses lack sequences in Us, where the BAC cassette was inserted,
and TB40-BAC4 contains mutations in RL5A, RL6, UL141, and
UL40 (48, 74), and TR contains a mutation in UL97 (C607Y) that
conveys ganciclovir resistance (75). These mutations could also
contribute to the growth characteristics observed.
Owing to its central role in determining tropism for a broad
range of clinically significant cell types, it is essential that an intact,
wild-type gH/gL/UL128L is present in any strain used to investi-
gate HCMV pathogenesis. More recently, other important impli-
cations of UL128L function have underscored the need for re-
search based on virus strains that are competent in this genome
region. Specifically, gH/gL/UL128L elicits a potent neutralizing
antibody response in a natural infection (76–81) and is considered
ideal for inclusion in new vaccine strategies (34, 82). The differ-
ences identified between levels of gH/gL/UL128L in various
strains analyzed have the potential to affect read-outs of the effi-
cacy of anti-gH/gL/UL128L antibodies. However, they also offer
significant advantages relating to the important issue of being able
to grow HCMV while minimizing the risk of mutation. For work
performed in fibroblast cells, viruses based onMerlin-UL128Lmut
offer an ideal defined, full-length genome that produces relatively
high titers. For work requiring infection of other cell types, Mer-
lin-UL128G!T produces larger amounts of cell-free virus that is
still able to infect epithelial and endothelial cells, potentially with
reduced risk of mutation in UL128L.
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